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INTRODUCTION 
 
Content 
 
The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities 
and towns of Massachusetts for the five-year time period 2010 through 2014.  For each city and 
town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive 
cancer and for all invasive cancer types combined.  These ratios compare the cancer incidence 
experience of each city or town with the cancer experience of the state as a whole.  The method 
involves comparing the number of cases that were observed for a city or town to the number of 
cases that would be expected if the city or town had the same cancer rates as the state as whole.  
The report is organized into the following sections: 
 
METHODS provides a detailed explanation of the data collection, data processing, and 
statistical techniques employed in this report. 
 
TABLES present data for selected types of cancer by city/town and sex. 
 
APPENDIX I provides a listing of International Classification of Diseases for Oncology 
codes used in the preparation of this report. 
 
APPENDIX II provides selected resources for information on cancer. 
 
APPENDIX III describes the Massachusetts Department of Public Health’s current cancer 
control initiatives, and provides links to bureaus within the department that address some 
aspect of cancer.  Links to resources for publications are also provided. 
 
Comparison with Previous Reports 
 
This report updates previous annual reports published by the Massachusetts Cancer Registry 
(MCR).   It is available on line at http://www.mass.gov/dph/mcr.  For questions about the report, 
contact the MCR at: 
  
 Massachusetts Cancer Registry 
 Office of Data Management and Outcomes Assessment 
Office of Population Health 
 Massachusetts Department of Public Health 
 250 Washington Street, 6
th
 floor 
 Boston, MA 02108-4619 
telephone 617-624-5642; fax 617-624-5695  
 
The preceding report, Cancer Incidence in Massachusetts 2009-2013:  City and Town 
Supplement, included data for diagnosis years 2009 through 2013.  This report contains data for 
the diagnosis years 2010 through 2014.  There have been no changes in this report’s format from 
the previous report.   
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METHODS 
 
Data Sources 
 
Cancer Incidence 
 
The MCR collects reports of newly diagnosed cancer cases from health care facilities and 
practitioners throughout Massachusetts. Facilities that  reported the 2010-2014 diagnoses that 
comprise this report  include 69 Massachusetts  acute care hospitals, 20 independent laboratories, 
10 surgical centers, 5  radiation/oncology centers, 10 medical practice associations, 4 endoscopy 
centers, and approximately 500 private practice physicians. The MCR signed the modified 
National Data Exchange Agreement on March 28, 2013. This is a single agreement that allows 
participating states to exchange data on cases diagnosed or treated in other areas.  Together with 
states participating in the agreement, and states with individual agreements, the MCR now has 
reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin 
Islands, Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. 
Currently the MCR collects information on in situ and invasive cancers and benign tumors of the 
brain and associated tissues. The MCR does not collect information on basal and squamous cell 
carcinomas of the skin. 
 
The MCR also collects information from reporting hospitals on cases diagnosed and treated in 
staff physician offices when this information is available. Not all hospitals report this type of 
case, however, some hospitals report such cases as if the patients had been diagnosed and treated 
by the hospital directly. Collecting these types of data makes the MCR’s overall case 
ascertainment more complete. Some cancer types that may be reported to the MCR in this manner 
are melanoma, prostate, colon/rectum, and oral cancers. 
 
In addition, the MCR identifies previously unreported cancer cases through review of death 
certificate data to further improve case completeness. This process is referred to as death 
clearance and identifies cancers mentioned on death certificates that were not previously reported 
to the MCR. In some instances, the MCR obtains additional information on these cases through 
follow-up activities with hospitals, nursing homes, hospice residences, and physicians’ offices. In 
other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is 
the only source of information for a cancer case. Thus these “death certificate only” cancer 
diagnoses are poorly documented and have not been confirmed by review of clinical and 
pathological information. Such cases are included in this report, but they comprise less than 3% 
of all cancer cases. 
 
All case reports that provided the basis for this report were coded following the International 
Classification of Diseases for Oncology, Third Edition (ICD-O-3), which was implemented in 
North America with cases diagnosed as of January 1, 2001. (1)  Please see Appendix A for the 
classification of cancers by ICD-O3 codes. 
 
Each year, the North American Association of Central Cancer Registries (NAACCR) reviews 
cancer registry data for quality, completeness, and timeliness.  For 2010-2014, the MCR’s annual 
case count was estimated by NAACCR to be more than 95% complete for each year. The MCR 
has achieved the gold standard for this certification element as well as for six other certification 
elements for each case year since 1997.  
 
The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed 
among Massachusetts residents during 2010-2014 and reported to the MCR as of June 14, 2018.  
These data include some additional cases diagnosed in 2009-2013 that were not counted in the 
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previous report,   Cancer Incidence in Massachusetts 2009-2013:  City and Town Supplement.   
The lag time between this report and the annual statewide report of 2010-2014 cancer cases is due 
to the fact that data for this city and town report needed to be cleaned for accuracy of residence 
within Massachusetts.  The statewide report presented data at the state level and did not require 
such accuracy of city and town of residence.  The numbers presented in this report may change 
slightly in future reports, reflecting late reported cases or corrections based on subsequent details 
from the reporting facilities.  Such changes might result in slight differences in numbers and rates 
in future reports of MCR data, reflecting the nature of population-based cancer registries that 
receive case reports on an ongoing basis. 
Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among 
Massachusetts residents during 2010-2014.  The Massachusetts data presented include invasive 
cancers only (except cancer of the urinary bladder, where in situ cancers are also included).  
Invasive cancers have spread beyond the layer of cells where they started and have the potential 
to spread to other parts of the body.  In situ cancers are neoplasms diagnosed at the earliest stage, 
before they have spread, when they are limited to a small number of cells and have not invaded 
the organ itself.  Typically, published incidence rates do not combine invasive and in situ cancers 
due to differences in the biologic significance, survival prognosis and types of treatment of the 
tumors.  Cancer of the urinary bladder is the only exception, due to the specific nature of the 
diagnostic techniques and treatment patterns. 
  
Presentation of Data 
 
Each city and town in Massachusetts is listed alphabetically in the TABLES section.  The 
observed number of cases, the expected number of cases, the standardized incidence ratios, and 
95% confidence intervals are presented for twenty-three main types of cancer and for all cancer 
types combined.  The “all cancers combined” category includes the twenty-three main types 
presented in this report and other malignant neoplasms.  This category is meant to provide a 
summary of the total cancer experience in a community.  As different cancers have different 
causes, this category does not reflect any specific risk factor that may be important for this 
community. 
 
Observed and Expected Case Counts 
 
The observed case count (Obs) for a particular type of cancer in a city/town is the actual number 
of newly diagnosed cases among residents of that city/town for a given time period.  
 
A city/town’s expected case count (Exp) for a certain type of cancer for this time period is a 
calculated number based on that city/town’s population distribution2  (by sex and among eighteen 
age groups) for the time period 2010-2014, and the corresponding statewide average annual age-
specific incidence rates.  The source of the city and town population data for the 2010-2014 
period was the US Census American Community Survey (ACS), an ongoing national survey that 
provides demographic estimates on a yearly basis.
2
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Standardized Incidence Ratios 
 
A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that 
describes in numerical terms how a city/town’s cancer experience in a given time period 
compares with that of the state as a whole. 
 An SIR of exactly 100 indicates that a city/town’s incidence of a certain type of cancer is 
equal to that expected based on statewide average age-specific incidence rates. 
 An SIR of more than 100 indicates that a city/town’s incidence of a certain type of cancer 
is higher than expected for that type of cancer based on statewide average annual age-
specific incidence rates.  For example, an SIR of 105 indicates that a city/town’s cancer 
incidence is 5% higher than expected based on statewide average annual age-specific 
incidence rates. 
 An SIR of less than 100 indicates that a city/town’s incidence of a certain type of cancer is 
lower than expected based on statewide average age-specific incidence rates.  For 
example, an SIR of 85 indicates that a city/town’s cancer incidence is 15% lower than 
expected based on statewide average annual age-specific incidence rates.  
 
Statistical Significance and Interpretation of SIRs 
 
The interpretation of the SIR depends on both how large it is and how stable it is.  Stability in this 
context refers to how much the SIR changes when there are small increases or decreases in the 
observed or expected number of cases.  Two SIRs may have the same size but not the same 
stability.  For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 
600 observed cases and 400 expected cases.  Both represent a 50 percent excess of observed 
cases.  However, in the first instance, one or two fewer cases would change the SIR a great deal, 
whereas in the second instance, even if there were several fewer cases, the SIR would only 
change minimally.  When the observed and expected numbers of cases are relatively small, their 
ratio is easily affected by one or two cases.  Conversely, when the observed and expected 
numbers of cases are relatively large, the value of the SIR is stable. 
 
A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the 
observed number of cases is at least 5), to indicate if the observed number of cases is significantly 
different from the expected number, or if the difference is most likely due to chance.  A 
confidence interval is a range of values around a measurement that indicates the precision of the 
measurement.  In this report, the 95% confidence interval is the range of estimated SIR values 
that has a 95% probability of including the true SIR for a specific city or town.  If the 95% 
confidence interval range does not include the value 100.0, then the number of observed cases is 
significantly different from the expected number of cases.  “Significantly different” means there 
is at most a 5% chance that the difference between the number of observed and expected cancer 
cases is due solely to chance alone.  If the confidence interval does contain the value 100.0, there 
is no significant difference between the observed and expected numbers.  Statistically, the width 
of the interval reflects the size of the population and the number of events; smaller populations 
and smaller observed numbers of cases yield less precise estimates that have wider confidence 
intervals.  Wide confidence intervals indicate instability, meaning that small changes in the 
observed or expected number of cases would change the SIR a great deal. 
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Examples: 
 SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the 
interval is above 100.0, indicating that the number of observed cases is statistically 
significantly higher than the expected number. 
 
 SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the 
interval is below 100.0, indicating that the number of observed cases is statistically 
significantly lower than the expected number. 
 
 SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating 
that the number of observed cases is NOT statistically significantly different from what is 
expected, and the difference is likely due to chance.  When the interval includes 100.0, then 
the true SIR may be 100.0. 
 
Example of Calculation of an SIR and Its Significance 
 
 
SIR = 
OBSERVED CASES 
X 100 
 EXPECTED CASES 
 
The following example illustrates the method of calculation for a hypothetical town for one type 
of cancer and one sex for the years 2007-2011: 
 
 
 Town X State Town X Town X 
 Age  Age-Specific Expected Observed 
 Group Population Incidence Rate Cases Cases 
 (A) (B) (C) = (A) x (B) (D) 
 00-04 74,657 0.0001 7.47 11 
 05-09 134,957 0.0002 26.99 25 
 10-14 54,463 0.0005 27.23 30 
 15-19 25,136 0.0015 37.70 40 
 20-24 17,012 0.0018 30.62 30 
    UP TO 
 85+ 6,337 0.0010 6.34 8 
  Total:     136.35 144 
 
 
SIR = 
Observed Cases 
X 100 = 
(column D total) 
X 100 = 
144 
X 100 ≈ 106 
Expected Cases (column C total) 136.35 
 
Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer 
in Town X is 6% higher than the corresponding statewide average incidence for this cancer.  
However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) 
indicates that the true value may be as low as 89.1 or as high as 124.3  Also, since the range 
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includes the value 100, it means that the observed number of cases is not statistically significantly 
higher or lower than what is expected. 
 
Whenever the number of observed cases is less than five, the corresponding SIR is neither 
calculated nor tested for statistical significance. This is indicated with an (nc) (“not calculated”).  
However, the number of observed and expected cases is shown in these circumstances. 
 
Notes about Data Interpretation 
 
The SIR is a useful indication of the disease categories that have relatively high or low rates for a 
given community.  These statistics, however, should be used with care.  Such statistics provide a 
starting point for further research and investigation into a possible health problem, but they do not 
by themselves confirm or deny the existence of a particular health problem.  Many factors 
unrelated to disease causation may contribute to an elevated SIR, including demographic factors, 
changes in diagnostic techniques, and changes in data collection or recording methods over time, 
as well as the natural variation in disease occurrence.   
 
When reviewing the data tables, it is important to keep in mind that an SIR compares the 
observed cancer incidence in a particular community with the expected incidence based on 
statewide average annual age-specific incidence rates.  This means that valid comparisons can 
only be made between a community and the state as a whole.  SIRs for different cities and towns 
CANNOT and SHOULD NOT be compared to each other.  (Comparisons between two communities 
would be valid only if there were no differences in the age and sex distributions of the two 
communities’ populations.) 
 
Another point to keep in mind when reviewing these data is the large number of statistical tests 
being performed in this report.  For each of the 351 cities and towns, we evaluate 18 types of 
cancer that can occur in both males and females, 3 types that occur only in females and 2 types 
that occur only in males, resulting in 41 gender/cancer categories.  This results in 14,391 possible 
calculations (351 cities and towns x 41 gender cancer categories).  Note that gender/cancer 
categories with less than 5 observed cases are not evaluated for statistical significance, so the 
actual numbers of tests is slightly lower than 14,391. This is important for the reader because 
when multiple significance tests are performed, some will result in a significant finding due to 
chance alone. Based on the number of calculations in this report, we expect 720 significant 
findings to be due to chance alone.  Half of these would be significant excesses (360) and half 
would be significant deficits (360).  There are statistical techniques that can be used to reduce this 
number, however use of these techniques leads to the opposite problem – true significant 
differences that may be missed.  We choose to err on the side of caution and identify more 
significant results, knowing that some will be due to chance alone.   
 
Data Limitations 
 
It should be emphasized that apparent increases or decreases in cancer incidence over time might 
reflect changes in diagnostic methods or case reporting rather than true changes in cancer 
incidence.  Four other limitations must be considered when interpreting cancer incidence data for 
Massachusetts cities and towns:  under-reporting in areas close to neighboring states; under-
reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect 
cities/towns; and standardized incidence ratios based on small numbers of cases. 
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Border Areas and Neighboring States 
 
Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of 
Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to 
the MCR. The MCR has reciprocal reporting agreements with 42 states and with the District of 
Columbia, the Virgin Islands, Puerto Rico, and Guam. 
 
Cases Diagnosed in Non-Hospital Settings 
 
During the time period covered by this report, the MCR’s primary information source for most 
newly diagnosed cases of cancer was hospitals. In addition the MCR collected information from 
reporting hospitals on cases diagnosed and treated in staff physician offices, when this 
information was available. Other reporting sources include dermatologists and dermatopathology 
laboratories, urologists’ offices and a general laboratory. Some types of cancer in this report may 
be under-reported because they are diagnosed primarily by private physicians, private 
laboratories, health maintenance organizations, radiotherapy centers that escape identification 
systems used by hospitals.  The most common types of cancer diagnosed or treated outside of the 
hospital include melanoma and prostate cancer.   The exact extent of this under-reporting has not 
been determined, but cases included in this report represent the great majority of cases statewide 
and provide an essential basis for evaluating statewide cancer incidence patterns. 
 
 
City/Town Misassignment 
 
In accordance with standard central cancer registry procedures, each case reported to the MCR 
ideally should be assigned to the city/town in which the patient lived at the time of diagnosis, 
based on the address provided by the reporting hospital.  In practice, however, a patient may 
provide the hospital with his/her mailing address (e.g., a post office box located outside the 
patient’s city/town of residence); a business address; a temporary address (e.g., the patient is 
staying with a relative while receiving treatment and reports the relative’s address as his/her 
own); or a locality or post office name (e.g., “Chestnut Hill” rather than “Boston,” “Brookline,” 
or “Newton”).  In addition, if a patient has moved since being diagnosed, the hospital may report 
the patient’s current address.  Because of the large number of cases reported to the MCR, and 
because data are reported to the MCR via electronic media, most city/town case assignments are 
performed by an automated computer process.  This simplified matching process may misassign 
some cases based on the reported locality name.  When MCR staff become aware of such 
misassignments, they manually correct the errors.  Furthermore, in order to minimize such errors, 
cases from fifty geographic localities prone to city/town misassignment are reviewed manually. 
 
Small Numbers of Cases 
 
Standardized incidence ratios based on small numbers of cases result in estimates that are very 
unstable.  This situation is common when the population of a city or town is small or if the 
particular cancer type is rare.  SIRs and statistical significance are not calculated when the 
number of observed cases for a specific category is less than five.  In these instances, the 
observed and expected cases are presented in the tables for qualitative comparison only. 
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APPENDIX I:  INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD 
EDITION) 
CODES USED FOR THIS REPORT 
1 
Cancer Site/Type
2 
ICD-O-3
 
Brain & Other  
Nervous System 
C70.0-C72.9 
except 9050-9055, 9140,  
9590-9992 
 
Breast 
 (includes in situ) 
C50.0 – C50.9 
except 9050-9055, 9140,  
9590-9992 
 
Bronchus & Lung C34.0 – C34.9  
except 9050-9055, 9140,  
9590-9992 
 
Cervix Uteri C53.0 – C53.9 
except 9050-9055, 9140,  
9590-9992 
 
Colon/ Rectum C18.0-C18.9, 
C19.9, C20.9, 
C26.0 
except 9050-9055, 9140,  
9590-9992 
 
Corpus Uteri  
& Uterus, NOS 
C54.0 – C54.9, 
C55.9 
except 9050-9055, 9140,  
9590-9992 
 
Esophagus C15.0-C15.9 
except 9050-9055, 9140,  
9590-9992 
 
Hodgkin Lymphoma C00.00 – C80.9  
(includes 9650-9667) 
 
Kidney &  
Renal Pelvis
3 
C64.9, C65.9 
except 9050-9055, 9140,  
9590-9992 
Larynx C32.0 – C32.9 
except 9050-9055, 9140,  
9590-9992 
Leukemia 
 
 
 
 
 
 
 
C00.0 – C80.9 
(includes 9733, 9742, 
9800-9801, 9805-9809, 9820, 9826, 9831-9836, 9840, 9860-9861, 
9863, 9865-9867, 9869-9876, 9891, 9895-9898, 9910-9911, 9920, 
9930-9931, 9940, 9945-9946, 9948, 9963-9964) 
 
C42.0, C42.1, C42.4 
(includes 9811-9818, 9823, 9827, 9837) 
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Liver and Intrahepatic 
Bile Ducts 
C22.0, C22.1 
except 9050-9055, 9140,  
9590-9992 
Melanoma of Skin C44.0 – C44.9 
(includes 8720-8790) 
Multiple Myeloma C00.0-C80.9 
(includes 9731, 9732, 
9734) 
 
Non – Hodgkin  
Lymphoma 
C02.4, C098, C099, C111, C142, C379, C422, C770-C779 
(includes 9590-9597, 9670-9671, 9673, 9675, 9678-9680, 
9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 
9714-9719, 9724-9729, 9735, 9737-9738, 9811-9818, 9823, 
9827, 9837) 
 
All sites except C02.4, C90.8-C09.9, C11.1, C14.2, C37.9, 
C42.2, C77.0-C77.9 (includes  9590-9597, 9670-9671, 9673, 
9675, 9678-9680, 9684, 9687, 9688, 9689-9691, 9695, 9698-
9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 
9737, 9738) 
 
All sites except C02.4, c09.8-C09.9, C11.1, C14.2, C37.9, 
C42.0-C42.2, c42.4, C77.0-C77.9 (includes 9811-9818, 
9823, 9827, 9837) 
  
 
Oral Cavity  
& Pharynx 
C00.0 – C14.8 
except 9050-9055, 9140,  
9590-9992 
 
Ovary C56.9 
except 9050-9055, 9140,  
9590-9992 
 
Pancreas C25.0 – C25.9 
except 9050-9055, 9140,  
9590-9992 
 
Prostate 
 
 
C61.9 
except 9050-9055, 9140,  
9590-9992 
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Stomach 
 
C16.0 – C16.9 
except 9050-9055, 9140,  
9590-9992 
 
Testis C62.0 – C62.9 
except 9050-9055, 9140,  
9590-9992 
 
Thyroid C73.9 
except 9050-9055, 9140,  
9590-9992 
 
Urinary Bladder 
(includes in situ) 
C67.0 – C67.9 
except 9050-9055, 9140,  
9590-9992 
 
 
 
1International Classification of Diseases for Oncology, 3d Ed. (includes codes added since publication) 
2 Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which 
includes invasive and in situ behaviors.  Non-invasive (in situ) cancers are not included. 
3 Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category 
that is not included in this cancer type. 
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APPENDIX II:  SELECTED RESOURCES FOR 
INFORMATION ON CANCER 
 
This Appendix contains a listing of selected resources for additional information on cancer. 
Cancers are complex diseases, many of which have multiple factors that may contribute to their 
development.   
 
For information on cancer risk factors or prevention, you may wish to contact the following: 
Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237) 
Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345) 
 
In addition, the following selected Internet websites provide information on cancer.  Many of 
these also provide links to other sites (not listed) which may be of interest. 
Massachusetts Department of Public Health:  http://www.mass.gov/dph 
 
American Cancer Society:  http://www.cancer.org 
 
Centers for Disease Control and Prevention 
 Home Page:  http://www.cdc.gov 
 Cancer Prevention and Control Program:  http://www.cdc.gov/cancer 
Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):   
http://www.fruitsandveggiesmorematters.org/ 
 
National Cancer Institute 
 Information:  http://www.cancer.gov 
 Cancer Literature in PubMed:  
https://www.ncbi.nlm.nih.gov/pubmed?cmd_current=Limits&pmfilter_Subsets=Cancer 
 Surveillance, Epidemiology, and End Results (SEER) Program data:  http://seer.cancer.gov 
 
Your Cancer Risk (Siteman Cancer Center at Barnes-Jewish Hospital and Washington 
University School of Medicine; formerly at Harvard Center for Cancer Prevention):  
http://www.yourdiseaserisk.wustl.edu 
 
OncoLink (Abramson Cancer Center of the University of Pennsylvania): 
http://www.oncolink.org 
 
Cancerquest (Emory University – Winship Cancer Institute):  www.cancerquest.org 
 
National Coalition for Cancer Survivorship:  http://www.canceradvocacy.org 
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APPENDIX III:  MDPH CANCER PREVENTION AND CONTROL INITIATIVES  
 
The Massachusetts Department of Public Health is working to reduce the incidence and mortality 
of cancer in the Commonwealth.  Partnerships between MDPH programs, researchers, healthcare 
providers and nonprofit organizations collect information about cancer, lead quality improvement 
projects, coordinate evidenced-based workshops for managing living with chronic disease 
(including cancer), provide education for health professionals and bring shared messages to the 
public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through 
healthy lifestyles, early diagnosis, and increased access to care. The Department’s programs 
address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, 
along with environmental and occupational hazards for cancer. Throughout all of our efforts there 
is an emphasis on reducing disparate health outcomes and unequal access to cancer care. 
 
MDPH Bureaus and Programs:  
Bureau of Environmental Health, www.mass.gov/dph/environmental_health  
Bureau of Substance Abuse Services, www.mass.gov/dph/bsas 
Comprehensive Cancer Prevention and Control Program, www.mass.gov/compcancer 
Men’s Health/Women’s Health/Care Coordination Program 
Tobacco Cessation and Prevention Program, www.mass.gov/dph/mtcp  
Occupational Health Surveillance Program, www.mass.gov/dph/ohsp 
Office of Elder Affairs www.mass.gov/elders/ 
Oral Health Program, www.mass.gov/dph/oralhealth  
Division of Prevention and Wellness www.mass.gov/dph/healthpromotion 
 
MDPH publications on cancer prevention and screening are available at the Massachusetts Health 
Promotion Clearinghouse, www.maclearinghouse.com.  
 
Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer 
Registry, telephone: 617-624-5642 and on the web at www.mass.gov/dph/mcr. 
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Abington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 13.6 95.8 (51.0-163.9)   Male 11 9.4 116.5 (58.1-208.5) 
Female 7 5.6 125.2 (50.1-257.9)   Female 10 8.6 116.2 (55.7-213.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.0 nc (nc-nc)   Male 6 3.0 198.9 (72.6-432.9) 
Female 4 2.8 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.5 nc (nc-nc)   Male 1 8.4 nc (nc-nc) 
Female 62 68.8 90.1 (69.1-115.5)   Female 4 8.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.6 65.6 (21.1-153.1) 
Female 3 2.4 nc (nc-nc)   Female 6 3.6 167.0 (61.0-363.5) 
Colon / Rectum            Ovary     
Male 21 15.7 133.4 (82.6-203.9)             
Female 22 16.6 132.3 (82.9-200.3)   Female 4 5.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.9 129.3 (41.7-301.7)   Male 8 5.1 155.9 (67.1-307.3) 
Female 0 1.1 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 51 49.7 102.6 (76.4-134.9) 
Female 3 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 8.7 195.2 (113.7-312.6)   Male 4 3.5 nc (nc-nc) 
Female 7 5.3 131.6 (52.7-271.2)   Female 5 2.3 220.3 (71.0-514.2) 
Larynx            Testis     
Male 4 2.3 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 6 0.7 801.6 (292.7-1744.8)             
Leukemia            Thyroid     
Male 3 5.8 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 7 4.9 143.0 (57.3-294.6)   Female 12 13.6 88.0 (45.4-153.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.5 109.2 (39.9-237.6)             
Female 2 2.0 nc (nc-nc)   Female 17 16.0 106.5 (62.0-170.6) 
Lung and Bronchus            All Sites / Types     
Male 39 25.1 155.4 (110.5-212.4)   Male 222 193.1 114.9 (100.3-131.1) 
Female 38 29.6 128.2 (90.7-176.0)   Female 245 225.3 108.7 (95.6-123.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
10 
Acton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 19.5 97.3 (58.6-152.0)   Male 15 13.8 108.7 (60.8-179.2) 
Female 5 7.3 68.1 (22.0-159.0)   Female 16 11.3 141.5 (80.8-229.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.4 157.5 (63.1-324.6)   Male 4 4.4 nc (nc-nc) 
Female 2 3.7 nc (nc-nc)   Female 5 3.5 142.0 (45.8-331.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 16 12.4 129.1 (73.7-209.6) 
Female 114 94.7 120.3 (99.3-144.6)   Female 12 10.9 109.7 (56.6-191.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 11.3 114.6 (60.9-195.9) 
Female 3 3.3 nc (nc-nc)   Female 5 4.8 104.7 (33.8-244.4) 
Colon / Rectum            Ovary     
Male 19 23.9 79.5 (47.8-124.1)             
Female 22 22.9 95.9 (60.1-145.2)   Female 10 8.0 125.6 (60.1-231.1) 
Esophagus            Pancreas     
Male 7 5.5 126.8 (50.8-261.3)   Male 6 7.5 80.5 (29.4-175.1) 
Female 4 1.4 nc (nc-nc)   Female 7 7.5 93.2 (37.3-192.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.7 nc (nc-nc)   Male 79 69.4 113.8 (90.1-141.8) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 12.8 nc (nc-nc)   Male 1 5.1 nc (nc-nc) 
Female 9 7.2 125.8 (57.4-238.9)   Female 2 3.1 nc (nc-nc) 
Larynx            Testis     
Male 3 3.3 nc (nc-nc)   Male 0 3.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 8.6 58.2 (18.7-135.8)   Male 6 6.4 94.4 (34.5-205.5) 
Female 10 6.3 159.1 (76.2-292.6)   Female 17 18.1 93.8 (54.6-150.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 8.1 nc (nc-nc)             
Female 3 2.5 nc (nc-nc)   Female 16 20.8 76.8 (43.9-124.7) 
Lung and Bronchus            All Sites / Types     
Male 15 35.6 42.2 (23.6-69.6)   Male 236 279.3 84.5 (74.0-96.0) 
Female 31 39.5 78.4 (53.3-111.3)   Female 319 302.4 105.5 (94.2-117.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
11 
Acushnet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 12.2 172.4 (106.7-263.6)   Male 6 7.7 78.1 (28.5-169.9) 
Female 3 4.5 nc (nc-nc)   Female 5 5.9 84.6 (27.3-197.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.3 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 9 6.9 130.3 (59.5-247.4) 
Female 46 48.9 94.1 (68.9-125.5)   Female 8 6.2 128.3 (55.2-252.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 5.7 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 13.1 122.4 (69.9-198.9)             
Female 13 13.1 99.3 (52.8-169.9)   Female 3 4.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.1 nc (nc-nc)   Male 5 4.3 115.8 (37.3-270.2) 
Female 0 0.9 nc (nc-nc)   Female 5 4.6 108.2 (34.9-252.5) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 39 36.6 106.5 (75.7-145.6) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.7 105.2 (42.1-216.7)   Male 2 2.9 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.9 nc (nc-nc)   Male 0 3.1 nc (nc-nc) 
Female 8 3.5 228.3 (98.3-449.8)   Female 7 8.4 83.3 (33.4-171.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.1 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 9 10.8 83.0 (37.9-157.5) 
Lung and Bronchus            All Sites / Types     
Male 28 21.1 132.7 (88.2-191.8)   Male 173 154.7 111.8 (95.8-129.8) 
Female 22 23.9 91.9 (57.6-139.2)   Female 153 164.9 92.8 (78.7-108.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
12 
Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 9.5 105.6 (50.6-194.2)   Male 3 5.9 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 5 5.1 98.3 (31.7-229.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.8 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 4 1.6 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 5.4 130.8 (52.4-269.5) 
Female 34 41.9 81.2 (56.2-113.5)   Female 7 5.4 130.3 (52.2-268.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.5 111.5 (35.9-260.1) 
Female 1 1.3 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 10.2 88.2 (40.3-167.5)             
Female 10 11.3 88.4 (42.3-162.6)   Female 3 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.4 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 30 30.3 98.9 (66.7-141.2) 
Female 2 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.2 nc (nc-nc)   Male 0 2.3 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.8 131.2 (42.3-306.1)   Male 3 2.3 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 7 7.2 97.6 (39.1-201.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.3 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 7 9.3 75.4 (30.2-155.4) 
Lung and Bronchus            All Sites / Types     
Male 24 16.8 143.2 (91.7-213.1)   Male 129 122.3 105.5 (88.1-125.3) 
Female 25 20.9 119.9 (77.6-177.0)   Female 130 142.0 91.6 (76.5-108.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
13 
Agawam 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 31.8 110.0 (76.6-152.9)   Male 21 20.4 103.1 (63.8-157.6) 
Female 10 13.9 72.1 (34.5-132.6)   Female 15 17.7 84.5 (47.3-139.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 6.2 nc (nc-nc)   Male 11 6.6 166.3 (82.9-297.6) 
Female 5 5.6 90.0 (29.0-210.0)   Female 7 6.2 112.8 (45.2-232.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 24 18.3 131.3 (84.1-195.3) 
Female 142 141.7 100.2 (84.4-118.1)   Female 17 18.8 90.3 (52.6-144.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 15.5 148.0 (93.8-222.1) 
Female 7 4.5 155.8 (62.4-321.0)   Female 13 7.8 166.1 (88.4-284.0) 
Colon / Rectum            Ovary     
Male 43 34.5 124.6 (90.1-167.8)             
Female 34 40.6 83.8 (58.0-117.1)   Female 8 12.4 64.6 (27.8-127.4) 
Esophagus            Pancreas     
Male 4 8.4 nc (nc-nc)   Male 10 11.5 86.9 (41.6-159.8) 
Female 2 2.6 nc (nc-nc)   Female 17 14.3 119.0 (69.3-190.6) 
Hodgkin Lymphoma            Prostate     
Male 3 2.3 nc (nc-nc)   Male 88 104.3 84.4 (67.7-104.0) 
Female 2 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 18.1 149.1 (98.3-217.0)   Male 9 7.7 116.5 (53.2-221.1) 
Female 6 11.4 52.6 (19.2-114.4)   Female 5 5.5 90.2 (29.1-210.6) 
Larynx            Testis     
Male 7 4.9 142.6 (57.1-293.7)   Male 1 4.0 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 13.0 84.9 (42.3-151.9)   Male 5 8.0 62.3 (20.1-145.4) 
Female 9 10.8 83.0 (37.9-157.6)   Female 18 24.3 74.0 (43.8-116.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 11.4 113.7 (60.5-194.5)             
Female 5 4.4 113.1 (36.4-263.9)   Female 24 31.6 76.0 (48.7-113.1) 
Lung and Bronchus            All Sites / Types     
Male 82 57.2 143.4 (114.0-178.0)   Male 448 418.2 107.1 (97.4-117.5) 
Female 88 69.8 126.0 (101.1-155.3)   Female 473 489.5 96.6 (88.1-105.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
14 
Alford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.8 nc (nc-nc)   Male 4 12.3 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 7 10.5 66.9 (26.8-137.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
15 
Amesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 14.3 126.3 (74.8-199.6)   Male 8 10.3 77.9 (33.5-153.5) 
Female 10 5.8 171.9 (82.3-316.2)   Female 5 8.8 56.7 (18.3-132.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.3 nc (nc-nc)   Male 4 3.2 nc (nc-nc) 
Female 6 2.7 219.1 (80.0-476.8)   Female 0 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 12 9.1 131.4 (67.8-229.5) 
Female 76 72.2 105.3 (83.0-131.8)   Female 10 8.6 117.0 (56.0-215.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.5 106.4 (48.5-201.9) 
Female 1 2.6 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 17.1 111.3 (67.0-173.8)             
Female 20 17.7 113.1 (69.1-174.7)   Female 6 6.1 98.9 (36.1-215.2) 
Esophagus            Pancreas     
Male 4 4.1 nc (nc-nc)   Male 8 5.5 145.2 (62.5-286.2) 
Female 2 1.1 nc (nc-nc)   Female 7 5.9 118.7 (47.5-244.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 71 52.8 134.5 (105.0-169.6) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 9.6 52.3 (16.9-122.1)   Male 3 3.7 nc (nc-nc) 
Female 5 5.5 90.3 (29.1-210.6)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.4 140.2 (64.0-266.2)   Male 6 4.8 125.1 (45.7-272.3) 
Female 8 4.9 164.8 (71.0-324.8)   Female 18 14.0 128.3 (76.0-202.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 6.0 115.7 (46.4-238.5)             
Female 2 2.0 nc (nc-nc)   Female 13 16.0 81.4 (43.3-139.2) 
Lung and Bronchus            All Sites / Types     
Male 31 26.4 117.4 (79.8-166.7)   Male 238 207.9 114.5 (100.4-130.0) 
Female 40 31.0 128.9 (92.1-175.5)   Female 247 233.5 105.8 (93.0-119.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
16 
Amherst 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 18.3 81.9 (45.8-135.0)   Male 13 12.1 107.7 (57.3-184.2) 
Female 2 7.2 nc (nc-nc)   Female 14 11.4 122.5 (66.9-205.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 5.1 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 2 4.5 nc (nc-nc)   Female 1 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 6 11.8 50.9 (18.6-110.8) 
Female 77 76.5 100.7 (79.4-125.8)   Female 13 10.7 121.6 (64.7-208.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.7 103.5 (47.3-196.6) 
Female 2 2.7 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 19.6 71.3 (39.0-119.7)             
Female 27 20.9 129.2 (85.1-188.0)   Female 9 7.4 122.3 (55.8-232.1) 
Esophagus            Pancreas     
Male 2 4.6 nc (nc-nc)   Male 9 6.4 139.8 (63.8-265.5) 
Female 0 1.4 nc (nc-nc)   Female 7 7.1 98.3 (39.4-202.6) 
Hodgkin Lymphoma            Prostate     
Male 0 4.0 nc (nc-nc)   Male 42 55.7 75.4 (54.3-101.9) 
Female 0 4.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 10.1 49.7 (16.0-116.0)   Male 0 4.4 nc (nc-nc) 
Female 7 6.3 110.9 (44.4-228.5)   Female 1 2.9 nc (nc-nc) 
Larynx            Testis     
Male 2 2.7 nc (nc-nc)   Male 1 7.0 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 9.2 98.0 (44.7-186.0)   Male 7 5.7 123.7 (49.5-254.8) 
Female 2 7.0 nc (nc-nc)   Female 3 20.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.5 nc (nc-nc)             
Female 0 2.5 nc (nc-nc)   Female 13 17.3 75.2 (40.0-128.7) 
Lung and Bronchus            All Sites / Types     
Male 14 32.6 43.0 (23.5-72.2)   Male 169 250.0 67.6 (57.8-78.6) 
Female 17 37.3 45.6 (26.5-73.0)   Female 219 278.6 78.6 (68.5-89.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
17 
Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 35.1 71.3 (46.1-105.3)   Male 26 22.6 115.0 (75.1-168.5) 
Female 9 12.3 73.1 (33.4-138.8)   Female 28 18.1 155.1 (103.0-224.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 7.0 114.6 (49.3-225.8)   Male 7 7.4 94.3 (37.8-194.3) 
Female 5 5.9 84.6 (27.3-197.5)   Female 12 5.8 207.3 (107.0-362.2) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 29 20.4 142.3 (95.3-204.4) 
Female 158 150.2 105.2 (89.4-122.9)   Female 18 17.9 100.4 (59.4-158.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 17.5 91.2 (52.1-148.2) 
Female 2 5.0 nc (nc-nc)   Female 2 7.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 31 38.7 80.1 (54.4-113.7)             
Female 39 37.3 104.6 (74.4-143.1)   Female 12 12.7 94.2 (48.6-164.6) 
Esophagus            Pancreas     
Male 9 9.4 96.0 (43.8-182.2)   Male 13 12.7 102.4 (54.5-175.1) 
Female 7 2.4 286.2 (114.7-589.8)   Female 13 12.6 103.3 (54.9-176.6) 
Hodgkin Lymphoma            Prostate     
Male 2 2.5 nc (nc-nc)   Male 107 116.6 91.8 (75.2-110.9) 
Female 3 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 20.4 93.0 (55.9-145.2)   Male 5 8.6 58.3 (18.8-136.1) 
Female 12 11.6 103.4 (53.4-180.7)   Female 4 5.0 nc (nc-nc) 
Larynx            Testis     
Male 3 5.5 nc (nc-nc)   Male 8 4.3 188.2 (81.0-370.8) 
Female 2 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 14.4 124.8 (73.9-197.2)   Male 14 9.1 153.4 (83.8-257.3) 
Female 11 10.4 106.3 (53.0-190.1)   Female 42 28.0 150.0 (108.1-202.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 12.8 62.4 (26.9-122.9)             
Female 2 4.1 nc (nc-nc)   Female 25 33.4 74.9 (48.4-110.5) 
Lung and Bronchus            All Sites / Types     
Male 40 63.4 63.1 (45.0-85.9)   Male 421 466.2 90.3 (81.9-99.4) 
Female 40 66.2 60.5 (43.2-82.3)   Female 476 488.4 97.5 (88.9-106.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
18 
Aquinnah 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 3 1.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.3 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.4 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
19 
Arlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 47 45.7 102.9 (75.6-136.8)   Male 27 29.4 91.9 (60.5-133.7) 
Female 17 18.4 92.5 (53.8-148.0)   Female 24 25.5 94.1 (60.3-140.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 9.0 100.3 (45.8-190.4)   Male 11 9.3 118.1 (58.9-211.4) 
Female 9 7.9 114.0 (52.0-216.4)   Female 5 8.4 59.6 (19.2-139.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.6 nc (nc-nc)   Male 19 26.5 71.8 (43.2-112.2) 
Female 209 201.8 103.6 (90.0-118.6)   Female 32 25.8 123.9 (84.7-174.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 21.6 83.5 (49.5-132.0) 
Female 5 7.0 71.3 (23.0-166.4)   Female 14 10.9 129.0 (70.5-216.4) 
Colon / Rectum            Ovary     
Male 44 50.3 87.4 (63.5-117.4)             
Female 52 55.0 94.6 (70.7-124.1)   Female 17 17.4 97.5 (56.8-156.1) 
Esophagus            Pancreas     
Male 11 11.5 95.6 (47.6-171.0)   Male 18 16.3 110.4 (65.4-174.4) 
Female 3 3.6 nc (nc-nc)   Female 16 18.9 84.5 (48.3-137.2) 
Hodgkin Lymphoma            Prostate     
Male 4 3.5 nc (nc-nc)   Male 136 136.6 99.6 (83.5-117.8) 
Female 6 2.9 207.3 (75.7-451.1)             
Kidney & Renal Pelvis            Stomach     
Male 27 25.5 105.9 (69.8-154.1)   Male 10 11.1 90.0 (43.1-165.5) 
Female 11 15.9 69.0 (34.4-123.5)   Female 7 7.5 93.3 (37.4-192.2) 
Larynx            Testis     
Male 5 6.7 74.8 (24.1-174.6)   Male 7 6.7 105.2 (42.2-216.8) 
Female 3 2.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 18.8 95.7 (56.7-151.3)   Male 13 12.0 108.3 (57.6-185.2) 
Female 12 15.0 80.2 (41.4-140.1)   Female 38 37.8 100.6 (71.2-138.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 15.7 95.7 (53.5-157.9)             
Female 4 6.0 nc (nc-nc)   Female 46 44.7 103.0 (75.4-137.3) 
Lung and Bronchus            All Sites / Types     
Male 73 79.7 91.6 (71.8-115.2)   Male 558 585.9 95.2 (87.5-103.5) 
Female 91 93.7 97.1 (78.2-119.2)   Female 677 682.8 99.2 (91.8-106.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
20 
Ashburnham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.0 100.0 (32.2-233.3)   Male 2 3.7 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 19 28.0 67.9 (40.9-106.1)   Female 1 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 6.2 nc (nc-nc)             
Female 7 6.0 116.5 (46.7-240.0)   Female 3 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.6 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 21 21.2 98.9 (61.2-151.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.7 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 0.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 2.3 261.7 (95.5-569.5)   Male 1 1.8 nc (nc-nc) 
Female 3 1.7 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 9.6 72.7 (29.1-149.8)   Male 71 77.8 91.3 (71.3-115.1) 
Female 4 11.3 nc (nc-nc)   Female 64 86.1 74.3 (57.2-94.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
21 
Ashby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.3 nc (nc-nc)   Male 4 2.3 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.7 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 13 14.7 88.4 (47.0-151.2)   Female 0 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.8 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.9 nc (nc-nc)             
Female 2 3.6 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 8 11.3 70.9 (30.5-139.7) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 2.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 2 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.4 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.3 nc (nc-nc)             
Female 2 0.4 nc (nc-nc)   Female 1 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 6.0 nc (nc-nc)   Male 41 45.6 90.0 (64.6-122.1) 
Female 3 6.4 nc (nc-nc)   Female 42 47.4 88.7 (63.9-119.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
22 
Ashfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 6 9.6 62.7 (22.9-136.4)   Female 0 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.9 nc (nc-nc)             
Female 3 2.4 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.8 nc (nc-nc)   Male 18 23.2 77.7 (46.0-122.9) 
Female 2 4.4 nc (nc-nc)   Female 20 31.3 63.8 (39.0-98.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
23 
Ashland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 16.1 112.1 (66.4-177.2)   Male 6 10.9 54.8 (20.0-119.3) 
Female 4 6.1 nc (nc-nc)   Female 3 9.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.4 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 8 9.8 81.5 (35.1-160.6) 
Female 62 73.7 84.1 (64.5-107.9)   Female 6 8.9 67.3 (24.6-146.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.8 57.1 (18.4-133.2) 
Female 1 2.6 nc (nc-nc)   Female 5 3.8 130.5 (42.1-304.6) 
Colon / Rectum            Ovary     
Male 11 18.6 59.3 (29.5-106.1)             
Female 21 18.2 115.5 (71.5-176.6)   Female 7 6.3 111.5 (44.7-229.8) 
Esophagus            Pancreas     
Male 10 4.4 225.9 (108.2-415.5)   Male 3 6.1 nc (nc-nc) 
Female 4 1.2 nc (nc-nc)   Female 6 6.2 96.3 (35.2-209.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 40 56.1 71.3 (51.0-97.2) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 10.0 49.9 (16.1-116.5)   Male 6 4.0 148.2 (54.1-322.6) 
Female 1 5.7 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Larynx            Testis     
Male 1 2.6 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 6.9 nc (nc-nc)   Male 3 4.7 nc (nc-nc) 
Female 6 5.2 116.1 (42.4-252.7)   Female 21 14.0 150.2 (93.0-229.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.3 79.3 (25.6-185.1)             
Female 3 2.1 nc (nc-nc)   Female 15 16.8 89.1 (49.8-146.9) 
Lung and Bronchus            All Sites / Types     
Male 24 29.1 82.3 (52.7-122.5)   Male 168 223.0 75.3 (64.4-87.6) 
Female 41 32.5 126.1 (90.5-171.1)   Female 224 241.5 92.8 (81.0-105.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
24 
Athol 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 14.6 123.4 (73.1-195.1)   Male 6 9.3 64.4 (23.5-140.1) 
Female 3 4.4 nc (nc-nc)   Female 3 6.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.8 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 2 8.2 nc (nc-nc) 
Female 44 49.7 88.5 (64.3-118.8)   Female 5 6.3 79.9 (25.7-186.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 7.1 99.2 (39.7-204.4) 
Female 1 1.7 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 15.4 110.6 (64.4-177.1)             
Female 14 13.0 107.3 (58.6-180.1)   Female 1 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.9 nc (nc-nc)   Male 4 5.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 5 4.5 110.0 (35.5-256.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 26 48.1 54.1 (35.3-79.3) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 8.2 122.5 (58.7-225.3)   Male 2 3.5 nc (nc-nc) 
Female 4 3.9 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 5.9 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 5 3.6 139.5 (45.0-325.6)   Female 11 9.1 121.2 (60.4-217.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.4 nc (nc-nc)             
Female 2 1.5 nc (nc-nc)   Female 20 11.4 175.6 (107.2-271.3) 
Lung and Bronchus            All Sites / Types     
Male 37 26.8 138.2 (97.3-190.5)   Male 167 191.2 87.3 (74.6-101.6) 
Female 32 23.0 138.9 (95.0-196.2)   Female 174 166.7 104.4 (89.4-121.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
25 
Attleboro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 41 42.0 97.6 (70.1-132.5)   Male 27 27.9 96.7 (63.7-140.7) 
Female 17 15.1 112.9 (65.8-180.8)   Female 23 22.3 103.3 (65.4-154.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 8.9 78.7 (31.5-162.2)   Male 6 8.9 67.6 (24.7-147.1) 
Female 7 7.2 97.5 (39.1-201.0)   Female 7 7.0 99.9 (40.0-205.7) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.5 nc (nc-nc)   Male 13 25.1 51.8 (27.6-88.7) 
Female 184 179.4 102.5 (88.3-118.5)   Female 17 21.8 78.1 (45.5-125.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 21.3 98.6 (61.0-150.7) 
Female 5 6.3 79.8 (25.7-186.3)   Female 12 9.3 128.9 (66.5-225.1) 
Colon / Rectum            Ovary     
Male 55 47.2 116.5 (87.8-151.7)             
Female 46 45.0 102.3 (74.9-136.5)   Female 22 15.4 143.2 (89.7-216.8) 
Esophagus            Pancreas     
Male 13 11.1 116.8 (62.1-199.8)   Male 21 15.3 137.4 (85.0-210.1) 
Female 5 3.0 168.2 (54.2-392.5)   Female 17 15.2 111.5 (64.9-178.5) 
Hodgkin Lymphoma            Prostate     
Male 7 3.6 191.9 (76.9-395.3)   Male 142 136.1 104.3 (87.9-123.0) 
Female 2 2.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 25.0 68.0 (39.6-108.8)   Male 5 10.4 48.2 (15.5-112.5) 
Female 12 14.0 85.6 (44.2-149.6)   Female 8 6.1 131.6 (56.7-259.4) 
Larynx            Testis     
Male 10 6.5 153.8 (73.6-282.8)   Male 10 6.9 145.0 (69.4-266.7) 
Female 3 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 17.9 83.9 (46.9-138.5)   Male 10 12.0 83.2 (39.8-153.0) 
Female 8 12.8 62.5 (26.9-123.3)   Female 24 35.1 68.3 (43.8-101.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 15.3 72.1 (35.9-128.9)             
Female 11 5.1 216.2 (107.8-386.8)   Female 48 40.0 120.1 (88.6-159.3) 
Lung and Bronchus            All Sites / Types     
Male 99 75.6 131.0 (106.5-159.5)   Male 571 563.2 101.4 (93.2-110.1) 
Female 78 80.5 96.9 (76.6-120.9)   Female 614 591.6 103.8 (95.7-112.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
26 
Auburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 19.4 139.2 (91.7-202.6)   Male 15 12.0 124.7 (69.8-205.8) 
Female 11 8.0 137.0 (68.3-245.2)   Female 11 10.3 106.9 (53.3-191.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.5 nc (nc-nc)   Male 5 3.9 127.3 (41.0-297.1) 
Female 4 3.2 nc (nc-nc)   Female 8 3.6 221.7 (95.4-436.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 11 10.9 101.3 (50.5-181.2) 
Female 83 83.5 99.5 (79.2-123.3)   Female 13 11.0 118.3 (62.9-202.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 8.8 124.7 (62.2-223.1) 
Female 0 2.6 nc (nc-nc)   Female 1 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 20 20.8 96.2 (58.7-148.5)             
Female 20 23.6 84.8 (51.8-130.9)   Female 7 7.2 96.7 (38.7-199.2) 
Esophagus            Pancreas     
Male 6 4.9 123.1 (44.9-267.9)   Male 6 6.9 87.6 (32.0-190.6) 
Female 1 1.6 nc (nc-nc)   Female 6 8.3 72.5 (26.5-157.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 56 58.7 95.4 (72.1-123.9) 
Female 3 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.5 95.6 (45.7-175.7)   Male 3 4.6 nc (nc-nc) 
Female 5 6.6 75.2 (24.2-175.6)   Female 4 3.2 nc (nc-nc) 
Larynx            Testis     
Male 8 2.8 281.8 (121.4-555.4)   Male 3 2.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.6 92.1 (36.9-189.8)   Male 5 4.6 109.6 (35.3-255.7) 
Female 6 6.2 96.3 (35.2-209.7)   Female 13 14.2 91.6 (48.7-156.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 6.4 108.7 (43.5-224.0)             
Female 0 2.5 nc (nc-nc)   Female 22 18.4 119.4 (74.8-180.8) 
Lung and Bronchus            All Sites / Types     
Male 37 34.2 108.0 (76.1-148.9)   Male 266 244.4 108.8 (96.1-122.7) 
Female 39 40.8 95.6 (68.0-130.7)   Female 282 285.8 98.7 (87.5-110.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
27 
Avon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 5.2 171.8 (78.4-326.2)   Male 5 3.2 154.1 (49.7-359.6) 
Female 1 2.0 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 8 2.9 273.4 (117.7-538.7) 
Female 26 21.8 119.5 (78.1-175.1)   Female 3 2.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.6 88.9 (28.7-207.6)             
Female 5 5.6 88.8 (28.6-207.1)   Female 3 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.4 nc (nc-nc)   Male 9 16.9 53.4 (24.4-101.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.9 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.1 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 1.8 275.0 (88.6-641.7)             
Female 0 0.7 nc (nc-nc)   Female 2 5.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 12 9.2 130.8 (67.5-228.5)   Male 78 67.4 115.8 (91.5-144.5) 
Female 14 10.9 128.6 (70.2-215.8)   Female 74 73.6 100.6 (79.0-126.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
28 
Ayer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 6.6 105.5 (42.2-217.3)   Male 1 4.7 nc (nc-nc) 
Female 4 2.5 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 0 4.2 nc (nc-nc) 
Female 35 29.9 117.2 (81.6-163.0)   Female 4 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.6 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.7 78.3 (28.6-170.5)             
Female 11 7.6 145.0 (72.3-259.6)   Female 3 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 1.8 325.3 (118.8-708.0)   Male 4 2.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 20 22.2 90.1 (55.0-139.1) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.2 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.9 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 4 6.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.6 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 12 6.2 192.3 (99.3-336.0) 
Lung and Bronchus            All Sites / Types     
Male 18 12.4 145.1 (86.0-229.4)   Male 87 93.0 93.5 (74.9-115.4) 
Female 19 13.5 140.3 (84.4-219.1)   Female 121 98.8 122.5 (101.6-146.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
29 
Barnstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 98 68.4 143.3 (116.3-174.6)   Male 60 41.1 145.9 (111.4-187.8) 
Female 28 23.4 119.7 (79.5-172.9)   Female 44 28.9 152.3 (110.7-204.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 11.4 122.7 (67.0-205.9)   Male 9 13.4 66.9 (30.5-127.0) 
Female 10 9.2 108.6 (52.0-199.8)   Female 13 10.5 124.4 (66.2-212.7) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.3 nc (nc-nc)   Male 46 36.6 125.6 (91.9-167.5) 
Female 312 242.9 128.4 (114.6-143.5)   Female 43 31.4 136.8 (99.0-184.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 32 29.8 107.2 (73.3-151.4) 
Female 8 7.1 113.3 (48.8-223.3)   Female 16 13.1 121.9 (69.6-197.9) 
Colon / Rectum            Ovary     
Male 59 69.5 84.9 (64.6-109.6)             
Female 60 64.8 92.6 (70.6-119.1)   Female 21 21.0 99.9 (61.8-152.8) 
Esophagus            Pancreas     
Male 21 17.2 122.4 (75.7-187.1)   Male 31 23.9 129.6 (88.1-184.0) 
Female 4 4.6 nc (nc-nc)   Female 19 23.5 80.9 (48.7-126.3) 
Hodgkin Lymphoma            Prostate     
Male 3 3.9 nc (nc-nc)   Male 236 209.4 112.7 (98.8-128.0) 
Female 0 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 32 35.1 91.1 (62.3-128.6)   Male 18 16.0 112.4 (66.6-177.7) 
Female 19 19.8 95.8 (57.7-149.7)   Female 10 8.8 113.5 (54.3-208.8) 
Larynx            Testis     
Male 6 9.9 60.5 (22.1-131.7)   Male 7 6.2 113.8 (45.6-234.5) 
Female 0 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 30 26.0 115.6 (77.9-165.0)   Male 10 14.2 70.2 (33.6-129.1) 
Female 27 17.6 153.3 (101.0-223.1)   Female 28 38.3 73.2 (48.6-105.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 27 22.6 119.3 (78.6-173.5)             
Female 6 7.6 79.1 (28.9-172.1)   Female 43 56.0 76.8 (55.6-103.5) 
Lung and Bronchus            All Sites / Types     
Male 91 121.6 74.8 (60.3-91.9)   Male 919 846.8 108.5 (101.6-115.8) 
Female 111 124.7 89.0 (73.2-107.2)   Female 885 826.5 107.1 (100.1-114.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
30 
Barre 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.0 120.4 (44.0-262.1)   Male 3 3.4 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 17 23.4 72.7 (42.3-116.3)   Female 0 2.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 5.8 172.6 (82.6-317.4)             
Female 2 6.2 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 16 18.0 89.0 (50.8-144.5) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.1 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 3 1.7 nc (nc-nc)   Female 1 4.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 7 5.2 133.6 (53.5-275.3) 
Lung and Bronchus            All Sites / Types     
Male 7 8.9 78.6 (31.5-162.0)   Male 60 69.9 85.8 (65.5-110.5) 
Female 6 10.5 57.3 (20.9-124.6)   Female 61 77.6 78.6 (60.1-101.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
31 
Becket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.2 158.5 (51.1-369.8)   Male 1 1.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 9 10.4 86.4 (39.4-164.1)   Female 2 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.1 159.2 (51.3-371.5)             
Female 2 2.5 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 4 9.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.6 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 5.6 88.5 (28.5-206.6)   Male 33 38.1 86.7 (59.7-121.8) 
Female 5 5.0 100.9 (32.5-235.5)   Female 27 33.9 79.7 (52.5-115.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
32 
Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 18.0 100.2 (59.3-158.3)   Male 14 10.8 129.0 (70.5-216.5) 
Female 5 6.0 83.5 (26.9-194.9)   Female 4 7.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.1 159.8 (51.5-372.9)   Male 5 3.5 144.7 (46.6-337.8) 
Female 0 2.5 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 15 9.7 155.3 (86.8-256.1) 
Female 67 62.9 106.5 (82.5-135.2)   Female 9 8.2 110.1 (50.2-208.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.4 107.8 (46.4-212.4) 
Female 0 2.0 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 18.7 80.4 (45.0-132.6)             
Female 15 17.7 84.9 (47.5-140.1)   Female 1 5.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 4.2 nc (nc-nc)   Male 8 6.1 130.4 (56.2-257.0) 
Female 2 1.1 nc (nc-nc)   Female 7 6.1 114.8 (46.0-236.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 58 45.9 126.3 (95.9-163.3) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 8.8 90.5 (39.0-178.3)   Male 6 4.2 142.5 (52.0-310.2) 
Female 2 5.1 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.0 142.5 (68.2-262.1)   Male 1 3.9 nc (nc-nc) 
Female 7 4.8 147.3 (59.0-303.5)   Female 11 11.0 100.1 (49.9-179.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.6 nc (nc-nc)             
Female 1 1.9 nc (nc-nc)   Female 6 13.6 44.2 (16.1-96.2) 
Lung and Bronchus            All Sites / Types     
Male 28 30.9 90.7 (60.2-131.1)   Male 226 212.5 106.4 (92.9-121.2) 
Female 26 30.6 84.9 (55.5-124.5)   Female 187 214.8 87.1 (75.0-100.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
33 
Belchertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 14.5 68.8 (32.9-126.5)   Male 6 10.0 60.1 (21.9-130.8) 
Female 3 4.5 nc (nc-nc)   Female 6 7.3 82.1 (30.0-178.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.2 189.8 (69.3-413.1)   Male 5 3.2 155.2 (50.0-362.2) 
Female 1 2.4 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 9 8.9 101.3 (46.2-192.3) 
Female 71 61.2 116.0 (90.6-146.3)   Female 15 6.9 217.6 (121.7-358.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.2 85.6 (34.3-176.4) 
Female 1 2.2 nc (nc-nc)   Female 5 3.0 165.3 (53.3-385.7) 
Colon / Rectum            Ovary     
Male 15 16.7 89.8 (50.2-148.1)             
Female 19 13.8 138.0 (83.1-215.5)   Female 5 5.1 97.7 (31.5-227.9) 
Esophagus            Pancreas     
Male 1 4.2 nc (nc-nc)   Male 4 5.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 6 4.5 132.2 (48.3-287.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 48 54.5 88.0 (64.9-116.7) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.3 85.8 (36.9-169.1)   Male 6 3.7 162.1 (59.2-352.7) 
Female 2 4.6 nc (nc-nc)   Female 5 1.8 271.7 (87.6-634.1) 
Larynx            Testis     
Male 2 2.5 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.2 96.8 (35.3-210.7)   Male 1 4.3 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 9 12.1 74.2 (33.9-140.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.0 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 20 13.9 144.2 (88.1-222.8) 
Lung and Bronchus            All Sites / Types     
Male 14 27.7 50.6 (27.6-84.9)   Male 164 207.5 79.0 (67.4-92.1) 
Female 20 25.0 80.1 (48.9-123.7)   Female 209 192.7 108.5 (94.3-124.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
34 
Bellingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 14.4 76.5 (38.1-136.9)   Male 10 10.2 98.1 (47.0-180.5) 
Female 3 5.8 nc (nc-nc)   Female 9 8.7 102.9 (47.0-195.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.2 nc (nc-nc)   Male 6 3.2 184.9 (67.5-402.4) 
Female 4 2.8 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 19 9.1 209.3 (125.9-326.8) 
Female 69 71.5 96.4 (75.0-122.1)   Female 12 8.4 142.2 (73.4-248.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.4 83.5 (33.5-172.1) 
Female 1 2.5 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 17.1 122.5 (75.8-187.3)             
Female 20 16.9 118.3 (72.2-182.7)   Female 3 6.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 7 4.1 169.0 (67.7-348.2)   Male 6 5.5 108.9 (39.8-237.1) 
Female 2 1.2 nc (nc-nc)   Female 8 5.9 136.5 (58.8-269.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 73 52.7 138.5 (108.5-174.1) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.5 84.3 (36.3-166.2)   Male 5 3.7 135.0 (43.5-315.0) 
Female 5 5.6 89.9 (29.0-209.9)   Female 1 2.3 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.3 79.5 (25.6-185.6)   Male 4 4.6 nc (nc-nc) 
Female 4 4.9 nc (nc-nc)   Female 16 13.9 114.9 (65.6-186.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.0 99.4 (36.3-216.4)             
Female 0 2.0 nc (nc-nc)   Female 17 16.3 104.4 (60.8-167.2) 
Lung and Bronchus            All Sites / Types     
Male 31 26.7 116.3 (79.0-165.0)   Male 246 207.3 118.7 (104.3-134.5) 
Female 22 31.4 70.0 (43.9-106.0)   Female 211 232.1 90.9 (79.1-104.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
35 
Belmont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 28.2 78.1 (48.9-118.3)   Male 16 17.5 91.5 (52.3-148.6) 
Female 3 10.1 nc (nc-nc)   Female 6 13.9 43.2 (15.8-94.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.2 114.7 (41.9-249.6)   Male 4 5.6 nc (nc-nc) 
Female 4 4.5 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.0 nc (nc-nc)   Male 18 15.8 113.9 (67.5-180.0) 
Female 125 111.3 112.3 (93.4-133.8)   Female 8 14.1 56.7 (24.4-111.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 12.6 39.7 (12.8-92.6) 
Female 1 3.8 nc (nc-nc)   Female 6 5.9 101.6 (37.1-221.0) 
Colon / Rectum            Ovary     
Male 21 30.0 69.9 (43.2-106.8)             
Female 23 29.8 77.3 (49.0-115.9)   Female 13 9.5 136.2 (72.5-233.0) 
Esophagus            Pancreas     
Male 5 7.0 71.7 (23.1-167.3)   Male 12 9.9 121.5 (62.7-212.2) 
Female 6 2.0 307.6 (112.3-669.6)   Female 11 10.3 107.0 (53.3-191.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 76 82.7 91.9 (72.4-115.1) 
Female 1 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 15.0 79.9 (41.2-139.6)   Male 5 6.7 74.5 (24.0-173.9) 
Female 3 8.9 nc (nc-nc)   Female 7 4.0 173.7 (69.6-358.0) 
Larynx            Testis     
Male 2 4.0 nc (nc-nc)   Male 6 3.5 173.1 (63.2-376.7) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 11.3 nc (nc-nc)   Male 8 6.7 119.1 (51.3-234.6) 
Female 5 8.2 60.7 (19.5-141.6)   Female 20 20.8 96.2 (58.7-148.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.2 nc (nc-nc)             
Female 3 3.3 nc (nc-nc)   Female 26 24.5 106.3 (69.4-155.8) 
Lung and Bronchus            All Sites / Types     
Male 33 49.0 67.4 (46.4-94.7)   Male 289 352.1 82.1 (72.9-92.1) 
Female 35 52.3 67.0 (46.6-93.1)   Female 334 375.3 89.0 (79.7-99.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
36 
Berkley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 6.6 nc (nc-nc)   Male 5 4.4 114.0 (36.7-266.0) 
Female 0 1.5 nc (nc-nc)   Female 6 2.8 216.4 (79.0-471.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.4 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.9 nc (nc-nc) 
Female 27 23.3 116.1 (76.5-168.9)   Female 6 2.4 247.0 (90.2-537.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.4 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 7.2 138.2 (66.1-254.1)             
Female 6 4.8 124.6 (45.5-271.2)   Female 0 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.8 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 18 22.1 81.5 (48.3-128.8) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.0 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.8 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 5 5.1 97.6 (31.4-227.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.5 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 9 5.1 178.2 (81.3-338.2) 
Lung and Bronchus            All Sites / Types     
Male 11 12.4 88.8 (44.3-158.9)   Male 73 89.3 81.8 (64.1-102.8) 
Female 9 8.5 105.6 (48.2-200.5)   Female 88 70.7 124.6 (99.9-153.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
37 
Berlin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.2 nc (nc-nc)   Male 6 2.5 238.1 (87.0-518.3) 
Female 2 1.2 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 0 2.3 nc (nc-nc) 
Female 12 13.8 87.2 (45.0-152.3)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.4 nc (nc-nc)             
Female 2 3.4 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.0 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 10 12.3 81.3 (38.9-149.6) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.2 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.6 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.1 160.5 (51.7-374.6) 
Lung and Bronchus            All Sites / Types     
Male 8 7.2 111.7 (48.1-220.2)   Male 55 51.4 106.9 (80.5-139.2) 
Female 5 6.3 79.4 (25.6-185.2)   Female 39 44.6 87.4 (62.1-119.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
38 
Bernardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.7 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 5 1.9 257.8 (83.1-601.7) 
Female 10 12.1 82.5 (39.5-151.7)   Female 3 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.8 nc (nc-nc)             
Female 2 3.0 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 14 10.6 131.9 (72.1-221.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.8 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.4 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 6.3 95.5 (34.9-207.9)   Male 40 43.9 91.1 (65.1-124.0) 
Female 4 5.9 nc (nc-nc)   Female 36 40.0 89.9 (63.0-124.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
39 
Beverly 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 42.5 122.3 (91.3-160.4)   Male 40 26.8 149.1 (106.5-203.0) 
Female 22 16.4 134.3 (84.1-203.3)   Female 31 22.8 136.0 (92.4-193.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 8.1 159.6 (84.9-272.9)   Male 10 8.6 116.9 (56.0-215.0) 
Female 6 7.2 83.1 (30.4-181.0)   Female 6 7.5 80.2 (29.3-174.5) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.4 nc (nc-nc)   Male 24 24.0 99.8 (63.9-148.5) 
Female 180 180.9 99.5 (85.5-115.2)   Female 19 23.0 82.6 (49.7-128.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 20.0 145.1 (97.2-208.5) 
Female 5 6.0 83.3 (26.8-194.3)   Female 12 9.7 123.1 (63.5-215.1) 
Colon / Rectum            Ovary     
Male 33 45.7 72.2 (49.7-101.4)             
Female 49 48.1 101.8 (75.3-134.6)   Female 15 15.7 95.3 (53.3-157.1) 
Esophagus            Pancreas     
Male 12 10.8 110.8 (57.2-193.5)   Male 17 15.1 112.8 (65.7-180.6) 
Female 5 3.3 153.8 (49.6-358.9)   Female 17 16.9 100.5 (58.5-161.0) 
Hodgkin Lymphoma            Prostate     
Male 1 3.3 nc (nc-nc)   Male 158 130.8 120.8 (102.7-141.1) 
Female 0 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 28 23.3 120.3 (79.9-173.8)   Male 4 10.2 nc (nc-nc) 
Female 18 14.3 126.0 (74.6-199.1)   Female 4 6.6 nc (nc-nc) 
Larynx            Testis     
Male 9 6.2 144.7 (66.1-274.8)   Male 8 5.8 136.9 (58.9-269.7) 
Female 3 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 27 17.2 156.7 (103.2-228.0)   Male 12 10.6 113.2 (58.4-197.8) 
Female 20 13.3 150.5 (91.9-232.4)   Female 30 33.9 88.4 (59.7-126.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 14.6 95.7 (52.3-160.5)             
Female 9 5.4 168.1 (76.7-319.2)   Female 38 40.7 93.4 (66.1-128.1) 
Lung and Bronchus            All Sites / Types     
Male 85 74.7 113.7 (90.8-140.6)   Male 636 544.3 116.8 (107.9-126.3) 
Female 89 85.1 104.6 (84.0-128.7)   Female 653 611.7 106.7 (98.7-115.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Billerica 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 40.2 139.2 (105.2-180.8)   Male 28 27.2 102.9 (68.3-148.7) 
Female 15 13.6 110.5 (61.8-182.2)   Female 23 20.7 111.2 (70.5-166.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 8.6 151.7 (80.7-259.5)   Male 11 8.7 125.8 (62.7-225.1) 
Female 5 6.7 75.2 (24.2-175.5)   Female 6 6.4 94.2 (34.4-205.1) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.5 nc (nc-nc)   Male 23 24.4 94.1 (59.6-141.2) 
Female 177 168.0 105.3 (90.4-122.1)   Female 19 19.9 95.5 (57.5-149.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 21.6 83.4 (49.4-131.9) 
Female 5 5.9 84.3 (27.2-196.7)   Female 10 8.5 117.6 (56.3-216.3) 
Colon / Rectum            Ovary     
Male 38 46.4 81.9 (58.0-112.5)             
Female 57 40.6 140.5 (106.4-182.1)   Female 12 14.1 84.8 (43.8-148.2) 
Esophagus            Pancreas     
Male 10 11.1 90.2 (43.2-165.9)   Male 13 14.9 87.5 (46.5-149.6) 
Female 2 2.7 nc (nc-nc)   Female 9 13.9 64.9 (29.6-123.2) 
Hodgkin Lymphoma            Prostate     
Male 6 3.5 171.1 (62.5-372.5)   Male 130 139.4 93.2 (77.9-110.7) 
Female 1 2.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 24.9 116.3 (77.9-167.1)   Male 9 10.1 89.4 (40.8-169.8) 
Female 8 12.9 61.9 (26.6-121.9)   Female 8 5.5 146.3 (63.0-288.3) 
Larynx            Testis     
Male 2 6.5 nc (nc-nc)   Male 5 6.6 76.0 (24.5-177.4) 
Female 0 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 28 17.0 164.3 (109.1-237.4)   Male 15 12.0 125.0 (69.9-206.1) 
Female 19 11.5 164.6 (99.1-257.1)   Female 35 33.2 105.4 (73.4-146.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 15.4 78.1 (40.3-136.5)             
Female 2 4.6 nc (nc-nc)   Female 39 37.1 105.1 (74.7-143.6) 
Lung and Bronchus            All Sites / Types     
Male 79 72.7 108.7 (86.0-135.5)   Male 567 555.5 102.1 (93.8-110.8) 
Female 106 73.4 144.3 (118.2-174.6)   Female 593 545.6 108.7 (100.1-117.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Blackstone 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 7.2 153.1 (76.3-274.0)   Male 6 5.2 115.4 (42.2-251.3) 
Female 4 3.0 nc (nc-nc)   Female 6 4.8 124.1 (45.3-270.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.7 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 4 4.6 nc (nc-nc) 
Female 28 39.7 70.5 (46.8-101.9)   Female 3 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.3 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 8.8 102.2 (46.7-194.1)             
Female 7 9.6 72.8 (29.2-150.0)   Female 5 3.3 149.4 (48.2-348.7) 
Esophagus            Pancreas     
Male 6 2.1 286.9 (104.8-624.5)   Male 1 2.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 26 26.3 98.8 (64.5-144.8) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.9 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.2 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 6 2.6 229.8 (83.9-500.2)   Female 3 7.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.1 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 7 8.7 80.1 (32.1-165.0) 
Lung and Bronchus            All Sites / Types     
Male 18 13.3 135.5 (80.2-214.1)   Male 117 105.0 111.5 (92.2-133.6) 
Female 11 16.0 68.7 (34.2-122.9)   Female 111 126.7 87.6 (72.1-105.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Blandford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.3 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 4 5.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.6 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 5.4 112.1 (40.9-244.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.4 nc (nc-nc)   Male 19 19.3 98.6 (59.3-154.0) 
Female 2 2.2 nc (nc-nc)   Female 17 17.0 99.7 (58.1-159.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
43 
Bolton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.8 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 3.0 168.7 (54.4-393.7) 
Female 28 19.4 144.6 (96.1-209.0)   Female 1 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.7 87.4 (28.2-203.8)             
Female 5 3.9 128.8 (41.5-300.6)   Female 3 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 21 16.6 126.5 (78.3-193.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.9 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 8 4.3 186.7 (80.4-367.8) 
Lung and Bronchus            All Sites / Types     
Male 2 8.8 nc (nc-nc)   Male 58 67.0 86.6 (65.7-111.9) 
Female 5 7.0 71.8 (23.1-167.4)   Female 60 57.8 103.9 (79.3-133.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Boston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 338 462.6 73.1 (65.5-81.3)   Male 249 315.3 79.0 (69.5-89.4) 
Female 143 181.6 78.8 (66.4-92.8)   Female 205 290.5 70.6 (61.2-80.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 74 109.4 67.6 (53.1-84.9)   Male 107 96.7 110.7 (90.7-133.8) 
Female 71 93.2 76.1 (59.5-96.1)   Female 124 83.6 148.3 (123.3-176.8) 
Breast            Non-Hodgkin Lymphoma     
Male 15 16.4 91.7 (51.3-151.2)   Male 265 285.3 92.9 (82.0-104.8) 
Female 1909 2115.3 90.2 (86.2-94.4)   Female 252 267.3 94.3 (83.0-106.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 265 232.9 113.8 (100.5-128.3) 
Female 88 83.2 105.8 (84.8-130.3)   Female 107 111.7 95.8 (78.5-115.7) 
Colon / Rectum            Ovary     
Male 557 519.1 107.3 (98.6-116.6)             
Female 581 542.1 107.2 (98.6-116.3)   Female 187 185.7 100.7 (86.8-116.2) 
Esophagus            Pancreas     
Male 122 120.9 100.9 (83.8-120.5)   Male 163 167.1 97.5 (83.1-113.7) 
Female 32 35.6 89.8 (61.4-126.7)   Female 176 184.2 95.5 (81.9-110.7) 
Hodgkin Lymphoma            Prostate     
Male 58 58.4 99.4 (75.4-128.5)   Male 1787 1465.8 121.9 (116.3-127.7) 
Female 32 51.5 62.2 (42.5-87.8)             
Kidney & Renal Pelvis            Stomach     
Male 235 274.4 85.6 (75.0-97.3)   Male 173 114.2 151.5 (129.8-175.9) 
Female 170 167.4 101.6 (86.9-118.0)   Female 118 73.9 159.8 (132.2-191.3) 
Larynx            Testis     
Male 90 70.3 128.0 (102.9-157.3)   Male 102 119.3 85.5 (69.7-103.8) 
Female 17 22.6 75.3 (43.9-120.6)             
Leukemia            Thyroid     
Male 174 206.6 84.2 (72.2-97.7)   Male 149 145.5 102.4 (86.6-120.2) 
Female 145 162.3 89.3 (75.4-105.1)   Female 451 490.0 92.0 (83.7-100.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 257 165.8 155.0 (136.6-175.1)             
Female 95 60.9 155.9 (126.1-190.6)   Female 435 464.2 93.7 (85.1-102.9) 
Lung and Bronchus            All Sites / Types     
Male 874 820.0 106.6 (99.6-113.9)   Male 6570 6276.4 104.7 (102.2-107.2) 
Female 875 953.2 91.8 (85.8-98.1)   Female 6789 7191.1 94.4 (92.2-96.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
45 
Bourne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 38 29.7 127.9 (90.5-175.6)   Male 25 17.6 142.1 (91.9-209.8) 
Female 9 10.9 82.7 (37.7-156.9)   Female 14 13.0 108.0 (59.0-181.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.9 nc (nc-nc)   Male 9 5.8 154.4 (70.4-293.1) 
Female 2 4.1 nc (nc-nc)   Female 4 4.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 13 15.8 82.2 (43.7-140.5) 
Female 87 107.0 81.3 (65.1-100.3)   Female 8 14.4 55.5 (23.9-109.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 12.5 128.5 (73.4-208.6) 
Female 2 3.1 nc (nc-nc)   Female 6 6.0 100.7 (36.8-219.2) 
Colon / Rectum            Ovary     
Male 26 30.0 86.5 (56.5-126.8)             
Female 28 30.8 91.0 (60.5-131.5)   Female 12 9.4 128.2 (66.2-224.0) 
Esophagus            Pancreas     
Male 12 7.3 165.0 (85.2-288.2)   Male 8 10.2 78.2 (33.7-154.0) 
Female 4 2.1 nc (nc-nc)   Female 9 11.1 81.1 (37.0-154.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.7 nc (nc-nc)   Male 85 86.2 98.6 (78.8-122.0) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 14.8 67.7 (32.4-124.5)   Male 7 6.9 101.3 (40.6-208.7) 
Female 8 8.8 91.0 (39.2-179.3)   Female 5 4.2 118.8 (38.3-277.3) 
Larynx            Testis     
Male 10 4.2 237.1 (113.5-436.0)   Male 2 2.7 nc (nc-nc) 
Female 4 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 11.2 44.7 (14.4-104.3)   Male 4 6.0 nc (nc-nc) 
Female 5 8.1 61.5 (19.8-143.5)   Female 21 16.5 127.0 (78.6-194.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.5 73.4 (29.4-151.3)             
Female 2 3.4 nc (nc-nc)   Female 22 24.2 91.0 (57.0-137.8) 
Lung and Bronchus            All Sites / Types     
Male 58 52.1 111.3 (84.5-143.9)   Male 369 359.9 102.5 (92.3-113.6) 
Female 61 56.1 108.7 (83.1-139.6)   Female 335 372.3 90.0 (80.6-100.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Boxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.7 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 22 20.4 107.6 (67.4-163.0)   Female 2 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 2.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.7 87.8 (28.3-204.9)             
Female 6 4.3 138.1 (50.4-300.5)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 15 18.2 82.2 (46.0-135.6) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.1 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 8.7 80.5 (32.3-165.9)   Male 61 69.0 88.4 (67.6-113.5) 
Female 9 7.8 116.0 (52.9-220.2)   Female 68 62.5 108.8 (84.5-137.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Boxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 9.4 63.6 (23.2-138.4)   Male 13 6.3 206.6 (109.9-353.3) 
Female 1 3.0 nc (nc-nc)   Female 9 4.3 206.9 (94.4-392.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.6 89.3 (28.8-208.5) 
Female 43 37.0 116.3 (84.1-156.6)   Female 3 4.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 5.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 10.5 nc (nc-nc)             
Female 7 8.8 79.3 (31.8-163.3)   Female 2 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.6 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 43 33.3 129.0 (93.3-173.8) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 5.7 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 2 1.6 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.8 130.0 (41.9-303.4)   Male 2 2.5 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 9 6.6 137.3 (62.6-260.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.7 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 6 8.5 70.6 (25.8-153.8) 
Lung and Bronchus            All Sites / Types     
Male 9 17.6 51.1 (23.3-96.9)   Male 109 129.3 84.3 (69.2-101.7) 
Female 10 16.6 60.3 (28.9-110.8)   Female 119 119.6 99.5 (82.4-119.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
48 
Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.4 110.7 (40.4-240.9)   Male 3 3.4 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 8 2.3 353.6 (152.3-696.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 27 18.5 146.0 (96.2-212.5)   Female 0 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 6.0 nc (nc-nc)             
Female 6 4.8 125.9 (46.0-274.1)   Female 2 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 15 16.6 90.5 (50.6-149.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.0 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.2 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.9 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 9.5 nc (nc-nc)   Male 55 69.5 79.1 (59.6-103.0) 
Female 5 8.1 62.0 (20.0-144.7)   Female 68 60.7 112.0 (87.0-142.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
49 
Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 46 39.7 115.9 (84.9-154.6)   Male 28 24.9 112.4 (74.7-162.4) 
Female 22 16.3 134.8 (84.4-204.1)   Female 22 21.1 104.4 (65.4-158.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 7.5 nc (nc-nc)   Male 6 7.9 75.7 (27.6-164.8) 
Female 6 6.7 89.4 (32.6-194.5)   Female 3 7.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 23 22.4 102.8 (65.2-154.3) 
Female 195 165.9 117.5 (101.6-135.2)   Female 19 22.1 86.0 (51.8-134.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 18.1 115.8 (71.7-177.0) 
Female 7 5.5 128.2 (51.3-264.1)   Female 11 9.1 120.2 (59.9-215.1) 
Colon / Rectum            Ovary     
Male 52 42.5 122.2 (91.3-160.3)             
Female 60 47.8 125.4 (95.7-161.5)   Female 16 14.5 110.4 (63.0-179.2) 
Esophagus            Pancreas     
Male 13 9.9 131.4 (69.9-224.7)   Male 15 14.0 107.4 (60.0-177.1) 
Female 3 3.1 nc (nc-nc)   Female 19 16.8 113.1 (68.0-176.6) 
Hodgkin Lymphoma            Prostate     
Male 5 2.9 170.0 (54.8-396.8)   Male 131 116.3 112.6 (94.2-133.7) 
Female 5 2.5 200.6 (64.6-468.1)             
Kidney & Renal Pelvis            Stomach     
Male 22 21.3 103.4 (64.8-156.5)   Male 8 9.5 84.3 (36.3-166.2) 
Female 13 13.5 96.6 (51.4-165.2)   Female 6 6.6 91.5 (33.4-199.2) 
Larynx            Testis     
Male 3 5.7 nc (nc-nc)   Male 6 5.2 114.6 (41.9-249.5) 
Female 6 1.9 319.5 (116.7-695.5)             
Leukemia            Thyroid     
Male 13 16.1 80.6 (42.9-137.8)   Male 8 9.7 82.7 (35.6-163.0) 
Female 19 13.0 146.0 (87.9-228.0)   Female 38 29.7 128.0 (90.6-175.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 13.4 97.2 (51.7-166.3)             
Female 5 5.1 97.5 (31.4-227.6)   Female 42 36.2 116.1 (83.7-157.0) 
Lung and Bronchus            All Sites / Types     
Male 58 69.0 84.0 (63.8-108.6)   Male 517 499.2 103.6 (94.8-112.9) 
Female 89 82.3 108.2 (86.9-133.1)   Female 655 576.4 113.6 (105.1-122.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
50 
Brewster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 18.5 97.4 (57.7-153.9)   Male 17 10.7 159.2 (92.7-255.0) 
Female 6 7.0 86.2 (31.5-187.7)   Female 10 7.8 128.3 (61.4-235.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.8 nc (nc-nc)   Male 2 3.6 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.6 nc (nc-nc)   Male 13 9.5 137.4 (73.1-234.9) 
Female 93 66.5 139.8 (112.9-171.3)   Female 16 9.0 177.5 (101.4-288.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.5 80.3 (29.3-174.7) 
Female 1 1.7 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 18.1 66.4 (34.3-116.0)             
Female 18 18.9 95.5 (56.5-150.9)   Female 6 5.8 102.7 (37.5-223.6) 
Esophagus            Pancreas     
Male 3 4.5 nc (nc-nc)   Male 5 6.3 80.0 (25.8-186.6) 
Female 1 1.4 nc (nc-nc)   Female 3 7.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 61 54.4 112.2 (85.8-144.1) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 9.0 nc (nc-nc)   Male 0 4.2 nc (nc-nc) 
Female 6 5.6 107.8 (39.4-234.6)   Female 1 2.6 nc (nc-nc) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.6 135.7 (61.9-257.5)   Male 0 3.3 nc (nc-nc) 
Female 7 5.0 140.4 (56.3-289.3)   Female 7 9.0 77.7 (31.1-160.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.8 103.2 (37.7-224.6)             
Female 0 2.2 nc (nc-nc)   Female 13 15.7 82.8 (44.0-141.6) 
Lung and Bronchus            All Sites / Types     
Male 33 33.3 99.2 (68.3-139.4)   Male 211 220.9 95.5 (83.1-109.3) 
Female 25 36.5 68.4 (44.3-101.0)   Female 237 232.0 102.1 (89.5-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
51 
Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 26.3 95.2 (61.6-140.5)   Male 13 17.2 75.5 (40.2-129.1) 
Female 13 7.6 172.0 (91.5-294.2)   Female 19 11.6 164.1 (98.8-256.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.6 126.1 (50.5-259.8)   Male 3 5.5 nc (nc-nc) 
Female 7 3.8 184.9 (74.1-381.0)   Female 2 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 8 15.8 50.7 (21.8-100.0) 
Female 79 90.7 87.1 (69.0-108.5)   Female 12 11.1 107.7 (55.6-188.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 13.2 105.8 (57.8-177.6) 
Female 4 3.1 nc (nc-nc)   Female 5 4.7 105.3 (33.9-245.7) 
Colon / Rectum            Ovary     
Male 29 29.6 97.9 (65.5-140.6)             
Female 17 22.4 75.8 (44.1-121.4)   Female 9 7.9 114.3 (52.2-217.1) 
Esophagus            Pancreas     
Male 4 6.9 nc (nc-nc)   Male 10 9.5 105.0 (50.3-193.0) 
Female 0 1.5 nc (nc-nc)   Female 8 7.7 103.8 (44.7-204.6) 
Hodgkin Lymphoma            Prostate     
Male 1 2.5 nc (nc-nc)   Male 79 84.1 94.0 (74.4-117.1) 
Female 0 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 15.4 64.9 (31.1-119.4)   Male 5 6.4 77.8 (25.1-181.6) 
Female 8 7.0 113.9 (49.0-224.4)   Female 3 3.1 nc (nc-nc) 
Larynx            Testis     
Male 3 4.0 nc (nc-nc)   Male 0 4.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 11.2 53.4 (19.5-116.2)   Male 11 7.4 148.3 (73.9-265.3) 
Female 4 6.5 nc (nc-nc)   Female 30 18.5 162.4 (109.5-231.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 9.4 160.3 (89.6-264.4)             
Female 3 2.6 nc (nc-nc)   Female 19 20.6 92.4 (55.6-144.3) 
Lung and Bronchus            All Sites / Types     
Male 45 45.9 98.0 (71.5-131.2)   Male 318 349.7 90.9 (81.2-101.5) 
Female 33 40.1 82.3 (56.6-115.6)   Female 295 300.4 98.2 (87.3-110.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
52 
Brimfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.7 nc (nc-nc)   Male 0 2.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 2.3 nc (nc-nc) 
Female 18 17.7 101.7 (60.3-160.8)   Female 4 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.4 nc (nc-nc)             
Female 1 4.1 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 9 14.8 60.6 (27.7-115.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 2.5 281.1 (112.6-579.2)   Male 2 1.0 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.6 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 7.2 97.0 (38.9-199.9)   Male 51 55.0 92.7 (69.1-121.9) 
Female 4 7.7 nc (nc-nc)   Female 38 56.0 67.8 (48.0-93.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
53 
Brockton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 80 83.9 95.3 (75.6-118.7)   Male 24 54.8 43.8 (28.0-65.2) 
Female 36 31.8 113.2 (79.3-156.8)   Female 30 46.4 64.7 (43.7-92.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 17 17.9 94.8 (55.2-151.7)   Male 11 17.5 62.9 (31.4-112.6) 
Female 20 15.3 130.4 (79.6-201.4)   Female 18 14.6 123.5 (73.2-195.2) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.9 nc (nc-nc)   Male 48 49.5 96.9 (71.4-128.5) 
Female 317 366.7 86.5 (77.2-96.5)   Female 38 45.5 83.5 (59.1-114.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 38 41.7 91.2 (64.5-125.1) 
Female 25 13.0 191.8 (124.1-283.2)   Female 23 19.2 119.7 (75.9-179.6) 
Colon / Rectum            Ovary     
Male 113 92.8 121.7 (100.3-146.4)             
Female 96 94.3 101.8 (82.5-124.4)   Female 44 31.5 139.6 (101.4-187.4) 
Esophagus            Pancreas     
Male 21 22.1 95.2 (58.9-145.6)   Male 35 30.4 115.2 (80.2-160.2) 
Female 6 6.3 95.8 (35.0-208.5)   Female 47 32.3 145.5 (106.9-193.5) 
Hodgkin Lymphoma            Prostate     
Male 6 7.3 82.1 (30.0-178.8)   Male 260 271.1 95.9 (84.6-108.3) 
Female 7 6.3 110.5 (44.3-227.6)             
Kidney & Renal Pelvis            Stomach     
Male 60 48.7 123.2 (94.0-158.6)   Male 31 20.5 151.0 (102.6-214.3) 
Female 23 29.1 79.1 (50.1-118.7)   Female 12 12.8 94.1 (48.6-164.3) 
Larynx            Testis     
Male 18 12.9 139.9 (82.9-221.1)   Male 12 13.3 90.0 (46.5-157.3) 
Female 4 4.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 30 36.0 83.3 (56.2-118.9)   Male 26 22.9 113.6 (74.2-166.4) 
Female 17 27.3 62.4 (36.3-99.8)   Female 86 73.0 117.8 (94.2-145.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 46 30.5 151.1 (110.6-201.5)             
Female 13 10.5 123.6 (65.8-211.4)   Female 79 80.7 97.9 (77.5-122.1) 
Lung and Bronchus            All Sites / Types     
Male 177 149.3 118.5 (101.7-137.3)   Male 1161 1116.0 104.0 (98.1-110.2) 
Female 195 168.4 115.8 (100.1-133.3)   Female 1251 1227.0 102.0 (96.4-107.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
54 
Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 4.3 116.9 (37.7-272.8)   Male 1 2.8 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 14 15.3 91.6 (50.0-153.7)   Female 5 2.0 252.6 (81.4-589.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 4.5 nc (nc-nc)             
Female 5 4.1 123.2 (39.7-287.5)   Female 1 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 11 14.7 75.1 (37.4-134.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.5 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.7 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.6 nc (nc-nc)             
Female 2 0.5 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 7.9 101.5 (43.7-199.9)   Male 46 57.0 80.7 (59.0-107.6) 
Female 13 7.6 171.9 (91.5-294.0)   Female 63 52.0 121.2 (93.2-155.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
55 
Brookline 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 50 53.0 94.4 (70.0-124.4)   Male 49 34.0 144.3 (106.8-190.8) 
Female 18 23.2 77.7 (46.0-122.8)   Female 37 32.9 112.5 (79.2-155.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 10.7 84.5 (38.5-160.3)   Male 12 10.8 110.9 (57.2-193.8) 
Female 14 10.5 133.0 (72.7-223.2)   Female 8 10.5 76.4 (32.9-150.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 35 30.5 114.6 (79.8-159.4) 
Female 228 247.9 92.0 (80.4-104.7)   Female 38 32.5 117.0 (82.8-160.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 24.9 112.6 (74.8-162.8) 
Female 3 8.8 nc (nc-nc)   Female 7 13.5 51.7 (20.7-106.6) 
Colon / Rectum            Ovary     
Male 33 56.2 58.8 (40.4-82.5)             
Female 41 67.0 61.2 (43.9-83.1)   Female 32 21.9 146.3 (100.1-206.6) 
Esophagus            Pancreas     
Male 5 13.7 36.4 (11.7-85.1)   Male 23 18.9 122.0 (77.3-183.0) 
Female 2 4.6 nc (nc-nc)   Female 27 23.8 113.4 (74.7-165.0) 
Hodgkin Lymphoma            Prostate     
Male 7 4.7 150.1 (60.1-309.2)   Male 159 170.4 93.3 (79.4-109.0) 
Female 5 5.0 99.6 (32.1-232.4)             
Kidney & Renal Pelvis            Stomach     
Male 36 29.6 121.4 (85.0-168.1)   Male 11 12.7 86.3 (43.0-154.4) 
Female 15 20.1 74.8 (41.8-123.3)   Female 6 9.1 65.8 (24.0-143.3) 
Larynx            Testis     
Male 3 8.0 nc (nc-nc)   Male 11 8.9 123.3 (61.5-220.6) 
Female 2 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 30 21.7 138.1 (93.1-197.1)   Male 14 13.9 101.1 (55.2-169.6) 
Female 29 19.4 149.9 (100.3-215.2)   Female 50 50.5 99.1 (73.6-130.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 18.2 54.8 (26.2-100.8)             
Female 5 7.5 66.8 (21.5-155.8)   Female 45 55.8 80.6 (58.8-107.9) 
Lung and Bronchus            All Sites / Types     
Male 57 95.2 59.9 (45.3-77.6)   Male 629 692.6 90.8 (83.9-98.2) 
Female 77 120.4 64.0 (50.5-80.0)   Female 759 857.8 88.5 (82.3-95.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
56 
Buckland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.3 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 7 11.3 61.8 (24.8-127.4)   Female 0 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.5 nc (nc-nc)             
Female 4 2.9 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 7 7.8 90.1 (36.1-185.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.3 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 0 2.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 4.1 nc (nc-nc)   Male 25 30.5 82.1 (53.1-121.2) 
Female 8 5.7 140.9 (60.7-277.6)   Female 31 37.9 81.7 (55.5-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
57 
Burlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 31.5 63.4 (38.7-98.0)   Male 18 19.2 93.5 (55.4-147.8) 
Female 6 10.6 56.4 (20.6-122.8)   Female 13 14.1 91.9 (48.9-157.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.6 142.3 (61.3-280.5)   Male 7 6.1 114.0 (45.7-235.0) 
Female 5 4.5 110.4 (35.6-257.6)   Female 4 4.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 23 17.2 134.1 (85.0-201.2) 
Female 132 116.4 113.4 (94.9-134.5)   Female 14 14.6 96.0 (52.5-161.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 13.3 75.0 (35.9-138.0) 
Female 3 3.8 nc (nc-nc)   Female 5 6.1 81.8 (26.4-190.8) 
Colon / Rectum            Ovary     
Male 26 32.7 79.6 (52.0-116.6)             
Female 26 30.5 85.4 (55.7-125.1)   Female 8 9.9 80.8 (34.8-159.1) 
Esophagus            Pancreas     
Male 3 7.6 nc (nc-nc)   Male 18 10.8 166.8 (98.8-263.6) 
Female 0 2.1 nc (nc-nc)   Female 7 10.7 65.3 (26.2-134.6) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 89 85.5 104.0 (83.6-128.0) 
Female 2 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 15.9 106.7 (62.1-170.9)   Male 4 7.4 nc (nc-nc) 
Female 5 9.3 53.7 (17.3-125.2)   Female 3 4.1 nc (nc-nc) 
Larynx            Testis     
Male 2 4.3 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 12.3 129.6 (74.0-210.5)   Male 10 7.1 141.0 (67.5-259.4) 
Female 5 8.4 59.7 (19.2-139.3)   Female 28 20.9 134.0 (89.0-193.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 9.9 100.8 (48.3-185.4)             
Female 3 3.4 nc (nc-nc)   Female 32 25.5 125.4 (85.8-177.0) 
Lung and Bronchus            All Sites / Types     
Male 41 54.8 74.8 (53.7-101.5)   Male 366 381.0 96.1 (86.5-106.4) 
Female 55 57.2 96.2 (72.5-125.2)   Female 383 391.3 97.9 (88.3-108.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
58 
Cambridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 47 74.3 63.3 (46.5-84.1)   Male 51 50.5 101.0 (75.2-132.8) 
Female 13 29.9 43.5 (23.1-74.3)   Female 46 48.0 95.9 (70.2-127.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 25 17.9 139.6 (90.3-206.1)   Male 17 15.2 111.8 (65.1-179.0) 
Female 14 15.1 92.5 (50.5-155.2)   Female 10 13.7 72.9 (34.9-134.0) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.6 nc (nc-nc)   Male 42 45.7 91.8 (66.2-124.1) 
Female 318 339.2 93.7 (83.7-104.6)   Female 45 43.8 102.6 (74.9-137.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 42 35.9 117.0 (84.3-158.2) 
Female 7 13.6 51.6 (20.7-106.3)   Female 16 18.2 87.9 (50.2-142.7) 
Colon / Rectum            Ovary     
Male 67 81.0 82.7 (64.1-105.1)             
Female 67 87.1 76.9 (59.6-97.7)   Female 29 30.2 96.0 (64.3-137.9) 
Esophagus            Pancreas     
Male 16 19.1 83.8 (47.9-136.1)   Male 32 26.4 121.1 (82.8-171.0) 
Female 5 6.0 83.8 (27.0-195.6)   Female 25 30.4 82.4 (53.3-121.6) 
Hodgkin Lymphoma            Prostate     
Male 8 10.7 74.8 (32.2-147.4)   Male 253 231.9 109.1 (96.1-123.4) 
Female 4 9.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 31 43.0 72.1 (49.0-102.4)   Male 12 18.1 66.3 (34.2-115.8) 
Female 17 27.1 62.7 (36.5-100.4)   Female 8 11.9 67.0 (28.9-132.0) 
Larynx            Testis     
Male 4 11.0 nc (nc-nc)   Male 19 22.5 84.4 (50.8-131.8) 
Female 1 3.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 28 33.2 84.3 (56.0-121.8)   Male 27 23.6 114.4 (75.3-166.4) 
Female 16 26.4 60.5 (34.6-98.3)   Female 85 81.0 104.9 (83.8-129.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 25.5 62.8 (35.9-102.0)             
Female 10 10.0 100.0 (47.9-184.0)   Female 65 75.8 85.8 (66.2-109.3) 
Lung and Bronchus            All Sites / Types     
Male 109 131.9 82.6 (67.9-99.7)   Male 914 1001.6 91.3 (85.4-97.4) 
Female 107 157.5 67.9 (55.7-82.1)   Female 981 1170.7 83.8 (78.6-89.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
59 
Canton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 26.4 87.2 (55.2-130.8)   Male 20 16.4 122.2 (74.6-188.8) 
Female 7 9.8 71.2 (28.5-146.7)   Female 14 12.8 109.0 (59.5-182.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.8 103.7 (33.4-242.1)   Male 10 5.3 189.0 (90.5-347.5) 
Female 6 4.1 145.0 (52.9-315.5)   Female 5 4.4 113.7 (36.7-265.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 12 14.7 81.7 (42.2-142.7) 
Female 106 104.3 101.6 (83.2-122.9)   Female 17 13.4 126.9 (73.9-203.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 11.8 93.5 (46.6-167.3) 
Female 4 3.4 nc (nc-nc)   Female 8 5.6 143.4 (61.8-282.7) 
Colon / Rectum            Ovary     
Male 35 27.7 126.5 (88.1-175.9)             
Female 30 28.3 105.9 (71.4-151.2)   Female 6 8.9 67.1 (24.5-146.1) 
Esophagus            Pancreas     
Male 9 6.6 136.7 (62.4-259.5)   Male 8 9.3 86.1 (37.1-169.6) 
Female 1 1.9 nc (nc-nc)   Female 9 10.0 89.6 (40.9-170.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 85 78.3 108.5 (86.7-134.2) 
Female 1 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 14.0 64.1 (29.3-121.8)   Male 6 6.3 95.6 (34.9-208.0) 
Female 5 8.4 59.4 (19.1-138.5)   Female 3 3.8 nc (nc-nc) 
Larynx            Testis     
Male 2 3.8 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 10.4 172.4 (102.1-272.4)   Male 11 6.1 179.0 (89.2-320.3) 
Female 5 7.8 64.2 (20.7-149.8)   Female 35 18.4 190.1 (132.4-264.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 8.7 nc (nc-nc)             
Female 0 3.1 nc (nc-nc)   Female 27 22.9 118.0 (77.8-171.7) 
Lung and Bronchus            All Sites / Types     
Male 51 46.6 109.3 (81.4-143.8)   Male 357 330.0 108.2 (97.2-120.0) 
Female 52 51.5 100.9 (75.4-132.3)   Female 373 355.1 105.0 (94.6-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
60 
Carlisle 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.4 nc (nc-nc)   Male 7 4.1 169.5 (67.9-349.2) 
Female 1 2.1 nc (nc-nc)   Female 7 2.9 239.9 (96.1-494.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 21 25.2 83.2 (51.5-127.2)   Female 5 3.0 164.7 (53.1-384.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 3.3 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 7.0 nc (nc-nc)             
Female 3 6.4 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.8 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 22.6 106.4 (68.1-158.3) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.8 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.5 198.3 (63.9-462.8)   Male 3 1.6 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 5 4.2 119.8 (38.6-279.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.5 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 9 5.6 159.6 (72.8-303.0) 
Lung and Bronchus            All Sites / Types     
Male 6 12.0 49.9 (18.2-108.7)   Male 67 86.2 77.7 (60.2-98.7) 
Female 3 11.5 nc (nc-nc)   Female 73 81.9 89.2 (69.9-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
61 
Carver 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 13.6 110.0 (61.5-181.4)   Male 10 8.6 116.3 (55.7-214.0) 
Female 8 5.3 151.6 (65.3-298.7)   Female 10 7.1 141.6 (67.8-260.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.5 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 0 2.3 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 3 7.7 nc (nc-nc) 
Female 42 59.8 70.3 (50.7-95.0)   Female 12 7.4 162.4 (83.8-283.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.4 94.2 (34.4-205.1) 
Female 1 1.9 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 14.5 96.7 (52.8-162.2)             
Female 11 15.2 72.5 (36.1-129.7)   Female 3 5.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 7 3.5 199.8 (80.1-411.7)   Male 5 4.9 102.0 (32.9-238.0) 
Female 0 1.0 nc (nc-nc)   Female 1 5.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 38 43.1 88.1 (62.3-120.9) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.5 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 8 4.7 171.5 (73.9-338.0)   Female 0 2.1 nc (nc-nc) 
Larynx            Testis     
Male 1 2.0 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.4 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 5 4.1 121.1 (39.0-282.6)   Female 6 10.0 60.1 (22.0-130.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.7 nc (nc-nc)             
Female 3 1.8 nc (nc-nc)   Female 14 13.7 102.0 (55.7-171.1) 
Lung and Bronchus            All Sites / Types     
Male 33 24.2 136.4 (93.9-191.6)   Male 165 175.1 94.2 (80.4-109.8) 
Female 41 27.8 147.7 (105.9-200.3)   Female 181 197.1 91.8 (78.9-106.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
62 
Charlemont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.9 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 10 6.6 151.4 (72.5-278.4)   Female 1 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.0 nc (nc-nc)             
Female 2 1.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 5.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.4 nc (nc-nc)   Male 23 23.5 97.7 (61.9-146.6) 
Female 2 3.2 nc (nc-nc)   Female 28 22.2 126.2 (83.8-182.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
63 
Charlton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 13.0 123.4 (70.5-200.3)   Male 4 8.7 nc (nc-nc) 
Female 7 4.0 174.7 (70.0-359.9)   Female 6 6.6 90.9 (33.2-197.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.7 223.7 (81.7-486.8)   Male 2 2.8 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 11 7.8 140.8 (70.2-251.9) 
Female 53 54.1 98.0 (73.4-128.2)   Female 6 6.2 97.3 (35.5-211.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.8 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 15.0 60.0 (27.4-113.9)             
Female 15 12.7 118.4 (66.2-195.3)   Female 2 4.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.5 nc (nc-nc)   Male 7 4.8 146.5 (58.7-301.9) 
Female 0 0.8 nc (nc-nc)   Female 5 4.2 120.4 (38.8-280.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 23 42.9 53.6 (34.0-80.4) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 7.8 127.7 (61.2-235.0)   Male 1 3.2 nc (nc-nc) 
Female 3 4.0 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 3 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.5 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 3 3.5 nc (nc-nc)   Female 16 10.8 147.6 (84.3-239.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.8 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 11 12.2 90.3 (45.0-161.6) 
Lung and Bronchus            All Sites / Types     
Male 21 22.9 91.6 (56.7-140.1)   Male 140 175.3 79.9 (67.2-94.2) 
Female 25 21.1 118.5 (76.7-175.0)   Female 181 170.8 105.9 (91.1-122.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
64 
Chatham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 14.4 104.5 (58.4-172.3)   Male 21 8.0 261.2 (161.6-399.2) 
Female 10 4.7 211.4 (101.2-388.8)   Female 14 5.0 281.6 (153.8-472.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.0 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 8 7.2 111.2 (47.9-219.1) 
Female 43 42.4 101.5 (73.5-136.8)   Female 7 6.0 117.6 (47.1-242.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 5.4 128.5 (51.5-264.8) 
Female 1 1.1 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 13.8 115.6 (66.0-187.8)             
Female 14 12.6 110.9 (60.6-186.0)   Female 3 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.4 nc (nc-nc)   Male 7 4.8 145.2 (58.2-299.2) 
Female 0 0.9 nc (nc-nc)   Female 6 4.8 125.0 (45.7-272.1) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 44 39.3 111.8 (81.3-150.1) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.6 91.1 (33.3-198.3)   Male 1 3.3 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 0 2.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 5.1 178.0 (81.2-337.9)   Male 4 2.3 nc (nc-nc) 
Female 3 3.3 nc (nc-nc)   Female 2 5.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.3 nc (nc-nc)             
Female 2 1.4 nc (nc-nc)   Female 11 9.9 111.4 (55.5-199.4) 
Lung and Bronchus            All Sites / Types     
Male 22 25.1 87.6 (54.9-132.6)   Male 183 165.2 110.8 (95.3-128.1) 
Female 24 24.7 97.3 (62.3-144.8)   Female 169 151.4 111.6 (95.4-129.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
65 
Chelmsford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 51 39.6 128.7 (95.8-169.2)   Male 20 25.4 78.6 (48.0-121.4) 
Female 16 15.3 104.7 (59.8-170.0)   Female 20 20.4 98.2 (59.9-151.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 7.6 144.8 (72.2-259.1)   Male 8 8.2 97.8 (42.1-192.7) 
Female 8 6.5 123.8 (53.3-244.0)   Female 11 7.0 157.8 (78.6-282.3) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 27 22.6 119.2 (78.6-173.5) 
Female 177 170.6 103.8 (89.0-120.2)   Female 16 21.2 75.5 (43.1-122.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 19.0 110.5 (68.4-169.0) 
Female 6 5.4 110.3 (40.3-240.2)   Female 8 8.9 89.5 (38.5-176.4) 
Colon / Rectum            Ovary     
Male 40 43.1 92.7 (66.2-126.3)             
Female 44 43.9 100.2 (72.8-134.6)   Female 22 14.5 151.6 (95.0-229.5) 
Esophagus            Pancreas     
Male 6 10.2 58.7 (21.4-127.7)   Male 18 14.2 126.8 (75.1-200.4) 
Female 4 3.0 nc (nc-nc)   Female 18 15.5 116.5 (69.0-184.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.8 nc (nc-nc)   Male 126 122.8 102.6 (85.5-122.2) 
Female 3 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 22.2 85.6 (51.5-133.8)   Male 4 9.6 nc (nc-nc) 
Female 12 13.5 88.8 (45.8-155.1)   Female 4 5.9 nc (nc-nc) 
Larynx            Testis     
Male 4 6.0 nc (nc-nc)   Male 5 5.1 98.5 (31.8-229.9) 
Female 1 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 15.9 106.6 (62.1-170.7)   Male 13 10.1 128.9 (68.6-220.4) 
Female 25 11.9 210.0 (135.9-310.1)   Female 29 29.6 97.8 (65.5-140.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 14.0 57.2 (24.6-112.8)             
Female 2 5.0 nc (nc-nc)   Female 50 38.0 131.4 (97.6-173.3) 
Lung and Bronchus            All Sites / Types     
Male 64 71.0 90.1 (69.4-115.0)   Male 513 512.2 100.2 (91.7-109.2) 
Female 79 82.4 95.9 (75.9-119.5)   Female 613 567.8 108.0 (99.6-116.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
66 
Chelsea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 22.1 63.2 (34.5-106.1)   Male 8 16.4 48.9 (21.1-96.4) 
Female 10 8.5 117.0 (56.0-215.2)   Female 10 14.4 69.5 (33.3-127.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.2 112.2 (45.0-231.2)   Male 5 4.9 102.4 (33.0-238.9) 
Female 6 4.9 122.6 (44.8-266.8)   Female 4 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 13 14.9 87.2 (46.4-149.1) 
Female 96 104.1 92.2 (74.7-112.6)   Female 16 12.9 124.0 (70.8-201.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 12.4 56.5 (22.6-116.4) 
Female 7 4.5 155.5 (62.3-320.4)   Female 8 5.4 147.0 (63.3-289.7) 
Colon / Rectum            Ovary     
Male 32 27.1 118.0 (80.7-166.6)             
Female 17 26.5 64.2 (37.4-102.8)   Female 5 9.0 55.6 (17.9-129.7) 
Esophagus            Pancreas     
Male 5 6.0 83.5 (26.9-195.0)   Male 9 8.3 108.6 (49.6-206.2) 
Female 0 1.7 nc (nc-nc)   Female 15 8.8 169.6 (94.9-279.7) 
Hodgkin Lymphoma            Prostate     
Male 2 3.2 nc (nc-nc)   Male 51 72.2 70.6 (52.6-92.8) 
Female 1 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 14.8 40.6 (14.8-88.3)   Male 12 5.7 209.4 (108.1-365.8) 
Female 11 8.1 135.5 (67.5-242.4)   Female 4 3.6 nc (nc-nc) 
Larynx            Testis     
Male 4 3.5 nc (nc-nc)   Male 4 6.9 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 11.1 108.3 (55.9-189.2)   Male 7 8.5 82.4 (33.0-169.7) 
Female 11 8.3 132.5 (66.1-237.1)   Female 41 25.6 160.3 (115.0-217.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 8.4 166.1 (90.7-278.7)             
Female 9 2.9 315.0 (143.7-598.0)   Female 15 22.2 67.5 (37.8-111.3) 
Lung and Bronchus            All Sites / Types     
Male 53 39.0 135.8 (101.7-177.7)   Male 299 318.7 93.8 (83.5-105.1) 
Female 64 44.1 145.1 (111.7-185.3)   Female 381 351.3 108.5 (97.8-119.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
67 
Cheshire 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 4.7 127.6 (46.6-277.7)   Male 5 2.8 176.8 (57.0-412.7) 
Female 2 1.5 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 14 17.1 81.8 (44.7-137.2)   Female 2 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 4.8 165.6 (71.3-326.2)             
Female 2 4.3 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.2 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 17 15.5 109.6 (63.8-175.5) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 7 4.0 174.8 (70.0-360.2) 
Lung and Bronchus            All Sites / Types     
Male 14 8.4 166.8 (91.1-280.0)   Male 64 59.5 107.5 (82.8-137.3) 
Female 3 8.3 nc (nc-nc)   Female 42 56.9 73.8 (53.1-99.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.2 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 4 5.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 1.6 317.3 (102.3-740.5)             
Female 1 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 5.1 118.6 (43.3-258.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 0.9 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.4 nc (nc-nc)   Male 23 19.1 120.5 (76.4-180.8) 
Female 2 2.3 nc (nc-nc)   Female 12 18.5 64.8 (33.4-113.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chesterfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 5.8 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.5 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 5.2 95.7 (30.8-223.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 2 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.4 nc (nc-nc)   Male 17 19.1 89.1 (51.9-142.7) 
Female 1 2.3 nc (nc-nc)   Female 10 18.1 55.3 (26.5-101.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chicopee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 63 64.5 97.7 (75.1-125.0)   Male 25 40.1 62.3 (40.3-91.9) 
Female 16 23.6 67.8 (38.7-110.1)   Female 20 31.2 64.1 (39.1-99.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 12.1 90.9 (45.3-162.7)   Male 12 12.9 92.9 (48.0-162.3) 
Female 12 9.9 121.3 (62.6-211.9)   Female 8 10.6 75.6 (32.6-149.0) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.2 nc (nc-nc)   Male 30 35.9 83.6 (56.4-119.3) 
Female 253 248.9 101.7 (89.5-115.0)   Female 36 32.4 111.1 (77.8-153.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 33 29.1 113.3 (78.0-159.2) 
Female 11 8.0 137.1 (68.4-245.4)   Female 24 13.4 178.5 (114.4-265.7) 
Colon / Rectum            Ovary     
Male 97 67.7 143.3 (116.2-174.8)             
Female 62 67.7 91.6 (70.2-117.4)   Female 30 21.7 138.5 (93.4-197.7) 
Esophagus            Pancreas     
Male 16 16.2 98.6 (56.3-160.1)   Male 21 22.6 92.7 (57.4-141.7) 
Female 7 4.6 152.1 (60.9-313.4)   Female 26 23.9 108.8 (71.0-159.4) 
Hodgkin Lymphoma            Prostate     
Male 6 4.7 127.9 (46.7-278.4)   Male 115 194.7 59.1 (48.8-70.9) 
Female 1 4.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 44 34.4 128.0 (93.0-171.9)   Male 9 15.3 58.7 (26.8-111.4) 
Female 27 20.2 133.7 (88.1-194.6)   Female 9 9.2 97.9 (44.7-185.8) 
Larynx            Testis     
Male 12 9.4 127.6 (65.9-222.9)   Male 10 8.3 120.0 (57.4-220.7) 
Female 0 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 25.8 77.6 (47.4-119.8)   Male 11 15.3 71.9 (35.8-128.6) 
Female 12 18.7 64.3 (33.2-112.4)   Female 32 44.5 71.9 (49.1-101.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 21.7 46.2 (22.1-84.9)             
Female 7 7.6 92.5 (37.1-190.6)   Female 51 55.6 91.7 (68.3-120.6) 
Lung and Bronchus            All Sites / Types     
Male 139 114.1 121.9 (102.4-143.9)   Male 740 813.5 91.0 (84.5-97.8) 
Female 130 123.9 105.0 (87.7-124.6)   Female 846 852.3 99.3 (92.7-106.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chilmark 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 2 6.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 1.3 nc (nc-nc)             
Female 0 1.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.3 nc (nc-nc)   Male 19 16.3 116.7 (70.2-182.2) 
Female 2 2.8 nc (nc-nc)   Female 8 19.3 41.4 (17.8-81.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clarksburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.7 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 5 8.2 61.3 (19.7-143.0)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.7 nc (nc-nc)             
Female 3 2.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.7 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 7.7 104.0 (44.8-205.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 4.8 103.4 (33.3-241.3)   Male 30 32.7 91.8 (61.9-131.0) 
Female 5 4.1 122.1 (39.3-284.9)   Female 25 27.5 90.8 (58.8-134.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 13.4 194.1 (126.7-284.4)   Male 6 8.9 67.7 (24.7-147.5) 
Female 5 5.1 97.2 (31.3-226.8)   Female 12 7.4 161.2 (83.2-281.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.8 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 6 8.0 75.3 (27.5-163.8) 
Female 51 59.0 86.4 (64.4-113.7)   Female 8 7.4 108.5 (46.7-213.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.9 73.0 (23.5-170.2) 
Female 3 2.1 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 14.9 113.9 (66.3-182.4)             
Female 14 15.5 90.4 (49.4-151.7)   Female 5 5.1 98.0 (31.6-228.7) 
Esophagus            Pancreas     
Male 5 3.6 138.6 (44.7-323.5)   Male 3 4.9 nc (nc-nc) 
Female 4 1.0 nc (nc-nc)   Female 3 5.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 56 45.2 123.8 (93.5-160.8) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 8.0 87.2 (34.9-179.6)   Male 3 3.3 nc (nc-nc) 
Female 5 4.6 108.6 (35.0-253.5)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 3 2.1 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 5.6 159.7 (72.9-303.2)   Male 2 3.8 nc (nc-nc) 
Female 6 4.3 139.8 (51.1-304.4)   Female 11 11.4 96.7 (48.2-173.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 4.9 164.3 (70.7-323.7)             
Female 1 1.7 nc (nc-nc)   Female 13 13.2 98.3 (52.3-168.2) 
Lung and Bronchus            All Sites / Types     
Male 28 24.2 115.9 (77.0-167.5)   Male 199 181.2 109.8 (95.1-126.2) 
Female 37 26.5 139.9 (98.5-192.8)   Female 205 197.2 104.0 (90.2-119.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Cohasset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.4 85.2 (36.7-167.9)   Male 5 6.1 82.3 (26.5-192.1) 
Female 6 3.4 175.8 (64.2-382.6)   Female 15 4.4 339.0 (189.6-559.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.8 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.4 111.6 (40.8-243.0) 
Female 41 37.0 110.9 (79.6-150.4)   Female 3 4.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.6 108.4 (34.9-253.0) 
Female 0 1.2 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 10.0 119.9 (61.9-209.4)             
Female 6 9.7 61.8 (22.6-134.5)   Female 4 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.5 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 31 30.0 103.3 (70.2-146.6) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.3 94.0 (30.3-219.3)   Male 0 2.3 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.8 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 5 2.7 185.5 (59.8-432.9)   Female 7 6.3 110.8 (44.4-228.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.5 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 6 8.2 72.9 (26.6-158.8) 
Lung and Bronchus            All Sites / Types     
Male 10 17.1 58.5 (28.0-107.6)   Male 110 122.9 89.5 (73.6-107.9) 
Female 13 18.2 71.4 (38.0-122.0)   Female 131 124.4 105.3 (88.0-124.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Colrain 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.5 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 10 7.8 128.7 (61.6-236.7)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.6 nc (nc-nc)             
Female 3 2.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 5 7.5 66.5 (21.4-155.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 5 1.8 276.0 (89.0-644.1) 
Lung and Bronchus            All Sites / Types     
Male 3 4.5 nc (nc-nc)   Male 22 31.3 70.3 (44.1-106.5) 
Female 4 3.5 nc (nc-nc)   Female 31 25.6 120.9 (82.1-171.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Concord 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 26.5 113.3 (76.4-161.8)   Male 22 16.3 134.6 (84.3-203.8) 
Female 10 9.3 107.4 (51.4-197.5)   Female 25 11.3 220.5 (142.6-325.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.7 106.6 (34.4-248.8)   Male 4 5.4 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 13 14.7 88.5 (47.1-151.4) 
Female 122 94.1 129.6 (107.7-154.8)   Female 9 12.5 72.1 (32.9-136.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 12.1 82.8 (39.6-152.3) 
Female 3 2.7 nc (nc-nc)   Female 7 5.2 134.2 (53.8-276.5) 
Colon / Rectum            Ovary     
Male 19 28.3 67.2 (40.5-105.0)             
Female 35 27.1 129.4 (90.1-179.9)   Female 14 8.2 171.1 (93.4-287.0) 
Esophagus            Pancreas     
Male 2 6.7 nc (nc-nc)   Male 8 9.3 86.1 (37.1-169.7) 
Female 0 1.8 nc (nc-nc)   Female 7 9.6 73.0 (29.3-150.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.6 nc (nc-nc)   Male 87 80.1 108.6 (87.0-133.9) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 14.2 56.2 (24.2-110.8)   Male 3 6.3 nc (nc-nc) 
Female 11 7.6 144.6 (72.1-258.7)   Female 0 3.7 nc (nc-nc) 
Larynx            Testis     
Male 1 3.9 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 10.3 67.9 (27.2-139.9)   Male 5 6.2 81.2 (26.2-189.4) 
Female 4 7.1 nc (nc-nc)   Female 15 14.5 103.6 (58.0-170.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 8.9 89.5 (38.6-176.4)             
Female 4 3.0 nc (nc-nc)   Female 23 21.2 108.6 (68.8-163.0) 
Lung and Bronchus            All Sites / Types     
Male 22 46.3 47.5 (29.8-71.9)   Male 286 332.5 86.0 (76.3-96.6) 
Female 27 47.0 57.4 (37.8-83.5)   Female 357 323.7 110.3 (99.1-122.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Conway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.2 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 7 9.7 72.4 (29.0-149.2)   Female 0 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.5 nc (nc-nc)             
Female 2 2.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 8.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 4.0 nc (nc-nc)   Male 28 30.1 93.1 (61.9-134.6) 
Female 1 4.1 nc (nc-nc)   Female 21 30.3 69.3 (42.9-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Cummington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.6 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 9 5.1 177.3 (80.9-336.7)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.6 nc (nc-nc)             
Female 4 1.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.6 nc (nc-nc)   Male 14 17.7 79.0 (43.1-132.5) 
Female 1 2.5 nc (nc-nc)   Female 21 17.3 121.6 (75.2-185.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Dalton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 9.9 70.9 (28.4-146.0)   Male 10 5.9 169.6 (81.2-311.9) 
Female 4 3.6 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.3 nc (nc-nc) 
Female 26 35.6 73.0 (47.7-107.0)   Female 2 4.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 10.2 88.7 (40.5-168.3)             
Female 9 10.1 89.1 (40.6-169.1)   Female 3 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.4 nc (nc-nc)   Male 1 3.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 30 26.8 112.0 (75.5-159.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.9 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.8 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 1 5.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.1 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 10 8.0 124.9 (59.8-229.7) 
Lung and Bronchus            All Sites / Types     
Male 14 17.3 81.0 (44.2-135.9)   Male 100 118.1 84.7 (68.9-103.0) 
Female 18 18.4 97.6 (57.8-154.3)   Female 97 123.0 78.8 (63.9-96.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
80 
Danvers 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 35.4 101.6 (71.2-140.7)   Male 18 21.7 83.1 (49.2-131.3) 
Female 11 12.8 85.7 (42.7-153.4)   Female 12 16.1 74.7 (38.6-130.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 6.2 176.3 (87.9-315.5)   Male 3 7.0 nc (nc-nc) 
Female 5 5.1 97.4 (31.4-227.4)   Female 3 5.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 15 19.4 77.4 (43.3-127.7) 
Female 138 129.3 106.7 (89.6-126.1)   Female 25 17.3 144.9 (93.7-213.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 15.5 103.1 (58.9-167.4) 
Female 4 4.0 nc (nc-nc)   Female 8 7.1 112.4 (48.4-221.5) 
Colon / Rectum            Ovary     
Male 34 36.9 92.1 (63.8-128.7)             
Female 37 37.2 99.5 (70.1-137.2)   Female 13 11.3 115.5 (61.4-197.5) 
Esophagus            Pancreas     
Male 10 8.7 115.0 (55.0-211.4)   Male 12 12.4 97.1 (50.1-169.7) 
Female 3 2.4 nc (nc-nc)   Female 14 13.2 106.4 (58.1-178.5) 
Hodgkin Lymphoma            Prostate     
Male 1 2.3 nc (nc-nc)   Male 104 101.2 102.7 (83.9-124.5) 
Female 3 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 18.3 114.8 (71.0-175.5)   Male 5 8.3 59.9 (19.3-139.8) 
Female 12 10.5 114.5 (59.1-200.0)   Female 5 5.1 98.0 (31.6-228.7) 
Larynx            Testis     
Male 4 5.0 nc (nc-nc)   Male 7 3.8 183.7 (73.6-378.6) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 13.8 86.8 (44.8-151.6)   Male 11 7.9 138.4 (69.0-247.7) 
Female 15 10.0 149.6 (83.7-246.8)   Female 30 21.7 138.0 (93.1-197.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 11.5 69.7 (30.0-137.3)             
Female 3 4.1 nc (nc-nc)   Female 42 28.5 147.6 (106.3-199.5) 
Lung and Bronchus            All Sites / Types     
Male 66 61.8 106.8 (82.6-135.9)   Male 434 434.8 99.8 (90.7-109.7) 
Female 54 64.8 83.4 (62.6-108.8)   Female 479 447.9 107.0 (97.6-117.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
81 
Dartmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 57 41.2 138.3 (104.7-179.2)   Male 24 25.1 95.6 (61.2-142.3) 
Female 18 15.0 120.0 (71.1-189.7)   Female 14 19.0 73.6 (40.2-123.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 7.4 67.3 (21.7-157.0)   Male 5 8.1 61.9 (19.9-144.4) 
Female 6 6.1 98.4 (35.9-214.2)   Female 4 6.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.4 nc (nc-nc)   Male 23 22.7 101.2 (64.1-151.8) 
Female 129 151.4 85.2 (71.1-101.2)   Female 15 20.2 74.1 (41.4-122.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 18.0 94.4 (55.0-151.2) 
Female 5 4.7 106.2 (34.2-247.9)   Female 10 8.5 117.9 (56.5-216.9) 
Colon / Rectum            Ovary     
Male 39 43.2 90.2 (64.1-123.3)             
Female 50 43.7 114.4 (84.9-150.8)   Female 8 13.3 60.0 (25.8-118.2) 
Esophagus            Pancreas     
Male 11 10.1 109.0 (54.4-195.1)   Male 13 14.2 91.2 (48.5-156.0) 
Female 2 2.9 nc (nc-nc)   Female 8 15.7 51.1 (22.0-100.7) 
Hodgkin Lymphoma            Prostate     
Male 2 3.2 nc (nc-nc)   Male 142 118.4 119.9 (101.0-141.3) 
Female 2 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 21.2 99.1 (61.3-151.5)   Male 15 9.7 155.1 (86.8-255.9) 
Female 18 12.2 147.1 (87.1-232.5)   Female 11 6.0 183.9 (91.7-329.0) 
Larynx            Testis     
Male 7 5.7 122.0 (48.9-251.3)   Male 6 5.5 109.6 (40.0-238.5) 
Female 1 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 16.2 86.2 (47.1-144.6)   Male 7 9.4 74.2 (29.7-152.9) 
Female 8 11.7 68.3 (29.4-134.6)   Female 33 26.0 126.9 (87.3-178.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 13.3 90.4 (46.7-158.0)             
Female 1 4.7 nc (nc-nc)   Female 32 33.9 94.3 (64.5-133.1) 
Lung and Bronchus            All Sites / Types     
Male 71 71.1 99.9 (78.0-126.0)   Male 517 507.9 101.8 (93.2-111.0) 
Female 42 75.5 55.6 (40.1-75.2)   Female 450 526.7 85.4 (77.7-93.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
82 
Dedham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 30.5 95.0 (63.6-136.4)   Male 24 18.6 128.9 (82.6-191.8) 
Female 12 12.7 94.2 (48.6-164.6)   Female 19 15.5 122.4 (73.6-191.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.5 145.7 (62.7-287.0)   Male 9 6.0 149.0 (68.0-283.0) 
Female 5 4.9 102.4 (33.0-239.1)   Female 2 5.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 23 16.9 136.1 (86.3-204.3) 
Female 155 123.4 125.7 (106.6-147.1)   Female 16 16.9 94.9 (54.2-154.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 13.1 122.5 (69.9-198.9) 
Female 3 3.8 nc (nc-nc)   Female 12 6.9 173.8 (89.7-303.7) 
Colon / Rectum            Ovary     
Male 31 32.0 96.8 (65.8-137.4)             
Female 28 36.9 75.9 (50.4-109.6)   Female 9 10.8 83.2 (38.0-158.0) 
Esophagus            Pancreas     
Male 4 7.4 nc (nc-nc)   Male 14 10.5 132.7 (72.5-222.7) 
Female 3 2.4 nc (nc-nc)   Female 18 13.0 138.0 (81.7-218.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.1 nc (nc-nc)   Male 89 85.6 104.0 (83.5-128.0) 
Female 5 1.7 288.0 (92.8-672.0)             
Kidney & Renal Pelvis            Stomach     
Male 20 15.8 126.8 (77.4-195.9)   Male 6 7.2 83.4 (30.5-181.6) 
Female 11 10.1 108.5 (54.1-194.2)   Female 8 5.1 157.9 (68.0-311.1) 
Larynx            Testis     
Male 4 4.2 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 12.1 99.4 (51.3-173.6)   Male 6 7.1 84.8 (31.0-184.7) 
Female 9 9.8 91.6 (41.8-174.0)   Female 29 20.6 140.7 (94.2-202.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 9.5 115.4 (57.5-206.5)             
Female 6 3.9 152.5 (55.7-331.9)   Female 27 26.8 100.8 (66.4-146.7) 
Lung and Bronchus            All Sites / Types     
Male 52 52.4 99.2 (74.1-130.1)   Male 405 373.1 108.6 (98.2-119.7) 
Female 79 63.8 123.9 (98.1-154.4)   Female 486 434.2 111.9 (102.2-122.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
83 
Deerfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.3 nc (nc-nc)   Male 5 3.2 157.6 (50.8-367.8) 
Female 4 2.2 nc (nc-nc)   Female 6 3.1 195.0 (71.2-424.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 21 25.5 82.2 (50.9-125.7)   Female 2 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.4 111.7 (40.8-243.1)             
Female 6 6.3 94.6 (34.6-206.0)   Female 1 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.3 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 14 16.8 83.6 (45.6-140.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.0 164.4 (53.0-383.7)   Male 0 1.1 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.9 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 8 5.7 139.4 (60.0-274.7) 
Lung and Bronchus            All Sites / Types     
Male 3 8.1 nc (nc-nc)   Male 55 64.5 85.3 (64.3-111.1) 
Female 7 11.7 60.0 (24.0-123.6)   Female 72 83.6 86.1 (67.4-108.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
84 
Dennis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 50 29.3 170.6 (126.6-224.9)   Male 36 16.2 222.3 (155.7-307.8) 
Female 15 10.9 137.4 (76.8-226.6)   Female 22 11.7 187.4 (117.4-283.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.2 nc (nc-nc)   Male 11 5.4 202.2 (100.8-361.8) 
Female 2 3.7 nc (nc-nc)   Female 1 4.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 14 14.4 97.0 (53.0-162.7) 
Female 109 100.6 108.3 (89.0-130.7)   Female 11 13.8 79.5 (39.6-142.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 10.5 151.8 (86.7-246.5) 
Female 2 2.6 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 27.4 91.2 (59.0-134.7)             
Female 26 28.6 91.0 (59.4-133.3)   Female 15 8.8 170.6 (95.4-281.4) 
Esophagus            Pancreas     
Male 14 6.8 206.5 (112.8-346.5)   Male 12 9.7 123.9 (64.0-216.5) 
Female 4 2.1 nc (nc-nc)   Female 13 10.8 120.0 (63.8-205.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.2 nc (nc-nc)   Male 100 78.8 126.9 (103.2-154.3) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 13.1 61.3 (26.4-120.8)   Male 2 6.6 nc (nc-nc) 
Female 5 8.6 58.1 (18.7-135.6)   Female 2 3.9 nc (nc-nc) 
Larynx            Testis     
Male 3 3.9 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 10.3 116.0 (59.9-202.6)   Male 2 4.6 nc (nc-nc) 
Female 6 7.6 79.3 (29.0-172.6)   Female 15 13.4 111.8 (62.5-184.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 8.3 96.6 (41.6-190.3)             
Female 2 3.4 nc (nc-nc)   Female 17 23.4 72.7 (42.3-116.3) 
Lung and Bronchus            All Sites / Types     
Male 45 51.7 87.1 (63.5-116.5)   Male 396 332.8 119.0 (107.6-131.3) 
Female 58 58.6 98.9 (75.1-127.9)   Female 363 355.1 102.2 (92.0-113.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
85 
Dighton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 8.8 113.9 (54.5-209.4)   Male 7 5.5 128.1 (51.3-263.9) 
Female 1 2.5 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.8 103.2 (33.2-240.7) 
Female 19 28.2 67.3 (40.5-105.0)   Female 3 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.0 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 9.4 137.8 (73.3-235.7)             
Female 5 7.5 66.7 (21.5-155.7)   Female 3 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 22 25.4 86.7 (54.3-131.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.6 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 5 2.3 220.7 (71.1-515.1)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.5 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.0 nc (nc-nc)             
Female 2 0.8 nc (nc-nc)   Female 7 6.2 113.4 (45.4-233.6) 
Lung and Bronchus            All Sites / Types     
Male 8 15.4 51.9 (22.4-102.3)   Male 102 109.6 93.1 (75.9-113.0) 
Female 14 13.4 104.3 (57.0-175.1)   Female 79 95.2 83.0 (65.7-103.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
86 
Douglas 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.7 90.3 (36.2-186.1)   Male 9 5.4 166.2 (75.8-315.5) 
Female 5 2.0 248.5 (80.1-580.0)   Female 3 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 4 4.9 nc (nc-nc) 
Female 33 31.3 105.4 (72.6-148.1)   Female 1 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.3 116.3 (37.5-271.5) 
Female 0 1.2 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.0 66.8 (24.4-145.5)             
Female 8 6.3 126.7 (54.6-249.7)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.2 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 24 27.4 87.4 (56.0-130.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 4.9 182.6 (83.3-346.7)   Male 2 2.0 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.4 nc (nc-nc)   Male 5 2.4 208.5 (67.2-486.5) 
Female 3 1.9 nc (nc-nc)   Female 8 6.6 121.4 (52.3-239.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.2 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 9 7.1 126.4 (57.7-240.0) 
Lung and Bronchus            All Sites / Types     
Male 14 14.4 96.9 (52.9-162.6)   Male 111 109.7 101.2 (83.2-121.8) 
Female 14 11.7 119.3 (65.1-200.1)   Female 105 95.0 110.6 (90.4-133.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
87 
Dover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 7.7 nc (nc-nc)   Male 11 5.4 203.1 (101.3-363.5) 
Female 0 2.0 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 7 4.9 144.0 (57.7-296.7) 
Female 28 25.6 109.2 (72.5-157.8)   Female 3 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.3 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.0 78.0 (31.2-160.7)             
Female 3 6.0 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 23 27.4 83.8 (53.1-125.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.9 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.4 nc (nc-nc)   Male 5 2.4 208.5 (67.2-486.5) 
Female 0 1.6 nc (nc-nc)   Female 5 4.5 111.8 (36.0-261.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.2 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 3 5.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 9 14.4 62.3 (28.4-118.3)   Male 91 109.7 82.9 (66.8-101.8) 
Female 7 11.3 62.1 (24.9-127.9)   Female 66 81.4 81.0 (62.7-103.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
88 
Dracut 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 29.8 134.3 (95.9-182.8)   Male 13 19.9 65.4 (34.8-111.8) 
Female 20 10.5 190.5 (116.3-294.2)   Female 15 15.7 95.8 (53.6-158.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 6.4 125.2 (53.9-246.8)   Male 7 6.3 111.0 (44.5-228.8) 
Female 5 5.0 100.1 (32.3-233.7)   Female 3 4.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 14 17.7 79.2 (43.2-132.8) 
Female 135 126.9 106.4 (89.2-125.9)   Female 14 15.2 91.9 (50.2-154.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 15.6 64.2 (30.8-118.1) 
Female 6 4.4 135.5 (49.5-295.0)   Female 10 6.5 154.1 (73.8-283.4) 
Colon / Rectum            Ovary     
Male 40 33.1 120.8 (86.3-164.4)             
Female 44 30.9 142.2 (103.3-191.0)   Female 11 10.8 102.1 (50.9-182.7) 
Esophagus            Pancreas     
Male 13 8.1 159.6 (84.9-272.9)   Male 9 10.9 82.3 (37.5-156.2) 
Female 5 2.1 239.3 (77.1-558.4)   Female 14 10.5 133.0 (72.6-223.1) 
Hodgkin Lymphoma            Prostate     
Male 0 2.5 nc (nc-nc)   Male 96 103.1 93.1 (75.4-113.7) 
Female 2 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 18.0 116.5 (72.1-178.1)   Male 11 7.4 149.5 (74.5-267.6) 
Female 14 9.9 141.3 (77.2-237.1)   Female 5 4.2 119.2 (38.4-278.2) 
Larynx            Testis     
Male 8 4.8 167.7 (72.2-330.5)   Male 5 4.7 107.5 (34.6-250.9) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 12.7 142.0 (84.1-224.4)   Male 5 8.4 59.8 (19.3-139.5) 
Female 9 8.8 102.1 (46.6-193.9)   Female 23 24.6 93.5 (59.2-140.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 11.3 88.2 (42.2-162.2)             
Female 5 3.6 139.0 (44.8-324.5)   Female 21 28.4 73.9 (45.7-113.0) 
Lung and Bronchus            All Sites / Types     
Male 64 54.8 116.7 (89.9-149.0)   Male 441 407.9 108.1 (98.3-118.7) 
Female 73 56.8 128.6 (100.8-161.7)   Female 480 415.0 115.7 (105.5-126.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
89 
Dudley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.1 99.3 (49.5-177.7)   Male 6 7.2 83.0 (30.3-180.8) 
Female 4 3.1 nc (nc-nc)   Female 5 5.0 100.3 (32.3-234.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.3 nc (nc-nc)   Male 4 2.3 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 4 6.6 nc (nc-nc) 
Female 45 40.7 110.6 (80.7-148.0)   Female 5 4.7 106.3 (34.3-248.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.2 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 12.0 108.6 (57.8-185.8)             
Female 11 9.5 115.6 (57.6-206.9)   Female 4 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.8 nc (nc-nc)   Male 5 4.0 126.3 (40.7-294.7) 
Female 3 0.6 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 34 33.0 102.9 (71.2-143.8) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 6.2 177.3 (88.4-317.2)   Male 5 2.7 185.1 (59.6-431.9) 
Female 4 3.1 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 4.7 212.9 (101.9-391.6)   Male 1 3.0 nc (nc-nc) 
Female 5 2.7 181.9 (58.6-424.4)   Female 11 8.3 132.2 (65.9-236.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.8 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 17 9.0 188.6 (109.8-302.0) 
Lung and Bronchus            All Sites / Types     
Male 25 19.7 126.7 (82.0-187.0)   Male 155 143.7 107.9 (91.6-126.3) 
Female 24 17.0 141.2 (90.4-210.1)   Female 167 130.5 128.0 (109.3-148.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
90 
Dunstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.1 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.7 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 15 15.1 99.4 (55.6-164.0)   Female 2 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.7 nc (nc-nc)             
Female 0 3.5 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 11.9 84.0 (40.2-154.5) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 3 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.4 147.8 (47.6-345.0) 
Lung and Bronchus            All Sites / Types     
Male 2 5.9 nc (nc-nc)   Male 41 45.1 90.9 (65.2-123.3) 
Female 9 6.0 151.3 (69.0-287.2)   Female 45 47.3 95.1 (69.4-127.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
91 
Duxbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 18.6 140.0 (91.4-205.1)   Male 30 11.5 260.2 (175.5-371.5) 
Female 2 6.3 nc (nc-nc)   Female 13 8.6 151.6 (80.6-259.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.5 144.6 (46.6-337.5)   Male 9 3.9 233.8 (106.7-443.8) 
Female 1 2.8 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 18 10.5 172.1 (101.9-272.0) 
Female 86 72.7 118.3 (94.6-146.1)   Female 6 8.9 67.6 (24.7-147.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.8 56.7 (18.3-132.3) 
Female 1 2.2 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 20.0 49.9 (23.9-91.7)             
Female 11 18.9 58.3 (29.1-104.4)   Female 8 6.2 129.7 (55.8-255.5) 
Esophagus            Pancreas     
Male 4 4.8 nc (nc-nc)   Male 5 6.6 75.4 (24.3-176.1) 
Female 1 1.2 nc (nc-nc)   Female 7 6.5 107.8 (43.2-222.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 81 59.6 135.9 (107.9-168.9) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 10.4 144.9 (81.1-239.0)   Male 1 4.5 nc (nc-nc) 
Female 2 5.6 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.4 94.3 (37.8-194.2)   Male 2 4.3 nc (nc-nc) 
Female 6 5.0 119.0 (43.5-259.1)   Female 8 12.4 64.6 (27.8-127.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.5 nc (nc-nc)             
Female 0 2.1 nc (nc-nc)   Female 9 16.1 55.9 (25.5-106.0) 
Lung and Bronchus            All Sites / Types     
Male 26 32.9 78.9 (51.5-115.7)   Male 266 239.1 111.3 (98.3-125.5) 
Female 21 33.0 63.7 (39.4-97.3)   Female 212 238.6 88.9 (77.3-101.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
92 
East Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 13.5 103.4 (56.5-173.5)   Male 12 9.0 132.6 (68.4-231.6) 
Female 3 5.9 nc (nc-nc)   Female 9 8.1 111.5 (50.9-211.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.8 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 8.1 123.2 (59.0-226.5) 
Female 45 67.6 66.6 (48.6-89.1)   Female 11 8.3 132.7 (66.2-237.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 7.0 128.9 (58.8-244.6) 
Female 1 2.2 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 15.2 138.3 (85.6-211.4)             
Female 10 17.0 58.8 (28.1-108.1)   Female 7 5.8 121.7 (48.8-250.8) 
Esophagus            Pancreas     
Male 5 3.6 137.3 (44.2-320.3)   Male 3 5.0 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 7 6.0 116.8 (46.8-240.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 50 45.1 110.8 (82.3-146.1) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 8.2 158.6 (84.3-271.2)   Male 1 3.4 nc (nc-nc) 
Female 5 5.3 93.8 (30.2-218.9)   Female 2 2.3 nc (nc-nc) 
Larynx            Testis     
Male 3 2.1 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.7 nc (nc-nc)   Male 2 3.9 nc (nc-nc) 
Female 4 4.7 nc (nc-nc)   Female 11 11.9 92.3 (46.0-165.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.0 100.4 (32.4-234.4)             
Female 1 1.9 nc (nc-nc)   Female 11 15.3 71.8 (35.8-128.5) 
Lung and Bronchus            All Sites / Types     
Male 26 24.9 104.4 (68.2-153.0)   Male 198 183.4 108.0 (93.5-124.1) 
Female 26 32.0 81.3 (53.1-119.1)   Female 178 223.6 79.6 (68.4-92.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
93 
East Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.9 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 5 10.6 47.2 (15.2-110.2)   Female 0 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.0 nc (nc-nc)             
Female 0 2.4 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 9.0 111.2 (53.2-204.5) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 4.9 nc (nc-nc)   Male 34 36.2 94.0 (65.1-131.4) 
Female 6 4.6 131.5 (48.0-286.2)   Female 25 33.7 74.3 (48.0-109.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
94 
East Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 20.8 77.0 (44.0-125.0)   Male 18 12.6 143.3 (84.9-226.5) 
Female 5 8.4 59.5 (19.2-138.9)   Female 9 10.2 88.5 (40.4-168.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.6 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 10 11.3 88.2 (42.2-162.2) 
Female 83 81.7 101.6 (80.9-125.9)   Female 7 11.2 62.5 (25.0-128.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.1 87.6 (37.7-172.6) 
Female 0 2.5 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 21.8 110.0 (70.4-163.6)             
Female 32 24.3 131.5 (89.9-185.6)   Female 14 7.2 194.6 (106.3-326.6) 
Esophagus            Pancreas     
Male 4 5.2 nc (nc-nc)   Male 6 7.2 83.0 (30.3-180.6) 
Female 1 1.6 nc (nc-nc)   Female 10 8.6 116.2 (55.6-213.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 51 61.6 82.8 (61.7-108.9) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 10.8 139.1 (77.8-229.4)   Male 6 4.9 122.6 (44.8-266.9) 
Female 5 6.7 74.5 (24.0-173.7)   Female 6 3.4 178.9 (65.3-389.5) 
Larynx            Testis     
Male 2 3.0 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 8.0 62.4 (20.1-145.7)   Male 3 4.6 nc (nc-nc) 
Female 2 6.5 nc (nc-nc)   Female 12 13.3 90.6 (46.7-158.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 6.7 nc (nc-nc)             
Female 1 2.6 nc (nc-nc)   Female 17 18.1 94.1 (54.8-150.7) 
Lung and Bronchus            All Sites / Types     
Male 37 36.1 102.5 (72.2-141.3)   Male 234 256.5 91.2 (79.9-103.7) 
Female 52 42.3 123.0 (91.9-161.3)   Female 290 287.1 101.0 (89.7-113.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Eastham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.2 98.0 (48.9-175.4)   Male 7 6.3 111.9 (44.8-230.5) 
Female 2 3.5 nc (nc-nc)   Female 12 4.0 300.8 (155.2-525.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.6 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 5.5 90.3 (29.1-210.6) 
Female 52 34.2 152.2 (113.6-199.6)   Female 4 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.4 135.5 (49.5-294.8) 
Female 1 0.9 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 10.8 92.8 (44.4-170.7)             
Female 11 9.4 117.1 (58.4-209.6)   Female 3 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.7 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 5 3.5 142.3 (45.8-332.0) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 40 33.1 120.8 (86.3-164.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.3 114.2 (41.7-248.7)   Male 0 2.5 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 4.0 201.3 (86.7-396.7)   Male 2 1.8 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 3 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.4 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 4 8.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 23 19.6 117.1 (74.2-175.7)   Male 149 131.6 113.3 (95.8-133.0) 
Female 12 18.8 63.8 (32.9-111.4)   Female 133 118.3 112.4 (94.1-133.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Easthampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 17.9 72.7 (38.7-124.3)   Male 8 11.9 67.4 (29.0-132.7) 
Female 3 7.2 nc (nc-nc)   Female 7 9.8 71.6 (28.7-147.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.6 140.4 (45.2-327.6)   Male 3 3.8 nc (nc-nc) 
Female 1 3.0 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 13 10.5 123.2 (65.6-210.8) 
Female 76 77.8 97.7 (77.0-122.3)   Female 9 10.0 90.1 (41.1-171.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 9.2 119.5 (59.6-213.9) 
Female 1 2.6 nc (nc-nc)   Female 5 4.2 119.4 (38.5-278.7) 
Colon / Rectum            Ovary     
Male 29 19.9 145.4 (97.4-208.8)             
Female 22 21.1 104.4 (65.4-158.1)   Female 1 6.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 4.8 nc (nc-nc)   Male 4 6.6 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 11 7.2 151.9 (75.7-271.8) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 49 60.2 81.4 (60.2-107.7) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.6 94.4 (45.2-173.6)   Male 5 4.4 112.6 (36.3-262.8) 
Female 8 6.2 128.7 (55.4-253.6)   Female 2 2.8 nc (nc-nc) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 7.3 nc (nc-nc)   Male 0 4.9 nc (nc-nc) 
Female 3 5.6 nc (nc-nc)   Female 7 14.3 48.9 (19.6-100.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.7 nc (nc-nc)             
Female 4 2.4 nc (nc-nc)   Female 19 17.4 109.2 (65.7-170.5) 
Lung and Bronchus            All Sites / Types     
Male 29 32.6 89.1 (59.6-127.9)   Male 203 241.0 84.2 (73.0-96.6) 
Female 35 37.4 93.6 (65.2-130.1)   Female 238 263.9 90.2 (79.1-102.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Easton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 21.0 128.3 (84.5-186.7)   Male 20 14.3 140.0 (85.5-216.3) 
Female 11 7.0 156.8 (78.2-280.6)   Female 14 10.9 128.3 (70.1-215.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.7 128.3 (46.9-279.3)   Male 4 4.6 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 5 3.3 150.8 (48.6-351.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 12 12.9 93.2 (48.1-162.8) 
Female 110 88.9 123.8 (101.7-149.2)   Female 9 10.5 85.9 (39.2-163.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 11.4 79.0 (36.0-150.0) 
Female 2 3.1 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 23.9 50.1 (25.9-87.6)             
Female 30 20.9 143.6 (96.9-205.1)   Female 9 7.5 119.8 (54.7-227.4) 
Esophagus            Pancreas     
Male 3 5.9 nc (nc-nc)   Male 12 7.8 153.4 (79.2-267.9) 
Female 3 1.4 nc (nc-nc)   Female 8 7.1 113.5 (48.9-223.6) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 87 74.9 116.1 (93.0-143.3) 
Female 0 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 13.2 98.4 (52.4-168.4)   Male 4 5.3 nc (nc-nc) 
Female 4 6.8 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Larynx            Testis     
Male 2 3.5 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 9.1 164.2 (91.9-270.9)   Male 10 6.2 160.7 (76.9-295.5) 
Female 4 6.1 nc (nc-nc)   Female 19 17.8 107.0 (64.4-167.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 8.2 158.6 (84.3-271.2)             
Female 4 2.5 nc (nc-nc)   Female 17 19.9 85.4 (49.7-136.7) 
Lung and Bronchus            All Sites / Types     
Male 40 39.1 102.4 (73.1-139.4)   Male 317 294.6 107.6 (96.1-120.1) 
Female 49 38.1 128.7 (95.2-170.2)   Female 339 287.0 118.1 (105.9-131.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Edgartown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.0 100.6 (40.3-207.4)   Male 17 4.5 378.0 (220.1-605.3) 
Female 1 1.6 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.3 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 24 17.7 135.9 (87.0-202.2)   Female 3 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 7.6 132.2 (63.3-243.1)             
Female 4 4.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.0 nc (nc-nc)   Male 0 2.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 24 25.5 94.1 (60.3-140.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 4.2 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.8 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 6 3.0 197.8 (72.2-430.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.7 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 0 4.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 12.6 79.5 (38.0-146.2)   Male 91 95.0 95.8 (77.1-117.6) 
Female 10 8.2 121.2 (58.0-222.9)   Female 64 58.6 109.1 (84.0-139.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Egremont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.5 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 6 7.2 83.4 (30.5-181.6)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 2.5 202.0 (65.1-471.4)             
Female 0 2.1 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 7.8 77.0 (28.1-167.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.2 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 4.4 nc (nc-nc)   Male 23 30.4 75.7 (48.0-113.6) 
Female 3 3.9 nc (nc-nc)   Female 22 25.3 86.9 (54.4-131.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Erving 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.8 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 6 7.7 77.6 (28.4-169.0)   Female 2 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.0 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 1 6.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 3.3 nc (nc-nc)   Male 15 24.7 60.8 (34.0-100.3) 
Female 3 3.5 nc (nc-nc)   Female 21 25.6 81.9 (50.7-125.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Essex 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 4.5 155.3 (62.2-320.0)   Male 8 2.9 276.8 (119.2-545.4) 
Female 1 1.3 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.8 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 3 0.6 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 13 16.5 78.7 (41.8-134.5)   Female 2 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 2.2 222.3 (71.6-518.8) 
Female 0 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 4.9 nc (nc-nc)             
Female 3 3.8 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.2 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 8 15.3 52.4 (22.5-103.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.6 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 1 3.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 8.2 134.8 (67.2-241.2)   Male 62 59.9 103.6 (79.4-132.8) 
Female 8 7.1 112.7 (48.5-222.0)   Female 49 52.6 93.2 (69.0-123.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Everett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 36.5 90.3 (62.2-126.8)   Male 18 24.4 73.6 (43.6-116.4) 
Female 12 13.2 90.8 (46.9-158.6)   Female 7 20.5 34.1 (13.7-70.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 8.1 nc (nc-nc)   Male 9 7.6 118.3 (54.0-224.6) 
Female 2 6.5 nc (nc-nc)   Female 2 6.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 17 21.9 77.8 (45.3-124.5) 
Female 139 157.3 88.4 (74.3-104.3)   Female 19 19.3 98.2 (59.1-153.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 17.9 111.4 (68.0-172.1) 
Female 16 6.1 264.3 (151.0-429.3)   Female 10 8.1 123.4 (59.1-226.9) 
Colon / Rectum            Ovary     
Male 39 40.6 96.0 (68.2-131.2)             
Female 30 40.9 73.3 (49.4-104.6)   Female 11 13.4 82.1 (40.9-147.0) 
Esophagus            Pancreas     
Male 14 9.4 148.6 (81.1-249.3)   Male 9 13.0 69.0 (31.5-131.1) 
Female 1 2.5 nc (nc-nc)   Female 15 13.5 110.9 (62.0-182.9) 
Hodgkin Lymphoma            Prostate     
Male 1 3.7 nc (nc-nc)   Male 97 110.9 87.4 (70.9-106.7) 
Female 3 2.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 28 21.3 131.4 (87.3-189.9)   Male 17 9.0 189.6 (110.4-303.5) 
Female 17 12.2 139.6 (81.3-223.5)   Female 6 5.6 108.1 (39.5-235.3) 
Larynx            Testis     
Male 6 5.5 109.0 (39.8-237.3)   Male 5 7.3 68.9 (22.2-160.7) 
Female 2 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 15.9 94.5 (52.8-155.9)   Male 12 10.7 112.5 (58.1-196.6) 
Female 11 11.6 94.9 (47.3-169.8)   Female 27 33.8 79.8 (52.6-116.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 20 12.9 155.0 (94.6-239.4)             
Female 6 4.4 137.9 (50.4-300.2)   Female 27 33.2 81.4 (53.7-118.5) 
Lung and Bronchus            All Sites / Types     
Male 71 65.8 107.8 (84.2-136.0)   Male 467 483.4 96.6 (88.0-105.8) 
Female 84 68.4 122.8 (98.0-152.1)   Female 485 523.1 92.7 (84.6-101.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
103 
Fairhaven 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 21.1 108.9 (69.0-163.4)   Male 5 13.0 38.5 (12.4-89.9) 
Female 18 8.6 209.4 (124.1-331.0)   Female 7 10.6 65.9 (26.4-135.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.7 nc (nc-nc)   Male 5 4.2 118.3 (38.1-276.2) 
Female 4 3.3 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 9 11.6 77.3 (35.3-146.7) 
Female 79 84.6 93.4 (73.9-116.4)   Female 15 11.5 131.0 (73.2-216.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 9.7 72.4 (29.0-149.1) 
Female 3 2.6 nc (nc-nc)   Female 2 4.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 22.3 44.9 (21.5-82.5)             
Female 19 24.9 76.4 (46.0-119.4)   Female 14 7.5 187.3 (102.3-314.3) 
Esophagus            Pancreas     
Male 3 5.4 nc (nc-nc)   Male 6 7.5 80.4 (29.3-174.9) 
Female 2 1.6 nc (nc-nc)   Female 9 8.9 101.5 (46.3-192.8) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 60 66.7 90.0 (68.6-115.8) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 11.3 149.9 (87.3-240.1)   Male 5 5.0 99.9 (32.2-233.1) 
Female 8 7.0 115.0 (49.5-226.7)   Female 3 3.4 nc (nc-nc) 
Larynx            Testis     
Male 4 3.1 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.1 85.9 (34.4-177.0)   Male 2 4.8 nc (nc-nc) 
Female 11 6.6 165.7 (82.6-296.5)   Female 12 14.0 85.6 (44.2-149.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 7.1 nc (nc-nc)             
Female 1 2.7 nc (nc-nc)   Female 19 19.0 99.8 (60.0-155.8) 
Lung and Bronchus            All Sites / Types     
Male 42 37.1 113.1 (81.5-152.9)   Male 236 267.2 88.3 (77.4-100.3) 
Female 39 43.3 90.0 (64.0-123.1)   Female 289 296.5 97.5 (86.6-109.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
104 
Fall River 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 101 85.8 117.7 (95.9-143.0)   Male 31 55.2 56.2 (38.2-79.8) 
Female 39 37.8 103.2 (73.4-141.0)   Female 25 50.3 49.7 (32.1-73.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 18 17.3 103.8 (61.5-164.1)   Male 12 17.5 68.5 (35.3-119.6) 
Female 10 16.1 62.2 (29.8-114.4)   Female 16 16.9 94.4 (53.9-153.3) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.0 nc (nc-nc)   Male 42 49.7 84.5 (60.9-114.2) 
Female 328 395.2 83.0 (74.3-92.5)   Female 49 52.0 94.2 (69.7-124.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 41 40.9 100.3 (71.9-136.0) 
Female 17 13.2 128.4 (74.7-205.5)   Female 18 21.6 83.5 (49.4-131.9) 
Colon / Rectum            Ovary     
Male 109 93.2 117.0 (96.0-141.1)             
Female 112 110.6 101.3 (83.4-121.9)   Female 16 34.5 46.4 (26.5-75.3) 
Esophagus            Pancreas     
Male 21 22.1 95.2 (58.9-145.5)   Male 30 30.7 97.8 (66.0-139.7) 
Female 4 7.3 nc (nc-nc)   Female 49 38.7 126.7 (93.7-167.5) 
Hodgkin Lymphoma            Prostate     
Male 10 7.3 137.0 (65.6-252.0)   Male 291 269.6 107.9 (95.9-121.1) 
Female 7 6.4 108.9 (43.6-224.3)             
Kidney & Renal Pelvis            Stomach     
Male 50 48.3 103.5 (76.8-136.4)   Male 30 20.7 144.6 (97.5-206.5) 
Female 32 31.9 100.2 (68.5-141.5)   Female 26 15.1 172.4 (112.6-252.7) 
Larynx            Testis     
Male 20 12.8 156.3 (95.4-241.4)   Male 10 13.6 73.4 (35.1-134.9) 
Female 8 4.5 176.8 (76.1-348.4)             
Leukemia            Thyroid     
Male 40 35.6 112.4 (80.3-153.1)   Male 15 22.6 66.5 (37.2-109.7) 
Female 35 30.5 114.8 (79.9-159.6)   Female 81 73.2 110.7 (87.9-137.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 31 29.6 104.7 (71.1-148.6)             
Female 14 12.0 116.8 (63.8-195.9)   Female 95 86.8 109.4 (88.5-133.8) 
Lung and Bronchus            All Sites / Types     
Male 236 152.5 154.8 (135.7-175.9)   Male 1233 1117.9 110.3 (104.2-116.6) 
Female 211 194.5 108.5 (94.3-124.2)   Female 1313 1363.3 96.3 (91.2-101.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Falmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 56.6 93.7 (70.2-122.5)   Male 33 32.2 102.5 (70.5-143.9) 
Female 13 20.5 63.4 (33.7-108.4)   Female 36 23.4 154.0 (107.9-213.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 8.6 163.0 (89.0-273.5)   Male 6 10.7 56.2 (20.5-122.4) 
Female 9 7.4 122.3 (55.8-232.2)   Female 8 9.0 88.9 (38.3-175.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.8 nc (nc-nc)   Male 35 28.8 121.6 (84.7-169.1) 
Female 208 196.3 106.0 (92.0-121.4)   Female 18 26.7 67.5 (40.0-106.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 22.1 131.3 (87.9-188.6) 
Female 3 5.4 nc (nc-nc)   Female 9 11.0 82.0 (37.4-155.6) 
Colon / Rectum            Ovary     
Male 43 55.2 77.9 (56.4-105.0)             
Female 53 56.2 94.3 (70.6-123.4)   Female 20 17.2 116.4 (71.1-179.8) 
Esophagus            Pancreas     
Male 12 13.4 89.3 (46.1-156.0)   Male 12 19.1 62.9 (32.5-109.8) 
Female 6 4.0 150.0 (54.8-326.4)   Female 13 20.8 62.6 (33.3-107.0) 
Hodgkin Lymphoma            Prostate     
Male 2 2.7 nc (nc-nc)   Male 169 159.0 106.3 (90.9-123.6) 
Female 1 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 32 26.6 120.1 (82.1-169.6)   Male 12 12.9 93.2 (48.1-162.9) 
Female 16 16.4 97.4 (55.6-158.2)   Female 5 7.6 65.6 (21.2-153.2) 
Larynx            Testis     
Male 12 7.7 155.7 (80.3-272.0)   Male 4 3.7 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 20.5 107.2 (67.2-162.3)   Male 7 9.9 70.5 (28.3-145.3) 
Female 8 14.8 54.0 (23.2-106.3)   Female 14 28.3 49.5 (27.0-83.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 17.0 94.4 (53.9-153.2)             
Female 4 6.4 nc (nc-nc)   Female 33 45.1 73.1 (50.3-102.7) 
Lung and Bronchus            All Sites / Types     
Male 76 99.7 76.2 (60.0-95.4)   Male 648 662.8 97.8 (90.4-105.6) 
Female 113 107.9 104.7 (86.3-125.9)   Female 643 686.9 93.6 (86.5-101.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Fitchburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 36.6 152.9 (115.5-198.6)   Male 13 24.2 53.8 (28.6-92.0) 
Female 16 13.8 115.8 (66.1-188.1)   Female 10 19.1 52.4 (25.1-96.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 8.0 nc (nc-nc)   Male 6 7.6 78.6 (28.7-171.1) 
Female 12 6.3 191.0 (98.6-333.7)   Female 7 6.2 112.7 (45.2-232.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 13 21.8 59.7 (31.8-102.1) 
Female 143 149.0 96.0 (80.9-113.1)   Female 19 19.2 98.9 (59.5-154.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 18.2 126.6 (80.3-190.0) 
Female 11 5.1 216.0 (107.7-386.5)   Female 9 8.0 112.3 (51.3-213.2) 
Colon / Rectum            Ovary     
Male 37 40.3 91.7 (64.6-126.4)             
Female 43 40.1 107.1 (77.5-144.3)   Female 13 13.0 99.9 (53.2-170.9) 
Esophagus            Pancreas     
Male 7 9.6 72.7 (29.1-149.8)   Male 13 13.2 98.5 (52.4-168.5) 
Female 1 2.7 nc (nc-nc)   Female 6 14.0 43.0 (15.7-93.5) 
Hodgkin Lymphoma            Prostate     
Male 2 3.6 nc (nc-nc)   Male 99 118.1 83.8 (68.1-102.0) 
Female 0 2.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 24 21.3 112.7 (72.2-167.7)   Male 15 8.9 167.6 (93.7-276.5) 
Female 12 12.1 99.5 (51.3-173.8)   Female 7 5.5 128.4 (51.4-264.5) 
Larynx            Testis     
Male 2 5.6 nc (nc-nc)   Male 6 6.7 88.9 (32.5-193.6) 
Female 2 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 15.8 88.7 (48.5-148.9)   Male 6 10.3 58.3 (21.3-127.0) 
Female 13 11.4 113.7 (60.5-194.5)   Female 27 28.9 93.4 (61.5-135.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 13.2 136.2 (80.7-215.3)             
Female 6 4.5 134.7 (49.2-293.2)   Female 26 32.8 79.4 (51.8-116.3) 
Lung and Bronchus            All Sites / Types     
Male 86 65.8 130.7 (104.5-161.4)   Male 486 489.4 99.3 (90.7-108.5) 
Female 85 72.7 116.9 (93.4-144.5)   Female 519 510.6 101.7 (93.1-110.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Florida 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 3 4.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.0 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.6 nc (nc-nc)   Male 8 12.1 66.2 (28.5-130.5) 
Female 1 1.9 nc (nc-nc)   Female 8 13.5 59.4 (25.6-117.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Foxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 17.5 68.7 (35.4-120.0)   Male 21 11.3 185.0 (114.5-282.9) 
Female 3 6.3 nc (nc-nc)   Female 10 9.2 108.7 (52.0-199.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 3.5 201.2 (80.6-414.7)   Male 2 3.7 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 12 10.2 117.6 (60.7-205.4) 
Female 87 76.5 113.7 (91.1-140.2)   Female 7 9.1 76.6 (30.7-157.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.6 81.1 (32.5-167.2) 
Female 1 2.6 nc (nc-nc)   Female 0 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 19.5 107.5 (66.5-164.3)             
Female 19 18.3 104.1 (62.6-162.6)   Female 8 6.5 123.8 (53.3-243.9) 
Esophagus            Pancreas     
Male 6 4.6 131.6 (48.1-286.5)   Male 3 6.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 5 6.2 80.4 (25.9-187.5) 
Hodgkin Lymphoma            Prostate     
Male 5 1.4 366.9 (118.2-856.2)   Male 66 54.2 121.7 (94.1-154.9) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 10.0 119.7 (61.8-209.1)   Male 8 4.3 187.2 (80.6-368.8) 
Female 8 6.0 134.3 (57.8-264.6)   Female 2 2.5 nc (nc-nc) 
Larynx            Testis     
Male 0 2.6 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.2 139.1 (66.6-255.9)   Male 8 4.7 170.4 (73.3-335.7) 
Female 6 5.2 115.5 (42.2-251.3)   Female 17 14.3 119.1 (69.3-190.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.2 nc (nc-nc)             
Female 1 2.2 nc (nc-nc)   Female 20 17.3 115.7 (70.7-178.7) 
Lung and Bronchus            All Sites / Types     
Male 30 30.7 97.6 (65.8-139.3)   Male 252 228.2 110.4 (97.2-124.9) 
Female 43 34.6 124.4 (90.0-167.6)   Female 267 248.4 107.5 (95.0-121.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Framingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 59 66.6 88.5 (67.4-114.2)   Male 42 43.1 97.4 (70.2-131.6) 
Female 21 25.8 81.4 (50.4-124.5)   Female 27 37.0 73.1 (48.1-106.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 13.5 66.5 (30.4-126.3)   Male 14 13.6 102.6 (56.1-172.2) 
Female 5 11.9 41.9 (13.5-97.7)   Female 11 11.7 93.7 (46.7-167.7) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.3 nc (nc-nc)   Male 41 38.7 105.9 (76.0-143.6) 
Female 288 287.3 100.3 (89.0-112.5)   Female 27 36.4 74.2 (48.9-107.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 31.5 88.8 (59.0-128.4) 
Female 18 10.3 175.6 (104.0-277.5)   Female 10 15.3 65.2 (31.2-120.0) 
Colon / Rectum            Ovary     
Male 64 72.2 88.7 (68.3-113.2)             
Female 77 77.0 99.9 (78.9-124.9)   Female 27 24.8 108.7 (71.6-158.1) 
Esophagus            Pancreas     
Male 10 17.0 58.8 (28.1-108.1)   Male 34 23.8 142.7 (98.8-199.4) 
Female 5 5.0 100.2 (32.3-233.9)   Female 29 26.5 109.4 (73.2-157.1) 
Hodgkin Lymphoma            Prostate     
Male 4 5.6 nc (nc-nc)   Male 201 204.1 98.5 (85.3-113.1) 
Female 9 5.0 179.4 (81.9-340.6)             
Kidney & Renal Pelvis            Stomach     
Male 50 37.3 133.9 (99.4-176.5)   Male 22 16.2 136.0 (85.2-205.9) 
Female 22 22.8 96.6 (60.5-146.3)   Female 8 10.5 76.3 (32.8-150.3) 
Larynx            Testis     
Male 6 9.9 60.5 (22.1-131.8)   Male 9 10.8 83.4 (38.1-158.3) 
Female 3 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 24 27.8 86.3 (55.3-128.4)   Male 24 17.8 135.2 (86.6-201.1) 
Female 21 21.9 96.1 (59.4-146.8)   Female 62 57.1 108.5 (83.2-139.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 27 23.1 117.0 (77.1-170.3)             
Female 7 8.4 83.2 (33.3-171.4)   Female 55 62.8 87.6 (66.0-114.0) 
Lung and Bronchus            All Sites / Types     
Male 113 117.9 95.9 (79.0-115.2)   Male 831 863.9 96.2 (89.8-103.0) 
Female 128 132.6 96.5 (80.5-114.8)   Female 949 973.5 97.5 (91.4-103.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Franklin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 27.8 97.2 (64.0-141.4)   Male 21 18.7 112.1 (69.4-171.4) 
Female 10 10.0 99.8 (47.8-183.6)   Female 17 15.3 111.0 (64.7-177.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.2 80.9 (26.1-188.8)   Male 11 5.9 185.8 (92.6-332.5) 
Female 6 5.1 118.0 (43.1-256.8)   Female 5 4.7 107.4 (34.6-250.6) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 15 16.9 88.9 (49.7-146.6) 
Female 136 124.1 109.6 (91.9-129.6)   Female 13 14.7 88.5 (47.1-151.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 14.5 117.0 (68.1-187.3) 
Female 7 4.5 156.8 (62.8-323.1)   Female 2 6.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 29 31.6 91.8 (61.5-131.9)             
Female 27 30.6 88.2 (58.1-128.3)   Female 12 10.4 115.0 (59.3-200.9) 
Esophagus            Pancreas     
Male 10 7.5 134.2 (64.2-246.8)   Male 14 10.2 136.8 (74.7-229.5) 
Female 1 2.0 nc (nc-nc)   Female 7 10.2 68.9 (27.6-142.0) 
Hodgkin Lymphoma            Prostate     
Male 2 2.5 nc (nc-nc)   Male 96 91.0 105.5 (85.5-128.8) 
Female 5 2.1 242.5 (78.2-566.0)             
Kidney & Renal Pelvis            Stomach     
Male 14 16.9 82.8 (45.2-139.0)   Male 12 6.9 173.7 (89.7-303.5) 
Female 17 9.5 178.5 (103.9-285.8)   Female 5 4.2 119.9 (38.6-279.7) 
Larynx            Testis     
Male 9 4.3 207.0 (94.5-393.0)   Male 8 4.5 177.7 (76.5-350.2) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 12.2 98.4 (50.8-171.9)   Male 16 8.2 195.3 (111.6-317.2) 
Female 6 8.8 68.5 (25.0-149.2)   Female 33 25.0 132.1 (90.9-185.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 10.3 77.7 (33.5-153.1)             
Female 0 3.4 nc (nc-nc)   Female 38 26.7 142.4 (100.8-195.4) 
Lung and Bronchus            All Sites / Types     
Male 43 50.2 85.7 (62.0-115.4)   Male 398 377.5 105.4 (95.3-116.3) 
Female 42 53.2 79.0 (56.9-106.7)   Female 414 403.5 102.6 (93.0-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Freetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 9.7 103.2 (49.4-189.9)   Male 3 6.4 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.8 nc (nc-nc) 
Female 43 37.6 114.3 (82.7-154.0)   Female 5 4.3 117.1 (37.7-273.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 5.1 137.2 (55.0-282.6) 
Female 3 1.3 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 10.8 110.8 (57.2-193.6)             
Female 3 8.4 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.7 nc (nc-nc)   Male 0 3.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 5 2.9 174.6 (56.3-407.5) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 42 33.9 124.1 (89.4-167.7) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.9 85.0 (27.4-198.5)   Male 3 2.4 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.0 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 6 7.3 81.8 (29.9-178.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.7 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 10 8.5 117.3 (56.1-215.7) 
Lung and Bronchus            All Sites / Types     
Male 16 17.6 90.7 (51.8-147.3)   Male 127 132.3 96.0 (80.0-114.2) 
Female 27 15.8 171.0 (112.6-248.8)   Female 138 119.1 115.9 (97.4-136.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gardner 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 22.1 63.2 (34.5-106.1)   Male 5 14.1 35.6 (11.5-83.0) 
Female 11 8.2 133.6 (66.6-239.1)   Female 8 10.9 73.4 (31.6-144.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 4.3 nc (nc-nc)   Male 3 4.5 nc (nc-nc) 
Female 6 3.5 171.9 (62.8-374.2)   Female 3 3.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 10 12.7 78.9 (37.8-145.1) 
Female 65 85.7 75.8 (58.5-96.7)   Female 11 11.3 97.2 (48.4-173.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 10.2 127.4 (67.8-217.9) 
Female 0 2.9 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 24.0 112.7 (74.2-164.0)             
Female 23 23.8 96.5 (61.2-144.8)   Female 9 7.5 120.6 (55.0-228.9) 
Esophagus            Pancreas     
Male 13 5.6 233.9 (124.4-399.9)   Male 8 7.8 102.8 (44.3-202.6) 
Female 2 1.6 nc (nc-nc)   Female 7 8.4 83.6 (33.5-172.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.8 nc (nc-nc)   Male 43 64.7 66.5 (48.1-89.6) 
Female 2 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 12.0 124.6 (69.7-205.6)   Male 3 5.3 nc (nc-nc) 
Female 7 7.0 100.5 (40.3-207.2)   Female 4 3.3 nc (nc-nc) 
Larynx            Testis     
Male 2 3.2 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 9.0 122.1 (60.9-218.4)   Male 2 5.7 nc (nc-nc) 
Female 10 6.7 150.3 (72.0-276.5)   Female 9 15.5 58.2 (26.6-110.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 7.5 173.0 (92.0-295.9)             
Female 4 2.7 nc (nc-nc)   Female 21 19.2 109.2 (67.6-167.0) 
Lung and Bronchus            All Sites / Types     
Male 53 38.4 138.0 (103.3-180.5)   Male 265 280.4 94.5 (83.5-106.6) 
Female 53 42.0 126.1 (94.4-164.9)   Female 286 295.5 96.8 (85.9-108.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Georgetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 8.6 nc (nc-nc)   Male 7 5.7 123.5 (49.5-254.5) 
Female 1 2.6 nc (nc-nc)   Female 2 4.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 5.1 156.6 (67.4-308.6) 
Female 32 35.1 91.2 (62.4-128.8)   Female 1 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.4 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.7 72.3 (29.0-149.0)             
Female 7 8.0 87.5 (35.1-180.4)   Female 0 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.3 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 35 29.3 119.5 (83.2-166.2) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.2 95.6 (30.8-223.1)   Male 2 2.1 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.6 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 4 6.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.1 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 11 7.9 139.3 (69.4-249.2) 
Lung and Bronchus            All Sites / Types     
Male 8 15.8 50.7 (21.8-100.0)   Male 105 116.4 90.2 (73.8-109.2) 
Female 12 14.7 81.6 (42.1-142.6)   Female 96 110.7 86.8 (70.3-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 6 7.7 77.6 (28.3-168.8)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.1 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 3 6.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 9 3.4 261.2 (119.2-495.9)   Male 22 26.0 84.8 (53.1-128.3) 
Female 4 3.3 nc (nc-nc)   Female 22 24.7 88.9 (55.7-134.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gloucester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 41 38.3 107.1 (76.9-145.3)   Male 27 23.7 113.8 (75.0-165.6) 
Female 23 14.8 155.6 (98.6-233.4)   Female 19 19.1 99.6 (60.0-155.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 6.8 nc (nc-nc)   Male 7 7.8 89.3 (35.8-183.9) 
Female 5 6.0 83.5 (26.9-194.8)   Female 3 6.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.3 nc (nc-nc)   Male 25 21.3 117.2 (75.8-173.0) 
Female 171 158.7 107.7 (92.2-125.1)   Female 24 20.3 118.4 (75.8-176.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 18.2 120.9 (75.8-183.1) 
Female 3 4.8 nc (nc-nc)   Female 10 8.5 117.4 (56.2-215.9) 
Colon / Rectum            Ovary     
Male 41 40.3 101.7 (73.0-138.0)             
Female 49 42.1 116.3 (86.0-153.7)   Female 20 13.7 146.1 (89.2-225.7) 
Esophagus            Pancreas     
Male 14 10.1 138.6 (75.7-232.5)   Male 24 13.8 174.4 (111.7-259.5) 
Female 1 2.9 nc (nc-nc)   Female 11 15.0 73.5 (36.7-131.6) 
Hodgkin Lymphoma            Prostate     
Male 3 2.4 nc (nc-nc)   Male 134 128.3 104.5 (87.5-123.7) 
Female 4 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 21.1 104.2 (65.3-157.8)   Male 9 9.2 98.3 (44.9-186.7) 
Female 13 12.7 102.3 (54.4-174.9)   Female 2 5.7 nc (nc-nc) 
Larynx            Testis     
Male 8 5.9 136.1 (58.6-268.2)   Male 4 3.9 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 24 14.9 160.6 (102.9-239.0)   Male 12 8.8 136.8 (70.6-239.0) 
Female 12 11.3 105.8 (54.6-184.8)   Female 26 26.1 99.5 (65.0-145.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 13.6 44.2 (16.1-96.2)             
Female 6 4.8 123.8 (45.2-269.4)   Female 27 36.3 74.4 (49.0-108.2) 
Lung and Bronchus            All Sites / Types     
Male 88 68.7 128.1 (102.7-157.8)   Male 561 497.0 112.9 (103.7-122.6) 
Female 101 78.0 129.5 (105.5-157.4)   Female 575 534.9 107.5 (98.9-116.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Goshen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.2 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 4 5.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.4 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 4.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.5 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.3 nc (nc-nc)   Male 13 16.9 77.0 (41.0-131.7) 
Female 0 2.4 nc (nc-nc)   Female 11 18.5 59.5 (29.7-106.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gosnold 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.2 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.3 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Grafton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 16.5 115.4 (69.5-180.3)   Male 9 11.1 81.3 (37.1-154.4) 
Female 5 5.7 88.3 (28.5-206.2)   Female 9 8.7 103.6 (47.3-196.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 3.6 251.1 (114.6-476.7)   Male 4 3.4 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 6 9.9 60.4 (22.1-131.5) 
Female 78 70.4 110.8 (87.5-138.2)   Female 7 8.3 84.6 (33.9-174.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 8.4 165.8 (90.6-278.3) 
Female 3 2.6 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 18.8 74.3 (40.6-124.7)             
Female 19 17.0 111.9 (67.3-174.7)   Female 4 5.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 4.3 nc (nc-nc)   Male 3 6.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 4 5.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.4 nc (nc-nc)   Male 59 52.0 113.5 (86.4-146.5) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 9.8 142.5 (77.8-239.1)   Male 2 4.1 nc (nc-nc) 
Female 5 5.4 91.9 (29.6-214.5)   Female 2 2.3 nc (nc-nc) 
Larynx            Testis     
Male 7 2.5 279.8 (112.1-576.5)   Male 3 2.7 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 7.2 153.8 (76.7-275.1)   Male 7 4.8 145.5 (58.3-299.8) 
Female 9 4.9 185.0 (84.4-351.2)   Female 15 14.3 104.6 (58.5-172.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.0 nc (nc-nc)             
Female 0 1.9 nc (nc-nc)   Female 15 15.3 98.2 (54.9-162.0) 
Lung and Bronchus            All Sites / Types     
Male 32 29.1 109.9 (75.1-155.1)   Male 232 220.3 105.3 (92.2-119.8) 
Female 36 30.8 117.0 (81.9-162.0)   Female 243 228.7 106.3 (93.3-120.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.1 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 7 3.7 189.9 (76.1-391.4) 
Female 18 30.3 59.4 (35.2-93.9)   Female 2 3.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.4 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 6.9 115.2 (49.6-227.0)             
Female 7 7.6 92.1 (36.9-189.9)   Female 4 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.7 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.5 nc (nc-nc)   Male 18 22.2 80.9 (47.9-127.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.8 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 8 2.3 347.8 (149.8-685.4)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.6 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 1 5.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.5 nc (nc-nc)             
Female 2 0.9 nc (nc-nc)   Female 6 6.9 87.4 (31.9-190.3) 
Lung and Bronchus            All Sites / Types     
Male 15 11.2 134.2 (75.1-221.4)   Male 83 85.7 96.8 (77.1-120.0) 
Female 11 13.1 84.2 (42.0-150.6)   Female 77 99.1 77.7 (61.3-97.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.2 nc (nc-nc) 
Female 7 7.5 93.0 (37.2-191.6)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.3 nc (nc-nc)             
Female 2 1.8 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 7.6 131.9 (63.1-242.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.2 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 5 1.8 285.2 (91.9-665.5) 
Lung and Bronchus            All Sites / Types     
Male 2 4.0 nc (nc-nc)   Male 28 28.8 97.4 (64.7-140.7) 
Female 4 3.5 nc (nc-nc)   Female 25 24.2 103.3 (66.8-152.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Great Barrington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 7.8 167.4 (89.1-286.3)   Male 8 4.9 162.1 (69.8-319.4) 
Female 6 3.8 159.8 (58.3-347.8)   Female 3 4.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 3 4.5 nc (nc-nc) 
Female 38 35.4 107.5 (76.1-147.5)   Female 4 4.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.6 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 8.4 71.3 (26.0-155.3)             
Female 11 10.5 104.3 (52.0-186.7)   Female 2 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.0 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 31 23.1 134.4 (91.3-190.7) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.2 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 3 1.1 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.2 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 8 5.4 147.2 (63.4-290.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.7 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 5 8.1 61.9 (20.0-144.5) 
Lung and Bronchus            All Sites / Types     
Male 17 13.4 126.8 (73.8-203.0)   Male 116 98.7 117.5 (97.1-140.9) 
Female 23 19.0 121.1 (76.8-181.8)   Female 126 125.5 100.4 (83.7-119.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Greenfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 21.5 83.6 (49.5-132.2)   Male 9 13.5 66.4 (30.3-126.1) 
Female 6 7.7 77.9 (28.4-169.5)   Female 7 10.2 68.7 (27.5-141.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.0 150.0 (54.8-326.5)   Male 4 4.4 nc (nc-nc) 
Female 6 3.2 187.5 (68.5-408.1)   Female 3 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 4 12.1 nc (nc-nc) 
Female 71 80.7 88.0 (68.7-111.0)   Female 12 10.6 113.1 (58.4-197.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 10.0 89.6 (40.9-170.1) 
Female 3 2.7 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 22.8 114.1 (74.5-167.2)             
Female 27 22.6 119.3 (78.6-173.6)   Female 6 7.0 85.4 (31.2-185.8) 
Esophagus            Pancreas     
Male 3 5.5 nc (nc-nc)   Male 9 7.7 116.5 (53.2-221.1) 
Female 3 1.5 nc (nc-nc)   Female 8 8.0 100.4 (43.2-197.8) 
Hodgkin Lymphoma            Prostate     
Male 5 1.5 326.3 (105.2-761.5)   Male 36 68.4 52.7 (36.9-72.9) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 11.7 59.6 (23.9-122.8)   Male 3 5.2 nc (nc-nc) 
Female 5 6.5 77.2 (24.9-180.1)   Female 4 3.1 nc (nc-nc) 
Larynx            Testis     
Male 1 3.3 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 8.6 70.1 (25.6-152.6)   Male 3 5.2 nc (nc-nc) 
Female 6 6.2 97.3 (35.5-211.7)   Female 4 14.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.6 nc (nc-nc)             
Female 5 2.5 200.2 (64.5-467.1)   Female 20 18.2 109.9 (67.1-169.7) 
Lung and Bronchus            All Sites / Types     
Male 27 38.3 70.6 (46.5-102.7)   Male 205 276.9 74.0 (64.2-84.9) 
Female 48 38.8 123.7 (91.2-164.0)   Female 275 277.2 99.2 (87.8-111.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 11.1 62.8 (25.2-129.4)   Male 3 7.5 nc (nc-nc) 
Female 0 3.6 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.3 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 3 6.8 nc (nc-nc) 
Female 38 48.0 79.1 (56.0-108.6)   Female 5 5.4 92.3 (29.7-215.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.0 99.6 (36.4-216.8) 
Female 2 1.6 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 12.8 124.7 (71.2-202.5)             
Female 10 11.1 90.4 (43.3-166.2)   Female 2 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.1 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 31 38.6 80.2 (54.5-113.9) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.9 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 5 1.4 358.0 (115.4-835.4) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.7 nc (nc-nc)   Male 6 3.2 190.2 (69.5-414.0) 
Female 0 3.0 nc (nc-nc)   Female 8 9.1 88.0 (37.9-173.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.4 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 12 10.8 110.8 (57.2-193.5) 
Lung and Bronchus            All Sites / Types     
Male 11 20.3 54.1 (27.0-96.9)   Male 122 153.5 79.5 (66.0-94.9) 
Female 10 19.8 50.5 (24.2-92.9)   Female 110 151.1 72.8 (59.8-87.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groveland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.5 70.8 (25.8-154.0)   Male 5 5.4 93.4 (30.1-218.0) 
Female 3 2.8 nc (nc-nc)   Female 11 3.9 285.4 (142.3-510.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.6 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 4.8 145.6 (58.3-300.0) 
Female 39 33.0 118.2 (84.0-161.5)   Female 6 3.9 152.1 (55.5-331.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.0 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 9.1 nc (nc-nc)             
Female 6 8.0 74.9 (27.4-163.1)   Female 4 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 5 3.0 165.0 (53.2-385.1) 
Female 1 0.6 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 29 26.6 108.8 (72.9-156.3) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.7 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.4 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 8 5.5 145.2 (62.5-286.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.9 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 5 7.7 65.3 (21.0-152.4) 
Lung and Bronchus            All Sites / Types     
Male 10 15.3 65.3 (31.2-120.0)   Male 86 109.3 78.7 (62.9-97.2) 
Female 14 15.1 92.8 (50.7-155.7)   Female 121 107.2 112.8 (93.6-134.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.0 86.2 (31.5-187.6)   Male 2 4.2 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.8 nc (nc-nc) 
Female 27 30.1 89.7 (59.1-130.5)   Female 5 4.2 120.3 (38.8-280.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 3.1 196.7 (71.8-428.1) 
Female 1 0.9 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 7.1 70.4 (22.7-164.4)             
Female 12 8.8 137.1 (70.7-239.4)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.8 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 19 21.6 88.1 (53.0-137.6) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.6 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.7 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 4 2.4 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 13 6.9 188.8 (100.4-322.8) 
Lung and Bronchus            All Sites / Types     
Male 5 12.3 40.6 (13.1-94.7)   Male 66 86.7 76.1 (58.8-96.8) 
Female 7 16.1 43.4 (17.4-89.3)   Female 88 106.3 82.8 (66.4-102.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Halifax 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.7 90.8 (36.4-187.1)   Male 4 5.2 nc (nc-nc) 
Female 1 3.0 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 32 34.9 91.8 (62.8-129.5)   Female 6 4.3 139.9 (51.1-304.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.0 126.2 (40.7-294.5) 
Female 1 1.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 8.9 146.6 (78.0-250.7)             
Female 13 9.0 143.8 (76.5-245.9)   Female 3 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.0 nc (nc-nc)   Male 8 2.8 283.7 (122.1-559.0) 
Female 1 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 36 23.9 150.5 (105.4-208.3) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 4.6 172.8 (74.4-340.6)   Male 1 1.9 nc (nc-nc) 
Female 5 2.7 183.3 (59.1-427.7)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.2 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 12 6.3 190.8 (98.5-333.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.8 nc (nc-nc)             
Female 2 1.0 nc (nc-nc)   Female 13 7.4 175.5 (93.4-300.1) 
Lung and Bronchus            All Sites / Types     
Male 17 13.9 122.2 (71.2-195.7)   Male 131 102.7 127.5 (106.6-151.3) 
Female 16 16.2 98.5 (56.3-159.9)   Female 128 114.9 111.4 (92.9-132.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hamilton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.0 75.1 (27.4-163.4)   Male 4 5.2 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 6 4.2 143.8 (52.5-313.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 3 1.3 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 41 34.5 118.8 (85.2-161.1)   Female 11 4.2 263.3 (131.3-471.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 8.8 nc (nc-nc)             
Female 11 8.6 127.4 (63.5-228.0)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 0 2.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 26 26.4 98.4 (64.3-144.2) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 4.7 171.5 (73.8-337.9)   Male 1 1.9 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.4 148.5 (47.9-346.7)   Male 5 2.1 232.7 (75.0-543.0) 
Female 3 2.4 nc (nc-nc)   Female 7 6.3 111.1 (44.5-228.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.9 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 5 7.7 64.6 (20.8-150.7) 
Lung and Bronchus            All Sites / Types     
Male 14 14.5 96.8 (52.9-162.4)   Male 100 106.6 93.8 (76.3-114.1) 
Female 12 15.7 76.3 (39.4-133.3)   Female 122 113.1 107.9 (89.6-128.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hampden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 8.4 95.6 (41.2-188.4)   Male 2 5.1 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 4.5 177.1 (76.2-348.9) 
Female 23 26.6 86.4 (54.7-129.6)   Female 2 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.7 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 8.5 nc (nc-nc)             
Female 3 7.2 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.1 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 20 25.7 77.7 (47.4-120.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.4 114.1 (36.8-266.2)   Male 1 2.0 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 5 0.6 801.5 (258.3-1870.3) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.2 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.8 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 5 6.0 82.7 (26.7-193.1) 
Lung and Bronchus            All Sites / Types     
Male 9 15.2 59.2 (27.0-112.3)   Male 81 104.3 77.7 (61.7-96.6) 
Female 8 13.0 61.6 (26.5-121.4)   Female 63 89.8 70.2 (53.9-89.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hancock 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 2 3.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.8 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.4 nc (nc-nc)   Male 11 10.7 102.7 (51.2-183.8) 
Female 2 1.5 nc (nc-nc)   Female 9 11.0 81.9 (37.4-155.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 12.5 112.2 (61.3-188.2)   Male 20 8.6 233.9 (142.8-361.2) 
Female 7 5.2 134.4 (53.8-276.8)   Female 4 7.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.8 178.9 (57.7-417.6)   Male 2 2.8 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 8 7.7 104.5 (45.0-205.9) 
Female 80 61.0 131.2 (104.0-163.3)   Female 10 7.4 134.3 (64.3-247.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.8 102.4 (41.0-210.9) 
Female 0 2.0 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 14.2 126.5 (74.9-200.0)             
Female 18 15.1 119.1 (70.5-188.2)   Female 5 5.2 96.4 (31.1-225.0) 
Esophagus            Pancreas     
Male 5 3.5 142.6 (45.9-332.7)   Male 1 4.7 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 5.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 64 43.8 146.2 (112.6-186.7) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.9 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 5 4.8 105.1 (33.9-245.4)   Female 0 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.1 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.5 109.1 (39.8-237.5)   Male 4 3.8 nc (nc-nc) 
Female 2 4.3 nc (nc-nc)   Female 12 11.2 106.7 (55.1-186.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.9 nc (nc-nc)             
Female 0 1.8 nc (nc-nc)   Female 18 13.9 129.6 (76.8-204.9) 
Lung and Bronchus            All Sites / Types     
Male 17 23.0 73.9 (43.0-118.4)   Male 188 174.4 107.8 (92.9-124.3) 
Female 30 27.7 108.4 (73.1-154.7)   Female 215 200.9 107.0 (93.2-122.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.5 115.9 (57.8-207.5)   Male 7 6.6 105.5 (42.3-217.5) 
Female 3 3.1 nc (nc-nc)   Female 3 5.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.1 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.0 nc (nc-nc) 
Female 31 43.0 72.0 (48.9-102.2)   Female 4 4.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 5.5 162.9 (74.3-309.2) 
Female 1 1.5 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 11.1 116.6 (62.0-199.4)             
Female 11 9.2 119.6 (59.6-213.9)   Female 3 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.8 nc (nc-nc)   Male 5 3.6 137.4 (44.3-320.7) 
Female 1 0.6 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 31 36.3 85.5 (58.1-121.4) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.3 79.1 (25.5-184.5)   Male 1 2.4 nc (nc-nc) 
Female 6 3.2 187.4 (68.4-407.8)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.2 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 4 2.7 nc (nc-nc)   Female 7 8.4 83.0 (33.3-171.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.9 nc (nc-nc)             
Female 3 1.1 nc (nc-nc)   Female 10 9.6 103.9 (49.7-191.1) 
Lung and Bronchus            All Sites / Types     
Male 24 17.8 135.0 (86.5-200.9)   Male 133 137.8 96.5 (80.8-114.4) 
Female 22 17.7 124.4 (77.9-188.4)   Female 121 133.6 90.6 (75.1-108.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hardwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 4.9 nc (nc-nc)   Male 5 3.0 169.4 (54.6-395.3) 
Female 1 1.1 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 11 13.4 81.8 (40.8-146.4)   Female 1 1.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.0 119.4 (43.6-259.8)             
Female 4 3.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 7 15.5 45.2 (18.1-93.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.6 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 1.7 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 8.9 79.0 (31.7-162.8)   Male 45 61.6 73.1 (53.3-97.8) 
Female 8 5.9 136.5 (58.8-268.9)   Female 35 43.1 81.2 (56.5-112.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harvard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 8.2 60.6 (19.5-141.5)   Male 1 5.7 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 6 5.1 117.5 (42.9-255.8) 
Female 21 23.6 88.9 (55.0-135.9)   Female 3 2.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.7 105.4 (34.0-245.9) 
Female 0 0.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 9.8 51.2 (16.5-119.6)             
Female 9 5.3 168.8 (77.0-320.5)   Female 3 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.4 nc (nc-nc)   Male 0 3.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 22 30.9 71.2 (44.6-107.7) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 5.4 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.4 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 5 4.4 113.7 (36.7-265.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.4 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 6 5.3 114.1 (41.7-248.4) 
Lung and Bronchus            All Sites / Types     
Male 5 15.5 32.3 (10.4-75.4)   Male 77 118.1 65.2 (51.4-81.5) 
Female 6 9.9 60.6 (22.1-132.0)   Female 67 73.8 90.8 (70.4-115.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 20.7 116.0 (74.3-172.6)   Male 21 11.9 176.3 (109.1-269.4) 
Female 9 8.2 110.3 (50.3-209.3)   Female 17 9.4 181.4 (105.6-290.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 8 4.0 201.7 (86.8-397.4) 
Female 4 3.0 nc (nc-nc)   Female 7 3.6 195.1 (78.2-402.0) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 17 10.7 159.2 (92.7-254.9) 
Female 109 79.3 137.5 (112.9-165.9)   Female 7 10.7 65.6 (26.3-135.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.2 109.6 (50.0-208.1) 
Female 1 2.2 nc (nc-nc)   Female 5 4.4 113.5 (36.6-264.9) 
Colon / Rectum            Ovary     
Male 24 20.2 119.1 (76.3-177.2)             
Female 35 22.2 157.4 (109.6-218.9)   Female 6 6.9 87.1 (31.8-189.5) 
Esophagus            Pancreas     
Male 4 5.0 nc (nc-nc)   Male 7 7.0 99.9 (40.0-205.9) 
Female 0 1.6 nc (nc-nc)   Female 11 8.2 133.4 (66.5-238.7) 
Hodgkin Lymphoma            Prostate     
Male 5 1.0 479.9 (154.6-1119.8)   Male 98 59.7 164.1 (133.2-199.9) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.0 100.0 (47.9-183.9)   Male 7 4.7 148.4 (59.5-305.9) 
Female 8 6.6 121.4 (52.3-239.3)   Female 1 3.0 nc (nc-nc) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.6 119.0 (54.3-225.9)   Male 5 3.8 131.4 (42.3-306.6) 
Female 6 5.9 101.3 (37.0-220.5)   Female 4 11.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.2 nc (nc-nc)             
Female 3 2.6 nc (nc-nc)   Female 20 18.4 108.5 (66.3-167.6) 
Lung and Bronchus            All Sites / Types     
Male 48 36.8 130.5 (96.2-173.0)   Male 326 245.7 132.7 (118.7-147.9) 
Female 42 42.7 98.3 (70.8-132.9)   Female 326 275.2 118.4 (105.9-132.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
135 
Hatfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.1 98.0 (31.6-228.6)   Male 4 3.1 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.9 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 16 19.8 80.9 (46.2-131.3)   Female 2 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.3 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.3 93.7 (30.2-218.6)             
Female 10 5.2 191.7 (91.8-352.7)   Female 4 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 16 15.5 103.1 (58.9-167.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 2.7 221.9 (81.0-482.9)   Male 2 1.2 nc (nc-nc) 
Female 5 1.6 315.5 (101.7-736.2)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.9 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.7 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 6 4.4 136.7 (49.9-297.6) 
Lung and Bronchus            All Sites / Types     
Male 8 9.4 85.2 (36.7-167.9)   Male 61 63.8 95.7 (73.2-122.9) 
Female 5 9.9 50.5 (16.3-117.9)   Female 64 66.1 96.9 (74.6-123.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Haverhill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 60.1 88.3 (66.1-115.4)   Male 28 38.7 72.3 (48.1-104.6) 
Female 31 21.8 142.2 (96.6-201.9)   Female 19 31.9 59.6 (35.9-93.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 12.2 115.2 (62.9-193.3)   Male 11 12.3 89.6 (44.7-160.4) 
Female 12 10.3 116.3 (60.0-203.2)   Female 7 10.1 69.6 (27.9-143.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.1 nc (nc-nc)   Male 33 35.0 94.4 (65.0-132.6) 
Female 246 250.4 98.2 (86.4-111.3)   Female 41 31.2 131.4 (94.3-178.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 32 28.9 110.9 (75.8-156.5) 
Female 8 8.9 90.2 (38.9-177.8)   Female 14 13.3 105.2 (57.5-176.6) 
Colon / Rectum            Ovary     
Male 68 66.2 102.7 (79.8-130.2)             
Female 72 65.8 109.4 (85.6-137.7)   Female 20 21.7 92.3 (56.4-142.6) 
Esophagus            Pancreas     
Male 11 15.3 71.7 (35.8-128.4)   Male 27 21.5 125.6 (82.7-182.7) 
Female 5 4.3 117.2 (37.8-273.5)   Female 24 22.5 106.5 (68.2-158.5) 
Hodgkin Lymphoma            Prostate     
Male 6 5.0 118.9 (43.4-258.8)   Male 148 184.5 80.2 (67.8-94.2) 
Female 3 4.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 33 33.8 97.8 (67.3-137.3)   Male 17 14.6 116.6 (67.9-186.7) 
Female 24 19.7 121.7 (77.9-181.1)   Female 8 8.9 89.8 (38.7-177.0) 
Larynx            Testis     
Male 10 8.9 113.0 (54.1-207.8)   Male 7 9.5 73.4 (29.4-151.2) 
Female 6 2.7 219.7 (80.2-478.2)             
Leukemia            Thyroid     
Male 21 25.1 83.6 (51.7-127.8)   Male 17 16.0 106.3 (61.9-170.2) 
Female 18 18.7 96.2 (57.0-152.0)   Female 57 49.2 115.9 (87.8-150.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 21.1 80.7 (47.0-129.2)             
Female 6 7.3 82.7 (30.2-180.0)   Female 62 55.8 111.2 (85.3-142.6) 
Lung and Bronchus            All Sites / Types     
Male 105 104.3 100.6 (82.3-121.8)   Male 711 779.2 91.2 (84.7-98.2) 
Female 138 112.5 122.7 (103.0-144.9)   Female 888 839.3 105.8 (99.0-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hawley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.4 nc (nc-nc)   Male 4 9.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 3 6.8 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Heath 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 2 3.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 3.6 139.8 (45.0-326.2) 
Female 1 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.4 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 1.7 nc (nc-nc)   Male 14 12.7 110.2 (60.2-185.0) 
Female 1 1.5 nc (nc-nc)   Female 11 10.7 103.0 (51.3-184.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 30.7 94.5 (63.2-135.7)   Male 34 18.2 187.3 (129.7-261.7) 
Female 9 11.5 78.3 (35.7-148.6)   Female 29 13.9 208.8 (139.8-299.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.2 134.1 (53.7-276.3)   Male 7 5.8 120.4 (48.2-248.1) 
Female 6 4.5 133.2 (48.6-289.9)   Female 5 5.1 98.3 (31.7-229.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 13 16.3 79.7 (42.4-136.3) 
Female 113 113.5 99.5 (82.0-119.7)   Female 25 15.3 163.5 (105.8-241.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 12.7 133.6 (77.8-214.0) 
Female 3 3.4 nc (nc-nc)   Female 5 6.3 79.0 (25.5-184.3) 
Colon / Rectum            Ovary     
Male 31 31.5 98.3 (66.8-139.6)             
Female 35 33.2 105.5 (73.5-146.8)   Female 9 9.9 90.8 (41.5-172.5) 
Esophagus            Pancreas     
Male 3 7.3 nc (nc-nc)   Male 8 10.5 75.9 (32.7-149.6) 
Female 7 2.2 318.8 (127.7-656.9)   Female 11 11.8 93.2 (46.4-166.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.7 nc (nc-nc)   Male 96 84.8 113.2 (91.7-138.2) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 15.2 92.3 (50.4-154.9)   Male 13 7.1 182.5 (97.1-312.2) 
Female 8 9.3 85.7 (36.9-168.9)   Female 1 4.5 nc (nc-nc) 
Larynx            Testis     
Male 2 4.1 nc (nc-nc)   Male 5 2.8 181.2 (58.4-422.9) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 11.9 126.4 (70.7-208.4)   Male 4 6.3 nc (nc-nc) 
Female 14 8.9 157.7 (86.2-264.7)   Female 30 18.0 166.6 (112.4-237.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 9.5 nc (nc-nc)             
Female 1 3.6 nc (nc-nc)   Female 20 25.3 79.1 (48.3-122.1) 
Lung and Bronchus            All Sites / Types     
Male 29 52.7 55.0 (36.8-79.0)   Male 365 366.6 99.6 (89.6-110.3) 
Female 40 58.5 68.4 (48.8-93.1)   Female 402 395.6 101.6 (91.9-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hinsdale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.9 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 17 9.6 177.0 (103.0-283.4)   Female 3 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.2 nc (nc-nc)             
Female 4 2.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 9.1 88.0 (37.9-173.4) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.6 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 5.0 141.4 (56.6-291.3)   Male 35 37.1 94.3 (65.7-131.2) 
Female 6 4.2 144.4 (52.7-314.2)   Female 43 31.3 137.6 (99.6-185.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holbrook 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 12.8 132.4 (77.1-212.0)   Male 5 8.3 60.2 (19.4-140.6) 
Female 8 4.4 180.0 (77.5-354.6)   Female 3 6.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.5 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 5 1.9 257.7 (83.1-601.4)   Female 6 2.0 292.7 (106.9-637.2) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 10 7.4 135.9 (65.0-249.9) 
Female 58 52.0 111.5 (84.6-144.1)   Female 8 6.3 127.5 (54.9-251.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.1 97.9 (35.7-213.0) 
Female 3 1.7 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 14.0 157.1 (98.4-237.8)             
Female 20 13.1 152.7 (93.2-235.8)   Female 9 4.4 203.4 (92.8-386.2) 
Esophagus            Pancreas     
Male 6 3.3 181.7 (66.3-395.4)   Male 6 4.6 130.9 (47.8-284.9) 
Female 0 0.9 nc (nc-nc)   Female 5 4.5 111.5 (35.9-260.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 51 38.8 131.5 (97.9-172.9) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 7.1 210.2 (117.6-346.8)   Male 2 3.1 nc (nc-nc) 
Female 4 4.1 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.1 136.1 (54.5-280.5)   Male 0 3.3 nc (nc-nc) 
Female 7 3.6 197.1 (78.9-406.0)   Female 8 9.4 84.8 (36.5-167.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.5 110.5 (35.6-258.0)             
Female 1 1.5 nc (nc-nc)   Female 9 11.6 77.9 (35.5-147.9) 
Lung and Bronchus            All Sites / Types     
Male 20 22.9 87.2 (53.2-134.7)   Male 194 165.3 117.4 (101.4-135.1) 
Female 34 24.1 141.1 (97.7-197.1)   Female 203 170.9 118.8 (103.0-136.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 19.1 78.6 (43.9-129.6)   Male 22 12.3 178.2 (111.6-269.8) 
Female 11 6.9 159.6 (79.6-285.6)   Female 11 9.6 114.2 (56.9-204.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.8 nc (nc-nc)   Male 7 4.0 175.6 (70.3-361.7) 
Female 6 3.1 194.4 (71.0-423.2)   Female 2 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 13 11.1 116.9 (62.2-199.9) 
Female 94 77.8 120.8 (97.6-147.8)   Female 8 9.8 81.8 (35.2-161.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 9.5 137.5 (73.2-235.2) 
Female 1 2.7 nc (nc-nc)   Female 5 4.1 121.1 (39.0-282.6) 
Colon / Rectum            Ovary     
Male 15 21.2 70.8 (39.6-116.8)             
Female 19 20.6 92.3 (55.5-144.1)   Female 7 6.7 104.6 (41.9-215.5) 
Esophagus            Pancreas     
Male 6 5.0 120.0 (43.8-261.1)   Male 11 6.9 158.4 (79.0-283.4) 
Female 0 1.3 nc (nc-nc)   Female 6 7.0 85.6 (31.3-186.3) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 62 60.9 101.7 (78.0-130.4) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.9 64.2 (25.7-132.3)   Male 2 4.7 nc (nc-nc) 
Female 6 6.1 98.1 (35.8-213.5)   Female 5 2.8 178.8 (57.6-417.3) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.8 89.2 (35.7-183.7)   Male 4 5.0 nc (nc-nc) 
Female 5 5.6 89.0 (28.7-207.6)   Female 11 14.5 76.0 (37.9-136.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.9 72.1 (23.2-168.3)             
Female 4 2.3 nc (nc-nc)   Female 30 17.2 174.0 (117.3-248.3) 
Lung and Bronchus            All Sites / Types     
Male 24 33.8 71.1 (45.5-105.8)   Male 242 250.6 96.6 (84.8-109.5) 
Female 29 35.9 80.9 (54.2-116.2)   Female 289 260.3 111.0 (98.6-124.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 3.1 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 3 0.7 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 8 10.5 76.0 (32.7-149.8)   Female 2 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 3.4 nc (nc-nc)             
Female 1 2.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.9 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 5 10.3 48.4 (15.6-112.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 5.9 85.4 (27.5-199.2)   Male 28 42.0 66.6 (44.3-96.3) 
Female 6 4.1 145.1 (53.0-315.9)   Female 34 32.4 104.8 (72.6-146.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holliston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 13.8 145.2 (88.6-224.2)   Male 11 9.2 119.9 (59.8-214.6) 
Female 3 5.0 nc (nc-nc)   Female 9 7.3 122.7 (56.0-232.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 2.9 239.7 (96.0-493.8)   Male 5 3.0 169.0 (54.5-394.3) 
Female 2 2.4 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 8.3 120.9 (57.9-222.4) 
Female 77 62.2 123.8 (97.7-154.7)   Female 5 7.3 68.9 (22.2-160.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.3 110.2 (47.4-217.1) 
Female 3 2.1 nc (nc-nc)   Female 5 3.2 158.1 (50.9-368.9) 
Colon / Rectum            Ovary     
Male 15 15.7 95.6 (53.4-157.6)             
Female 14 15.1 93.0 (50.8-156.0)   Female 3 5.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.7 nc (nc-nc)   Male 3 5.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 5.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 53 47.2 112.4 (84.2-147.0) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 8.4 119.5 (57.2-219.7)   Male 1 3.4 nc (nc-nc) 
Female 4 4.8 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Larynx            Testis     
Male 3 2.2 nc (nc-nc)   Male 5 1.9 265.4 (85.5-619.4) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.9 102.5 (37.4-223.2)   Male 5 3.9 128.5 (41.4-300.0) 
Female 4 4.1 nc (nc-nc)   Female 14 11.4 123.0 (67.2-206.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.2 nc (nc-nc)             
Female 4 1.7 nc (nc-nc)   Female 19 13.9 136.3 (82.0-212.9) 
Lung and Bronchus            All Sites / Types     
Male 15 24.8 60.4 (33.8-99.7)   Male 205 188.1 109.0 (94.6-125.0) 
Female 23 27.0 85.2 (54.0-127.8)   Female 206 199.9 103.0 (89.5-118.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
145 
Holyoke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 37.8 76.7 (51.4-110.2)   Male 15 23.5 63.7 (35.6-105.1) 
Female 13 15.6 83.2 (44.2-142.2)   Female 11 21.1 52.2 (26.0-93.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 7.5 145.9 (72.7-261.0)   Male 4 7.4 nc (nc-nc) 
Female 5 6.9 72.9 (23.5-170.1)   Female 1 7.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 17 21.4 79.4 (46.2-127.2) 
Female 128 162.9 78.6 (65.5-93.4)   Female 18 21.4 84.1 (49.8-132.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 27 16.7 161.5 (106.4-235.0) 
Female 7 5.6 124.6 (49.9-256.7)   Female 7 8.9 78.9 (31.6-162.6) 
Colon / Rectum            Ovary     
Male 41 40.6 101.0 (72.5-137.0)             
Female 45 45.9 97.9 (71.4-131.1)   Female 13 14.2 91.4 (48.6-156.4) 
Esophagus            Pancreas     
Male 6 9.1 66.0 (24.1-143.7)   Male 14 13.2 106.0 (57.9-177.9) 
Female 0 3.0 nc (nc-nc)   Female 22 16.0 137.1 (85.9-207.6) 
Hodgkin Lymphoma            Prostate     
Male 4 3.2 nc (nc-nc)   Male 95 105.2 90.3 (73.1-110.4) 
Female 7 2.8 253.1 (101.4-521.5)             
Kidney & Renal Pelvis            Stomach     
Male 21 19.8 106.2 (65.7-162.3)   Male 7 9.0 77.9 (31.2-160.5) 
Female 10 13.3 75.4 (36.1-138.7)   Female 9 6.2 144.2 (65.8-273.7) 
Larynx            Testis     
Male 8 5.2 154.2 (66.4-303.8)   Male 1 6.0 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 15.8 63.2 (30.3-116.3)   Male 1 9.3 nc (nc-nc) 
Female 8 13.0 61.7 (26.5-121.5)   Female 24 31.1 77.2 (49.4-114.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 12.3 202.9 (131.3-299.6)             
Female 6 4.9 121.5 (44.4-264.6)   Female 43 35.3 121.7 (88.1-163.9) 
Lung and Bronchus            All Sites / Types     
Male 75 64.2 116.8 (91.8-146.4)   Male 464 469.3 98.9 (90.1-108.3) 
Female 76 79.7 95.3 (75.1-119.3)   Female 511 564.6 90.5 (82.8-98.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopedale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 6.1 98.2 (35.9-213.7)   Male 3 3.8 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 26 24.9 104.5 (68.3-153.2)   Female 1 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.9 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 6.9 87.0 (31.8-189.4)             
Female 8 6.9 115.2 (49.6-227.1)   Female 1 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.5 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 22 17.1 128.8 (80.7-195.0) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.3 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.6 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 8 4.8 167.7 (72.2-330.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.1 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 6 5.2 114.6 (41.9-249.5) 
Lung and Bronchus            All Sites / Types     
Male 13 10.0 130.3 (69.3-222.8)   Male 86 76.2 112.8 (90.2-139.3) 
Female 11 11.1 98.9 (49.3-177.0)   Female 82 83.8 97.8 (77.8-121.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopkinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.8 93.1 (46.4-166.6)   Male 9 8.5 105.5 (48.1-200.2) 
Female 9 4.3 211.4 (96.4-401.2)   Female 11 7.1 155.5 (77.5-278.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.9 172.7 (55.6-403.0)   Male 2 2.7 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 7.7 91.1 (36.5-187.7) 
Female 58 59.6 97.4 (73.9-125.9)   Female 6 6.6 91.3 (33.3-198.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.1 112.8 (48.6-222.2) 
Female 4 2.2 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 14.6 68.6 (32.8-126.1)             
Female 12 13.5 88.6 (45.7-154.8)   Female 3 4.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.4 nc (nc-nc)   Male 5 4.5 110.2 (35.5-257.1) 
Female 1 0.8 nc (nc-nc)   Female 7 4.3 162.6 (65.1-335.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 53 42.9 123.7 (92.6-161.7) 
Female 3 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 8.1 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 0 4.4 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Larynx            Testis     
Male 3 2.0 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 5.4 nc (nc-nc)   Male 9 4.1 220.3 (100.5-418.3) 
Female 1 3.9 nc (nc-nc)   Female 16 12.1 132.1 (75.5-214.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.9 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 12 12.7 94.4 (48.7-165.0) 
Lung and Bronchus            All Sites / Types     
Male 15 21.7 69.1 (38.7-114.0)   Male 166 172.5 96.2 (82.2-112.0) 
Female 22 23.3 94.3 (59.1-142.8)   Female 179 185.6 96.5 (82.8-111.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hubbardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.3 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 2.7 188.4 (60.7-439.6) 
Female 16 17.8 89.8 (51.3-145.8)   Female 2 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 6 0.8 708.2 (258.6-1541.5) 
Colon / Rectum            Ovary     
Male 0 5.1 nc (nc-nc)             
Female 5 3.9 129.4 (41.7-302.0)   Female 2 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 12 14.7 81.6 (42.1-142.5) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.7 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.8 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 5 3.6 138.7 (44.7-323.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 7.7 nc (nc-nc)   Male 45 59.5 75.7 (55.2-101.3) 
Female 8 6.5 122.2 (52.6-240.9)   Female 60 54.2 110.7 (84.4-142.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hudson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 22.0 104.7 (66.3-157.1)   Male 13 14.2 91.7 (48.8-156.8) 
Female 8 8.2 97.3 (41.9-191.8)   Female 10 11.2 89.5 (42.9-164.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.3 162.3 (65.0-334.4)   Male 4 4.6 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.8 nc (nc-nc)   Male 7 12.7 55.2 (22.1-113.8) 
Female 89 92.8 95.9 (77.0-118.0)   Female 11 11.4 96.8 (48.3-173.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 10.8 120.3 (64.0-205.8) 
Female 2 3.0 nc (nc-nc)   Female 6 4.8 124.7 (45.5-271.5) 
Colon / Rectum            Ovary     
Male 26 23.9 108.8 (71.1-159.4)             
Female 34 23.2 146.6 (101.5-204.8)   Female 8 7.9 101.4 (43.7-199.8) 
Esophagus            Pancreas     
Male 4 5.8 nc (nc-nc)   Male 1 7.9 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 7 8.3 84.8 (34.0-174.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 69 73.5 93.8 (73.0-118.8) 
Female 2 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 12.8 62.6 (27.0-123.3)   Male 3 5.3 nc (nc-nc) 
Female 10 7.4 134.5 (64.4-247.4)   Female 5 3.1 159.1 (51.3-371.4) 
Larynx            Testis     
Male 1 3.4 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 8.9 67.4 (24.6-146.7)   Male 6 5.8 103.8 (37.9-226.0) 
Female 1 6.5 nc (nc-nc)   Female 28 16.5 170.1 (113.0-245.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.7 65.0 (20.9-151.6)             
Female 2 2.7 nc (nc-nc)   Female 22 20.8 105.6 (66.1-159.9) 
Lung and Bronchus            All Sites / Types     
Male 28 40.4 69.3 (46.1-100.2)   Male 251 291.6 86.1 (75.8-97.4) 
Female 34 44.8 75.8 (52.5-106.0)   Female 309 308.1 100.3 (89.4-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hull 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 13.8 115.8 (66.1-188.0)   Male 17 8.8 193.1 (112.4-309.2) 
Female 7 5.4 130.7 (52.3-269.2)   Female 14 7.1 195.8 (107.0-328.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.5 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 3 7.8 nc (nc-nc) 
Female 60 60.9 98.5 (75.1-126.8)   Female 12 7.4 161.1 (83.2-281.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.8 88.8 (32.4-193.3) 
Female 4 1.8 nc (nc-nc)   Female 7 3.2 220.5 (88.3-454.3) 
Colon / Rectum            Ovary     
Male 15 14.7 102.3 (57.2-168.8)             
Female 15 15.1 99.5 (55.7-164.2)   Female 6 5.2 115.1 (42.0-250.5) 
Esophagus            Pancreas     
Male 2 3.7 nc (nc-nc)   Male 5 5.0 99.5 (32.1-232.1) 
Female 1 1.1 nc (nc-nc)   Female 6 5.3 112.8 (41.2-245.6) 
Hodgkin Lymphoma            Prostate     
Male 4 0.8 nc (nc-nc)   Male 43 46.9 91.8 (66.4-123.6) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 7.8 140.6 (70.1-251.6)   Male 3 3.4 nc (nc-nc) 
Female 6 4.9 123.3 (45.0-268.5)   Female 1 2.0 nc (nc-nc) 
Larynx            Testis     
Male 4 2.2 nc (nc-nc)   Male 5 1.3 385.4 (124.2-899.4) 
Female 2 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.4 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 2 4.1 nc (nc-nc)   Female 7 10.1 69.4 (27.8-143.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 5.1 253.2 (134.7-433.1)             
Female 0 1.8 nc (nc-nc)   Female 17 14.2 119.8 (69.8-191.8) 
Lung and Bronchus            All Sites / Types     
Male 22 25.6 86.0 (53.9-130.2)   Male 193 182.3 105.9 (91.5-121.9) 
Female 33 29.6 111.6 (76.8-156.8)   Female 218 200.6 108.7 (94.7-124.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
151 
Huntington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 10 9.2 108.7 (52.0-199.9)   Female 3 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.4 nc (nc-nc)             
Female 3 2.0 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 4 7.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 3 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 3.9 154.5 (56.4-336.3)   Male 33 29.7 111.0 (76.4-155.9) 
Female 5 4.1 120.8 (38.9-281.9)   Female 33 29.1 113.5 (78.1-159.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
152 
Ipswich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 17.8 95.4 (55.6-152.8)   Male 17 11.3 150.4 (87.6-240.8) 
Female 9 6.7 133.6 (61.0-253.6)   Female 8 8.6 93.4 (40.2-183.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.3 nc (nc-nc)   Male 1 3.7 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 13 10.1 128.4 (68.3-219.6) 
Female 88 72.2 121.9 (97.7-150.1)   Female 8 9.3 86.4 (37.2-170.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.6 104.6 (47.7-198.5) 
Female 2 2.2 nc (nc-nc)   Female 7 3.9 180.7 (72.4-372.4) 
Colon / Rectum            Ovary     
Male 17 19.3 87.9 (51.2-140.7)             
Female 16 19.3 82.7 (47.2-134.3)   Female 5 6.2 80.6 (26.0-188.2) 
Esophagus            Pancreas     
Male 10 4.7 214.5 (102.7-394.5)   Male 7 6.4 108.6 (43.5-223.8) 
Female 3 1.3 nc (nc-nc)   Female 6 6.9 87.5 (31.9-190.4) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 66 58.0 113.8 (88.0-144.8) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 10.0 59.9 (21.9-130.4)   Male 3 4.3 nc (nc-nc) 
Female 6 5.7 104.5 (38.1-227.4)   Female 6 2.6 228.7 (83.5-497.8) 
Larynx            Testis     
Male 2 2.8 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 7.0 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 5 5.1 97.7 (31.5-228.0)   Female 14 11.5 121.8 (66.5-204.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.3 78.9 (25.4-184.1)             
Female 4 2.2 nc (nc-nc)   Female 14 16.5 84.8 (46.3-142.3) 
Lung and Bronchus            All Sites / Types     
Male 22 32.3 68.1 (42.7-103.1)   Male 239 232.0 103.0 (90.4-117.0) 
Female 26 35.2 73.9 (48.3-108.3)   Female 251 242.6 103.5 (91.1-117.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
153 
Kingston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 14.3 83.9 (43.3-146.5)   Male 16 9.1 175.4 (100.2-284.9) 
Female 6 5.6 106.6 (38.9-232.0)   Female 10 7.5 133.5 (63.9-245.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.7 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 4 2.4 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 7 8.1 86.1 (34.5-177.4) 
Female 51 61.8 82.5 (61.5-108.5)   Female 8 7.8 102.8 (44.3-202.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.7 74.1 (23.9-173.0) 
Female 4 2.0 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 15.4 90.7 (49.5-152.1)             
Female 9 16.6 54.1 (24.7-102.7)   Female 2 5.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.6 nc (nc-nc)   Male 12 5.1 234.3 (120.9-409.3) 
Female 4 1.1 nc (nc-nc)   Female 9 5.7 157.0 (71.6-298.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 41 43.0 95.3 (68.3-129.2) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 7.8 89.3 (35.8-184.1)   Male 5 3.5 144.0 (46.4-336.1) 
Female 2 4.9 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Larynx            Testis     
Male 2 2.2 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 5.8 156.3 (71.3-296.8)   Male 5 3.5 142.6 (45.9-332.7) 
Female 4 4.5 nc (nc-nc)   Female 15 10.9 137.0 (76.6-226.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 5.1 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 15 13.3 113.2 (63.3-186.7) 
Lung and Bronchus            All Sites / Types     
Male 26 25.6 101.6 (66.3-148.8)   Male 183 182.9 100.1 (86.1-115.7) 
Female 27 29.3 92.2 (60.7-134.1)   Female 203 207.0 98.1 (85.0-112.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
154 
Lakeville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 11.5 87.0 (41.7-160.1)   Male 8 7.7 103.8 (44.7-204.5) 
Female 5 3.9 127.0 (40.9-296.4)   Female 4 6.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.4 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 6.9 72.7 (23.4-169.8) 
Female 49 50.6 96.9 (71.7-128.1)   Female 5 5.8 85.6 (27.6-199.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.3 111.5 (44.7-229.6) 
Female 1 1.7 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 13.0 76.9 (36.8-141.5)             
Female 9 11.8 76.5 (34.9-145.2)   Female 5 4.2 117.7 (37.9-274.6) 
Esophagus            Pancreas     
Male 4 3.2 nc (nc-nc)   Male 2 4.3 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 4 4.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 35 42.2 82.9 (57.7-115.3) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.2 69.5 (22.4-162.1)   Male 4 2.9 nc (nc-nc) 
Female 2 3.9 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Larynx            Testis     
Male 2 1.9 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.8 nc (nc-nc)   Male 5 3.2 156.4 (50.4-364.9) 
Female 2 3.3 nc (nc-nc)   Female 15 9.3 160.9 (90.0-265.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.5 nc (nc-nc)             
Female 3 1.4 nc (nc-nc)   Female 13 11.7 111.6 (59.4-190.8) 
Lung and Bronchus            All Sites / Types     
Male 14 21.6 64.8 (35.4-108.8)   Male 139 160.5 86.6 (72.8-102.2) 
Female 19 21.4 88.8 (53.4-138.7)   Female 161 161.2 99.9 (85.1-116.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
155 
Lancaster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 8.2 84.9 (34.0-175.0)   Male 6 5.5 108.7 (39.7-236.6) 
Female 4 2.2 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 7 5.0 141.0 (56.5-290.6) 
Female 28 28.2 99.5 (66.1-143.7)   Female 3 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 9.0 99.6 (45.5-189.1)             
Female 4 6.7 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 34 28.5 119.2 (82.6-166.6) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.9 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.5 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 5 5.6 90.1 (29.0-210.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.0 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 3 6.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 15.0 46.6 (18.7-96.0)   Male 100 112.9 88.6 (72.1-107.7) 
Female 11 12.3 89.5 (44.6-160.2)   Female 81 91.3 88.7 (70.4-110.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Lanesborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.8 nc (nc-nc)   Male 5 2.0 246.4 (79.4-575.0) 
Female 1 1.0 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 11 12.5 87.9 (43.8-157.3)   Female 1 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 3.3 nc (nc-nc)             
Female 3 3.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 10 11.3 88.6 (42.4-162.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.9 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 3 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.2 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 1 0.3 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 9 5.5 164.1 (74.9-311.6)   Male 45 42.2 106.7 (77.8-142.8) 
Female 3 5.3 nc (nc-nc)   Female 36 40.3 89.2 (62.5-123.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
157 
Lawrence 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 49.4 109.4 (82.2-142.7)   Male 9 34.6 26.0 (11.9-49.4) 
Female 16 19.7 81.1 (46.3-131.7)   Female 9 32.8 27.4 (12.5-52.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 12.8 70.4 (32.1-133.7)   Male 11 10.7 103.2 (51.5-184.7) 
Female 8 11.3 71.1 (30.6-140.1)   Female 18 9.3 193.4 (114.5-305.6) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.8 nc (nc-nc)   Male 21 31.3 67.1 (41.5-102.6) 
Female 175 250.4 69.9 (59.9-81.1)   Female 35 29.9 117.2 (81.6-163.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 31 26.6 116.4 (79.1-165.2) 
Female 18 9.9 182.0 (107.8-287.7)   Female 12 12.8 93.5 (48.2-163.3) 
Colon / Rectum            Ovary     
Male 57 57.1 99.8 (75.6-129.3)             
Female 44 61.3 71.8 (52.2-96.4)   Female 10 21.4 46.7 (22.3-85.9) 
Esophagus            Pancreas     
Male 8 13.4 59.6 (25.7-117.5)   Male 19 18.3 104.0 (62.6-162.3) 
Female 9 3.9 230.4 (105.1-437.4)   Female 14 20.3 68.8 (37.6-115.5) 
Hodgkin Lymphoma            Prostate     
Male 4 6.1 nc (nc-nc)   Male 217 165.2 131.4 (114.5-150.1) 
Female 7 5.3 132.4 (53.1-272.9)             
Kidney & Renal Pelvis            Stomach     
Male 24 31.2 77.0 (49.3-114.6)   Male 21 12.4 168.7 (104.4-257.9) 
Female 24 19.3 124.6 (79.8-185.5)   Female 16 8.3 192.6 (110.0-312.8) 
Larynx            Testis     
Male 10 7.9 127.0 (60.8-233.5)   Male 9 12.0 74.8 (34.1-142.0) 
Female 3 2.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 23.4 68.3 (39.0-110.9)   Male 14 16.4 85.6 (46.8-143.7) 
Female 19 18.8 101.3 (60.9-158.1)   Female 62 56.7 109.4 (83.9-140.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 37 19.0 195.0 (137.3-268.8)             
Female 14 6.8 205.1 (112.0-344.2)   Female 49 54.5 89.9 (66.5-118.8) 
Lung and Bronchus            All Sites / Types     
Male 92 89.4 102.9 (83.0-126.2)   Male 723 694.7 104.1 (96.6-111.9) 
Female 97 103.4 93.8 (76.1-114.5)   Female 716 823.3 87.0 (80.7-93.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Lee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 9.1 165.3 (92.4-272.6)   Male 6 5.3 113.1 (41.3-246.1) 
Female 1 2.6 nc (nc-nc)   Female 6 3.5 172.3 (62.9-374.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 5 1.1 438.5 (141.3-1023.3)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 4.7 nc (nc-nc) 
Female 26 28.9 89.9 (58.7-131.7)   Female 3 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.0 67.0 (24.5-145.9)             
Female 6 7.2 83.7 (30.6-182.1)   Female 2 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 2.3 222.1 (71.6-518.4)   Male 3 3.1 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 20 27.1 73.8 (45.1-114.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.5 111.5 (35.9-260.2)   Male 0 2.1 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 4 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.4 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 3 4.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 5 6.8 73.9 (23.8-172.5) 
Lung and Bronchus            All Sites / Types     
Male 19 16.1 118.2 (71.2-184.7)   Male 107 110.0 97.2 (79.7-117.5) 
Female 18 14.3 125.9 (74.6-199.1)   Female 97 96.8 100.2 (81.3-122.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
159 
Leicester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 12.0 100.4 (51.8-175.4)   Male 14 7.8 178.4 (97.4-299.3) 
Female 5 4.8 104.9 (33.8-244.8)   Female 7 6.4 109.0 (43.7-224.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.4 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 2 7.0 nc (nc-nc) 
Female 43 52.5 81.9 (59.3-110.3)   Female 4 6.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.0 132.3 (57.0-260.8) 
Female 4 1.7 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 13.2 83.6 (41.7-149.6)             
Female 7 13.6 51.6 (20.7-106.2)   Female 6 4.6 131.9 (48.2-287.0) 
Esophagus            Pancreas     
Male 5 3.2 154.8 (49.9-361.4)   Male 1 4.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 29 40.0 72.4 (48.5-104.0) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.0 71.4 (23.0-166.6)   Male 2 2.9 nc (nc-nc) 
Female 6 4.2 141.6 (51.7-308.1)   Female 0 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.9 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 4.9 244.5 (126.2-427.1)   Male 4 3.2 nc (nc-nc) 
Female 5 3.7 135.5 (43.7-316.1)   Female 5 9.3 53.5 (17.3-124.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.5 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 13 12.0 108.7 (57.8-185.8) 
Lung and Bronchus            All Sites / Types     
Male 17 21.8 77.8 (45.3-124.7)   Male 144 160.5 89.7 (75.6-105.6) 
Female 19 25.7 73.9 (44.4-115.3)   Female 148 176.4 83.9 (70.9-98.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
160 
Lenox 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 11.3 150.1 (87.4-240.3)   Male 8 6.0 133.4 (57.5-262.9) 
Female 2 3.9 nc (nc-nc)   Female 6 4.1 146.4 (53.4-318.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.4 110.9 (40.5-241.3) 
Female 38 33.5 113.4 (80.3-155.7)   Female 4 4.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 10.6 141.6 (79.2-233.6)             
Female 16 10.9 146.3 (83.6-237.7)   Female 6 3.0 198.1 (72.3-431.1) 
Esophagus            Pancreas     
Male 1 2.5 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 5 4.1 122.0 (39.3-284.7) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 24 27.6 86.9 (55.7-129.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.6 108.3 (34.9-252.7)   Male 0 2.5 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.9 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.0 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 7 7.7 90.6 (36.3-186.7) 
Lung and Bronchus            All Sites / Types     
Male 12 18.5 65.0 (33.5-113.5)   Male 110 122.1 90.1 (74.1-108.6) 
Female 18 19.3 93.5 (55.4-147.7)   Female 127 122.7 103.5 (86.3-123.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
161 
Leominster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 60 46.9 127.9 (97.6-164.7)   Male 22 29.5 74.6 (46.7-112.9) 
Female 28 15.2 183.7 (122.0-265.5)   Female 17 21.8 78.0 (45.4-124.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 8.7 57.3 (18.5-133.6)   Male 11 9.5 116.2 (57.9-208.0) 
Female 8 6.9 115.2 (49.6-227.1)   Female 4 7.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.6 nc (nc-nc)   Male 24 26.5 90.5 (57.9-134.6) 
Female 176 173.7 101.3 (86.9-117.5)   Female 24 21.6 110.9 (71.0-165.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 21.5 102.2 (64.0-154.8) 
Female 9 6.0 149.2 (68.1-283.3)   Female 10 9.2 109.1 (52.2-200.7) 
Colon / Rectum            Ovary     
Male 43 50.8 84.7 (61.3-114.1)             
Female 33 46.0 71.8 (49.4-100.8)   Female 30 14.9 200.8 (135.5-286.7) 
Esophagus            Pancreas     
Male 13 11.7 111.0 (59.0-189.8)   Male 13 16.5 78.7 (41.9-134.6) 
Female 3 2.9 nc (nc-nc)   Female 17 15.6 109.1 (63.5-174.6) 
Hodgkin Lymphoma            Prostate     
Male 1 3.5 nc (nc-nc)   Male 136 137.6 98.8 (82.9-116.9) 
Female 3 2.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 25.3 118.6 (80.0-169.3)   Male 13 11.2 115.6 (61.5-197.7) 
Female 14 13.7 102.5 (56.0-172.0)   Female 2 6.2 nc (nc-nc) 
Larynx            Testis     
Male 9 6.8 133.3 (60.8-253.0)   Male 3 6.3 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 18.8 90.6 (52.7-145.1)   Male 12 11.6 103.4 (53.3-180.5) 
Female 12 12.7 94.6 (48.8-165.3)   Female 23 33.5 68.7 (43.6-103.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 15.8 44.4 (17.8-91.5)             
Female 3 5.0 nc (nc-nc)   Female 43 38.1 113.0 (81.8-152.2) 
Lung and Bronchus            All Sites / Types     
Male 79 81.4 97.0 (76.8-120.9)   Male 559 590.8 94.6 (86.9-102.8) 
Female 90 79.4 113.3 (91.1-139.3)   Female 597 581.1 102.7 (94.7-111.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
162 
Leverett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.0 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 11 10.6 103.5 (51.6-185.2)   Female 1 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.4 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.0 nc (nc-nc)             
Female 1 2.4 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 4 10.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.6 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 5.5 90.7 (29.2-211.8)   Male 24 38.8 61.9 (39.6-92.1) 
Female 3 5.2 nc (nc-nc)   Female 34 34.5 98.5 (68.2-137.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
163 
Lexington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 40.7 61.4 (39.8-90.7)   Male 28 25.1 111.5 (74.1-161.2) 
Female 5 15.6 32.1 (10.3-74.9)   Female 22 19.5 112.9 (70.7-170.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 7.3 82.0 (30.0-178.6)   Male 11 8.2 133.6 (66.6-239.1) 
Female 4 6.3 nc (nc-nc)   Female 8 7.0 114.8 (49.4-226.1) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.4 nc (nc-nc)   Male 18 22.5 79.9 (47.3-126.3) 
Female 175 162.0 108.0 (92.6-125.3)   Female 24 21.1 113.7 (72.9-169.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 18.6 91.2 (53.1-146.0) 
Female 1 4.9 nc (nc-nc)   Female 7 8.8 79.5 (31.8-163.8) 
Colon / Rectum            Ovary     
Male 38 43.1 88.2 (62.4-121.1)             
Female 32 45.3 70.6 (48.3-99.7)   Female 15 14.0 107.3 (60.0-176.9) 
Esophagus            Pancreas     
Male 3 10.3 nc (nc-nc)   Male 10 14.4 69.6 (33.3-128.1) 
Female 0 3.0 nc (nc-nc)   Female 17 15.9 106.8 (62.2-171.0) 
Hodgkin Lymphoma            Prostate     
Male 1 2.4 nc (nc-nc)   Male 131 124.0 105.6 (88.3-125.3) 
Female 1 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 21.9 77.8 (45.3-124.6)   Male 3 9.7 nc (nc-nc) 
Female 4 13.1 nc (nc-nc)   Female 6 6.2 97.3 (35.5-211.9) 
Larynx            Testis     
Male 3 6.0 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 16.0 87.2 (47.7-146.4)   Male 8 9.3 86.0 (37.0-169.4) 
Female 12 12.1 99.2 (51.2-173.3)   Female 36 26.3 136.9 (95.9-189.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 13.8 nc (nc-nc)             
Female 5 5.0 100.9 (32.5-235.5)   Female 29 36.0 80.7 (54.0-115.8) 
Lung and Bronchus            All Sites / Types     
Male 28 71.8 39.0 (25.9-56.4)   Male 405 512.1 79.1 (71.6-87.2) 
Female 45 80.2 56.1 (40.9-75.1)   Female 490 552.5 88.7 (81.0-96.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
164 
Leyden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 3.9 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.5 nc (nc-nc)   Male 10 11.8 84.7 (40.5-155.7) 
Female 2 1.5 nc (nc-nc)   Female 13 11.9 109.0 (58.0-186.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
165 
Lincoln 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 9.4 nc (nc-nc)   Male 7 5.5 127.7 (51.2-263.1) 
Female 8 2.6 306.1 (131.8-603.2)   Female 8 3.6 222.5 (95.8-438.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.6 318.9 (102.8-744.3)   Male 3 1.8 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 4 4.9 nc (nc-nc) 
Female 47 29.1 161.8 (118.9-215.1)   Female 4 3.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.7 136.7 (44.0-319.0) 
Female 0 1.0 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.5 73.5 (29.5-151.5)             
Female 5 7.8 64.3 (20.7-150.2)   Female 4 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.1 nc (nc-nc)   Male 5 3.2 157.8 (50.8-368.2) 
Female 0 0.5 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 43 23.5 183.2 (132.6-246.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.4 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.6 165.7 (60.5-360.6)   Male 4 1.9 nc (nc-nc) 
Female 7 2.3 309.0 (123.8-636.7)   Female 4 5.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.8 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 11 6.5 168.3 (83.9-301.1) 
Lung and Bronchus            All Sites / Types     
Male 7 15.6 44.7 (17.9-92.2)   Male 121 108.4 111.6 (92.6-133.3) 
Female 9 13.5 66.6 (30.4-126.5)   Female 126 98.0 128.5 (107.1-153.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
166 
Littleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 8.0 174.0 (95.0-291.9)   Male 6 5.7 104.7 (38.2-227.8) 
Female 1 3.6 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 10 5.1 195.4 (93.5-359.3) 
Female 42 42.4 99.0 (71.3-133.8)   Female 4 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.6 130.2 (47.5-283.4) 
Female 0 1.4 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 9.6 52.3 (16.9-122.2)             
Female 7 10.8 64.8 (26.0-133.5)   Female 6 3.6 165.0 (60.3-359.2) 
Esophagus            Pancreas     
Male 1 2.3 nc (nc-nc)   Male 6 3.1 192.1 (70.1-418.1) 
Female 0 0.7 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 33 28.7 114.9 (79.1-161.4) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.3 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 3 3.3 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.5 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 9 7.7 117.5 (53.6-223.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.3 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 14 9.5 148.0 (80.8-248.3) 
Lung and Bronchus            All Sites / Types     
Male 20 15.1 132.8 (81.1-205.0)   Male 130 115.3 112.8 (94.2-133.9) 
Female 14 19.4 72.2 (39.5-121.2)   Female 122 139.8 87.3 (72.5-104.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
167 
Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 22.3 67.1 (37.5-110.7)   Male 18 13.2 136.9 (81.1-216.3) 
Female 7 8.2 85.6 (34.3-176.3)   Female 14 10.0 140.6 (76.8-236.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.6 nc (nc-nc)   Male 2 4.3 nc (nc-nc) 
Female 4 3.2 nc (nc-nc)   Female 1 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 10 11.9 84.3 (40.3-155.0) 
Female 86 80.2 107.2 (85.8-132.4)   Female 12 10.9 110.6 (57.1-193.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 9.4 53.3 (17.2-124.4) 
Female 0 2.4 nc (nc-nc)   Female 0 4.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 23.2 47.5 (23.7-85.0)             
Female 15 24.3 61.7 (34.5-101.7)   Female 5 7.1 70.6 (22.7-164.7) 
Esophagus            Pancreas     
Male 3 5.3 nc (nc-nc)   Male 3 7.7 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 4 8.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 54 63.1 85.6 (64.3-111.7) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 11.0 99.9 (49.8-178.9)   Male 5 5.2 96.1 (31.0-224.3) 
Female 3 6.6 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Larynx            Testis     
Male 1 3.0 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 8.4 178.3 (99.7-294.0)   Male 5 4.5 111.5 (35.9-260.2) 
Female 2 6.4 nc (nc-nc)   Female 9 12.9 69.9 (31.9-132.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.0 nc (nc-nc)             
Female 6 2.5 238.0 (86.9-518.0)   Female 12 17.7 67.8 (35.0-118.5) 
Lung and Bronchus            All Sites / Types     
Male 24 38.2 62.9 (40.3-93.6)   Male 213 267.6 79.6 (69.3-91.0) 
Female 24 40.5 59.3 (38.0-88.3)   Female 234 281.3 83.2 (72.9-94.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
168 
Lowell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 75 81.8 91.7 (72.1-114.9)   Male 32 56.9 56.2 (38.5-79.4) 
Female 37 31.9 115.9 (81.6-159.7)   Female 26 49.1 53.0 (34.6-77.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 15 19.8 75.9 (42.5-125.2)   Male 17 17.5 97.1 (56.5-155.4) 
Female 14 16.1 87.0 (47.5-146.0)   Female 23 14.7 156.5 (99.2-234.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 3.0 nc (nc-nc)   Male 44 51.3 85.8 (62.3-115.2) 
Female 307 371.9 82.5 (73.6-92.3)   Female 36 46.5 77.4 (54.2-107.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 58 44.1 131.5 (99.9-170.0) 
Female 17 14.0 121.2 (70.6-194.1)   Female 13 19.6 66.4 (35.3-113.5) 
Colon / Rectum            Ovary     
Male 87 94.7 91.9 (73.6-113.4)             
Female 101 96.5 104.7 (85.3-127.2)   Female 25 32.3 77.4 (50.1-114.2) 
Esophagus            Pancreas     
Male 22 22.2 99.0 (62.0-150.0)   Male 29 30.5 95.2 (63.8-136.8) 
Female 4 6.2 nc (nc-nc)   Female 28 32.5 86.2 (57.2-124.5) 
Hodgkin Lymphoma            Prostate     
Male 14 9.3 149.8 (81.8-251.4)   Male 214 277.2 77.2 (67.2-88.3) 
Female 4 7.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 59 51.1 115.6 (88.0-149.1)   Male 25 20.6 121.2 (78.4-178.9) 
Female 34 29.4 115.7 (80.1-161.7)   Female 32 13.1 244.5 (167.2-345.2) 
Larynx            Testis     
Male 16 13.1 122.2 (69.8-198.5)   Male 14 18.6 75.4 (41.2-126.6) 
Female 6 4.0 151.1 (55.2-329.0)             
Leukemia            Thyroid     
Male 35 37.3 94.0 (65.4-130.7)   Male 17 26.2 64.9 (37.8-104.0) 
Female 35 28.4 123.4 (85.9-171.6)   Female 79 80.0 98.7 (78.1-123.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 65 31.6 205.9 (158.9-262.4)             
Female 7 10.7 65.5 (26.2-135.0)   Female 81 81.2 99.7 (79.2-124.0) 
Lung and Bronchus            All Sites / Types     
Male 178 147.7 120.5 (103.4-139.6)   Male 1135 1145.1 99.1 (93.4-105.1) 
Female 191 166.5 114.7 (99.0-132.2)   Female 1200 1252.9 95.8 (90.4-101.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
169 
Ludlow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 25.4 110.2 (73.2-159.3)   Male 12 16.3 73.7 (38.0-128.7) 
Female 4 10.2 nc (nc-nc)   Female 15 13.1 114.1 (63.8-188.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 4.8 nc (nc-nc)   Male 3 5.2 nc (nc-nc) 
Female 2 4.2 nc (nc-nc)   Female 5 4.6 108.4 (34.9-253.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 14 14.5 96.7 (52.8-162.2) 
Female 88 108.1 81.4 (65.3-100.3)   Female 13 14.0 92.8 (49.4-158.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 12.5 56.0 (22.4-115.5) 
Female 7 3.3 209.7 (84.0-432.1)   Female 4 5.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 29 27.6 104.9 (70.3-150.7)             
Female 27 29.5 91.5 (60.3-133.1)   Female 9 9.3 96.5 (44.0-183.1) 
Esophagus            Pancreas     
Male 2 6.7 nc (nc-nc)   Male 8 9.2 87.3 (37.6-172.0) 
Female 2 2.0 nc (nc-nc)   Female 12 10.4 114.9 (59.3-200.8) 
Hodgkin Lymphoma            Prostate     
Male 2 1.8 nc (nc-nc)   Male 67 83.1 80.6 (62.5-102.4) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 14.4 159.5 (101.1-239.4)   Male 8 6.2 129.8 (55.9-255.8) 
Female 5 8.7 57.6 (18.6-134.4)   Female 4 4.0 nc (nc-nc) 
Larynx            Testis     
Male 4 3.9 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 10.1 69.1 (27.7-142.4)   Male 4 6.4 nc (nc-nc) 
Female 6 8.0 75.3 (27.5-163.8)   Female 6 18.0 33.3 (12.2-72.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.3 75.6 (30.3-155.8)             
Female 2 3.3 nc (nc-nc)   Female 22 24.4 90.3 (56.6-136.7) 
Lung and Bronchus            All Sites / Types     
Male 32 45.6 70.2 (48.0-99.1)   Male 292 333.2 87.6 (77.9-98.3) 
Female 34 53.2 63.9 (44.2-89.2)   Female 299 367.4 81.4 (72.4-91.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
170 
Lunenburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 12.7 70.8 (32.3-134.3)   Male 8 8.0 99.6 (42.9-196.3) 
Female 6 4.2 142.3 (52.0-309.8)   Female 3 6.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.4 nc (nc-nc)   Male 4 2.6 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 7.3 69.0 (22.2-160.9) 
Female 55 50.8 108.2 (81.5-140.8)   Female 6 6.2 97.5 (35.6-212.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 6.1 147.0 (67.1-279.2) 
Female 1 1.6 nc (nc-nc)   Female 0 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 14.0 99.7 (54.5-167.3)             
Female 14 12.5 112.1 (61.2-188.1)   Female 3 4.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.3 nc (nc-nc)   Male 4 4.5 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 0.9 nc (nc-nc)   Male 42 40.1 104.8 (75.5-141.7) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 7.2 97.7 (39.1-201.3)   Male 2 3.1 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 3 1.9 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 5.1 157.9 (68.0-311.1)   Male 4 3.2 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 10 9.0 110.6 (52.9-203.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.4 nc (nc-nc)             
Female 3 1.5 nc (nc-nc)   Female 15 11.9 126.2 (70.6-208.1) 
Lung and Bronchus            All Sites / Types     
Male 24 22.4 107.0 (68.6-159.3)   Male 168 164.2 102.3 (87.4-119.0) 
Female 16 22.7 70.5 (40.3-114.5)   Female 156 165.8 94.1 (79.9-110.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
171 
Lynn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 72 71.3 101.0 (79.1-127.3)   Male 43 48.4 88.8 (64.3-119.6) 
Female 25 28.7 87.1 (56.4-128.7)   Female 31 42.7 72.6 (49.3-103.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 19 16.5 115.4 (69.4-180.2)   Male 32 15.2 211.1 (144.4-298.0) 
Female 17 14.2 119.4 (69.5-191.2)   Female 16 13.1 121.7 (69.5-197.7) 
Breast            Non-Hodgkin Lymphoma     
Male 5 2.6 194.2 (62.6-453.2)   Male 51 43.8 116.4 (86.7-153.1) 
Female 325 328.7 98.9 (88.4-110.2)   Female 51 41.2 123.8 (92.2-162.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 50 36.8 135.9 (100.8-179.1) 
Female 16 12.0 133.8 (76.4-217.2)   Female 19 17.4 109.2 (65.7-170.6) 
Colon / Rectum            Ovary     
Male 120 81.8 146.8 (121.7-175.5)             
Female 111 85.6 129.6 (106.6-156.1)   Female 24 28.6 84.0 (53.8-125.0) 
Esophagus            Pancreas     
Male 21 18.9 111.0 (68.7-169.7)   Male 27 26.1 103.6 (68.3-150.8) 
Female 5 5.6 89.4 (28.8-208.6)   Female 24 29.2 82.2 (52.7-122.3) 
Hodgkin Lymphoma            Prostate     
Male 5 7.4 67.4 (21.7-157.2)   Male 290 232.0 125.0 (111.0-140.2) 
Female 2 6.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 35 43.1 81.2 (56.5-112.9)   Male 21 17.8 118.1 (73.1-180.5) 
Female 28 26.2 106.9 (71.0-154.6)   Female 22 11.6 189.9 (118.9-287.5) 
Larynx            Testis     
Male 15 11.1 134.8 (75.4-222.4)   Male 14 14.6 96.1 (52.5-161.3) 
Female 4 3.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 46 31.6 145.6 (106.6-194.2)   Male 20 21.7 92.2 (56.3-142.4) 
Female 32 25.3 126.6 (86.6-178.7)   Female 53 68.3 77.6 (58.2-101.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 57 26.3 216.5 (164.0-280.6)             
Female 18 9.5 188.7 (111.8-298.2)   Female 73 72.3 101.0 (79.2-127.0) 
Lung and Bronchus            All Sites / Types     
Male 195 127.2 153.3 (132.5-176.4)   Male 1230 972.1 126.5 (119.6-133.8) 
Female 171 150.5 113.7 (97.3-132.0)   Female 1176 1110.3 105.9 (99.9-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
172 
Lynnfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 15.7 76.2 (39.3-133.1)   Male 24 9.9 242.3 (155.2-360.5) 
Female 10 5.4 184.8 (88.5-339.8)   Female 13 7.1 184.4 (98.1-315.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.8 nc (nc-nc)   Male 5 3.2 154.8 (49.9-361.4) 
Female 4 2.3 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 14 8.8 158.9 (86.8-266.6) 
Female 60 58.7 102.2 (78.0-131.6)   Female 13 7.4 175.1 (93.2-299.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.5 67.0 (21.6-156.3) 
Female 0 1.8 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 17.0 76.6 (40.7-130.9)             
Female 21 15.7 133.8 (82.8-204.6)   Female 8 5.0 158.6 (68.3-312.6) 
Esophagus            Pancreas     
Male 1 4.1 nc (nc-nc)   Male 5 5.6 89.4 (28.8-208.5) 
Female 0 1.1 nc (nc-nc)   Female 7 5.5 127.3 (51.0-262.2) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 44 49.7 88.6 (64.4-118.9) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 8.7 80.6 (32.3-166.0)   Male 2 3.8 nc (nc-nc) 
Female 4 4.7 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Larynx            Testis     
Male 1 2.4 nc (nc-nc)   Male 6 1.6 373.7 (136.4-813.3) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 6.1 179.5 (89.5-321.3)   Male 6 3.8 159.3 (58.2-346.7) 
Female 3 4.2 nc (nc-nc)   Female 18 9.9 181.4 (107.5-286.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 5.5 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 17 13.1 129.8 (75.6-207.9) 
Lung and Bronchus            All Sites / Types     
Male 19 28.2 67.3 (40.5-105.1)   Male 190 202.0 94.1 (81.2-108.4) 
Female 29 28.4 102.0 (68.3-146.5)   Female 233 197.4 118.0 (103.4-134.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
173 
Malden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 46.7 57.8 (38.1-84.1)   Male 10 32.5 30.7 (14.7-56.5) 
Female 21 18.9 111.4 (68.9-170.3)   Female 16 29.4 54.3 (31.0-88.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 10.9 46.1 (14.8-107.5)   Male 7 10.1 69.1 (27.7-142.4) 
Female 7 9.3 75.0 (30.0-154.5)   Female 5 8.7 57.3 (18.4-133.6) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.7 nc (nc-nc)   Male 43 29.2 147.2 (106.5-198.3) 
Female 185 223.3 82.9 (71.3-95.7)   Female 26 27.6 94.3 (61.6-138.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 24.7 93.2 (59.1-139.9) 
Female 15 8.7 172.8 (96.7-285.1)   Female 11 11.6 94.7 (47.2-169.4) 
Colon / Rectum            Ovary     
Male 71 53.4 132.9 (103.8-167.6)             
Female 72 57.6 125.0 (97.8-157.5)   Female 16 19.2 83.4 (47.6-135.5) 
Esophagus            Pancreas     
Male 17 12.6 134.9 (78.6-216.1)   Male 20 17.2 116.2 (70.9-179.4) 
Female 8 3.6 219.8 (94.6-433.1)   Female 18 19.3 93.3 (55.3-147.5) 
Hodgkin Lymphoma            Prostate     
Male 3 5.3 nc (nc-nc)   Male 128 152.3 84.0 (70.1-99.9) 
Female 4 4.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 28.9 124.8 (87.4-172.7)   Male 16 11.7 136.3 (77.9-221.4) 
Female 21 17.4 120.9 (74.8-184.8)   Female 7 7.8 89.7 (35.9-184.9) 
Larynx            Testis     
Male 9 7.4 121.4 (55.4-230.5)   Male 7 10.8 65.0 (26.0-133.9) 
Female 2 2.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 20.7 106.1 (66.5-160.6)   Male 15 15.1 99.4 (55.6-163.9) 
Female 16 16.6 96.5 (55.1-156.6)   Female 59 49.1 120.3 (91.5-155.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 17.7 141.5 (91.6-208.9)             
Female 16 6.3 255.2 (145.8-414.5)   Female 50 48.0 104.2 (77.3-137.3) 
Lung and Bronchus            All Sites / Types     
Male 116 83.9 138.3 (114.3-165.9)   Male 639 644.5 99.1 (91.6-107.1) 
Female 108 97.9 110.3 (90.5-133.2)   Female 740 746.7 99.1 (92.1-106.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
174 
Manchester by the Sea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 8.1 nc (nc-nc)   Male 9 4.7 191.1 (87.2-362.7) 
Female 1 2.7 nc (nc-nc)   Female 5 3.4 146.6 (47.2-342.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.3 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 8 4.2 188.5 (81.2-371.4) 
Female 29 29.3 99.0 (66.3-142.2)   Female 2 3.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 8.3 nc (nc-nc)             
Female 6 7.6 79.4 (29.0-172.7)   Female 1 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.0 nc (nc-nc)   Male 0 2.8 nc (nc-nc) 
Female 3 0.5 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 23.3 102.9 (65.9-153.1) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.0 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 0 2.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 3 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.0 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 8 4.6 174.3 (75.1-343.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.6 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 6 6.7 89.1 (32.5-193.9) 
Lung and Bronchus            All Sites / Types     
Male 8 13.7 58.3 (25.1-114.9)   Male 84 97.0 86.6 (69.1-107.2) 
Female 8 14.6 55.0 (23.7-108.3)   Female 86 97.8 87.9 (70.3-108.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
175 
Mansfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 16.7 143.3 (91.8-213.2)   Male 25 12.2 205.5 (132.9-303.3) 
Female 0 5.8 nc (nc-nc)   Female 21 10.3 203.9 (126.2-311.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 4.2 189.3 (81.5-373.0)   Male 5 3.8 131.9 (42.5-307.8) 
Female 6 3.4 178.9 (65.3-389.3)   Female 1 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.6 nc (nc-nc)   Male 13 11.0 118.4 (63.0-202.5) 
Female 93 83.6 111.3 (89.8-136.3)   Female 3 9.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 9.9 101.0 (48.4-185.8) 
Female 1 3.2 nc (nc-nc)   Female 1 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 20.6 121.3 (78.4-179.0)             
Female 27 19.0 142.4 (93.8-207.1)   Female 8 7.0 114.7 (49.4-226.0) 
Esophagus            Pancreas     
Male 1 4.8 nc (nc-nc)   Male 5 6.4 77.8 (25.1-181.5) 
Female 1 1.2 nc (nc-nc)   Female 6 5.9 101.3 (37.0-220.5) 
Hodgkin Lymphoma            Prostate     
Male 0 1.8 nc (nc-nc)   Male 60 59.3 101.1 (77.2-130.2) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 11.4 114.5 (60.9-195.8)   Male 5 4.4 114.7 (37.0-267.8) 
Female 5 6.2 81.2 (26.2-189.4)   Female 4 2.5 nc (nc-nc) 
Larynx            Testis     
Male 0 2.8 nc (nc-nc)   Male 8 3.5 231.6 (99.7-456.4) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 7.8 76.6 (28.0-166.8)   Male 15 5.9 254.9 (142.6-420.5) 
Female 11 5.4 202.7 (101.0-362.6)   Female 17 18.1 93.7 (54.6-150.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 6.9 131.0 (59.8-248.7)             
Female 3 2.1 nc (nc-nc)   Female 11 18.0 61.2 (30.5-109.5) 
Lung and Bronchus            All Sites / Types     
Male 35 30.6 114.5 (79.7-159.2)   Male 284 243.5 116.6 (103.4-131.0) 
Female 34 31.7 107.4 (74.4-150.1)   Female 282 260.5 108.2 (96.0-121.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
176 
Marblehead 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 27.4 83.8 (53.1-125.8)   Male 41 16.5 248.1 (178.0-336.6) 
Female 10 9.7 103.2 (49.4-189.7)   Female 26 12.6 205.7 (134.3-301.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.7 nc (nc-nc)   Male 8 5.5 146.7 (63.2-289.2) 
Female 3 4.1 nc (nc-nc)   Female 7 4.4 158.3 (63.4-326.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 14 14.9 94.1 (51.4-157.9) 
Female 126 107.1 117.6 (98.0-140.0)   Female 13 13.4 97.3 (51.7-166.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 11.9 92.1 (45.9-164.9) 
Female 5 3.3 151.9 (49.0-354.6)   Female 7 5.7 123.3 (49.4-254.0) 
Colon / Rectum            Ovary     
Male 25 28.5 87.8 (56.8-129.6)             
Female 23 28.1 81.9 (51.9-122.9)   Female 6 9.1 65.6 (23.9-142.7) 
Esophagus            Pancreas     
Male 9 6.8 132.6 (60.5-251.7)   Male 10 9.6 104.5 (50.0-192.2) 
Female 2 1.9 nc (nc-nc)   Female 13 9.9 131.9 (70.2-225.5) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 95 80.5 118.0 (95.5-144.3) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 14.2 84.6 (43.7-147.8)   Male 6 6.5 92.9 (33.9-202.3) 
Female 6 8.5 70.4 (25.7-153.3)   Female 1 3.8 nc (nc-nc) 
Larynx            Testis     
Male 2 3.9 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 10.6 104.0 (51.9-186.1)   Male 7 5.8 120.6 (48.3-248.4) 
Female 8 7.6 105.9 (45.6-208.6)   Female 14 17.7 79.2 (43.3-132.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 8.9 nc (nc-nc)             
Female 1 3.2 nc (nc-nc)   Female 20 24.2 82.5 (50.4-127.4) 
Lung and Bronchus            All Sites / Types     
Male 28 48.2 58.1 (38.6-83.9)   Male 339 336.8 100.7 (90.2-112.0) 
Female 39 51.5 75.8 (53.9-103.6)   Female 364 356.9 102.0 (91.8-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
177 
Marion 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 7.5 66.6 (21.5-155.4)   Male 10 4.5 222.1 (106.3-408.5) 
Female 4 2.8 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.3 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 11 4.1 269.8 (134.5-482.7) 
Female 34 27.1 125.5 (86.9-175.4)   Female 3 3.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.4 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.7 117.4 (53.6-222.8)             
Female 11 8.0 137.9 (68.7-246.7)   Female 0 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 0 2.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 14 24.9 56.3 (30.7-94.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.0 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 2.8 281.2 (121.1-554.0)   Male 3 1.6 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 5 4.1 122.3 (39.4-285.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 7 6.2 112.9 (45.2-232.7) 
Lung and Bronchus            All Sites / Types     
Male 7 13.4 52.1 (20.9-107.3)   Male 84 95.2 88.3 (70.4-109.3) 
Female 18 13.8 130.3 (77.2-205.9)   Female 107 94.7 113.0 (92.6-136.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
178 
Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 39.5 86.0 (59.6-120.2)   Male 25 26.3 95.2 (61.6-140.5) 
Female 11 13.4 81.8 (40.8-146.4)   Female 14 19.9 70.4 (38.5-118.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 8.2 73.2 (26.7-159.3)   Male 7 8.3 84.5 (33.8-174.1) 
Female 10 6.3 157.6 (75.5-289.9)   Female 6 6.2 96.8 (35.4-210.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.4 nc (nc-nc)   Male 18 23.4 76.9 (45.6-121.5) 
Female 144 158.9 90.6 (76.4-106.7)   Female 23 19.4 118.6 (75.1-177.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 19.6 101.9 (62.2-157.4) 
Female 6 5.7 105.1 (38.4-228.9)   Female 19 8.2 232.2 (139.7-362.6) 
Colon / Rectum            Ovary     
Male 43 44.2 97.2 (70.3-130.9)             
Female 50 39.8 125.7 (93.3-165.7)   Female 15 13.5 111.1 (62.2-183.3) 
Esophagus            Pancreas     
Male 12 10.3 116.6 (60.2-203.7)   Male 13 14.3 91.1 (48.5-155.9) 
Female 6 2.6 227.7 (83.2-495.6)   Female 15 13.5 110.9 (62.0-182.9) 
Hodgkin Lymphoma            Prostate     
Male 7 3.4 207.3 (83.1-427.2)   Male 107 122.6 87.3 (71.5-105.4) 
Female 3 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 23.0 95.6 (59.9-144.7)   Male 5 9.7 51.3 (16.5-119.7) 
Female 10 12.5 80.1 (38.4-147.3)   Female 5 5.4 93.1 (30.0-217.2) 
Larynx            Testis     
Male 7 6.0 115.8 (46.4-238.6)   Male 3 6.5 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 16.6 84.2 (46.0-141.2)   Male 11 11.1 99.1 (49.4-177.4) 
Female 14 11.3 123.6 (67.5-207.4)   Female 44 31.7 139.0 (101.0-186.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 14.2 91.2 (48.5-156.0)             
Female 8 4.5 177.0 (76.2-348.8)   Female 33 35.1 94.1 (64.8-132.2) 
Lung and Bronchus            All Sites / Types     
Male 52 70.8 73.5 (54.9-96.4)   Male 451 521.9 86.4 (78.6-94.8) 
Female 71 71.8 98.8 (77.2-124.7)   Female 551 525.2 104.9 (96.3-114.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
179 
Marshfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 27.4 69.3 (41.7-108.2)   Male 31 17.9 172.8 (117.4-245.2) 
Female 10 9.0 110.8 (53.0-203.8)   Female 28 13.5 206.8 (137.4-298.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 5.5 180.2 (86.3-331.4)   Male 13 5.8 225.1 (119.7-384.9) 
Female 5 4.4 113.7 (36.6-265.3)   Female 1 4.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 13 16.1 80.8 (43.0-138.1) 
Female 142 114.7 123.8 (104.3-145.9)   Female 12 13.4 89.4 (46.2-156.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 14.4 83.3 (43.0-145.4) 
Female 6 3.8 159.4 (58.2-347.0)   Female 4 5.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 30.7 68.4 (42.3-104.6)             
Female 26 26.4 98.5 (64.4-144.4)   Female 10 9.7 103.3 (49.4-189.9) 
Esophagus            Pancreas     
Male 8 7.5 106.4 (45.8-209.7)   Male 12 10.2 118.1 (61.0-206.4) 
Female 0 1.9 nc (nc-nc)   Female 12 9.1 132.0 (68.1-230.6) 
Hodgkin Lymphoma            Prostate     
Male 2 2.0 nc (nc-nc)   Male 112 97.0 115.4 (95.0-138.9) 
Female 3 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 16.5 121.2 (74.0-187.2)   Male 3 6.8 nc (nc-nc) 
Female 6 8.8 68.6 (25.0-149.2)   Female 3 3.6 nc (nc-nc) 
Larynx            Testis     
Male 1 4.4 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 11.4 131.8 (73.7-217.3)   Male 9 7.3 123.0 (56.1-233.5) 
Female 6 7.4 80.6 (29.4-175.4)   Female 19 21.0 90.6 (54.5-141.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 10.4 125.2 (66.6-214.2)             
Female 1 3.2 nc (nc-nc)   Female 21 26.7 78.7 (48.7-120.3) 
Lung and Bronchus            All Sites / Types     
Male 46 50.0 92.0 (67.3-122.7)   Male 390 374.1 104.2 (94.2-115.1) 
Female 65 50.0 130.0 (100.3-165.7)   Female 407 366.7 111.0 (100.5-122.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
180 
Mashpee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 23.0 130.3 (87.9-186.1)   Male 14 13.3 104.9 (57.3-176.1) 
Female 7 9.0 77.7 (31.1-160.1)   Female 18 10.2 176.7 (104.7-279.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.6 nc (nc-nc)   Male 5 4.4 112.6 (36.3-262.8) 
Female 1 3.3 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 15 11.9 125.9 (70.4-207.6) 
Female 88 86.6 101.6 (81.5-125.2)   Female 15 11.6 128.9 (72.1-212.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 9.2 162.3 (90.8-267.7) 
Female 1 2.3 nc (nc-nc)   Female 5 4.8 104.3 (33.6-243.3) 
Colon / Rectum            Ovary     
Male 19 22.7 83.8 (50.4-130.8)             
Female 21 24.3 86.3 (53.4-131.9)   Female 5 7.6 66.1 (21.3-154.2) 
Esophagus            Pancreas     
Male 5 5.6 89.7 (28.9-209.3)   Male 10 7.8 128.5 (61.5-236.3) 
Female 0 1.7 nc (nc-nc)   Female 9 9.0 100.5 (45.8-190.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 65 66.1 98.3 (75.9-125.4) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 11.2 98.5 (49.1-176.2)   Male 3 5.3 nc (nc-nc) 
Female 8 7.3 109.0 (46.9-214.8)   Female 2 3.2 nc (nc-nc) 
Larynx            Testis     
Male 4 3.2 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 3 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 8.5 106.2 (48.5-201.6)   Male 3 4.4 nc (nc-nc) 
Female 10 6.5 154.1 (73.8-283.3)   Female 10 12.3 81.0 (38.8-149.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 7.0 85.3 (31.2-185.8)             
Female 0 2.8 nc (nc-nc)   Female 12 20.0 60.1 (31.0-104.9) 
Lung and Bronchus            All Sites / Types     
Male 39 40.6 96.0 (68.3-131.3)   Male 278 273.9 101.5 (89.9-114.2) 
Female 48 48.5 99.0 (73.0-131.3)   Female 287 302.3 94.9 (84.3-106.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
181 
Mattapoisett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 8.0 149.3 (77.0-260.8)   Male 7 5.1 138.5 (55.5-285.4) 
Female 4 2.7 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 1 4.5 nc (nc-nc) 
Female 38 31.4 120.9 (85.6-166.0)   Female 5 3.8 131.1 (42.2-305.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 3.9 337.5 (179.5-577.1) 
Female 1 0.9 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 8.3 144.6 (74.6-252.6)             
Female 4 7.5 nc (nc-nc)   Female 5 2.7 187.2 (60.3-436.9) 
Esophagus            Pancreas     
Male 3 2.2 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 42 27.5 152.9 (110.2-206.7) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.6 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.1 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.8 nc (nc-nc)             
Female 3 0.9 nc (nc-nc)   Female 12 7.4 162.3 (83.7-283.4) 
Lung and Bronchus            All Sites / Types     
Male 18 15.1 119.1 (70.5-188.2)   Male 139 105.6 131.7 (110.7-155.5) 
Female 10 14.8 67.3 (32.2-123.9)   Female 106 102.6 103.3 (84.6-125.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
182 
Maynard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 12.3 97.6 (50.4-170.5)   Male 6 7.9 75.9 (27.7-165.2) 
Female 2 3.6 nc (nc-nc)   Female 6 5.5 109.1 (39.8-237.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.4 nc (nc-nc)   Male 0 2.6 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 7.1 nc (nc-nc) 
Female 45 44.0 102.3 (74.6-136.9)   Female 3 5.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.0 83.8 (27.0-195.6) 
Female 1 1.6 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 13.4 142.1 (85.5-221.9)             
Female 16 10.7 149.1 (85.2-242.1)   Female 1 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.2 nc (nc-nc)   Male 4 4.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 4 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 31 38.7 80.2 (54.5-113.8) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 7.0 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 3 3.4 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.0 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 4 3.0 nc (nc-nc)   Female 11 8.7 127.1 (63.4-227.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.4 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 4 10.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 22.0 45.5 (21.8-83.6)   Male 119 160.0 74.4 (61.6-89.0) 
Female 17 18.9 89.8 (52.3-143.9)   Female 139 143.6 96.8 (81.4-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
183 
Medfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 13.4 67.3 (30.7-127.8)   Male 12 8.7 137.3 (70.8-239.8) 
Female 4 3.5 nc (nc-nc)   Female 8 5.8 138.7 (59.7-273.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 4 7.9 nc (nc-nc) 
Female 40 48.7 82.1 (58.7-111.9)   Female 5 5.4 93.1 (30.0-217.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 6.7 133.4 (60.9-253.3) 
Female 0 1.7 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 14.9 93.9 (51.3-157.6)             
Female 9 11.1 80.9 (36.9-153.6)   Female 3 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.5 nc (nc-nc)   Male 4 4.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 53 43.1 122.8 (92.0-160.7) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.8 77.2 (28.2-168.0)   Male 1 3.3 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Larynx            Testis     
Male 0 2.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.5 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 6 3.1 194.1 (70.9-422.5)   Female 6 9.5 63.1 (23.1-137.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 4.9 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 8 10.8 74.1 (31.9-146.0) 
Lung and Bronchus            All Sites / Types     
Male 11 23.9 46.1 (23.0-82.5)   Male 149 176.9 84.2 (71.2-98.9) 
Female 11 18.9 58.0 (28.9-103.9)   Female 119 151.5 78.5 (65.1-94.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
184 
Medford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 55.3 101.3 (76.5-131.6)   Male 20 35.2 56.8 (34.7-87.8) 
Female 19 22.2 85.7 (51.6-133.9)   Female 18 31.3 57.6 (34.1-91.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 10.9 128.5 (70.2-215.6)   Male 11 11.0 99.6 (49.6-178.1) 
Female 11 9.8 112.6 (56.1-201.4)   Female 11 10.0 110.0 (54.9-196.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.9 nc (nc-nc)   Male 29 31.6 91.7 (61.4-131.6) 
Female 228 236.6 96.3 (84.2-109.7)   Female 27 31.1 86.9 (57.3-126.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 24.8 112.7 (74.9-162.9) 
Female 8 8.5 94.6 (40.7-186.5)   Female 14 12.9 108.8 (59.4-182.5) 
Colon / Rectum            Ovary     
Male 70 59.4 117.8 (91.8-148.8)             
Female 75 64.5 116.3 (91.5-145.8)   Female 23 20.8 110.5 (70.1-165.9) 
Esophagus            Pancreas     
Male 14 13.6 102.9 (56.2-172.7)   Male 16 19.3 82.8 (47.3-134.5) 
Female 7 4.3 164.3 (65.8-338.4)   Female 16 22.5 71.2 (40.7-115.6) 
Hodgkin Lymphoma            Prostate     
Male 6 5.0 119.2 (43.5-259.5)   Male 153 158.6 96.5 (81.8-113.0) 
Female 5 4.5 111.3 (35.9-259.8)             
Kidney & Renal Pelvis            Stomach     
Male 27 29.6 91.2 (60.1-132.7)   Male 15 13.3 113.2 (63.3-186.7) 
Female 25 19.1 130.9 (84.7-193.2)   Female 8 8.8 91.1 (39.2-179.4) 
Larynx            Testis     
Male 9 7.9 114.2 (52.1-216.8)   Male 12 9.9 120.8 (62.4-211.0) 
Female 3 2.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 28 22.6 124.2 (82.5-179.4)   Male 11 14.3 76.8 (38.3-137.5) 
Female 17 18.2 93.4 (54.4-149.6)   Female 41 47.5 86.2 (61.9-117.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 18.1 137.7 (89.1-203.4)             
Female 7 7.3 96.5 (38.7-198.8)   Female 54 52.8 102.2 (76.8-133.4) 
Lung and Bronchus            All Sites / Types     
Male 114 96.3 118.4 (97.7-142.2)   Male 715 697.2 102.6 (95.2-110.4) 
Female 134 114.2 117.4 (98.3-139.0)   Female 828 816.6 101.4 (94.6-108.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
185 
Medway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 11.5 112.9 (60.1-193.1)   Male 9 7.9 113.5 (51.8-215.5) 
Female 2 4.4 nc (nc-nc)   Female 3 6.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.5 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 11 7.2 152.9 (76.2-273.7) 
Female 58 54.5 106.5 (80.9-137.7)   Female 9 6.6 137.0 (62.5-260.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.5 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 13.7 124.2 (72.3-198.9)             
Female 9 14.3 63.1 (28.8-119.9)   Female 5 4.6 107.5 (34.7-251.0) 
Esophagus            Pancreas     
Male 5 3.3 152.8 (49.2-356.5)   Male 3 4.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 3 4.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 54 41.7 129.6 (97.3-169.1) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.4 81.0 (29.6-176.4)   Male 1 2.9 nc (nc-nc) 
Female 1 4.1 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 1 2.0 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.0 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 5 3.9 128.7 (41.5-300.3)   Female 11 10.5 104.5 (52.1-186.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.7 106.7 (34.4-249.1)             
Female 2 1.5 nc (nc-nc)   Female 12 11.8 101.5 (52.4-177.2) 
Lung and Bronchus            All Sites / Types     
Male 19 21.0 90.5 (54.5-141.4)   Male 175 163.4 107.1 (91.8-124.2) 
Female 21 22.6 93.0 (57.5-142.1)   Female 161 177.7 90.6 (77.2-105.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
186 
Melrose 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 30.0 50.0 (28.0-82.5)   Male 16 19.1 83.6 (47.8-135.8) 
Female 9 11.2 80.2 (36.6-152.3)   Female 22 15.6 141.5 (88.6-214.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.8 86.2 (27.8-201.1)   Male 4 6.1 nc (nc-nc) 
Female 9 4.9 182.3 (83.2-346.2)   Female 3 5.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 23 17.2 133.6 (84.7-200.5) 
Female 130 124.2 104.7 (87.4-124.3)   Female 19 15.8 120.4 (72.4-188.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 14.1 78.0 (38.9-139.6) 
Female 2 4.3 nc (nc-nc)   Female 5 6.7 75.0 (24.2-175.1) 
Colon / Rectum            Ovary     
Male 45 32.5 138.5 (101.0-185.3)             
Female 34 33.1 102.7 (71.1-143.6)   Female 7 10.7 65.3 (26.1-134.5) 
Esophagus            Pancreas     
Male 9 7.7 117.4 (53.6-222.9)   Male 16 10.6 150.5 (86.0-244.4) 
Female 0 2.2 nc (nc-nc)   Female 13 11.5 113.1 (60.2-193.5) 
Hodgkin Lymphoma            Prostate     
Male 0 2.2 nc (nc-nc)   Male 83 92.8 89.4 (71.2-110.9) 
Female 2 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 16.8 77.2 (41.1-132.1)   Male 5 7.2 69.2 (22.3-161.5) 
Female 8 9.9 81.1 (34.9-159.7)   Female 3 4.5 nc (nc-nc) 
Larynx            Testis     
Male 7 4.4 158.9 (63.7-327.4)   Male 3 4.3 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 12.2 155.5 (93.6-242.9)   Male 9 7.8 115.2 (52.6-218.8) 
Female 10 9.2 109.1 (52.2-200.7)   Female 26 23.2 111.9 (73.1-164.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 10.2 48.9 (15.8-114.2)             
Female 5 3.7 135.6 (43.7-316.5)   Female 32 27.9 114.6 (78.3-161.7) 
Lung and Bronchus            All Sites / Types     
Male 47 52.9 88.8 (65.3-118.1)   Male 371 386.5 96.0 (86.5-106.3) 
Female 60 58.3 102.9 (78.5-132.5)   Female 437 419.3 104.2 (94.7-114.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
187 
Mendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 6.1 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 4 3.7 nc (nc-nc) 
Female 17 24.2 70.2 (40.9-112.4)   Female 5 2.7 187.5 (60.4-437.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.3 150.5 (48.5-351.2) 
Female 0 0.9 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 7.0 nc (nc-nc)             
Female 5 5.1 97.2 (31.3-226.9)   Female 2 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.7 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 21 22.0 95.6 (59.2-146.2) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.8 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.6 195.3 (63.0-455.9)   Male 0 1.7 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 6 4.7 126.8 (46.3-275.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 8 5.6 143.6 (61.9-283.1) 
Lung and Bronchus            All Sites / Types     
Male 5 10.9 45.7 (14.7-106.6)   Male 62 84.7 73.2 (56.1-93.9) 
Female 7 9.5 73.6 (29.5-151.7)   Female 75 74.8 100.3 (78.9-125.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
188 
Merrimac 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.0 85.3 (31.1-185.6)   Male 4 4.6 nc (nc-nc) 
Female 4 2.4 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.4 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 22 30.9 71.1 (44.6-107.7)   Female 3 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.5 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.8 116.1 (53.0-220.4)             
Female 5 7.5 67.1 (21.6-156.6)   Female 5 2.6 190.5 (61.4-444.4) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 23 23.7 97.0 (61.4-145.5) 
Female 2 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.1 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.9 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 2 5.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.6 nc (nc-nc)             
Female 3 0.8 nc (nc-nc)   Female 1 7.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 13 12.9 100.6 (53.5-172.1)   Male 90 94.1 95.6 (76.9-117.5) 
Female 22 13.3 164.8 (103.3-249.6)   Female 92 99.0 92.9 (74.9-113.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
189 
Methuen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 45.8 93.8 (67.9-126.3)   Male 21 30.5 68.9 (42.6-105.3) 
Female 22 18.3 120.1 (75.3-181.9)   Female 24 25.6 93.9 (60.2-139.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 9.8 123.0 (63.5-214.8)   Male 10 9.7 102.7 (49.2-188.9) 
Female 11 8.2 134.1 (66.8-239.9)   Female 8 8.4 95.7 (41.2-188.5) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.6 nc (nc-nc)   Male 34 27.4 124.2 (86.0-173.6) 
Female 184 206.6 89.1 (76.7-102.9)   Female 25 25.8 96.7 (62.6-142.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 23.6 93.3 (58.4-141.2) 
Female 9 7.0 128.1 (58.5-243.2)   Female 8 10.9 73.7 (31.7-145.2) 
Colon / Rectum            Ovary     
Male 46 51.1 90.1 (66.0-120.2)             
Female 54 53.5 100.9 (75.8-131.6)   Female 15 17.7 84.8 (47.4-139.9) 
Esophagus            Pancreas     
Male 9 12.4 72.8 (33.2-138.2)   Male 14 16.9 82.8 (45.2-138.9) 
Female 3 3.6 nc (nc-nc)   Female 22 18.5 118.6 (74.3-179.6) 
Hodgkin Lymphoma            Prostate     
Male 7 3.9 178.7 (71.6-368.2)   Male 149 154.7 96.3 (81.5-113.1) 
Female 1 3.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 27.4 109.7 (74.0-156.6)   Male 17 11.4 149.6 (87.1-239.5) 
Female 23 16.4 140.4 (88.9-210.6)   Female 3 7.2 nc (nc-nc) 
Larynx            Testis     
Male 10 7.3 136.7 (65.4-251.3)   Male 13 7.1 183.9 (97.8-314.5) 
Female 5 2.3 219.1 (70.6-511.2)             
Leukemia            Thyroid     
Male 27 19.5 138.4 (91.2-201.4)   Male 16 12.8 125.1 (71.4-203.1) 
Female 18 14.9 120.5 (71.4-190.4)   Female 42 38.7 108.5 (78.2-146.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 17.2 87.0 (48.7-143.6)             
Female 6 6.0 99.8 (36.4-217.2)   Female 46 45.9 100.3 (73.4-133.8) 
Lung and Bronchus            All Sites / Types     
Male 101 83.5 120.9 (98.5-146.9)   Male 639 622.3 102.7 (94.9-111.0) 
Female 128 97.1 131.8 (109.9-156.7)   Female 721 691.2 104.3 (96.8-112.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
190 
Middleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 24.9 128.4 (87.8-181.2)   Male 19 16.2 117.0 (70.4-182.7) 
Female 12 8.8 136.7 (70.5-238.7)   Female 9 12.7 70.7 (32.2-134.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.1 117.6 (42.9-256.0)   Male 5 5.3 95.2 (30.7-222.1) 
Female 5 4.0 125.0 (40.3-291.7)   Female 6 4.1 147.2 (53.8-320.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 12 14.7 81.7 (42.2-142.8) 
Female 115 104.3 110.3 (91.1-132.4)   Female 8 12.5 63.8 (27.5-125.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 12.7 94.4 (48.7-165.0) 
Female 6 3.5 172.1 (62.8-374.6)   Female 8 5.3 149.7 (64.5-295.0) 
Colon / Rectum            Ovary     
Male 33 27.8 118.8 (81.8-166.9)             
Female 25 25.8 97.1 (62.8-143.3)   Female 11 8.9 124.3 (62.0-222.4) 
Esophagus            Pancreas     
Male 8 6.7 118.7 (51.1-233.9)   Male 13 9.1 142.8 (76.0-244.3) 
Female 3 1.7 nc (nc-nc)   Female 11 8.9 123.8 (61.7-221.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.9 nc (nc-nc)   Male 90 86.5 104.0 (83.6-127.8) 
Female 2 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 14.9 140.7 (87.1-215.1)   Male 6 6.1 98.2 (35.8-213.7) 
Female 5 8.2 61.3 (19.8-143.1)   Female 0 3.4 nc (nc-nc) 
Larynx            Testis     
Male 4 3.9 nc (nc-nc)   Male 5 3.4 148.3 (47.8-346.2) 
Female 6 1.1 526.8 (192.3-1146.6)             
Leukemia            Thyroid     
Male 12 10.4 115.4 (59.6-201.6)   Male 7 6.7 104.3 (41.8-214.9) 
Female 13 7.2 181.6 (96.6-310.6)   Female 24 19.5 122.9 (78.7-182.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 9.1 143.0 (76.1-244.6)             
Female 7 2.9 238.9 (95.7-492.3)   Female 31 23.3 133.1 (90.4-189.0) 
Lung and Bronchus            All Sites / Types     
Male 62 45.4 136.4 (104.6-174.9)   Male 384 337.6 113.7 (102.6-125.7) 
Female 69 47.7 144.6 (112.5-183.0)   Female 407 341.8 119.1 (107.8-131.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Middlefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.0 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.9 nc (nc-nc)   Male 9 13.2 68.3 (31.2-129.7) 
Female 2 1.4 nc (nc-nc)   Female 8 9.9 80.8 (34.8-159.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Middleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 10.7 139.6 (78.1-230.3)   Male 9 7.2 124.7 (56.9-236.8) 
Female 2 2.8 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.3 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 3 1.3 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 14 6.5 214.1 (117.0-359.3) 
Female 43 33.2 129.6 (93.8-174.6)   Female 7 4.0 175.6 (70.3-361.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.7 87.8 (28.3-204.9) 
Female 1 1.1 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 12.3 89.2 (44.5-159.7)             
Female 11 8.1 136.3 (68.0-244.0)   Female 0 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.9 nc (nc-nc)   Male 3 4.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 35 37.5 93.3 (65.0-129.8) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 6.6 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 5 2.6 191.2 (61.6-446.2)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.5 110.0 (35.5-256.7)   Male 2 3.2 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 8 6.0 132.9 (57.2-261.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.0 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 12 7.5 159.9 (82.5-279.3) 
Lung and Bronchus            All Sites / Types     
Male 21 19.1 110.0 (68.0-168.1)   Male 156 148.1 105.4 (89.5-123.3) 
Female 16 15.4 103.6 (59.2-168.2)   Female 128 108.7 117.8 (98.3-140.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Milford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 45 26.3 170.9 (124.6-228.7)   Male 14 17.4 80.3 (43.9-134.7) 
Female 14 9.7 144.0 (78.6-241.6)   Female 14 14.3 97.6 (53.3-163.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 5.5 nc (nc-nc)   Male 4 5.5 nc (nc-nc) 
Female 5 4.6 108.2 (34.9-252.6)   Female 8 4.5 177.6 (76.5-349.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 23 15.7 146.4 (92.8-219.6) 
Female 110 113.7 96.8 (79.5-116.6)   Female 21 14.1 149.4 (92.5-228.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 13.1 106.7 (58.3-179.0) 
Female 4 4.0 nc (nc-nc)   Female 5 5.9 84.1 (27.1-196.3) 
Colon / Rectum            Ovary     
Male 31 29.7 104.3 (70.8-148.0)             
Female 30 29.2 102.7 (69.3-146.6)   Female 9 9.8 92.3 (42.1-175.2) 
Esophagus            Pancreas     
Male 10 6.8 146.0 (69.9-268.6)   Male 8 9.5 83.8 (36.1-165.2) 
Female 2 1.9 nc (nc-nc)   Female 7 9.9 70.4 (28.2-145.0) 
Hodgkin Lymphoma            Prostate     
Male 5 2.3 218.4 (70.4-509.7)   Male 105 82.4 127.4 (104.2-154.3) 
Female 1 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 15.4 110.5 (64.3-176.9)   Male 14 6.5 215.3 (117.6-361.3) 
Female 13 8.9 146.7 (78.1-250.9)   Female 1 4.0 nc (nc-nc) 
Larynx            Testis     
Male 2 4.0 nc (nc-nc)   Male 4 4.4 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.2 98.5 (49.1-176.3)   Male 3 7.5 nc (nc-nc) 
Female 11 8.3 133.0 (66.3-238.0)   Female 23 22.4 102.8 (65.1-154.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 9.4 63.7 (23.2-138.6)             
Female 3 3.2 nc (nc-nc)   Female 30 25.1 119.6 (80.7-170.7) 
Lung and Bronchus            All Sites / Types     
Male 47 46.5 101.1 (74.3-134.4)   Male 396 348.7 113.6 (102.7-125.3) 
Female 60 50.9 117.9 (90.0-151.8)   Female 404 377.7 107.0 (96.8-117.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 14.3 132.8 (79.9-207.5)   Male 6 9.5 63.3 (23.1-137.8) 
Female 2 4.9 nc (nc-nc)   Female 9 7.2 125.3 (57.2-238.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.9 nc (nc-nc)   Male 6 3.0 196.8 (71.9-428.3) 
Female 1 2.3 nc (nc-nc)   Female 7 2.3 305.8 (122.5-630.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 17 8.6 198.8 (115.7-318.3) 
Female 63 58.7 107.3 (82.5-137.3)   Female 3 7.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.4 135.2 (64.7-248.6) 
Female 3 2.0 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 15.9 62.9 (30.1-115.6)             
Female 15 14.7 101.8 (56.9-167.9)   Female 5 5.0 100.6 (32.4-234.7) 
Esophagus            Pancreas     
Male 6 3.9 154.0 (56.2-335.3)   Male 6 5.3 113.4 (41.4-246.7) 
Female 4 1.0 nc (nc-nc)   Female 10 5.0 199.8 (95.7-367.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 54 49.5 109.1 (81.9-142.3) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 8.7 160.7 (87.8-269.7)   Male 2 3.5 nc (nc-nc) 
Female 6 4.6 130.5 (47.7-284.1)   Female 3 2.0 nc (nc-nc) 
Larynx            Testis     
Male 4 2.3 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 5.9 134.8 (58.0-265.7)   Male 10 4.0 248.6 (119.0-457.2) 
Female 6 4.1 145.9 (53.3-317.6)   Female 13 11.2 116.3 (61.9-198.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.1 117.0 (42.7-254.7)             
Female 1 1.7 nc (nc-nc)   Female 9 13.2 68.4 (31.2-129.9) 
Lung and Bronchus            All Sites / Types     
Male 46 26.2 175.5 (128.5-234.1)   Male 247 194.4 127.1 (111.7-144.0) 
Female 31 26.2 118.1 (80.3-167.7)   Female 208 192.7 108.0 (93.8-123.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 6.3 174.4 (86.9-312.1)   Male 3 4.7 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 32 35.0 91.4 (62.5-129.0)   Female 5 4.1 121.9 (39.3-284.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.1 147.7 (53.9-321.6) 
Female 2 1.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 8.2 122.3 (58.5-224.9)             
Female 10 8.5 117.8 (56.4-216.6)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 31 24.5 126.6 (86.0-179.7) 
Female 3 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.5 132.1 (48.3-287.6)   Male 0 1.7 nc (nc-nc) 
Female 4 2.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.9 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 5 2.4 211.4 (68.1-493.4)   Female 11 6.7 164.1 (81.8-293.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 7 7.8 89.8 (36.0-185.1) 
Lung and Bronchus            All Sites / Types     
Male 9 12.1 74.6 (34.1-141.7)   Male 106 96.1 110.2 (90.3-133.3) 
Female 15 15.4 97.1 (54.3-160.2)   Female 117 113.4 103.2 (85.4-123.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 2.1 242.6 (78.2-566.2)   Male 1 1.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 13 12.8 101.9 (54.2-174.3)   Female 2 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.8 nc (nc-nc)             
Female 1 3.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 12 7.9 151.0 (77.9-263.7) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.6 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.9 nc (nc-nc)             
Female 1 0.3 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 3.9 179.3 (71.8-369.5)   Male 44 32.2 136.6 (99.2-183.3) 
Female 11 5.3 207.2 (103.3-370.7)   Female 37 41.0 90.3 (63.5-124.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Milton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 27.2 62.5 (36.4-100.1)   Male 34 17.1 199.2 (137.9-278.4) 
Female 9 10.7 84.1 (38.4-159.7)   Female 24 14.2 168.8 (108.1-251.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 5.4 nc (nc-nc)   Male 5 5.5 90.9 (29.3-212.0) 
Female 5 4.7 105.5 (34.0-246.2)   Female 11 4.8 228.6 (114.0-409.1) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 17 15.5 109.6 (63.8-175.6) 
Female 141 114.4 123.3 (103.7-145.4)   Female 11 14.8 74.3 (37.0-132.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 12.7 63.0 (27.1-124.1) 
Female 4 3.8 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 29.3 81.9 (52.5-121.9)             
Female 28 31.5 89.0 (59.1-128.7)   Female 18 9.9 181.5 (107.5-286.8) 
Esophagus            Pancreas     
Male 9 6.9 130.3 (59.4-247.3)   Male 9 9.7 93.2 (42.5-176.9) 
Female 4 2.1 nc (nc-nc)   Female 11 11.0 100.4 (50.1-179.7) 
Hodgkin Lymphoma            Prostate     
Male 2 2.1 nc (nc-nc)   Male 100 83.8 119.3 (97.0-145.1) 
Female 5 1.9 269.0 (86.7-627.7)             
Kidney & Renal Pelvis            Stomach     
Male 12 14.9 80.3 (41.4-140.3)   Male 5 6.5 76.7 (24.7-179.1) 
Female 12 9.2 130.7 (67.5-228.4)   Female 5 4.3 116.8 (37.6-272.6) 
Larynx            Testis     
Male 1 4.0 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 11.2 115.8 (61.6-198.0)   Male 5 6.8 73.8 (23.8-172.2) 
Female 8 8.7 91.9 (39.6-181.1)   Female 34 20.9 162.5 (112.5-227.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 9.3 53.8 (17.3-125.6)             
Female 1 3.4 nc (nc-nc)   Female 33 25.2 131.1 (90.2-184.1) 
Lung and Bronchus            All Sites / Types     
Male 34 47.8 71.2 (49.3-99.5)   Male 338 348.9 96.9 (86.8-107.8) 
Female 48 55.2 87.0 (64.2-115.4)   Female 445 390.6 113.9 (103.6-125.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
198 
Monroe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.1 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.0 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
199 
Monson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 11.3 88.4 (42.3-162.6)   Male 5 7.1 69.9 (22.5-163.2) 
Female 1 3.2 nc (nc-nc)   Female 1 4.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.0 nc (nc-nc)   Male 0 2.4 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 45 41.5 108.4 (79.0-145.0)   Female 7 4.8 144.7 (58.0-298.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 5.6 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 12.4 72.6 (33.1-137.8)             
Female 5 9.5 52.7 (17.0-122.9)   Female 0 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.0 nc (nc-nc)   Male 4 4.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 28 37.6 74.5 (49.5-107.6) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.4 77.8 (25.1-181.6)   Male 1 2.7 nc (nc-nc) 
Female 0 3.2 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.4 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 3 7.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.1 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 7 9.8 71.2 (28.5-146.7) 
Lung and Bronchus            All Sites / Types     
Male 15 20.2 74.4 (41.6-122.7)   Male 106 148.1 71.6 (58.6-86.6) 
Female 14 17.9 78.2 (42.7-131.2)   Female 106 132.1 80.3 (65.7-97.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
200 
Montague 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 10.1 79.6 (34.3-156.8)   Male 8 6.2 129.5 (55.8-255.2) 
Female 6 3.9 152.5 (55.7-332.0)   Female 1 5.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.8 276.7 (89.2-645.8)   Male 3 2.0 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.5 90.3 (29.1-210.6) 
Female 35 42.2 83.0 (57.8-115.4)   Female 3 5.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.5 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 10.5 85.4 (39.0-162.1)             
Female 12 11.6 103.7 (53.5-181.1)   Female 8 3.7 217.6 (93.7-428.7) 
Esophagus            Pancreas     
Male 4 2.5 nc (nc-nc)   Male 0 3.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 21 30.7 68.4 (42.3-104.6) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.3 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Larynx            Testis     
Male 3 1.4 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.0 176.6 (70.8-363.9)   Male 1 2.3 nc (nc-nc) 
Female 5 3.1 160.2 (51.6-373.8)   Female 3 7.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.3 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 12 9.8 122.9 (63.4-214.7) 
Lung and Bronchus            All Sites / Types     
Male 18 17.5 102.8 (60.9-162.5)   Male 119 126.1 94.4 (78.2-112.9) 
Female 17 20.1 84.5 (49.2-135.2)   Female 125 143.5 87.1 (72.5-103.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
201 
Monterey 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.7 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 5 4.5 111.2 (35.9-259.6)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.7 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 5.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.0 nc (nc-nc)   Male 11 20.7 53.2 (26.5-95.2) 
Female 1 2.4 nc (nc-nc)   Female 11 15.4 71.6 (35.7-128.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
202 
Montgomery 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.2 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 3 4.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.3 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 4.1 194.7 (83.8-383.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 2.1 nc (nc-nc)   Male 17 15.8 107.6 (62.6-172.2) 
Female 0 2.0 nc (nc-nc)   Female 7 14.8 47.4 (19.0-97.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
203 
Mount Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.3 nc (nc-nc)             
Female 2 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.5 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 3 4.8 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
204 
Nahant 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 4.6 109.2 (35.2-254.7)   Male 8 2.8 290.0 (124.9-571.4) 
Female 1 2.2 nc (nc-nc)   Female 7 2.6 270.7 (108.4-557.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 17 20.8 81.7 (47.6-130.9)   Female 2 2.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.1 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.8 105.0 (33.8-245.0)             
Female 6 6.3 95.6 (34.9-208.2)   Female 1 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 21 14.7 142.4 (88.1-217.7) 
Female 2 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.4 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.5 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 5 4.8 105.2 (33.9-245.5) 
Lung and Bronchus            All Sites / Types     
Male 10 8.0 125.0 (59.8-229.8)   Male 73 57.8 126.3 (99.0-158.8) 
Female 6 10.8 55.6 (20.3-121.1)   Female 64 73.3 87.3 (67.2-111.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
205 
Nantucket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 10.9 82.7 (37.7-157.0)   Male 18 7.3 246.9 (146.3-390.3) 
Female 3 3.3 nc (nc-nc)   Female 19 5.0 380.9 (229.2-594.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.3 nc (nc-nc)   Male 8 2.3 341.4 (147.0-672.8) 
Female 2 1.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.5 nc (nc-nc) 
Female 52 40.3 128.9 (96.3-169.1)   Female 4 4.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 5.5 182.3 (87.3-335.3) 
Female 0 1.5 nc (nc-nc)   Female 5 2.1 243.5 (78.5-568.3) 
Colon / Rectum            Ovary     
Male 7 12.0 58.3 (23.3-120.1)             
Female 13 9.6 134.7 (71.7-230.4)   Female 3 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.9 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 4 0.7 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 4 1.0 nc (nc-nc)   Male 33 35.6 92.6 (63.7-130.0) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 6.5 nc (nc-nc)   Male 0 2.7 nc (nc-nc) 
Female 0 3.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.7 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.6 153.3 (61.4-315.8)   Male 2 3.1 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 13 8.1 161.4 (85.8-276.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.0 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 11 9.1 121.5 (60.6-217.4) 
Lung and Bronchus            All Sites / Types     
Male 15 19.8 75.8 (42.4-125.0)   Male 141 146.4 96.3 (81.1-113.6) 
Female 20 18.1 110.7 (67.6-171.0)   Female 168 131.9 127.4 (108.9-148.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
206 
Natick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 34.4 84.2 (56.4-120.9)   Male 17 22.6 75.3 (43.9-120.6) 
Female 11 13.4 82.2 (41.0-147.0)   Female 18 18.9 95.1 (56.3-150.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 7.1 99.1 (39.7-204.3)   Male 3 7.2 nc (nc-nc) 
Female 8 6.1 131.6 (56.7-259.3)   Female 5 6.2 80.9 (26.1-188.8) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 16 20.3 78.9 (45.1-128.2) 
Female 135 157.0 86.0 (72.1-101.8)   Female 13 19.0 68.4 (36.4-117.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 17.2 104.9 (62.1-165.8) 
Female 2 5.3 nc (nc-nc)   Female 12 8.1 148.3 (76.5-259.1) 
Colon / Rectum            Ovary     
Male 38 38.1 99.8 (70.6-136.9)             
Female 44 39.5 111.4 (80.9-149.5)   Female 19 13.3 143.0 (86.1-223.4) 
Esophagus            Pancreas     
Male 10 9.1 110.2 (52.7-202.6)   Male 10 12.5 80.0 (38.3-147.0) 
Female 4 2.6 nc (nc-nc)   Female 10 13.5 74.1 (35.5-136.3) 
Hodgkin Lymphoma            Prostate     
Male 2 2.8 nc (nc-nc)   Male 110 110.9 99.2 (81.5-119.5) 
Female 1 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 20.1 99.7 (60.9-154.0)   Male 9 8.4 106.6 (48.7-202.4) 
Female 12 12.3 97.3 (50.2-169.9)   Female 1 5.3 nc (nc-nc) 
Larynx            Testis     
Male 6 5.3 113.5 (41.4-247.0)   Male 7 5.1 136.5 (54.7-281.2) 
Female 4 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 14.4 90.1 (47.9-154.1)   Male 13 9.4 138.4 (73.6-236.6) 
Female 5 11.0 45.6 (14.7-106.5)   Female 28 28.8 97.1 (64.5-140.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 12.4 56.5 (22.7-116.5)             
Female 3 4.5 nc (nc-nc)   Female 40 34.8 114.9 (82.1-156.5) 
Lung and Bronchus            All Sites / Types     
Male 47 61.6 76.3 (56.0-101.4)   Male 415 456.6 90.9 (82.4-100.1) 
Female 55 72.1 76.3 (57.4-99.3)   Female 462 516.0 89.5 (81.5-98.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
207 
Needham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 36.8 95.0 (66.2-132.2)   Male 30 22.1 135.6 (91.5-193.6) 
Female 16 13.1 122.5 (70.0-199.0)   Female 18 17.0 106.0 (62.8-167.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 6.5 138.9 (63.4-263.8)   Male 8 7.1 113.0 (48.7-222.7) 
Female 11 5.5 199.5 (99.4-357.0)   Female 4 5.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.2 nc (nc-nc)   Male 27 20.0 135.1 (89.0-196.5) 
Female 170 137.6 123.5 (105.7-143.6)   Female 24 17.9 134.2 (85.9-199.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 16.0 68.7 (34.2-122.9) 
Female 2 4.4 nc (nc-nc)   Female 5 7.6 66.1 (21.3-154.3) 
Colon / Rectum            Ovary     
Male 29 38.7 74.9 (50.1-107.5)             
Female 41 39.0 105.1 (75.4-142.6)   Female 11 11.9 92.1 (45.9-164.9) 
Esophagus            Pancreas     
Male 7 8.9 78.5 (31.5-161.8)   Male 9 12.8 70.2 (32.0-133.2) 
Female 2 2.5 nc (nc-nc)   Female 16 13.7 116.8 (66.7-189.7) 
Hodgkin Lymphoma            Prostate     
Male 3 2.2 nc (nc-nc)   Male 115 106.0 108.5 (89.6-130.2) 
Female 2 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 18.8 90.5 (52.7-144.9)   Male 5 8.6 57.9 (18.7-135.1) 
Female 11 10.9 100.6 (50.1-180.0)   Female 3 5.3 nc (nc-nc) 
Larynx            Testis     
Male 2 5.0 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 14.5 68.8 (32.9-126.5)   Male 8 8.0 100.1 (43.1-197.2) 
Female 14 10.5 132.7 (72.5-222.7)   Female 31 23.6 131.2 (89.1-186.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 11.9 42.0 (13.5-97.9)             
Female 1 4.2 nc (nc-nc)   Female 31 30.5 101.7 (69.1-144.3) 
Lung and Bronchus            All Sites / Types     
Male 41 62.5 65.6 (47.1-89.1)   Male 404 449.5 89.9 (81.3-99.1) 
Female 39 65.3 59.7 (42.5-81.7)   Female 486 470.1 103.4 (94.4-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
208 
New Ashford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.3 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.5 nc (nc-nc)   Male 3 4.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
209 
New Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 102 94.8 107.5 (87.7-130.6)   Male 27 60.1 44.9 (29.6-65.4) 
Female 31 38.4 80.7 (54.8-114.5)   Female 23 51.3 44.8 (28.4-67.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 16 18.8 85.3 (48.7-138.6)   Male 19 19.1 99.6 (59.9-155.5) 
Female 13 16.7 77.9 (41.4-133.1)   Female 15 17.2 87.4 (48.9-144.2) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.3 nc (nc-nc)   Male 44 54.1 81.3 (59.0-109.1) 
Female 345 396.4 87.0 (78.1-96.7)   Female 49 52.7 93.0 (68.8-123.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 55 43.9 125.3 (94.4-163.1) 
Female 16 13.5 118.6 (67.8-192.7)   Female 27 21.9 123.4 (81.3-179.5) 
Colon / Rectum            Ovary     
Male 121 101.9 118.7 (98.5-141.9)             
Female 105 112.8 93.1 (76.1-112.7)   Female 28 34.9 80.3 (53.4-116.1) 
Esophagus            Pancreas     
Male 28 23.9 116.9 (77.7-169.0)   Male 36 33.6 107.3 (75.1-148.5) 
Female 9 7.3 122.8 (56.0-233.1)   Female 53 39.5 134.2 (100.5-175.6) 
Hodgkin Lymphoma            Prostate     
Male 8 7.7 104.4 (44.9-205.7)   Male 307 288.8 106.3 (94.7-118.9) 
Female 5 6.8 73.8 (23.8-172.3)             
Kidney & Renal Pelvis            Stomach     
Male 56 52.0 107.8 (81.4-139.9)   Male 39 22.8 171.4 (121.9-234.3) 
Female 35 32.2 108.8 (75.7-151.3)   Female 21 15.4 136.5 (84.4-208.6) 
Larynx            Testis     
Male 27 13.8 195.1 (128.5-283.8)   Male 10 14.2 70.3 (33.7-129.3) 
Female 8 4.5 179.1 (77.1-353.0)             
Leukemia            Thyroid     
Male 33 39.0 84.6 (58.2-118.8)   Male 21 23.9 88.0 (54.4-134.5) 
Female 20 31.6 63.4 (38.7-97.9)   Female 77 74.8 102.9 (81.2-128.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 65 32.2 202.0 (155.9-257.5)             
Female 13 12.2 106.3 (56.6-181.8)   Female 83 87.2 95.2 (75.8-118.0) 
Lung and Bronchus            All Sites / Types     
Male 254 166.9 152.2 (134.0-172.1)   Male 1370 1214.1 112.8 (106.9-119.0) 
Female 198 194.5 101.8 (88.1-117.0)   Female 1297 1379.1 94.0 (89.0-99.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
210 
New Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 2 4.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.3 nc (nc-nc)             
Female 4 1.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 4.2 143.9 (52.6-313.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.0 nc (nc-nc)   Male 19 15.7 120.9 (72.8-188.8) 
Female 2 2.1 nc (nc-nc)   Female 13 15.2 85.4 (45.4-146.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
211 
New Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.8 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 10 9.0 111.4 (53.3-204.9)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.8 nc (nc-nc)             
Female 3 2.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 9.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 5.0 nc (nc-nc)   Male 19 35.3 53.8 (32.4-84.0) 
Female 3 4.4 nc (nc-nc)   Female 24 29.6 81.2 (52.0-120.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
212 
New Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 3 5.2 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.7 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.5 nc (nc-nc)             
Female 4 1.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 5.1 98.4 (31.7-229.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.8 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.5 nc (nc-nc)   Male 15 18.6 80.7 (45.2-133.2) 
Female 1 2.3 nc (nc-nc)   Female 16 16.8 95.0 (54.3-154.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
213 
Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 8.2 97.1 (41.8-191.4)   Male 14 5.4 257.1 (140.5-431.5) 
Female 3 2.7 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.6 313.2 (100.9-730.9)   Male 2 1.8 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.8 nc (nc-nc) 
Female 35 34.0 102.9 (71.7-143.2)   Female 4 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 9.3 96.9 (44.2-183.9)             
Female 4 7.8 nc (nc-nc)   Female 4 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 31 28.5 108.8 (73.9-154.4) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.9 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 6 2.6 230.9 (84.3-502.5)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.3 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 8 6.2 130.1 (56.0-256.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.2 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 8 7.7 104.2 (44.9-205.3) 
Lung and Bronchus            All Sites / Types     
Male 14 15.3 91.6 (50.0-153.7)   Male 106 111.8 94.8 (77.6-114.6) 
Female 9 15.2 59.2 (27.0-112.4)   Female 95 108.0 88.0 (71.2-107.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
214 
Newburyport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 20.0 85.1 (49.5-136.3)   Male 23 13.0 176.9 (112.1-265.4) 
Female 8 8.5 94.6 (40.8-186.5)   Female 18 11.2 160.2 (94.9-253.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.9 nc (nc-nc)   Male 1 4.2 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 5 3.9 128.8 (41.5-300.7) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.7 nc (nc-nc)   Male 15 11.6 129.1 (72.2-212.9) 
Female 98 93.6 104.7 (85.0-127.6)   Female 10 11.8 85.0 (40.7-156.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 10.2 127.3 (67.7-217.7) 
Female 0 2.9 nc (nc-nc)   Female 5 5.0 100.0 (32.2-233.3) 
Colon / Rectum            Ovary     
Male 25 22.2 112.8 (73.0-166.5)             
Female 22 24.3 90.6 (56.8-137.2)   Female 6 8.1 74.4 (27.2-161.9) 
Esophagus            Pancreas     
Male 3 5.4 nc (nc-nc)   Male 5 7.3 68.1 (22.0-159.0) 
Female 0 1.7 nc (nc-nc)   Female 5 8.6 58.2 (18.8-135.9) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 91 68.7 132.5 (106.7-162.7) 
Female 3 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 11.8 76.3 (34.8-144.8)   Male 4 4.9 nc (nc-nc) 
Female 3 7.4 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Larynx            Testis     
Male 0 3.2 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.1 86.2 (34.5-177.7)   Male 11 5.2 211.8 (105.6-379.0) 
Female 2 6.6 nc (nc-nc)   Female 23 15.7 146.1 (92.6-219.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.5 nc (nc-nc)             
Female 3 2.8 nc (nc-nc)   Female 25 21.7 115.3 (74.6-170.3) 
Lung and Bronchus            All Sites / Types     
Male 27 36.4 74.2 (48.9-108.0)   Male 283 268.7 105.3 (93.4-118.4) 
Female 39 44.9 86.9 (61.8-118.8)   Female 309 312.7 98.8 (88.1-110.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
215 
Newton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 95 96.7 98.3 (79.5-120.2)   Male 72 59.7 120.7 (94.4-152.0) 
Female 43 34.2 125.6 (90.9-169.1)   Female 67 46.8 143.2 (110.9-181.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 22 17.9 122.6 (76.8-185.6)   Male 31 19.4 159.8 (108.6-226.9) 
Female 17 15.4 110.2 (64.2-176.5)   Female 16 15.6 102.7 (58.7-166.8) 
Breast            Non-Hodgkin Lymphoma     
Male 4 3.3 nc (nc-nc)   Male 66 53.9 122.4 (94.6-155.7) 
Female 434 377.4 115.0 (104.4-126.4)   Female 61 47.9 127.3 (97.4-163.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 26 43.5 59.7 (39.0-87.5) 
Female 8 12.5 64.0 (27.5-126.0)   Female 32 20.3 157.9 (108.0-223.0) 
Colon / Rectum            Ovary     
Male 88 101.9 86.4 (69.3-106.4)             
Female 76 100.7 75.4 (59.4-94.4)   Female 46 32.6 141.1 (103.3-188.2) 
Esophagus            Pancreas     
Male 12 24.3 49.3 (25.5-86.2)   Male 34 33.9 100.2 (69.4-140.1) 
Female 7 6.7 105.0 (42.1-216.4)   Female 49 35.1 139.6 (103.3-184.6) 
Hodgkin Lymphoma            Prostate     
Male 7 6.9 101.9 (40.8-210.0)   Male 326 294.3 110.8 (99.1-123.5) 
Female 3 6.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 51 51.6 98.9 (73.6-130.0)   Male 21 22.9 91.6 (56.7-140.0) 
Female 19 30.0 63.3 (38.1-98.9)   Female 14 13.7 102.1 (55.8-171.3) 
Larynx            Testis     
Male 10 14.1 71.1 (34.0-130.7)   Male 12 11.6 103.2 (53.3-180.3) 
Female 1 4.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 37 38.5 96.1 (67.7-132.5)   Male 34 22.6 150.4 (104.1-210.1) 
Female 25 28.1 88.9 (57.5-131.2)   Female 87 69.0 126.0 (100.9-155.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 32.3 77.5 (50.1-114.4)             
Female 9 11.2 80.0 (36.5-151.9)   Female 91 84.5 107.7 (86.7-132.3) 
Lung and Bronchus            All Sites / Types     
Male 124 170.1 72.9 (60.6-86.9)   Male 1166 1218.8 95.7 (90.3-101.3) 
Female 157 177.5 88.5 (75.2-103.4)   Female 1376 1274.1 108.0 (102.4-113.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
216 
Norfolk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 11.4 70.4 (30.3-138.8)   Male 20 8.6 233.1 (142.3-360.0) 
Female 1 2.5 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.8 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 7.6 65.8 (21.2-153.5) 
Female 42 37.2 112.9 (81.4-152.7)   Female 1 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.3 68.2 (22.0-159.1) 
Female 0 1.3 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 14.0 85.6 (44.2-149.5)             
Female 7 7.8 90.3 (36.2-186.0)   Female 1 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 3.5 170.5 (62.3-371.1)   Male 2 4.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 40 45.7 87.4 (62.5-119.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 8.3 133.3 (66.5-238.5)   Male 4 3.0 nc (nc-nc) 
Female 4 2.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 4 2.1 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.2 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 8 7.2 110.5 (47.6-217.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.2 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 5 8.6 58.2 (18.7-135.8) 
Lung and Bronchus            All Sites / Types     
Male 18 21.7 83.0 (49.2-131.2)   Male 154 174.6 88.2 (74.8-103.3) 
Female 12 14.2 84.6 (43.7-147.9)   Female 103 113.7 90.6 (74.0-109.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
217 
North Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 17.2 98.6 (57.4-157.9)   Male 5 10.4 47.9 (15.4-111.7) 
Female 11 6.1 179.7 (89.6-321.6)   Female 7 7.8 89.9 (36.0-185.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.0 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 8 9.3 85.7 (36.9-168.9) 
Female 52 63.1 82.5 (61.6-108.1)   Female 7 8.3 84.6 (33.9-174.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 7.2 124.6 (56.8-236.5) 
Female 1 2.0 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 17.6 147.8 (96.5-216.6)             
Female 16 17.5 91.5 (52.3-148.6)   Female 5 5.5 91.2 (29.4-212.9) 
Esophagus            Pancreas     
Male 8 4.2 192.8 (83.0-379.9)   Male 0 5.9 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 10 6.3 159.8 (76.5-293.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 43 47.7 90.2 (65.2-121.4) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 8.7 149.9 (79.7-256.3)   Male 4 4.0 nc (nc-nc) 
Female 2 5.1 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 4 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.7 74.7 (24.1-174.3)   Male 5 3.8 131.6 (42.4-307.2) 
Female 3 4.8 nc (nc-nc)   Female 7 10.8 64.6 (25.9-133.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 5.4 166.9 (76.2-316.8)             
Female 3 1.9 nc (nc-nc)   Female 12 14.0 85.9 (44.3-150.0) 
Lung and Bronchus            All Sites / Types     
Male 27 30.2 89.4 (58.9-130.0)   Male 206 208.5 98.8 (85.7-113.2) 
Female 46 31.8 144.6 (105.9-192.9)   Female 209 217.0 96.3 (83.7-110.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
218 
North Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 42 29.3 143.5 (103.4-194.0)   Male 15 19.0 79.0 (44.2-130.3) 
Female 9 11.5 78.3 (35.7-148.7)   Female 16 15.6 102.7 (58.7-166.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.9 101.2 (37.0-220.3)   Male 6 6.0 99.5 (36.3-216.6) 
Female 6 5.0 119.9 (43.8-261.0)   Female 6 5.2 115.4 (42.1-251.1) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.0 nc (nc-nc)   Male 19 17.1 111.0 (66.8-173.4) 
Female 115 126.4 91.0 (75.1-109.2)   Female 15 15.9 94.1 (52.7-155.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 14.4 62.4 (28.5-118.5) 
Female 3 4.2 nc (nc-nc)   Female 3 6.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 28 32.6 85.8 (57.0-124.1)             
Female 43 34.3 125.3 (90.7-168.8)   Female 8 10.8 74.0 (31.8-145.7) 
Esophagus            Pancreas     
Male 6 7.6 79.2 (28.9-172.4)   Male 10 10.5 94.9 (45.4-174.6) 
Female 1 2.2 nc (nc-nc)   Female 9 11.8 76.2 (34.8-144.6) 
Hodgkin Lymphoma            Prostate     
Male 3 2.4 nc (nc-nc)   Male 93 91.4 101.7 (82.1-124.6) 
Female 4 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 16.7 89.8 (50.2-148.1)   Male 7 7.1 98.1 (39.3-202.1) 
Female 5 10.0 50.0 (16.1-116.8)   Female 7 4.7 150.1 (60.1-309.3) 
Larynx            Testis     
Male 0 4.4 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 12.2 98.0 (50.6-171.2)   Male 13 7.8 165.8 (88.2-283.6) 
Female 11 9.3 117.9 (58.8-211.0)   Female 21 23.0 91.3 (56.5-139.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 10.5 57.3 (20.9-124.8)             
Female 5 3.7 135.2 (43.6-315.5)   Female 22 27.5 80.1 (50.2-121.3) 
Lung and Bronchus            All Sites / Types     
Male 37 51.2 72.2 (50.8-99.5)   Male 372 382.9 97.2 (87.5-107.6) 
Female 47 59.1 79.5 (58.4-105.8)   Female 388 425.4 91.2 (82.4-100.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
219 
North Attleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 22.5 93.5 (57.8-142.9)   Male 14 16.0 87.4 (47.7-146.6) 
Female 7 8.5 82.1 (32.9-169.3)   Female 22 13.4 164.1 (102.8-248.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.4 92.1 (29.7-214.9)   Male 6 5.0 119.1 (43.5-259.2) 
Female 7 4.4 158.9 (63.7-327.5)   Female 3 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 17 14.4 117.6 (68.5-188.4) 
Female 107 108.0 99.1 (81.2-119.7)   Female 14 12.7 110.2 (60.2-184.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 13.0 84.5 (42.1-151.3) 
Female 2 4.0 nc (nc-nc)   Female 6 5.5 109.6 (40.0-238.6) 
Colon / Rectum            Ovary     
Male 34 26.9 126.3 (87.5-176.5)             
Female 23 26.5 86.9 (55.1-130.4)   Female 4 9.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 8 6.4 125.0 (53.8-246.3)   Male 10 8.6 116.1 (55.6-213.5) 
Female 1 1.7 nc (nc-nc)   Female 9 8.8 102.7 (46.9-195.0) 
Hodgkin Lymphoma            Prostate     
Male 2 2.3 nc (nc-nc)   Male 84 81.8 102.7 (81.9-127.2) 
Female 1 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 14.9 100.3 (56.1-165.5)   Male 3 5.8 nc (nc-nc) 
Female 10 8.2 121.6 (58.2-223.6)   Female 4 3.6 nc (nc-nc) 
Larynx            Testis     
Male 6 3.8 157.4 (57.5-342.5)   Male 4 4.3 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 10.2 58.6 (21.4-127.6)   Male 7 7.5 93.3 (37.4-192.2) 
Female 6 7.6 79.0 (28.9-172.0)   Female 22 22.1 99.5 (62.3-150.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 9.2 87.1 (37.5-171.7)             
Female 1 2.9 nc (nc-nc)   Female 19 23.5 80.7 (48.6-126.1) 
Lung and Bronchus            All Sites / Types     
Male 40 41.6 96.3 (68.8-131.1)   Male 333 325.4 102.3 (91.6-113.9) 
Female 41 45.0 91.2 (65.4-123.7)   Female 337 349.5 96.4 (86.4-107.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
220 
North Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.5 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 13 19.5 66.7 (35.5-114.0)   Female 3 2.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.4 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.2 nc (nc-nc)             
Female 7 5.1 136.4 (54.6-281.0)   Female 4 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.2 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 18 15.1 119.1 (70.6-188.3) 
Female 2 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.8 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.0 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 3.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.8 nc (nc-nc)             
Female 2 0.6 nc (nc-nc)   Female 8 4.2 190.0 (81.8-374.4) 
Lung and Bronchus            All Sites / Types     
Male 9 8.6 105.0 (47.9-199.4)   Male 68 62.5 108.7 (84.4-137.8) 
Female 7 9.1 77.3 (31.0-159.3)   Female 63 65.0 96.9 (74.4-123.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
221 
North Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 14.2 91.3 (48.6-156.1)   Male 15 9.9 152.2 (85.1-251.1) 
Female 9 5.4 166.0 (75.7-315.1)   Female 12 8.3 145.4 (75.0-254.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.2 nc (nc-nc)   Male 4 3.2 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 9 8.8 101.8 (46.5-193.3) 
Female 83 69.2 119.9 (95.5-148.6)   Female 5 8.0 62.5 (20.1-145.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.0 62.7 (20.2-146.3) 
Female 3 2.3 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 16.6 102.4 (59.6-164.0)             
Female 13 16.5 78.9 (42.0-135.0)   Female 4 5.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 7 4.1 172.8 (69.2-356.1)   Male 4 5.4 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 6 5.5 108.7 (39.7-236.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 51 51.9 98.2 (73.1-129.1) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.2 108.9 (52.2-200.4)   Male 3 3.6 nc (nc-nc) 
Female 2 5.3 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.1 146.6 (66.9-278.2)   Male 4 4.4 nc (nc-nc) 
Female 7 4.5 155.9 (62.4-321.1)   Female 17 13.1 130.0 (75.7-208.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.7 87.5 (28.2-204.3)             
Female 3 1.8 nc (nc-nc)   Female 17 15.3 111.0 (64.6-177.7) 
Lung and Bronchus            All Sites / Types     
Male 19 26.4 71.9 (43.3-112.3)   Male 201 202.4 99.3 (86.1-114.1) 
Female 25 29.8 83.8 (54.2-123.7)   Female 221 221.1 100.0 (87.2-114.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
222 
Northampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 31 29.0 106.9 (72.6-151.7)   Male 12 18.5 64.9 (33.5-113.3) 
Female 11 11.2 98.5 (49.1-176.3)   Female 10 15.9 62.7 (30.0-115.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.6 126.0 (50.5-259.7)   Male 1 6.0 nc (nc-nc) 
Female 5 5.2 97.0 (31.3-226.5)   Female 10 5.1 194.6 (93.1-357.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 16 16.7 96.0 (54.8-155.9) 
Female 166 124.5 133.3 (113.8-155.2)   Female 13 15.9 81.9 (43.6-140.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 13.8 94.1 (50.1-161.0) 
Female 3 4.2 nc (nc-nc)   Female 6 6.8 88.8 (32.4-193.2) 
Colon / Rectum            Ovary     
Male 30 31.2 96.2 (64.9-137.4)             
Female 33 32.7 101.0 (69.5-141.8)   Female 15 11.0 136.6 (76.4-225.4) 
Esophagus            Pancreas     
Male 7 7.6 92.1 (36.9-189.7)   Male 8 10.3 77.4 (33.3-152.5) 
Female 4 2.2 nc (nc-nc)   Female 14 11.4 122.8 (67.1-206.1) 
Hodgkin Lymphoma            Prostate     
Male 2 2.3 nc (nc-nc)   Male 62 93.6 66.2 (50.8-84.9) 
Female 2 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 16.3 49.0 (21.1-96.6)   Male 6 7.0 85.8 (31.3-186.8) 
Female 7 9.9 70.8 (28.4-145.9)   Female 4 4.4 nc (nc-nc) 
Larynx            Testis     
Male 3 4.4 nc (nc-nc)   Male 6 4.1 147.4 (53.8-320.9) 
Female 3 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.6 94.6 (47.1-169.2)   Male 4 7.4 nc (nc-nc) 
Female 7 9.2 75.9 (30.4-156.4)   Female 9 24.1 37.3 (17.0-70.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 10.1 49.7 (16.0-116.0)             
Female 3 3.8 nc (nc-nc)   Female 36 28.7 125.6 (87.9-173.9) 
Lung and Bronchus            All Sites / Types     
Male 39 51.7 75.4 (53.6-103.1)   Male 294 378.0 77.8 (69.1-87.2) 
Female 46 58.3 79.0 (57.8-105.3)   Female 440 422.2 104.2 (94.7-114.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
223 
Northborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 16.0 131.5 (81.4-201.0)   Male 9 10.3 87.4 (39.9-166.0) 
Female 8 5.5 146.1 (62.9-288.0)   Female 6 7.7 78.0 (28.5-169.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.1 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 5 2.5 199.0 (64.1-464.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 9 9.3 97.0 (44.2-184.1) 
Female 80 62.4 128.1 (101.6-159.5)   Female 6 7.8 77.2 (28.2-168.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.8 63.9 (20.6-149.1) 
Female 1 2.1 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 17.9 56.0 (26.8-103.0)             
Female 15 16.6 90.6 (50.7-149.4)   Female 2 5.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 9 4.1 219.1 (100.0-415.9)   Male 6 5.8 103.9 (37.9-226.2) 
Female 0 1.1 nc (nc-nc)   Female 6 5.6 107.5 (39.2-233.9) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 48 49.7 96.5 (71.2-128.0) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.0 77.6 (31.1-159.8)   Male 1 3.9 nc (nc-nc) 
Female 4 4.9 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Larynx            Testis     
Male 1 2.4 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.5 138.5 (63.2-262.8)   Male 3 4.1 nc (nc-nc) 
Female 5 4.5 109.9 (35.4-256.6)   Female 9 11.5 78.5 (35.8-148.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.7 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 15 13.7 109.1 (61.0-180.0) 
Lung and Bronchus            All Sites / Types     
Male 13 28.1 46.3 (24.6-79.1)   Male 179 207.7 86.2 (74.0-99.8) 
Female 24 28.5 84.1 (53.9-125.2)   Female 206 208.0 99.0 (86.0-113.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
224 
Northbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 15.6 108.7 (63.3-174.0)   Male 11 10.3 107.0 (53.4-191.5) 
Female 6 5.6 106.4 (38.9-231.7)   Female 10 8.2 121.6 (58.2-223.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.2 nc (nc-nc)   Male 10 3.3 301.4 (144.3-554.3) 
Female 1 2.7 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 6 9.2 65.1 (23.8-141.7) 
Female 53 65.3 81.2 (60.8-106.2)   Female 9 8.1 111.1 (50.7-210.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.8 128.6 (61.6-236.5) 
Female 2 2.3 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 17.4 57.4 (27.5-105.6)             
Female 24 16.9 141.9 (90.9-211.1)   Female 5 5.6 89.4 (28.8-208.7) 
Esophagus            Pancreas     
Male 1 4.1 nc (nc-nc)   Male 5 5.7 87.9 (28.3-205.1) 
Female 1 1.1 nc (nc-nc)   Female 7 5.8 121.3 (48.6-249.9) 
Hodgkin Lymphoma            Prostate     
Male 2 1.2 nc (nc-nc)   Male 54 50.1 107.8 (80.9-140.6) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 9.1 154.2 (84.2-258.7)   Male 4 3.9 nc (nc-nc) 
Female 4 5.1 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Larynx            Testis     
Male 2 2.5 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 6.5 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 4 4.9 nc (nc-nc)   Female 11 12.8 85.7 (42.7-153.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.7 nc (nc-nc)             
Female 1 1.9 nc (nc-nc)   Female 21 14.4 146.0 (90.3-223.2) 
Lung and Bronchus            All Sites / Types     
Male 28 28.2 99.4 (66.0-143.7)   Male 197 207.3 95.1 (82.2-109.3) 
Female 25 29.3 85.4 (55.2-126.1)   Female 213 217.8 97.8 (85.1-111.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
225 
Northfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.7 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 11 13.9 79.4 (39.6-142.0)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.1 121.7 (39.2-283.9)             
Female 2 3.3 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.0 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 7 13.1 53.3 (21.3-109.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.2 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.5 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.4 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.2 156.2 (50.3-364.5) 
Lung and Bronchus            All Sites / Types     
Male 3 6.6 nc (nc-nc)   Male 35 50.0 70.0 (48.7-97.3) 
Female 5 6.2 81.0 (26.1-189.1)   Female 39 45.0 86.6 (61.6-118.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
226 
Norton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 17.5 74.3 (39.5-127.0)   Male 14 11.8 119.0 (65.0-199.7) 
Female 7 6.2 113.7 (45.6-234.3)   Female 11 9.3 117.8 (58.7-210.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.8 132.8 (42.8-310.0)   Male 2 3.7 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 7 10.6 66.0 (26.5-136.0) 
Female 75 75.2 99.8 (78.5-125.1)   Female 10 9.0 110.5 (52.9-203.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.4 85.3 (36.7-168.2) 
Female 2 2.6 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 20.0 129.7 (84.7-190.0)             
Female 20 19.0 105.2 (64.3-162.5)   Female 7 6.5 108.0 (43.3-222.5) 
Esophagus            Pancreas     
Male 6 4.8 125.2 (45.7-272.6)   Male 9 6.5 139.4 (63.6-264.7) 
Female 1 1.2 nc (nc-nc)   Female 11 6.4 172.9 (86.2-309.3) 
Hodgkin Lymphoma            Prostate     
Male 3 1.6 nc (nc-nc)   Male 51 59.9 85.1 (63.4-111.9) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 10.7 130.5 (71.3-218.9)   Male 3 4.3 nc (nc-nc) 
Female 8 5.8 138.9 (59.8-273.6)   Female 2 2.6 nc (nc-nc) 
Larynx            Testis     
Male 2 2.8 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.5 106.7 (45.9-210.2)   Male 8 5.1 155.8 (67.1-307.0) 
Female 8 5.3 151.9 (65.4-299.4)   Female 15 14.8 101.6 (56.8-167.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 6.7 104.3 (41.8-214.9)             
Female 1 2.1 nc (nc-nc)   Female 22 16.8 131.1 (82.1-198.4) 
Lung and Bronchus            All Sites / Types     
Male 27 31.6 85.3 (56.2-124.2)   Male 237 240.8 98.4 (86.3-111.8) 
Female 26 32.3 80.6 (52.6-118.1)   Female 256 246.3 103.9 (91.6-117.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
227 
Norwell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 12.5 96.1 (49.6-167.9)   Male 8 7.8 102.5 (44.2-202.1) 
Female 4 4.6 nc (nc-nc)   Female 13 6.0 218.2 (116.1-373.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.4 254.4 (92.9-553.7)   Male 1 2.5 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 5 2.1 239.2 (77.1-558.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 7 7.0 99.7 (39.9-205.4) 
Female 48 50.1 95.8 (70.7-127.1)   Female 11 6.4 173.1 (86.3-309.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.9 85.2 (27.5-198.9) 
Female 1 1.5 nc (nc-nc)   Female 5 2.7 187.6 (60.4-437.7) 
Colon / Rectum            Ovary     
Male 10 13.5 73.8 (35.3-135.7)             
Female 8 13.5 59.1 (25.4-116.4)   Female 6 4.3 139.9 (51.1-304.5) 
Esophagus            Pancreas     
Male 2 3.2 nc (nc-nc)   Male 4 4.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 4 4.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.8 nc (nc-nc)   Male 39 38.3 101.8 (72.4-139.2) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.8 88.0 (32.1-191.6)   Male 3 3.0 nc (nc-nc) 
Female 2 4.0 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.8 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.0 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 4 8.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.3 163.0 (65.3-335.9)             
Female 0 1.5 nc (nc-nc)   Female 16 11.1 144.5 (82.6-234.8) 
Lung and Bronchus            All Sites / Types     
Male 13 21.9 59.4 (31.6-101.5)   Male 147 159.0 92.5 (78.1-108.7) 
Female 13 24.2 53.8 (28.6-92.0)   Female 161 168.0 95.8 (81.6-111.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
228 
Norwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 32.1 49.9 (28.5-81.0)   Male 34 20.0 169.7 (117.5-237.1) 
Female 10 12.7 78.8 (37.7-144.9)   Female 25 16.5 151.5 (98.0-223.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 6.0 166.1 (79.5-305.5)   Male 7 6.4 109.0 (43.7-224.6) 
Female 6 5.3 114.3 (41.7-248.7)   Female 7 5.7 123.4 (49.4-254.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 18 17.9 100.7 (59.7-159.2) 
Female 137 131.0 104.6 (87.8-123.6)   Female 20 17.3 115.5 (70.5-178.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 14.2 120.0 (69.9-192.2) 
Female 4 4.3 nc (nc-nc)   Female 6 7.1 84.1 (30.7-183.1) 
Colon / Rectum            Ovary     
Male 52 33.9 153.4 (114.6-201.2)             
Female 56 37.2 150.7 (113.8-195.7)   Female 12 11.4 105.3 (54.3-183.9) 
Esophagus            Pancreas     
Male 10 7.9 126.6 (60.6-232.8)   Male 17 11.1 153.2 (89.2-245.3) 
Female 3 2.4 nc (nc-nc)   Female 19 12.9 146.8 (88.3-229.2) 
Hodgkin Lymphoma            Prostate     
Male 3 2.4 nc (nc-nc)   Male 79 90.5 87.3 (69.1-108.8) 
Female 3 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 16.9 82.9 (45.3-139.1)   Male 10 7.6 131.2 (62.8-241.4) 
Female 16 10.6 150.9 (86.2-245.1)   Female 5 5.1 98.8 (31.8-230.5) 
Larynx            Testis     
Male 7 4.6 153.7 (61.6-316.7)   Male 7 4.4 158.0 (63.3-325.5) 
Female 3 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 12.9 85.5 (42.6-153.0)   Male 13 7.8 167.6 (89.1-286.6) 
Female 12 10.1 118.7 (61.3-207.3)   Female 27 23.4 115.5 (76.1-168.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 10.5 124.2 (66.1-212.4)             
Female 2 4.0 nc (nc-nc)   Female 30 28.4 105.6 (71.2-150.8) 
Lung and Bronchus            All Sites / Types     
Male 58 56.1 103.4 (78.5-133.7)   Male 449 397.7 112.9 (102.7-123.9) 
Female 87 65.3 133.3 (106.8-164.4)   Female 522 452.3 115.4 (105.7-125.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
229 
Oak Bluffs 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 7.6 118.2 (53.9-224.4)   Male 8 4.5 176.6 (76.0-348.0) 
Female 0 2.4 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 24 24.0 100.1 (64.1-148.9)   Female 1 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.1 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 4 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.5 120.0 (54.8-227.8)             
Female 4 6.8 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.8 nc (nc-nc)   Male 5 2.6 189.0 (60.9-441.0) 
Female 0 0.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 16 21.1 75.7 (43.2-122.9) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.7 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.9 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.4 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 7 5.5 128.0 (51.3-263.8) 
Lung and Bronchus            All Sites / Types     
Male 11 13.8 80.0 (39.9-143.1)   Male 84 90.7 92.6 (73.9-114.6) 
Female 15 12.5 119.9 (67.1-197.8)   Female 81 83.2 97.3 (77.3-121.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
230 
Oakham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 7 7.5 93.8 (37.6-193.2)   Female 2 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.4 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 7.4 107.5 (46.3-211.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.3 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 3.9 nc (nc-nc)   Male 23 29.1 78.9 (50.0-118.5) 
Female 1 3.0 nc (nc-nc)   Female 22 23.4 94.0 (58.9-142.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Orange 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.4 85.4 (36.8-168.2)   Male 1 6.0 nc (nc-nc) 
Female 4 3.0 nc (nc-nc)   Female 2 4.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.8 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 4 1.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.4 111.2 (40.6-242.1) 
Female 33 35.2 93.7 (64.5-131.6)   Female 4 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 10.0 49.8 (16.1-116.3)             
Female 6 8.7 69.1 (25.2-150.4)   Female 2 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.5 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 3 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 28 30.6 91.5 (60.8-132.2) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.3 131.9 (52.8-271.8)   Male 0 2.3 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.7 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 5 6.2 80.7 (26.0-188.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.4 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 12 8.1 147.7 (76.2-258.0) 
Lung and Bronchus            All Sites / Types     
Male 20 17.2 116.4 (71.1-179.7)   Male 111 123.1 90.2 (74.2-108.6) 
Female 19 16.3 116.7 (70.3-182.3)   Female 118 115.3 102.3 (84.7-122.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Orleans 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 15.4 84.2 (44.8-144.1)   Male 21 8.4 249.4 (154.3-381.3) 
Female 5 5.1 98.9 (31.9-230.7)   Female 12 5.3 224.3 (115.8-391.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.1 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 13 7.5 172.8 (91.9-295.5) 
Female 61 46.2 132.1 (101.0-169.7)   Female 6 6.4 93.4 (34.1-203.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.6 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 14.2 98.8 (54.0-165.7)             
Female 13 13.4 97.0 (51.6-165.8)   Female 3 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.7 nc (nc-nc)   Male 5 5.1 98.3 (31.7-229.3) 
Female 0 1.0 nc (nc-nc)   Female 8 5.1 157.7 (67.9-310.7) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 32 43.8 73.1 (50.0-103.2) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 6.9 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 2 3.9 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 5.2 190.6 (91.2-350.5)   Male 1 2.3 nc (nc-nc) 
Female 3 3.5 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.3 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 8 10.9 73.6 (31.7-145.1) 
Lung and Bronchus            All Sites / Types     
Male 8 27.6 29.0 (12.5-57.2)   Male 153 176.3 86.8 (73.6-101.7) 
Female 18 26.7 67.3 (39.9-106.4)   Female 175 163.2 107.2 (91.9-124.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Otis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.7 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 14 7.6 185.0 (101.1-310.4)   Female 3 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.8 nc (nc-nc)             
Female 2 1.9 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 8.5 82.7 (33.1-170.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 4.9 141.4 (56.7-291.4)   Male 24 33.8 71.1 (45.5-105.8) 
Female 6 3.8 156.5 (57.2-340.7)   Female 32 25.1 127.7 (87.3-180.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Oxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 10.9 137.6 (77.0-227.0)   Male 12 7.9 151.2 (78.0-264.1) 
Female 6 4.9 123.1 (44.9-267.9)   Female 12 7.2 167.4 (86.4-292.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.7 nc (nc-nc)   Male 6 2.5 241.0 (88.0-524.7) 
Female 0 2.3 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 11 7.1 155.0 (77.3-277.4) 
Female 58 58.3 99.6 (75.6-128.7)   Female 11 7.1 155.2 (77.4-277.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.5 122.5 (52.8-241.4) 
Female 1 2.0 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 13.3 82.8 (41.3-148.2)             
Female 15 14.5 103.2 (57.7-170.2)   Female 8 5.0 160.7 (69.2-316.6) 
Esophagus            Pancreas     
Male 3 3.2 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 6 4.9 123.1 (44.9-267.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 40 41.2 97.1 (69.3-132.2) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.5 79.6 (29.1-173.2)   Male 1 2.8 nc (nc-nc) 
Female 6 4.6 131.8 (48.1-286.9)   Female 3 1.9 nc (nc-nc) 
Larynx            Testis     
Male 4 1.9 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 5.0 198.4 (95.0-364.9)   Male 7 3.8 185.5 (74.3-382.2) 
Female 7 4.1 172.7 (69.2-355.9)   Female 15 11.1 135.2 (75.6-223.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 4.6 197.3 (90.0-374.5)             
Female 1 1.7 nc (nc-nc)   Female 20 13.1 152.6 (93.2-235.7) 
Lung and Bronchus            All Sites / Types     
Male 41 20.5 200.2 (143.6-271.5)   Male 202 161.3 125.2 (108.5-143.7) 
Female 26 26.1 99.5 (65.0-145.8)   Female 223 191.3 116.6 (101.8-132.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
235 
Palmer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 11.1 179.7 (109.7-277.5)   Male 13 7.8 165.6 (88.1-283.3) 
Female 8 4.9 163.7 (70.5-322.5)   Female 7 6.7 104.6 (41.9-215.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 2.5 279.4 (111.9-575.8)   Male 1 2.5 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.9 nc (nc-nc) 
Female 61 54.1 112.7 (86.2-144.8)   Female 8 6.8 117.6 (50.6-231.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.3 94.8 (34.6-206.3) 
Female 1 1.8 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 13.1 99.5 (52.9-170.1)             
Female 13 14.2 91.6 (48.7-156.7)   Female 8 4.7 171.0 (73.6-337.0) 
Esophagus            Pancreas     
Male 3 3.2 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 6 5.0 119.2 (43.5-259.4) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 35 39.8 88.0 (61.3-122.4) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 7.2 209.5 (117.2-345.6)   Male 5 2.9 174.8 (56.3-407.8) 
Female 5 4.3 116.9 (37.7-272.9)   Female 4 1.9 nc (nc-nc) 
Larynx            Testis     
Male 5 1.9 261.7 (84.3-610.7)   Male 2 1.9 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.8 124.5 (45.5-271.0)   Male 1 3.5 nc (nc-nc) 
Female 5 3.9 127.1 (41.0-296.6)   Female 8 9.8 81.3 (35.0-160.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.6 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 13 12.2 106.2 (56.5-181.6) 
Lung and Bronchus            All Sites / Types     
Male 31 20.9 148.2 (100.7-210.4)   Male 184 158.6 116.0 (99.9-134.0) 
Female 15 25.5 58.8 (32.9-96.9)   Female 182 182.0 100.0 (86.0-115.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Paxton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.1 97.7 (31.5-227.9)   Male 7 3.3 211.8 (84.8-436.3) 
Female 2 1.8 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 19 20.2 94.0 (56.6-146.8)   Female 1 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 5.5 nc (nc-nc)             
Female 6 5.1 118.0 (43.1-256.8)   Female 1 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.4 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 22 17.6 124.8 (78.2-189.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.0 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 3 0.8 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.1 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 1 3.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.9 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 5 4.8 105.2 (33.9-245.6) 
Lung and Bronchus            All Sites / Types     
Male 5 9.4 52.9 (17.1-123.6)   Male 74 68.9 107.3 (84.3-134.7) 
Female 5 9.4 52.9 (17.1-123.5)   Female 56 67.2 83.3 (62.9-108.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Peabody 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 95 74.7 127.2 (102.9-155.5)   Male 40 43.8 91.2 (65.2-124.3) 
Female 39 27.7 140.7 (100.0-192.3)   Female 37 33.5 110.5 (77.8-152.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 12.2 65.6 (28.2-129.2)   Male 18 14.3 125.5 (74.3-198.3) 
Female 12 10.5 114.8 (59.3-200.6)   Female 17 12.1 140.1 (81.6-224.4) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.4 nc (nc-nc)   Male 39 39.3 99.1 (70.5-135.5) 
Female 288 265.3 108.6 (96.4-121.8)   Female 63 36.7 171.8 (132.0-219.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 33 30.3 108.8 (74.9-152.8) 
Female 12 8.2 146.3 (75.5-255.7)   Female 14 15.0 93.2 (50.9-156.3) 
Colon / Rectum            Ovary     
Male 62 75.6 82.1 (62.9-105.2)             
Female 85 80.6 105.5 (84.3-130.5)   Female 19 23.4 81.3 (48.9-126.9) 
Esophagus            Pancreas     
Male 16 17.8 90.0 (51.4-146.1)   Male 23 25.3 91.0 (57.7-136.6) 
Female 3 5.3 nc (nc-nc)   Female 23 28.6 80.3 (50.9-120.6) 
Hodgkin Lymphoma            Prostate     
Male 3 4.3 nc (nc-nc)   Male 215 204.5 105.1 (91.5-120.1) 
Female 7 3.7 191.6 (76.7-394.7)             
Kidney & Renal Pelvis            Stomach     
Male 29 36.2 80.0 (53.6-114.9)   Male 14 17.2 81.4 (44.4-136.5) 
Female 12 21.8 55.0 (28.4-96.0)   Female 6 11.1 54.1 (19.7-117.7) 
Larynx            Testis     
Male 17 10.1 168.6 (98.1-269.9)   Male 9 7.1 125.9 (57.5-239.1) 
Female 2 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 27 28.2 95.8 (63.1-139.3)   Male 16 15.1 106.1 (60.6-172.2) 
Female 27 21.2 127.5 (84.0-185.5)   Female 44 43.6 100.9 (73.3-135.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 22.9 78.4 (46.5-124.0)             
Female 13 8.5 152.9 (81.3-261.5)   Female 53 58.1 91.2 (68.3-119.3) 
Lung and Bronchus            All Sites / Types     
Male 128 127.8 100.2 (83.6-119.1)   Male 908 884.8 102.6 (96.1-109.5) 
Female 159 137.8 115.4 (98.1-134.8)   Female 1032 938.5 110.0 (103.3-116.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pelham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 6 7.7 78.3 (28.6-170.4)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.0 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 6.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.5 nc (nc-nc)   Male 17 25.4 67.0 (39.0-107.3) 
Female 1 3.7 nc (nc-nc)   Female 15 25.6 58.7 (32.8-96.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pembroke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 16.3 116.6 (70.1-182.0)   Male 7 11.1 63.2 (25.3-130.2) 
Female 7 5.8 121.3 (48.6-250.0)   Female 15 9.1 164.5 (92.0-271.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.5 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 13 9.9 131.2 (69.8-224.4) 
Female 78 75.7 103.0 (81.4-128.6)   Female 8 8.8 91.4 (39.4-180.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 8.8 135.8 (70.1-237.3) 
Female 1 2.7 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 28 18.6 150.2 (99.8-217.1)             
Female 19 17.6 107.9 (64.9-168.5)   Female 6 6.4 94.3 (34.4-205.3) 
Esophagus            Pancreas     
Male 5 4.5 110.0 (35.5-256.8)   Male 7 6.1 115.6 (46.3-238.1) 
Female 1 1.2 nc (nc-nc)   Female 5 5.9 85.4 (27.5-199.2) 
Hodgkin Lymphoma            Prostate     
Male 0 1.4 nc (nc-nc)   Male 69 58.1 118.8 (92.4-150.4) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 10.2 107.8 (53.8-192.9)   Male 6 4.1 146.8 (53.6-319.6) 
Female 7 5.7 122.8 (49.2-253.1)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 3 2.7 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.0 143.2 (68.6-263.4)   Male 7 4.8 144.4 (57.9-297.6) 
Female 5 5.0 99.8 (32.1-232.8)   Female 24 14.8 161.7 (103.6-240.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.4 nc (nc-nc)             
Female 1 2.1 nc (nc-nc)   Female 17 17.1 99.4 (57.9-159.1) 
Lung and Bronchus            All Sites / Types     
Male 34 29.9 113.6 (78.6-158.7)   Male 262 227.5 115.2 (101.7-130.0) 
Female 46 31.3 146.8 (107.5-195.9)   Female 269 241.0 111.6 (98.7-125.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pepperell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 11.0 45.4 (14.6-106.0)   Male 6 7.6 79.3 (29.0-172.6) 
Female 3 3.4 nc (nc-nc)   Female 2 5.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.4 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 4 1.8 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 6.8 73.7 (23.7-172.0) 
Female 52 47.2 110.1 (82.2-144.4)   Female 4 5.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.3 95.9 (35.0-208.8) 
Female 0 1.7 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 13.0 107.6 (58.8-180.6)             
Female 15 10.5 142.8 (79.9-235.5)   Female 4 3.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.1 nc (nc-nc)   Male 6 4.2 144.3 (52.7-314.0) 
Female 0 0.7 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 30 39.7 75.6 (51.0-107.9) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.0 85.1 (31.1-185.3)   Male 2 2.8 nc (nc-nc) 
Female 5 3.5 141.3 (45.6-329.9)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.7 105.3 (33.9-245.7)   Male 5 3.3 150.6 (48.5-351.5) 
Female 4 3.0 nc (nc-nc)   Female 8 9.4 85.3 (36.7-168.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.5 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 18 10.6 169.9 (100.6-268.5) 
Lung and Bronchus            All Sites / Types     
Male 26 20.2 128.7 (84.1-188.6)   Male 143 155.7 91.8 (77.4-108.2) 
Female 17 19.2 88.6 (51.6-141.8)   Female 154 147.7 104.3 (88.4-122.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Peru 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.9 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 2 3.7 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.1 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.7 nc (nc-nc)   Male 10 13.1 76.2 (36.5-140.1) 
Female 0 1.4 nc (nc-nc)   Female 4 11.6 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Petersham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 1.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 4 6.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.0 nc (nc-nc)             
Female 0 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 5.3 112.3 (41.0-244.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.1 nc (nc-nc)   Male 21 22.5 93.5 (57.9-142.9) 
Female 0 3.2 nc (nc-nc)   Female 11 22.4 49.0 (24.4-87.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Phillipston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.4 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 6 6.8 88.1 (32.2-191.8)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.8 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 9 5.7 158.5 (72.3-300.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 2.6 nc (nc-nc)   Male 23 21.3 107.7 (68.3-161.7) 
Female 5 2.5 197.6 (63.7-461.2)   Female 21 20.7 101.5 (62.8-155.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pittsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 70 52.9 132.4 (103.2-167.3)   Male 29 32.7 88.6 (59.3-127.2) 
Female 21 20.8 100.9 (62.5-154.3)   Female 22 27.0 81.6 (51.1-123.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 9.7 144.7 (79.0-242.8)   Male 10 10.6 93.9 (45.0-172.8) 
Female 5 8.5 59.0 (19.0-137.6)   Female 3 9.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 29 29.4 98.5 (66.0-141.5) 
Female 189 215.3 87.8 (75.7-101.2)   Female 26 28.4 91.6 (59.8-134.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 31 24.2 128.0 (86.9-181.7) 
Female 4 6.9 nc (nc-nc)   Female 10 11.8 84.7 (40.5-155.8) 
Colon / Rectum            Ovary     
Male 62 56.1 110.6 (84.8-141.7)             
Female 79 60.3 131.0 (103.7-163.3)   Female 13 18.8 69.2 (36.8-118.3) 
Esophagus            Pancreas     
Male 27 13.5 200.7 (132.2-292.0)   Male 18 18.6 96.5 (57.2-152.6) 
Female 5 4.0 123.9 (39.9-289.2)   Female 19 21.3 89.1 (53.6-139.2) 
Hodgkin Lymphoma            Prostate     
Male 3 3.6 nc (nc-nc)   Male 155 164.7 94.1 (79.9-110.2) 
Female 1 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 28.4 105.5 (71.1-150.6)   Male 11 12.6 87.3 (43.5-156.3) 
Female 21 17.4 120.6 (74.6-184.3)   Female 8 8.2 97.2 (41.9-191.6) 
Larynx            Testis     
Male 11 7.8 141.3 (70.4-252.9)   Male 10 6.4 156.6 (75.0-288.0) 
Female 2 2.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 20.9 105.4 (66.0-159.5)   Male 14 12.4 112.8 (61.6-189.3) 
Female 9 16.4 55.0 (25.1-104.3)   Female 33 37.4 88.1 (60.6-123.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 18.0 94.4 (54.9-151.1)             
Female 6 6.6 90.4 (33.0-196.7)   Female 52 48.2 107.8 (80.5-141.4) 
Lung and Bronchus            All Sites / Types     
Male 102 93.2 109.5 (89.3-132.9)   Male 726 671.7 108.1 (100.4-116.2) 
Female 149 106.8 139.5 (118.0-163.8)   Female 737 741.4 99.4 (92.4-106.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Plainfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 4 3.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.0 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.9 nc (nc-nc)   Male 9 13.3 67.9 (31.0-128.9) 
Female 3 1.7 nc (nc-nc)   Female 9 11.6 77.7 (35.5-147.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
246 
Plainville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 6.9 158.7 (79.1-283.9)   Male 6 5.0 120.5 (44.0-262.3) 
Female 2 2.9 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 4 1.6 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 10 4.5 221.3 (106.0-407.1) 
Female 40 36.5 109.7 (78.4-149.4)   Female 3 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 8.5 94.0 (40.5-185.2)             
Female 9 8.9 100.8 (46.0-191.3)   Female 6 3.1 194.1 (70.9-422.4) 
Esophagus            Pancreas     
Male 0 2.0 nc (nc-nc)   Male 7 2.7 256.3 (102.7-528.1) 
Female 0 0.6 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 32 26.7 119.8 (81.9-169.1) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 4.7 212.1 (101.5-390.0)   Male 0 1.8 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 3 1.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.1 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 7 2.5 282.1 (113.0-581.2)   Female 6 7.4 80.8 (29.5-175.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.9 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 7 8.0 87.4 (35.0-180.1) 
Lung and Bronchus            All Sites / Types     
Male 18 12.9 139.8 (82.8-221.0)   Male 136 102.5 132.7 (111.3-156.9) 
Female 20 15.4 129.7 (79.2-200.3)   Female 128 117.8 108.6 (90.6-129.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
247 
Plymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 71 64.4 110.3 (86.2-139.2)   Male 64 41.9 152.7 (117.6-195.0) 
Female 22 23.7 92.8 (58.1-140.4)   Female 53 32.7 162.0 (121.3-211.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 12.7 110.5 (60.3-185.4)   Male 11 13.6 81.0 (40.4-144.9) 
Female 11 10.5 104.3 (52.0-186.7)   Female 10 11.0 90.8 (43.5-167.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.3 nc (nc-nc)   Male 48 37.5 127.9 (94.3-169.5) 
Female 303 274.6 110.3 (98.3-123.5)   Female 28 33.5 83.5 (55.5-120.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 37 32.5 113.9 (80.2-156.9) 
Female 6 8.8 68.2 (24.9-148.4)   Female 15 14.3 104.6 (58.5-172.5) 
Colon / Rectum            Ovary     
Male 72 70.3 102.5 (80.2-129.1)             
Female 62 69.1 89.7 (68.8-115.0)   Female 34 23.3 145.7 (100.9-203.6) 
Esophagus            Pancreas     
Male 20 17.4 114.7 (70.0-177.1)   Male 27 23.5 114.8 (75.7-167.1) 
Female 1 4.7 nc (nc-nc)   Female 23 24.2 94.9 (60.2-142.5) 
Hodgkin Lymphoma            Prostate     
Male 3 4.9 nc (nc-nc)   Male 237 222.6 106.5 (93.3-120.9) 
Female 1 3.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 37 38.0 97.5 (68.6-134.3)   Male 12 15.7 76.3 (39.4-133.2) 
Female 21 21.5 97.6 (60.4-149.1)   Female 10 9.3 107.8 (51.6-198.2) 
Larynx            Testis     
Male 12 10.2 117.4 (60.6-205.1)   Male 6 8.7 69.3 (25.3-151.0) 
Female 1 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 28 26.2 107.0 (71.1-154.7)   Male 23 17.1 134.5 (85.2-201.8) 
Female 15 19.0 78.8 (44.1-130.0)   Female 72 48.0 149.9 (117.3-188.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 30 23.6 127.3 (85.9-181.8)             
Female 6 7.9 76.0 (27.8-165.5)   Female 70 62.5 112.0 (87.3-141.5) 
Lung and Bronchus            All Sites / Types     
Male 144 117.9 122.1 (103.0-143.8)   Male 987 866.8 113.9 (106.9-121.2) 
Female 144 127.3 113.1 (95.4-133.1)   Female 987 904.0 109.2 (102.5-116.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
248 
Plympton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 3.5 172.5 (63.0-375.4)   Male 2 2.3 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 15 12.5 119.8 (67.0-197.7)   Female 0 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.8 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.8 nc (nc-nc)             
Female 4 2.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.0 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 13 12.8 101.6 (54.1-173.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.4 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.3 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 6.5 nc (nc-nc)   Male 40 48.0 83.3 (59.5-113.4) 
Female 7 5.5 128.3 (51.4-264.5)   Female 50 39.8 125.7 (93.3-165.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
249 
Princeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.2 154.1 (49.6-359.5)   Male 6 2.3 260.2 (95.0-566.3) 
Female 0 1.2 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 0.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 16 16.3 98.2 (56.1-159.5)   Female 1 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 2.0 501.4 (240.1-922.2) 
Female 0 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.9 127.8 (41.2-298.3)             
Female 1 3.6 nc (nc-nc)   Female 5 1.4 361.3 (116.4-843.1) 
Esophagus            Pancreas     
Male 3 1.0 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 16 13.0 122.9 (70.2-199.6) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 2.2 227.1 (73.2-530.0)   Male 0 0.8 nc (nc-nc) 
Female 4 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 2 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.4 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 6.1 nc (nc-nc)   Male 70 48.3 145.0 (113.0-183.2) 
Female 3 6.8 nc (nc-nc)   Female 49 51.3 95.5 (70.7-126.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
250 
Provincetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 5.6 nc (nc-nc)   Male 6 3.6 167.6 (61.2-364.9) 
Female 5 1.7 297.5 (95.9-694.2)   Female 3 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.2 nc (nc-nc) 
Female 15 17.4 86.0 (48.1-141.9)   Female 1 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.0 168.8 (54.4-393.9) 
Female 0 0.5 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 6.4 109.7 (44.0-226.1)             
Female 9 4.6 195.2 (89.1-370.6)   Female 4 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.6 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 12 20.3 59.2 (30.5-103.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.3 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.1 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 10.1 98.8 (47.3-181.8)   Male 74 75.8 97.6 (76.6-122.5) 
Female 10 9.1 109.8 (52.5-201.9)   Female 71 59.0 120.4 (94.0-151.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
251 
Quincy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 103 94.8 108.7 (88.7-131.8)   Male 53 61.4 86.3 (64.7-112.9) 
Female 32 35.0 91.4 (62.5-129.0)   Female 61 50.2 121.4 (92.9-156.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 20 19.1 104.9 (64.0-161.9)   Male 14 19.4 72.1 (39.4-121.0) 
Female 16 15.6 102.9 (58.8-167.0)   Female 14 16.0 87.5 (47.8-146.8) 
Breast            Non-Hodgkin Lymphoma     
Male 5 3.3 152.0 (49.0-354.6)   Male 46 55.2 83.4 (61.0-111.2) 
Female 382 389.5 98.1 (88.5-108.4)   Female 63 49.5 127.4 (97.9-163.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 64 44.7 143.1 (110.2-182.7) 
Female 22 13.7 160.3 (100.4-242.7)   Female 25 20.8 120.3 (77.8-177.6) 
Colon / Rectum            Ovary     
Male 133 103.1 129.0 (108.0-152.9)             
Female 96 103.5 92.8 (75.1-113.3)   Female 31 33.9 91.5 (62.1-129.8) 
Esophagus            Pancreas     
Male 28 24.1 116.2 (77.2-168.0)   Male 27 33.9 79.6 (52.5-115.9) 
Female 11 6.8 161.0 (80.3-288.1)   Female 36 35.7 100.9 (70.7-139.7) 
Hodgkin Lymphoma            Prostate     
Male 9 8.3 107.8 (49.2-204.7)   Male 254 288.8 87.9 (77.5-99.5) 
Female 8 6.7 119.6 (51.5-235.7)             
Kidney & Renal Pelvis            Stomach     
Male 48 52.9 90.8 (66.9-120.4)   Male 30 23.1 130.2 (87.8-185.8) 
Female 29 31.0 93.5 (62.6-134.3)   Female 15 14.0 107.3 (60.0-177.0) 
Larynx            Testis     
Male 17 14.1 120.6 (70.2-193.1)   Male 18 16.5 109.1 (64.6-172.4) 
Female 5 4.4 114.4 (36.9-266.9)             
Leukemia            Thyroid     
Male 26 39.1 66.4 (43.4-97.4)   Male 26 25.3 102.6 (67.0-150.3) 
Female 25 28.8 86.9 (56.2-128.3)   Female 59 77.0 76.6 (58.3-98.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 62 32.6 190.0 (145.7-243.6)             
Female 16 11.4 140.0 (80.0-227.4)   Female 81 86.4 93.8 (74.5-116.6) 
Lung and Bronchus            All Sites / Types     
Male 242 167.3 144.7 (127.0-164.1)   Male 1323 1227.5 107.8 (102.0-113.7) 
Female 237 183.5 129.2 (113.3-146.7)   Female 1362 1319.7 103.2 (97.8-108.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
252 
Randolph 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 35.8 95.0 (65.8-132.7)   Male 12 22.6 53.2 (27.4-92.9) 
Female 7 13.2 52.9 (21.2-108.9)   Female 15 18.6 80.5 (45.0-132.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 6.8 88.1 (32.2-191.8)   Male 7 7.3 95.9 (38.4-197.6) 
Female 5 5.9 84.0 (27.1-196.1)   Female 10 6.1 164.4 (78.7-302.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.2 nc (nc-nc)   Male 13 20.3 63.9 (34.0-109.3) 
Female 127 149.9 84.7 (70.6-100.8)   Female 18 18.8 95.6 (56.6-151.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 16.6 42.3 (16.9-87.1) 
Female 5 5.1 97.5 (31.4-227.5)   Female 9 7.9 113.3 (51.7-215.1) 
Colon / Rectum            Ovary     
Male 38 38.4 99.0 (70.0-135.8)             
Female 44 39.0 112.7 (81.9-151.3)   Female 10 12.9 77.8 (37.2-143.1) 
Esophagus            Pancreas     
Male 6 9.1 66.0 (24.1-143.7)   Male 10 12.7 78.9 (37.8-145.2) 
Female 3 2.6 nc (nc-nc)   Female 7 13.5 52.0 (20.8-107.2) 
Hodgkin Lymphoma            Prostate     
Male 2 2.7 nc (nc-nc)   Male 114 108.8 104.8 (86.4-125.9) 
Female 0 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 19.5 112.8 (70.7-170.8)   Male 8 8.6 93.0 (40.1-183.3) 
Female 10 11.8 84.9 (40.7-156.2)   Female 6 5.3 112.3 (41.0-244.4) 
Larynx            Testis     
Male 6 5.3 113.3 (41.4-246.5)   Male 0 4.9 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 14.4 62.4 (28.5-118.5)   Male 13 8.8 147.9 (78.7-252.9) 
Female 2 10.8 nc (nc-nc)   Female 33 28.1 117.6 (81.0-165.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 12.3 97.9 (50.5-171.0)             
Female 2 4.4 nc (nc-nc)   Female 35 33.6 104.2 (72.6-145.0) 
Lung and Bronchus            All Sites / Types     
Male 38 63.2 60.1 (42.6-82.6)   Male 384 456.6 84.1 (75.9-93.0) 
Female 56 69.2 80.9 (61.1-105.1)   Female 434 501.1 86.6 (78.7-95.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
253 
Raynham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 13.8 122.8 (71.5-196.5)   Male 8 9.2 87.2 (37.6-171.9) 
Female 7 5.4 129.8 (52.0-267.4)   Female 10 7.3 136.6 (65.4-251.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.9 nc (nc-nc)   Male 5 2.9 173.0 (55.8-403.8) 
Female 1 2.4 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 12 8.2 147.0 (75.9-256.8) 
Female 64 59.1 108.3 (83.4-138.2)   Female 6 7.5 79.9 (29.2-173.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.2 69.6 (22.4-162.4) 
Female 1 2.0 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 28 15.6 179.6 (119.3-259.6)             
Female 18 15.5 116.1 (68.7-183.4)   Female 5 5.1 98.0 (31.6-228.8) 
Esophagus            Pancreas     
Male 5 3.7 134.7 (43.4-314.2)   Male 7 5.1 137.1 (54.9-282.5) 
Female 3 1.1 nc (nc-nc)   Female 5 5.4 92.0 (29.6-214.7) 
Hodgkin Lymphoma            Prostate     
Male 3 1.0 nc (nc-nc)   Male 47 46.7 100.7 (73.9-133.8) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 8.3 157.3 (83.7-269.1)   Male 1 3.4 nc (nc-nc) 
Female 10 4.7 211.3 (101.2-388.7)   Female 4 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.2 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 5.8 nc (nc-nc)   Male 6 3.8 159.1 (58.1-346.3) 
Female 4 4.3 nc (nc-nc)   Female 27 10.8 249.2 (164.2-362.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.3 nc (nc-nc)             
Female 3 1.8 nc (nc-nc)   Female 16 13.2 120.9 (69.1-196.3) 
Lung and Bronchus            All Sites / Types     
Male 29 25.2 115.2 (77.1-165.5)   Male 219 187.3 117.0 (102.0-133.5) 
Female 32 28.6 111.7 (76.4-157.7)   Female 245 199.7 122.7 (107.8-139.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
254 
Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 24.7 117.3 (78.6-168.5)   Male 12 16.3 73.6 (38.0-128.5) 
Female 11 10.2 108.2 (53.9-193.6)   Female 16 13.8 115.9 (66.2-188.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.1 116.7 (42.6-254.0)   Male 5 5.2 95.6 (30.8-223.2) 
Female 7 4.5 156.3 (62.6-322.0)   Female 3 4.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 16 14.6 109.2 (62.4-177.4) 
Female 131 111.9 117.1 (97.9-138.9)   Female 6 14.2 42.2 (15.4-92.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 12.7 86.4 (43.1-154.6) 
Female 1 3.7 nc (nc-nc)   Female 7 6.0 117.2 (46.9-241.4) 
Colon / Rectum            Ovary     
Male 33 27.6 119.8 (82.4-168.2)             
Female 23 29.8 77.1 (48.9-115.7)   Female 13 9.6 135.0 (71.8-230.9) 
Esophagus            Pancreas     
Male 7 6.7 104.8 (42.0-215.9)   Male 7 9.1 77.2 (30.9-159.1) 
Female 1 2.0 nc (nc-nc)   Female 9 10.4 86.6 (39.5-164.4) 
Hodgkin Lymphoma            Prostate     
Male 1 2.0 nc (nc-nc)   Male 62 83.9 73.9 (56.7-94.8) 
Female 4 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 14.8 94.6 (51.7-158.7)   Male 4 6.1 nc (nc-nc) 
Female 9 8.9 101.7 (46.4-193.0)   Female 1 4.1 nc (nc-nc) 
Larynx            Testis     
Male 1 3.9 nc (nc-nc)   Male 5 3.5 141.4 (45.6-330.1) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 10.4 125.0 (66.5-213.8)   Male 7 6.9 102.0 (40.9-210.2) 
Female 10 8.2 121.3 (58.1-223.1)   Female 25 20.3 122.9 (79.5-181.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 9.1 120.5 (60.1-215.7)             
Female 5 3.3 150.1 (48.4-350.4)   Female 27 24.9 108.6 (71.6-158.1) 
Lung and Bronchus            All Sites / Types     
Male 36 44.7 80.5 (56.3-111.4)   Male 305 334.2 91.3 (81.3-102.1) 
Female 43 52.5 81.9 (59.2-110.3)   Female 391 376.8 103.8 (93.7-114.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
255 
Rehoboth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 13.8 58.1 (25.0-114.6)   Male 8 8.9 89.9 (38.7-177.1) 
Female 3 3.5 nc (nc-nc)   Female 4 5.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.7 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 6 8.0 74.7 (27.3-162.6) 
Female 44 47.5 92.6 (67.3-124.3)   Female 7 5.3 131.5 (52.7-270.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 7.1 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 15.3 71.9 (35.9-128.7)             
Female 11 10.5 105.2 (52.4-188.2)   Female 3 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.7 nc (nc-nc)   Male 1 5.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 38 46.7 81.4 (57.6-111.7) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 8.1 74.2 (27.1-161.5)   Male 1 3.4 nc (nc-nc) 
Female 6 3.5 170.3 (62.2-370.7)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 2.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.6 88.6 (28.5-206.7)   Male 0 3.7 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 7 9.3 75.5 (30.2-155.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 5.1 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 14 11.0 127.5 (69.7-214.0) 
Lung and Bronchus            All Sites / Types     
Male 23 24.4 94.3 (59.7-141.5)   Male 126 184.2 68.4 (57.0-81.4) 
Female 17 19.1 89.1 (51.9-142.7)   Female 139 148.8 93.4 (78.6-110.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
256 
Revere 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 49 49.7 98.6 (73.0-130.4)   Male 23 33.5 68.6 (43.5-102.9) 
Female 15 19.6 76.4 (42.7-125.9)   Female 27 27.6 97.8 (64.4-142.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 10.8 102.0 (50.8-182.5)   Male 7 10.3 67.9 (27.2-139.9) 
Female 11 8.6 127.3 (63.5-227.8)   Female 9 8.9 100.8 (46.0-191.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 30 30.0 99.9 (67.4-142.6) 
Female 195 217.3 89.7 (77.6-103.2)   Female 25 27.7 90.4 (58.5-133.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 24.8 80.8 (49.3-124.8) 
Female 5 7.5 66.8 (21.5-155.9)   Female 16 11.5 138.7 (79.2-225.2) 
Colon / Rectum            Ovary     
Male 60 55.9 107.3 (81.9-138.1)             
Female 42 57.2 73.4 (52.9-99.2)   Female 14 18.8 74.5 (40.7-125.1) 
Esophagus            Pancreas     
Male 8 12.9 62.1 (26.7-122.4)   Male 24 18.0 133.5 (85.5-198.6) 
Female 3 3.9 nc (nc-nc)   Female 14 19.9 70.3 (38.4-117.9) 
Hodgkin Lymphoma            Prostate     
Male 8 4.9 161.7 (69.6-318.5)   Male 123 155.9 78.9 (65.6-94.1) 
Female 8 3.5 231.5 (99.7-456.2)             
Kidney & Renal Pelvis            Stomach     
Male 33 29.3 112.6 (77.5-158.2)   Male 21 12.3 170.9 (105.8-261.3) 
Female 27 17.3 156.0 (102.8-227.0)   Female 12 7.8 153.2 (79.1-267.6) 
Larynx            Testis     
Male 9 7.5 119.9 (54.7-227.6)   Male 8 10.1 79.5 (34.2-156.6) 
Female 7 2.4 287.9 (115.4-593.3)             
Leukemia            Thyroid     
Male 27 21.3 126.7 (83.5-184.4)   Male 11 14.9 73.9 (36.9-132.3) 
Female 15 16.1 93.5 (52.3-154.1)   Female 51 41.4 123.2 (91.7-162.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 17.7 141.6 (91.6-209.0)             
Female 7 6.4 108.9 (43.6-224.4)   Female 36 48.3 74.5 (52.2-103.2) 
Lung and Bronchus            All Sites / Types     
Male 117 88.3 132.5 (109.6-158.8)   Male 663 663.5 99.9 (92.5-107.8) 
Female 136 103.1 131.9 (110.7-156.0)   Female 729 734.4 99.3 (92.2-106.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
257 
Richmond 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 3.4 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 6 9.7 61.8 (22.6-134.5)   Female 1 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 3.3 nc (nc-nc)             
Female 1 2.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.8 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 9 10.2 87.9 (40.1-166.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.2 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 6.0 nc (nc-nc)   Male 20 40.5 49.4 (30.2-76.3) 
Female 1 5.0 nc (nc-nc)   Female 19 32.9 57.8 (34.8-90.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
258 
Rochester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 5.3 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 5 1.9 269.8 (87.0-629.7)   Female 2 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.1 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 26 22.4 116.2 (75.9-170.3)   Female 2 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 6.0 83.2 (26.8-194.3)             
Female 8 5.7 140.3 (60.4-276.5)   Female 2 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.5 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 25 19.6 127.6 (82.6-188.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.4 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.2 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 3 5.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 10.0 110.0 (54.8-196.8)   Male 74 75.3 98.3 (77.2-123.4) 
Female 6 9.5 63.5 (23.2-138.1)   Female 67 73.5 91.1 (70.6-115.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
259 
Rockland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 17.8 112.6 (68.7-173.9)   Male 14 11.9 117.7 (64.3-197.5) 
Female 10 7.2 139.4 (66.8-256.5)   Female 12 9.5 126.1 (65.1-220.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.8 132.4 (42.7-309.0)   Male 4 3.8 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 1 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 11 10.7 102.8 (51.2-183.9) 
Female 82 79.6 103.1 (82.0-127.9)   Female 17 10.0 170.4 (99.2-272.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 9.2 108.9 (52.1-200.2) 
Female 2 2.6 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 19.9 110.8 (69.4-167.7)             
Female 23 20.3 113.2 (71.7-169.9)   Female 6 6.7 88.9 (32.5-193.5) 
Esophagus            Pancreas     
Male 8 4.8 165.3 (71.2-325.8)   Male 7 6.5 107.0 (42.9-220.4) 
Female 1 1.4 nc (nc-nc)   Female 7 7.2 97.1 (38.9-200.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 67 61.6 108.7 (84.3-138.1) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 10.8 129.9 (71.0-218.0)   Male 5 4.4 113.2 (36.5-264.2) 
Female 16 6.4 251.1 (143.4-407.8)   Female 8 2.7 291.6 (125.5-574.6) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.5 133.7 (64.0-246.0)   Male 3 5.1 nc (nc-nc) 
Female 11 5.7 194.3 (96.9-347.6)   Female 19 13.9 136.6 (82.2-213.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.7 nc (nc-nc)             
Female 4 2.4 nc (nc-nc)   Female 22 18.0 122.1 (76.5-184.9) 
Lung and Bronchus            All Sites / Types     
Male 34 32.5 104.6 (72.4-146.1)   Male 267 243.7 109.6 (96.8-123.5) 
Female 51 38.5 132.4 (98.6-174.1)   Female 324 265.7 121.9 (109.0-136.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
260 
Rockport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 11.7 77.1 (35.2-146.3)   Male 8 6.9 116.5 (50.2-229.5) 
Female 2 4.7 nc (nc-nc)   Female 7 5.5 126.5 (50.7-260.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.8 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 3 1.7 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.4 nc (nc-nc)   Male 3 6.1 nc (nc-nc) 
Female 47 46.1 102.0 (74.9-135.6)   Female 5 6.2 80.8 (26.0-188.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.0 99.4 (32.0-232.0) 
Female 0 1.3 nc (nc-nc)   Female 6 2.6 232.4 (84.9-505.8) 
Colon / Rectum            Ovary     
Male 10 11.6 86.1 (41.2-158.4)             
Female 5 13.3 37.7 (12.1-87.9)   Female 5 4.1 123.4 (39.8-287.9) 
Esophagus            Pancreas     
Male 2 3.0 nc (nc-nc)   Male 2 4.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 3 4.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 40 37.2 107.6 (76.8-146.5) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 5.9 135.0 (58.1-266.1)   Male 0 2.7 nc (nc-nc) 
Female 6 3.8 158.9 (58.0-345.9)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.3 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 5 6.8 73.7 (23.8-172.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.8 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 9 10.6 85.2 (38.9-161.7) 
Lung and Bronchus            All Sites / Types     
Male 16 21.0 76.2 (43.5-123.8)   Male 130 144.3 90.1 (75.3-107.0) 
Female 14 24.2 57.7 (31.5-96.9)   Female 141 160.0 88.1 (74.2-103.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rowe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 0.7 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.2 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.2 nc (nc-nc)   Male 4 8.6 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 7.2 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rowley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.9 102.0 (37.2-222.0)   Male 4 4.1 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 5 3.4 147.6 (47.6-344.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 26 27.8 93.5 (61.1-137.0)   Female 4 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.5 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 6.7 133.5 (60.9-253.5)             
Female 7 7.0 100.2 (40.1-206.4)   Female 3 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.8 nc (nc-nc)   Male 5 2.3 216.3 (69.7-504.8) 
Female 0 0.4 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 21 23.9 87.8 (54.3-134.2) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.9 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.5 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 8 5.2 153.3 (66.0-302.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 4 6.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 11.2 98.3 (49.0-176.0)   Male 78 86.4 90.3 (71.4-112.7) 
Female 5 11.8 42.2 (13.6-98.6)   Female 83 90.2 92.0 (73.3-114.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Royalston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.5 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 9 5.4 165.8 (75.7-314.8)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.7 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 5.2 192.2 (92.0-353.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.8 nc (nc-nc)   Male 21 20.5 102.4 (63.4-156.6) 
Female 1 2.3 nc (nc-nc)   Female 19 17.1 111.1 (66.9-173.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Russell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.5 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 11 6.9 158.3 (78.9-283.2)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 1.7 nc (nc-nc)             
Female 6 1.7 362.9 (132.5-789.9)   Female 2 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 5.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 2.8 nc (nc-nc)   Male 18 20.8 86.4 (51.2-136.6) 
Female 3 3.3 nc (nc-nc)   Female 29 22.7 127.5 (85.4-183.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rutland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.7 74.9 (24.1-174.8)   Male 6 4.7 126.4 (46.1-275.1) 
Female 2 2.1 nc (nc-nc)   Female 0 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.6 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.3 115.2 (37.1-268.9) 
Female 40 29.9 133.8 (95.6-182.2)   Female 3 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.9 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 8.2 122.7 (58.7-225.6)             
Female 7 6.7 104.4 (41.8-215.2)   Female 2 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.9 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 26 25.4 102.3 (66.8-149.9) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.6 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 2.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.0 197.3 (72.0-429.5)   Male 0 2.3 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 3 6.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.7 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 6 6.6 91.1 (33.3-198.2) 
Lung and Bronchus            All Sites / Types     
Male 17 12.2 139.6 (81.3-223.6)   Male 99 97.9 101.1 (82.2-123.1) 
Female 9 11.3 79.8 (36.4-151.5)   Female 88 93.0 94.6 (75.9-116.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 34.8 100.5 (70.0-139.7)   Male 32 23.5 136.3 (93.2-192.5) 
Female 11 16.5 66.6 (33.2-119.2)   Female 22 23.3 94.3 (59.1-142.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 7.6 144.1 (71.8-257.8)   Male 4 7.3 nc (nc-nc) 
Female 2 7.4 nc (nc-nc)   Female 13 7.5 173.2 (92.1-296.2) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 30 21.2 141.4 (95.4-201.9) 
Female 169 180.0 93.9 (80.3-109.1)   Female 21 23.3 90.3 (55.9-138.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 17.9 123.1 (77.1-186.4) 
Female 5 6.3 79.9 (25.8-186.6)   Female 14 9.8 143.1 (78.2-240.1) 
Colon / Rectum            Ovary     
Male 42 39.8 105.5 (76.0-142.5)             
Female 36 48.9 73.7 (51.6-102.0)   Female 9 15.8 56.9 (26.0-108.0) 
Esophagus            Pancreas     
Male 12 9.2 131.0 (67.6-228.9)   Male 10 12.8 78.2 (37.4-143.9) 
Female 6 3.2 188.7 (68.9-410.8)   Female 14 16.9 83.1 (45.4-139.4) 
Hodgkin Lymphoma            Prostate     
Male 3 3.5 nc (nc-nc)   Male 145 112.2 129.2 (109.1-152.1) 
Female 9 3.3 276.6 (126.2-525.2)             
Kidney & Renal Pelvis            Stomach     
Male 26 20.8 125.1 (81.7-183.3)   Male 16 8.7 184.3 (105.3-299.3) 
Female 17 14.4 118.2 (68.8-189.2)   Female 2 6.7 nc (nc-nc) 
Larynx            Testis     
Male 4 5.4 nc (nc-nc)   Male 6 6.9 87.1 (31.8-189.7) 
Female 3 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 15.0 106.5 (60.8-173.0)   Male 11 10.4 106.2 (52.9-190.0) 
Female 16 13.7 117.0 (66.9-190.1)   Female 45 35.3 127.6 (93.0-170.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 12.8 109.5 (59.8-183.8)             
Female 2 5.5 nc (nc-nc)   Female 44 40.4 109.0 (79.2-146.4) 
Lung and Bronchus            All Sites / Types     
Male 74 62.1 119.1 (93.5-149.5)   Male 566 470.9 120.2 (110.5-130.5) 
Female 98 84.7 115.7 (93.9-141.0)   Female 613 615.3 99.6 (91.9-107.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 9.9 121.2 (62.5-211.7)   Male 10 6.5 154.3 (73.9-283.8) 
Female 4 3.2 nc (nc-nc)   Female 3 4.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.0 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 5.8 102.7 (37.5-223.6) 
Female 47 40.7 115.4 (84.8-153.4)   Female 8 4.6 172.8 (74.4-340.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 5.2 270.7 (147.9-454.2) 
Female 1 1.3 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 10.8 138.3 (77.3-228.1)             
Female 15 9.1 164.9 (92.2-271.9)   Female 7 3.4 205.7 (82.4-423.9) 
Esophagus            Pancreas     
Male 2 2.7 nc (nc-nc)   Male 5 3.7 135.4 (43.6-315.9) 
Female 1 0.7 nc (nc-nc)   Female 6 3.2 187.1 (68.3-407.3) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 28 36.2 77.3 (51.3-111.7) 
Female 2 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.0 133.7 (57.6-263.5)   Male 3 2.4 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.0 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 8 7.3 109.2 (47.0-215.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.7 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 11 9.5 116.4 (58.0-208.2) 
Lung and Bronchus            All Sites / Types     
Male 21 18.4 114.0 (70.5-174.3)   Male 139 136.2 102.0 (85.8-120.5) 
Female 28 17.6 159.3 (105.8-230.2)   Female 167 128.8 129.6 (110.7-150.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sandisfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 4.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.9 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 4.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.4 nc (nc-nc)   Male 12 22.2 54.1 (27.9-94.5) 
Female 3 1.8 nc (nc-nc)   Female 9 13.2 68.1 (31.1-129.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sandwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 24.3 131.8 (90.1-186.0)   Male 19 15.5 122.9 (74.0-192.0) 
Female 8 8.3 96.3 (41.5-189.7)   Female 15 11.7 128.4 (71.8-211.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 4.6 218.0 (104.4-401.0)   Male 4 5.1 nc (nc-nc) 
Female 6 3.8 159.4 (58.2-346.9)   Female 1 3.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 17 13.8 123.1 (71.7-197.1) 
Female 116 97.4 119.0 (98.4-142.8)   Female 13 11.9 109.2 (58.1-186.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 11.9 83.7 (40.1-154.0) 
Female 1 3.1 nc (nc-nc)   Female 8 5.1 157.1 (67.7-309.6) 
Colon / Rectum            Ovary     
Male 19 26.3 72.3 (43.5-113.0)             
Female 20 24.1 83.0 (50.7-128.1)   Female 9 8.4 107.5 (49.1-204.2) 
Esophagus            Pancreas     
Male 5 6.5 77.4 (24.9-180.6)   Male 14 8.8 159.3 (87.0-267.3) 
Female 3 1.7 nc (nc-nc)   Female 10 8.4 119.4 (57.1-219.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.6 nc (nc-nc)   Male 94 80.3 117.1 (94.7-143.3) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 13.8 72.5 (34.7-133.3)   Male 6 5.9 101.9 (37.2-221.7) 
Female 7 7.6 91.8 (36.8-189.1)   Female 4 3.3 nc (nc-nc) 
Larynx            Testis     
Male 4 3.8 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 9.7 102.8 (49.2-189.0)   Male 2 6.0 nc (nc-nc) 
Female 3 6.7 nc (nc-nc)   Female 11 17.2 64.0 (31.9-114.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.8 67.9 (24.8-147.9)             
Female 1 2.8 nc (nc-nc)   Female 24 22.5 106.6 (68.3-158.7) 
Lung and Bronchus            All Sites / Types     
Male 30 44.0 68.1 (46.0-97.3)   Male 331 319.0 103.8 (92.9-115.6) 
Female 44 44.9 98.0 (71.2-131.5)   Female 333 320.1 104.0 (93.2-115.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
270 
Saugus 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 48 31.0 154.6 (114.0-205.0)   Male 18 20.0 90.1 (53.4-142.4) 
Female 20 13.2 151.8 (92.7-234.4)   Female 20 17.4 115.1 (70.3-177.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.8 85.7 (27.6-200.1)   Male 6 6.5 91.8 (33.5-199.9) 
Female 8 5.5 146.0 (62.9-287.8)   Female 5 6.0 83.2 (26.8-194.2) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.1 nc (nc-nc)   Male 29 17.9 161.7 (108.3-232.3) 
Female 147 143.8 102.2 (86.4-120.1)   Female 25 18.3 136.9 (88.6-202.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 14.8 128.6 (77.4-200.9) 
Female 4 4.5 nc (nc-nc)   Female 6 7.7 78.2 (28.6-170.3) 
Colon / Rectum            Ovary     
Male 48 33.5 143.5 (105.8-190.2)             
Female 32 37.8 84.6 (57.9-119.5)   Female 5 12.4 40.5 (13.0-94.4) 
Esophagus            Pancreas     
Male 13 8.1 161.3 (85.8-275.8)   Male 15 11.2 134.0 (74.9-221.0) 
Female 4 2.6 nc (nc-nc)   Female 15 13.4 112.1 (62.7-185.0) 
Hodgkin Lymphoma            Prostate     
Male 2 2.2 nc (nc-nc)   Male 79 96.8 81.6 (64.6-101.7) 
Female 3 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 26 17.4 149.1 (97.4-218.5)   Male 6 7.6 79.3 (28.9-172.5) 
Female 8 11.5 69.6 (30.0-137.2)   Female 2 5.1 nc (nc-nc) 
Larynx            Testis     
Male 7 4.8 145.9 (58.4-300.5)   Male 9 3.9 230.4 (105.1-437.4) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 12.4 137.3 (79.9-219.9)   Male 11 7.8 140.4 (70.0-251.2) 
Female 3 10.3 nc (nc-nc)   Female 20 24.4 82.1 (50.1-126.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 11.0 155.1 (90.3-248.3)             
Female 5 4.3 115.8 (37.3-270.2)   Female 28 32.8 85.3 (56.7-123.3) 
Lung and Bronchus            All Sites / Types     
Male 66 56.0 117.8 (91.1-149.9)   Male 485 402.1 120.6 (110.1-131.8) 
Female 88 69.8 126.1 (101.1-155.4)   Female 490 483.0 101.4 (92.7-110.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Savoy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 2 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.5 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 1.6 nc (nc-nc)   Male 7 12.1 58.0 (23.2-119.4) 
Female 1 1.2 nc (nc-nc)   Female 10 9.6 103.7 (49.6-190.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Scituate 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 22.9 91.6 (56.7-140.1)   Male 40 14.2 281.8 (201.3-383.7) 
Female 12 8.0 149.5 (77.2-261.2)   Female 29 10.7 271.7 (181.9-390.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.1 146.3 (53.4-318.4)   Male 7 4.6 151.2 (60.6-311.5) 
Female 3 3.5 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 6 12.7 47.3 (17.3-103.0) 
Female 89 89.5 99.4 (79.8-122.4)   Female 9 11.2 80.6 (36.8-153.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 10.6 84.8 (38.7-161.0) 
Female 1 2.8 nc (nc-nc)   Female 7 4.7 147.6 (59.1-304.2) 
Colon / Rectum            Ovary     
Male 21 24.4 86.0 (53.2-131.5)             
Female 20 23.6 84.7 (51.7-130.8)   Female 8 7.6 104.7 (45.1-206.3) 
Esophagus            Pancreas     
Male 7 5.8 120.0 (48.1-247.3)   Male 7 8.1 86.5 (34.7-178.2) 
Female 1 1.5 nc (nc-nc)   Female 4 8.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.4 nc (nc-nc)   Male 66 69.5 94.9 (73.4-120.8) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 12.3 56.7 (22.7-116.9)   Male 6 5.5 110.0 (40.1-239.3) 
Female 6 7.0 85.2 (31.1-185.4)   Female 4 3.2 nc (nc-nc) 
Larynx            Testis     
Male 2 3.4 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 9.0 110.7 (53.0-203.5)   Male 1 5.2 nc (nc-nc) 
Female 7 6.4 109.4 (43.8-225.5)   Female 18 15.2 118.6 (70.2-187.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 7.9 101.7 (43.8-200.3)             
Female 3 2.7 nc (nc-nc)   Female 21 20.0 104.9 (64.9-160.3) 
Lung and Bronchus            All Sites / Types     
Male 33 40.4 81.6 (56.2-114.7)   Male 291 288.6 100.8 (89.6-113.1) 
Female 45 41.9 107.4 (78.3-143.7)   Female 316 297.8 106.1 (94.7-118.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Seekonk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 17.9 61.3 (30.6-109.7)   Male 6 11.5 52.3 (19.1-113.8) 
Female 2 5.4 nc (nc-nc)   Female 8 7.9 101.6 (43.7-200.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.3 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 15 10.2 147.5 (82.5-243.2) 
Female 37 65.6 56.4 (39.7-77.7)   Female 5 7.8 63.7 (20.5-148.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 8.7 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 5 3.4 148.3 (47.8-346.0) 
Colon / Rectum            Ovary     
Male 12 19.1 62.9 (32.5-110.0)             
Female 9 15.7 57.2 (26.1-108.6)   Female 6 5.6 107.6 (39.3-234.2) 
Esophagus            Pancreas     
Male 0 4.8 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 7 5.4 129.7 (52.0-267.3) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 35 58.5 59.8 (41.7-83.2) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 10.2 49.1 (15.8-114.5)   Male 2 4.3 nc (nc-nc) 
Female 0 5.1 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 7.1 84.8 (31.0-184.7)   Male 0 4.4 nc (nc-nc) 
Female 2 4.4 nc (nc-nc)   Female 8 12.1 66.3 (28.5-130.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.4 nc (nc-nc)             
Female 0 1.9 nc (nc-nc)   Female 8 15.0 53.4 (23.0-105.1) 
Lung and Bronchus            All Sites / Types     
Male 20 33.2 60.2 (36.7-92.9)   Male 141 234.4 60.2 (50.6-70.9) 
Female 26 29.7 87.5 (57.2-128.3)   Female 139 213.4 65.1 (54.8-76.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sharon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 18.8 58.4 (29.1-104.5)   Male 13 12.4 105.2 (56.0-179.9) 
Female 7 6.1 115.5 (46.3-237.9)   Female 17 9.3 181.9 (105.9-291.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.8 nc (nc-nc)   Male 6 4.0 149.4 (54.6-325.2) 
Female 1 3.1 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 14 11.1 126.2 (68.9-211.7) 
Female 88 78.4 112.3 (90.1-138.3)   Female 6 9.1 66.1 (24.1-143.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 9.9 60.4 (22.1-131.5) 
Female 0 2.7 nc (nc-nc)   Female 1 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 21.4 51.4 (25.6-92.0)             
Female 10 18.6 53.8 (25.8-99.0)   Female 5 6.6 76.0 (24.5-177.3) 
Esophagus            Pancreas     
Male 4 5.2 nc (nc-nc)   Male 9 7.0 128.6 (58.7-244.2) 
Female 2 1.2 nc (nc-nc)   Female 8 6.2 129.3 (55.7-254.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 64 65.9 97.1 (74.7-124.0) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 11.4 61.6 (24.7-126.9)   Male 4 4.7 nc (nc-nc) 
Female 8 6.0 134.4 (57.9-264.8)   Female 3 2.5 nc (nc-nc) 
Larynx            Testis     
Male 2 3.0 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 7.7 77.5 (28.3-168.7)   Male 9 5.1 177.7 (81.1-337.4) 
Female 4 5.2 nc (nc-nc)   Female 26 14.8 175.5 (114.6-257.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.2 nc (nc-nc)             
Female 3 2.1 nc (nc-nc)   Female 18 17.7 101.8 (60.3-161.0) 
Lung and Bronchus            All Sites / Types     
Male 17 34.1 49.9 (29.0-79.8)   Male 217 256.2 84.7 (73.8-96.7) 
Female 38 32.9 115.5 (81.7-158.5)   Female 265 250.1 106.0 (93.6-119.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sheffield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.1 97.2 (31.3-226.8)   Male 4 3.1 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 14 17.7 79.2 (43.3-132.9)   Female 1 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 2.3 220.8 (71.2-515.3) 
Female 0 0.5 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.3 nc (nc-nc)             
Female 4 4.2 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.3 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 21 16.1 130.4 (80.7-199.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.7 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.7 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 6 4.2 142.1 (51.9-309.4) 
Lung and Bronchus            All Sites / Types     
Male 5 9.3 54.0 (17.4-126.1)   Male 60 64.1 93.6 (71.4-120.5) 
Female 11 8.5 129.6 (64.6-232.0)   Female 55 57.9 95.1 (71.6-123.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shelburne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.8 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 11 11.7 94.0 (46.9-168.3)   Female 2 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.4 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.0 nc (nc-nc)             
Female 3 3.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 9.7 102.6 (49.1-188.7) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.1 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 7 2.7 255.4 (102.3-526.3) 
Lung and Bronchus            All Sites / Types     
Male 3 5.2 nc (nc-nc)   Male 35 37.2 94.0 (65.4-130.7) 
Female 7 5.9 118.9 (47.6-245.0)   Female 45 39.6 113.5 (82.8-151.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sherborn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 5.4 183.8 (88.0-338.0)   Male 5 3.4 148.3 (47.8-346.1) 
Female 2 1.6 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 18 19.5 92.3 (54.7-145.8)   Female 5 2.3 216.5 (69.8-505.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 5.8 137.2 (59.1-270.4)             
Female 3 4.8 nc (nc-nc)   Female 5 1.7 300.1 (96.7-700.4) 
Esophagus            Pancreas     
Male 0 1.4 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 14 17.3 80.7 (44.1-135.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.0 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.1 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.9 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 9.7 51.8 (16.7-120.9)   Male 61 69.6 87.6 (67.0-112.6) 
Female 5 8.9 56.4 (18.2-131.7)   Female 54 63.4 85.2 (64.0-111.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shirley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 6.0 231.8 (126.6-389.0)   Male 2 4.8 nc (nc-nc) 
Female 6 2.0 292.8 (106.9-637.3)   Female 1 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.6 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 8 4.3 188.1 (81.0-370.7) 
Female 28 25.6 109.2 (72.6-157.9)   Female 2 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.9 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 7.9 152.3 (78.6-266.0)             
Female 7 5.9 117.8 (47.2-242.8)   Female 2 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.8 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 29 22.6 128.3 (85.9-184.2) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 4.5 156.1 (62.5-321.6)   Male 0 1.7 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.9 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 4 4.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 2.7 259.6 (104.0-534.8)             
Female 0 0.7 nc (nc-nc)   Female 12 5.8 208.2 (107.5-363.7) 
Lung and Bronchus            All Sites / Types     
Male 17 11.3 150.0 (87.4-240.3)   Male 122 93.4 130.6 (108.4-155.9) 
Female 10 11.4 87.7 (42.0-161.3)   Female 91 82.4 110.5 (89.0-135.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shrewsbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 42 36.7 114.5 (82.5-154.8)   Male 18 23.7 76.0 (45.0-120.2) 
Female 12 12.3 97.8 (50.5-170.9)   Female 22 17.8 123.7 (77.5-187.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 7.4 67.9 (21.9-158.4)   Male 10 7.6 131.0 (62.7-240.9) 
Female 0 5.8 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.3 nc (nc-nc)   Male 25 21.4 116.6 (75.5-172.2) 
Female 165 144.7 114.0 (97.3-132.8)   Female 15 17.7 85.0 (47.5-140.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 17.9 67.2 (34.7-117.4) 
Female 5 5.1 98.7 (31.8-230.2)   Female 4 7.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 44 40.5 108.6 (78.9-145.8)             
Female 32 36.9 86.8 (59.3-122.5)   Female 14 12.2 114.4 (62.5-192.0) 
Esophagus            Pancreas     
Male 8 9.5 83.9 (36.1-165.3)   Male 9 13.2 68.3 (31.2-129.7) 
Female 6 2.4 247.7 (90.5-539.2)   Female 10 12.5 80.3 (38.4-147.6) 
Hodgkin Lymphoma            Prostate     
Male 2 2.9 nc (nc-nc)   Male 128 115.8 110.6 (92.2-131.5) 
Female 4 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 24 21.0 114.3 (73.2-170.1)   Male 3 8.9 nc (nc-nc) 
Female 7 11.3 62.2 (24.9-128.1)   Female 6 5.0 119.3 (43.6-259.8) 
Larynx            Testis     
Male 2 5.5 nc (nc-nc)   Male 4 5.2 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 15.2 78.9 (40.7-137.8)   Male 16 9.7 164.5 (94.0-267.1) 
Female 11 10.3 106.6 (53.1-190.8)   Female 19 28.0 67.8 (40.8-105.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 12.9 100.9 (53.6-172.5)             
Female 3 4.0 nc (nc-nc)   Female 31 31.1 99.6 (67.7-141.4) 
Lung and Bronchus            All Sites / Types     
Male 63 65.0 96.9 (74.5-124.0)   Male 492 480.1 102.5 (93.6-112.0) 
Female 66 65.1 101.4 (78.4-129.0)   Female 475 477.1 99.6 (90.8-108.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
280 
Shutesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.6 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 8 9.0 88.5 (38.1-174.4)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.9 nc (nc-nc)             
Female 2 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 3 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 6.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 3.0 nc (nc-nc)   Male 11 24.4 45.1 (22.5-80.8) 
Female 2 3.7 nc (nc-nc)   Female 22 28.6 76.8 (48.1-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Somerset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 26.2 122.1 (83.5-172.4)   Male 7 15.7 44.5 (17.8-91.8) 
Female 13 10.0 130.3 (69.3-222.9)   Female 10 11.9 83.9 (40.2-154.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.4 113.6 (36.6-265.2)   Male 0 5.1 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 6 4.4 137.1 (50.1-298.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 13 14.1 92.5 (49.2-158.2) 
Female 79 98.0 80.6 (63.8-100.4)   Female 16 13.2 121.6 (69.5-197.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 11.2 71.5 (30.8-140.9) 
Female 0 2.9 nc (nc-nc)   Female 7 5.4 129.5 (51.9-266.9) 
Colon / Rectum            Ovary     
Male 28 26.9 104.1 (69.1-150.4)             
Female 34 28.1 121.0 (83.8-169.0)   Female 7 8.5 82.4 (33.0-169.7) 
Esophagus            Pancreas     
Male 7 6.4 109.4 (43.8-225.3)   Male 10 9.0 110.7 (53.0-203.6) 
Female 0 1.9 nc (nc-nc)   Female 15 10.2 147.2 (82.3-242.8) 
Hodgkin Lymphoma            Prostate     
Male 3 1.6 nc (nc-nc)   Male 73 76.2 95.9 (75.1-120.5) 
Female 0 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 13.3 97.6 (51.9-166.9)   Male 10 6.1 163.7 (78.4-301.0) 
Female 6 8.1 74.3 (27.1-161.7)   Female 5 3.8 130.1 (41.9-303.5) 
Larynx            Testis     
Male 4 3.7 nc (nc-nc)   Male 6 2.6 232.8 (85.0-506.6) 
Female 2 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 10.0 130.3 (69.3-222.8)   Male 4 5.5 nc (nc-nc) 
Female 10 7.5 133.7 (64.0-246.0)   Female 20 15.5 128.9 (78.7-199.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 8.3 nc (nc-nc)             
Female 0 3.1 nc (nc-nc)   Female 14 21.7 64.5 (35.2-108.2) 
Lung and Bronchus            All Sites / Types     
Male 48 46.0 104.3 (76.9-138.3)   Male 320 319.3 100.2 (89.5-111.8) 
Female 38 51.7 73.4 (52.0-100.8)   Female 314 341.1 92.0 (82.1-102.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Somerville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 50.5 67.4 (46.7-94.2)   Male 27 36.0 74.9 (49.4-109.0) 
Female 17 19.0 89.3 (52.0-143.1)   Female 20 33.0 60.6 (37.0-93.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 13.0 69.1 (31.5-131.2)   Male 10 10.7 93.8 (44.9-172.5) 
Female 11 10.2 108.0 (53.8-193.2)   Female 12 8.8 136.1 (70.3-237.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 35 32.4 107.9 (75.2-150.1) 
Female 185 226.2 81.8 (70.4-94.5)   Female 21 28.8 73.0 (45.2-111.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 25.4 82.7 (51.2-126.4) 
Female 11 10.0 109.9 (54.8-196.6)   Female 12 11.9 101.2 (52.3-176.9) 
Colon / Rectum            Ovary     
Male 51 57.6 88.6 (65.9-116.4)             
Female 45 57.7 78.0 (56.9-104.4)   Female 24 19.9 120.4 (77.1-179.2) 
Esophagus            Pancreas     
Male 13 13.0 100.2 (53.3-171.4)   Male 18 18.2 98.9 (58.6-156.3) 
Female 3 3.7 nc (nc-nc)   Female 19 19.3 98.6 (59.3-154.0) 
Hodgkin Lymphoma            Prostate     
Male 9 7.9 114.0 (52.0-216.5)   Male 137 152.6 89.8 (75.4-106.1) 
Female 4 6.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 35 30.5 114.7 (79.9-159.6)   Male 16 12.7 126.3 (72.1-205.1) 
Female 22 17.9 123.1 (77.1-186.3)   Female 14 7.8 179.0 (97.8-300.4) 
Larynx            Testis     
Male 9 7.6 117.9 (53.8-223.8)   Male 11 17.7 62.3 (31.1-111.5) 
Female 3 2.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 23.3 72.9 (42.4-116.7)   Male 21 18.0 116.5 (72.1-178.1) 
Female 17 17.6 96.3 (56.1-154.3)   Female 45 58.9 76.4 (55.7-102.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 26 17.9 145.4 (94.9-213.0)             
Female 14 6.4 220.0 (120.2-369.1)   Female 49 48.6 100.9 (74.6-133.3) 
Lung and Bronchus            All Sites / Types     
Male 115 88.8 129.5 (106.9-155.4)   Male 664 693.2 95.8 (88.6-103.4) 
Female 98 99.7 98.3 (79.8-119.8)   Female 705 774.7 91.0 (84.4-98.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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South Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 20.1 64.7 (34.4-110.6)   Male 15 12.5 120.3 (67.3-198.4) 
Female 12 8.0 149.7 (77.3-261.6)   Female 12 10.5 114.1 (58.9-199.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 9 11.1 81.2 (37.0-154.1) 
Female 96 84.1 114.2 (92.5-139.4)   Female 12 10.9 109.6 (56.6-191.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 9.1 77.3 (31.0-159.2) 
Female 5 2.6 189.0 (60.9-441.1)   Female 5 4.6 109.2 (35.2-254.7) 
Colon / Rectum            Ovary     
Male 22 21.0 104.8 (65.7-158.7)             
Female 32 22.8 140.3 (95.9-198.0)   Female 6 7.4 81.4 (29.7-177.1) 
Esophagus            Pancreas     
Male 3 5.1 nc (nc-nc)   Male 2 7.1 nc (nc-nc) 
Female 3 1.5 nc (nc-nc)   Female 9 8.1 111.3 (50.8-211.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.3 nc (nc-nc)   Male 54 60.9 88.6 (66.6-115.7) 
Female 0 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 10.7 75.0 (32.3-147.8)   Male 5 4.8 104.6 (33.7-244.0) 
Female 8 6.9 116.1 (50.0-228.8)   Female 1 3.1 nc (nc-nc) 
Larynx            Testis     
Male 4 3.0 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 7.8 64.5 (20.8-150.5)   Male 4 4.6 nc (nc-nc) 
Female 8 6.5 123.5 (53.2-243.4)   Female 14 15.4 91.2 (49.8-153.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.8 nc (nc-nc)             
Female 0 2.6 nc (nc-nc)   Female 29 18.9 153.2 (102.6-220.0) 
Lung and Bronchus            All Sites / Types     
Male 35 35.8 97.9 (68.2-136.1)   Male 220 252.1 87.3 (76.1-99.6) 
Female 36 42.2 85.4 (59.8-118.2)   Female 314 289.7 108.4 (96.7-121.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Southampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.1 74.2 (27.1-161.5)   Male 0 4.8 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 1 4.4 nc (nc-nc) 
Female 24 27.3 88.0 (56.4-130.9)   Female 3 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 8.4 95.4 (41.1-188.0)             
Female 6 6.4 93.8 (34.3-204.2)   Female 1 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.0 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.5 nc (nc-nc)   Male 20 24.0 83.2 (50.8-128.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.2 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 2 5.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.6 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 7 6.2 112.2 (45.0-231.2) 
Lung and Bronchus            All Sites / Types     
Male 7 13.6 51.4 (20.6-105.8)   Male 73 99.4 73.5 (57.6-92.4) 
Female 16 12.2 131.2 (75.0-213.1)   Female 78 88.0 88.7 (70.1-110.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
285 
Southborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 9.4 95.8 (43.7-182.0)   Male 9 6.3 142.4 (65.0-270.3) 
Female 5 3.2 155.9 (50.2-363.7)   Female 3 4.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.0 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 5.6 nc (nc-nc) 
Female 46 40.3 114.2 (83.6-152.3)   Female 4 4.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.1 98.8 (31.8-230.5) 
Female 1 1.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 10.9 54.8 (20.0-119.4)             
Female 9 9.9 91.3 (41.7-173.3)   Female 1 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.5 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 28 31.6 88.5 (58.8-128.0) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 5.7 175.0 (83.8-321.8)   Male 1 2.4 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 4 1.5 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.0 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 6 7.8 76.9 (28.1-167.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.6 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 6 8.7 68.9 (25.1-149.9) 
Lung and Bronchus            All Sites / Types     
Male 14 16.6 84.3 (46.0-141.4)   Male 125 128.0 97.7 (81.3-116.4) 
Female 12 17.3 69.2 (35.7-120.9)   Female 115 130.0 88.5 (73.0-106.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
286 
Southbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 16.1 105.7 (61.5-169.2)   Male 6 10.4 57.5 (21.0-125.2) 
Female 7 6.9 101.4 (40.6-209.0)   Female 4 9.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.3 nc (nc-nc)   Male 6 3.3 184.3 (67.3-401.2) 
Female 2 3.0 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 11 9.4 117.2 (58.4-209.7) 
Female 58 72.6 79.9 (60.7-103.3)   Female 14 9.5 146.6 (80.1-246.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.7 103.7 (44.7-204.4) 
Female 4 2.4 nc (nc-nc)   Female 0 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 20 17.8 112.4 (68.6-173.6)             
Female 20 20.3 98.8 (60.3-152.5)   Female 10 6.4 157.4 (75.4-289.5) 
Esophagus            Pancreas     
Male 3 4.1 nc (nc-nc)   Male 8 5.8 139.0 (59.9-273.9) 
Female 0 1.3 nc (nc-nc)   Female 2 7.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 52 48.3 107.7 (80.5-141.3) 
Female 4 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.0 88.6 (38.2-174.7)   Male 6 3.9 153.3 (56.0-333.7) 
Female 10 5.8 171.8 (82.3-316.0)   Female 4 2.8 nc (nc-nc) 
Larynx            Testis     
Male 7 2.4 297.9 (119.3-613.7)   Male 1 2.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 6.8 102.8 (41.2-211.8)   Male 2 4.3 nc (nc-nc) 
Female 10 5.6 177.7 (85.1-326.8)   Female 10 13.1 76.2 (36.5-140.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 5.6 142.3 (61.3-280.3)             
Female 0 2.3 nc (nc-nc)   Female 19 16.4 116.0 (69.8-181.1) 
Lung and Bronchus            All Sites / Types     
Male 49 28.1 174.5 (129.1-230.7)   Male 245 208.0 117.8 (103.5-133.5) 
Female 26 34.7 75.0 (49.0-109.9)   Female 231 249.5 92.6 (81.0-105.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
287 
Southwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 10.3 116.4 (60.1-203.3)   Male 6 6.7 89.5 (32.7-194.7) 
Female 2 4.2 nc (nc-nc)   Female 3 5.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.0 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.1 nc (nc-nc) 
Female 45 44.9 100.3 (73.2-134.3)   Female 6 5.8 102.7 (37.5-223.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.1 98.2 (31.6-229.2) 
Female 0 1.4 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 11.5 61.0 (24.4-125.7)             
Female 15 12.5 120.0 (67.1-197.9)   Female 3 3.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.7 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 30 32.9 91.3 (61.6-130.3) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 5.9 168.3 (80.6-309.6)   Male 2 2.5 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.6 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.2 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 5 3.3 149.5 (48.2-348.8)   Female 6 7.9 76.4 (27.9-166.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.7 nc (nc-nc)             
Female 3 1.4 nc (nc-nc)   Female 9 9.9 91.2 (41.6-173.2) 
Lung and Bronchus            All Sites / Types     
Male 19 18.3 104.0 (62.6-162.4)   Male 122 135.7 89.9 (74.6-107.3) 
Female 14 21.5 65.2 (35.6-109.4)   Female 128 152.7 83.8 (69.9-99.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
288 
Spencer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 11.9 184.7 (115.7-279.7)   Male 12 8.1 148.1 (76.5-258.8) 
Female 11 4.2 262.6 (130.9-469.8)   Female 5 6.0 83.3 (26.9-194.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.6 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 6 1.9 308.7 (112.7-671.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 7.2 83.2 (30.4-181.1) 
Female 45 49.2 91.4 (66.7-122.3)   Female 9 6.0 150.1 (68.5-284.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 6.5 168.3 (83.9-301.2) 
Female 1 1.6 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 13.3 67.5 (30.8-128.1)             
Female 12 12.1 99.5 (51.4-173.9)   Female 1 4.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.4 147.0 (47.4-343.1)   Male 5 4.5 112.1 (36.1-261.6) 
Female 1 0.8 nc (nc-nc)   Female 5 4.2 117.7 (37.9-274.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 35 43.6 80.2 (55.9-111.5) 
Female 3 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 7.5 133.0 (63.7-244.7)   Male 1 3.0 nc (nc-nc) 
Female 6 3.8 157.0 (57.3-341.7)   Female 2 1.7 nc (nc-nc) 
Larynx            Testis     
Male 1 2.0 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 5.1 216.4 (107.9-387.2)   Male 2 3.5 nc (nc-nc) 
Female 4 3.5 nc (nc-nc)   Female 9 9.2 98.3 (44.9-186.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 4.7 127.6 (46.6-277.7)             
Female 2 1.4 nc (nc-nc)   Female 17 11.2 152.2 (88.6-243.8) 
Lung and Bronchus            All Sites / Types     
Male 34 22.2 153.5 (106.3-214.5)   Male 188 167.6 112.2 (96.7-129.4) 
Female 25 22.4 111.7 (72.3-164.9)   Female 182 162.0 112.3 (96.6-129.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
289 
Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 87 118.9 73.1 (58.6-90.2)   Male 28 78.8 35.5 (23.6-51.3) 
Female 40 47.2 84.7 (60.5-115.3)   Female 26 71.0 36.6 (23.9-53.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 31 27.0 114.6 (77.9-162.7)   Male 22 24.9 88.2 (55.3-133.6) 
Female 21 24.1 87.1 (53.9-133.1)   Female 29 21.8 133.0 (89.0-191.0) 
Breast            Non-Hodgkin Lymphoma     
Male 7 4.2 166.7 (66.8-343.4)   Male 76 71.5 106.3 (83.7-133.0) 
Female 512 552.9 92.6 (84.8-101.0)   Female 67 68.6 97.6 (75.7-124.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 71 59.5 119.3 (93.2-150.5) 
Female 42 20.0 210.2 (151.5-284.2)   Female 20 29.1 68.8 (42.0-106.3) 
Colon / Rectum            Ovary     
Male 142 132.2 107.4 (90.5-126.6)             
Female 155 140.0 110.7 (94.0-129.6)   Female 40 47.8 83.6 (59.7-113.9) 
Esophagus            Pancreas     
Male 33 31.4 105.2 (72.4-147.8)   Male 48 43.0 111.7 (82.4-148.1) 
Female 8 9.3 85.9 (37.0-169.2)   Female 51 47.8 106.6 (79.4-140.2) 
Hodgkin Lymphoma            Prostate     
Male 14 12.1 115.5 (63.1-193.8)   Male 328 384.0 85.4 (76.4-95.2) 
Female 15 10.8 138.8 (77.6-228.9)             
Kidney & Renal Pelvis            Stomach     
Male 84 69.9 120.2 (95.9-148.8)   Male 35 29.2 119.9 (83.5-166.8) 
Female 55 43.7 125.8 (94.8-163.8)   Female 21 19.0 110.4 (68.3-168.8) 
Larynx            Testis     
Male 17 18.3 92.9 (54.1-148.7)   Male 12 22.6 53.0 (27.4-92.6) 
Female 10 6.0 166.5 (79.7-306.3)             
Leukemia            Thyroid     
Male 49 52.5 93.3 (69.0-123.3)   Male 15 34.2 43.9 (24.5-72.4) 
Female 39 41.7 93.6 (66.6-128.0)   Female 78 114.0 68.4 (54.1-85.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 61 43.2 141.3 (108.1-181.5)             
Female 14 16.0 87.6 (47.8-146.9)   Female 115 123.1 93.5 (77.2-112.2) 
Lung and Bronchus            All Sites / Types     
Male 240 212.5 112.9 (99.1-128.2)   Male 1530 1599.2 95.7 (90.9-100.6) 
Female 252 250.3 100.7 (88.6-113.9)   Female 1763 1851.6 95.2 (90.8-99.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
290 
Sterling 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 7.2 152.7 (76.1-273.2)   Male 8 5.0 161.0 (69.3-317.2) 
Female 4 2.8 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 4 1.6 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 4.5 176.0 (75.8-346.8) 
Female 41 35.4 115.8 (83.1-157.1)   Female 1 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 8.8 90.9 (39.2-179.2)             
Female 2 8.9 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.1 nc (nc-nc)   Male 4 2.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 42 27.8 150.9 (108.7-204.0) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 4.9 164.6 (70.9-324.3)   Male 1 1.8 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.2 189.9 (69.3-413.4)   Male 3 2.3 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 7 6.7 104.1 (41.7-214.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.9 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 10 7.6 130.8 (62.6-240.5) 
Lung and Bronchus            All Sites / Types     
Male 10 13.2 75.9 (36.4-139.7)   Male 130 104.8 124.0 (103.6-147.2) 
Female 18 14.6 123.1 (72.9-194.6)   Female 112 114.0 98.3 (80.9-118.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
291 
Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.6 nc (nc-nc)   Male 7 2.1 327.5 (131.2-674.8) 
Female 1 1.5 nc (nc-nc)   Female 6 1.6 372.7 (136.1-811.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 10 12.9 77.3 (37.0-142.2)   Female 2 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.6 nc (nc-nc)             
Female 7 4.1 170.7 (68.4-351.6)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 12 10.2 118.0 (60.9-206.2) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.3 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 7 2.9 243.7 (97.6-502.1) 
Lung and Bronchus            All Sites / Types     
Male 1 6.5 nc (nc-nc)   Male 40 43.2 92.5 (66.1-126.0) 
Female 2 7.7 nc (nc-nc)   Female 48 47.6 100.8 (74.3-133.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
292 
Stoneham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 28.7 83.7 (53.6-124.6)   Male 12 17.4 68.8 (35.5-120.2) 
Female 10 10.1 98.7 (47.2-181.5)   Female 10 13.5 73.9 (35.4-135.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.9 122.3 (44.7-266.2)   Male 7 5.7 122.9 (49.3-253.3) 
Female 4 4.3 nc (nc-nc)   Female 9 4.6 196.4 (89.6-372.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 17 15.6 109.0 (63.5-174.5) 
Female 137 108.9 125.9 (105.7-148.8)   Female 13 14.0 92.9 (49.4-158.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 12.7 133.6 (77.8-213.9) 
Female 4 3.5 nc (nc-nc)   Female 6 5.9 101.6 (37.1-221.1) 
Colon / Rectum            Ovary     
Male 36 30.0 120.2 (84.2-166.4)             
Female 28 29.4 95.3 (63.3-137.7)   Female 14 9.5 148.1 (80.9-248.6) 
Esophagus            Pancreas     
Male 5 7.2 69.6 (22.4-162.3)   Male 6 10.0 60.3 (22.0-131.2) 
Female 0 2.0 nc (nc-nc)   Female 14 10.4 135.1 (73.8-226.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.8 nc (nc-nc)   Male 51 86.3 59.1 (44.0-77.7) 
Female 2 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 15.0 86.7 (46.1-148.3)   Male 10 6.7 148.5 (71.1-273.0) 
Female 9 8.7 103.4 (47.2-196.3)   Female 5 4.0 124.0 (40.0-289.4) 
Larynx            Testis     
Male 3 4.1 nc (nc-nc)   Male 5 3.0 167.2 (53.9-390.3) 
Female 4 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 11.0 154.9 (90.2-248.0)   Male 10 6.4 157.1 (75.2-288.9) 
Female 10 8.0 124.3 (59.5-228.5)   Female 26 19.1 136.0 (88.8-199.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.4 74.5 (29.9-153.6)             
Female 9 3.3 270.4 (123.4-513.4)   Female 36 24.7 145.5 (101.9-201.4) 
Lung and Bronchus            All Sites / Types     
Male 41 50.2 81.6 (58.6-110.8)   Male 332 355.8 93.3 (83.5-103.9) 
Female 54 52.4 103.1 (77.4-134.5)   Female 427 369.6 115.5 (104.8-127.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
293 
Stoughton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 31 32.7 94.9 (64.5-134.7)   Male 16 20.4 78.5 (44.8-127.5) 
Female 17 13.1 130.2 (75.8-208.4)   Female 23 17.2 133.5 (84.6-200.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 6.0 nc (nc-nc)   Male 9 6.7 135.3 (61.7-256.8) 
Female 6 5.5 109.9 (40.1-239.2)   Female 7 5.9 118.1 (47.3-243.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 15 18.3 81.8 (45.7-134.9) 
Female 133 139.9 95.1 (79.6-112.7)   Female 26 18.0 144.2 (94.1-211.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 15.1 72.9 (36.3-130.4) 
Female 2 4.5 nc (nc-nc)   Female 3 7.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 35 34.5 101.5 (70.7-141.1)             
Female 39 37.9 102.9 (73.2-140.7)   Female 14 12.1 115.5 (63.1-193.8) 
Esophagus            Pancreas     
Male 11 8.4 130.9 (65.3-234.3)   Male 13 11.6 111.9 (59.5-191.4) 
Female 5 2.6 195.5 (63.0-456.3)   Female 20 13.4 149.2 (91.1-230.4) 
Hodgkin Lymphoma            Prostate     
Male 3 2.3 nc (nc-nc)   Male 97 103.5 93.7 (76.0-114.3) 
Female 6 1.9 316.2 (115.5-688.2)             
Kidney & Renal Pelvis            Stomach     
Male 25 17.8 140.5 (90.9-207.4)   Male 9 7.8 115.2 (52.6-218.6) 
Female 17 11.2 151.8 (88.4-243.1)   Female 6 5.2 116.2 (42.4-252.8) 
Larynx            Testis     
Male 9 4.9 183.7 (83.8-348.7)   Male 6 3.9 152.5 (55.7-332.0) 
Female 2 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 12.9 92.8 (47.9-162.1)   Male 9 7.8 115.9 (52.9-220.0) 
Female 8 10.4 77.2 (33.2-152.1)   Female 27 24.2 111.4 (73.4-162.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 11.2 107.0 (55.2-187.0)             
Female 2 4.3 nc (nc-nc)   Female 22 31.9 69.0 (43.2-104.5) 
Lung and Bronchus            All Sites / Types     
Male 62 58.2 106.5 (81.7-136.6)   Male 429 418.5 102.5 (93.0-112.7) 
Female 59 67.5 87.4 (66.6-112.8)   Female 494 475.1 104.0 (95.0-113.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
294 
Stow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 8.2 195.3 (111.6-317.3)   Male 4 5.2 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.5 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 4 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 4.7 nc (nc-nc) 
Female 28 30.0 93.3 (62.0-134.9)   Female 4 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 3.9 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 9.0 100.2 (45.7-190.2)             
Female 8 6.7 119.7 (51.5-235.9)   Female 5 2.5 200.1 (64.5-466.9) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 30 26.0 115.4 (77.8-164.7) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.6 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 2 1.2 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.3 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 7 5.5 127.1 (50.9-261.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.9 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 9 7.0 128.9 (58.8-244.6) 
Lung and Bronchus            All Sites / Types     
Male 7 14.5 48.2 (19.3-99.2)   Male 96 106.1 90.5 (73.3-110.5) 
Female 10 12.8 78.0 (37.4-143.5)   Female 103 94.8 108.7 (88.7-131.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
295 
Sturbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 10.6 160.2 (93.3-256.5)   Male 9 6.8 132.3 (60.4-251.2) 
Female 5 3.7 134.6 (43.4-314.1)   Female 8 5.2 153.1 (65.9-301.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 8 6.1 132.0 (56.9-260.2) 
Female 38 43.0 88.4 (62.5-121.3)   Female 4 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.2 95.8 (30.9-223.6) 
Female 1 1.5 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 11.5 69.5 (29.9-136.9)             
Female 10 10.9 91.9 (44.0-169.0)   Female 2 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.8 nc (nc-nc)   Male 4 3.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 7 3.8 183.8 (73.6-378.7) 
Hodgkin Lymphoma            Prostate     
Male 3 0.7 nc (nc-nc)   Male 39 35.4 110.2 (78.3-150.6) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.1 98.6 (36.0-214.6)   Male 2 2.6 nc (nc-nc) 
Female 2 3.4 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.3 116.3 (37.5-271.5)   Male 0 2.6 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 5 7.9 63.2 (20.4-147.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.9 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 18 9.6 187.0 (110.8-295.5) 
Lung and Bronchus            All Sites / Types     
Male 21 19.4 108.3 (67.0-165.5)   Male 151 140.1 107.8 (91.3-126.4) 
Female 14 19.8 70.8 (38.7-118.8)   Female 135 142.2 95.0 (79.6-112.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
296 
Sudbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 19.2 73.0 (39.9-122.5)   Male 17 12.8 133.1 (77.5-213.1) 
Female 1 6.3 nc (nc-nc)   Female 9 9.3 96.6 (44.1-183.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.0 175.2 (70.2-361.0)   Male 5 4.2 119.9 (38.6-279.8) 
Female 5 3.1 163.8 (52.8-382.2)   Female 3 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 7 11.4 61.5 (24.6-126.7) 
Female 118 79.4 148.6 (123.0-178.0)   Female 14 9.3 151.2 (82.6-253.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 10.3 nc (nc-nc) 
Female 0 2.6 nc (nc-nc)   Female 5 4.0 124.5 (40.1-290.5) 
Colon / Rectum            Ovary     
Male 27 21.5 125.6 (82.7-182.7)             
Female 13 19.1 68.1 (36.2-116.5)   Female 9 6.7 135.2 (61.7-256.6) 
Esophagus            Pancreas     
Male 1 5.4 nc (nc-nc)   Male 9 7.1 126.0 (57.5-239.2) 
Female 2 1.3 nc (nc-nc)   Female 4 6.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 67 68.3 98.1 (76.0-124.6) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 11.8 76.1 (34.7-144.4)   Male 3 4.8 nc (nc-nc) 
Female 6 6.0 99.3 (36.3-216.3)   Female 3 2.6 nc (nc-nc) 
Larynx            Testis     
Male 2 3.2 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.0 87.0 (34.8-179.2)   Male 7 5.3 133.0 (53.3-274.1) 
Female 5 5.3 95.0 (30.6-221.7)   Female 19 14.4 132.2 (79.5-206.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.4 67.1 (21.6-156.7)             
Female 1 2.2 nc (nc-nc)   Female 18 17.8 101.2 (59.9-160.0) 
Lung and Bronchus            All Sites / Types     
Male 13 35.8 36.3 (19.3-62.1)   Male 223 264.5 84.3 (73.6-96.1) 
Female 29 34.0 85.4 (57.2-122.6)   Female 292 253.8 115.0 (102.2-129.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
297 
Sunderland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.2 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 17 10.4 163.1 (95.0-261.2)   Female 0 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.5 nc (nc-nc)             
Female 3 2.5 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 8 10.4 77.2 (33.3-152.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.4 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 5.5 nc (nc-nc)   Male 32 42.8 74.7 (51.1-105.5) 
Female 3 4.4 nc (nc-nc)   Female 34 34.7 97.9 (67.8-136.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
298 
Sutton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 10.0 130.2 (69.2-222.6)   Male 10 6.5 152.8 (73.1-281.0) 
Female 5 2.5 196.8 (63.4-459.2)   Female 7 4.3 161.6 (64.7-333.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 9 5.9 152.3 (69.5-289.2) 
Female 38 36.6 103.7 (73.4-142.4)   Female 3 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 5.3 nc (nc-nc) 
Female 3 1.3 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 11.3 53.0 (19.4-115.4)             
Female 8 7.8 103.0 (44.3-202.9)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.7 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 30 34.2 87.7 (59.2-125.3) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 6.1 147.8 (67.5-280.7)   Male 2 2.5 nc (nc-nc) 
Female 5 2.7 187.1 (60.3-436.7)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 4.1 193.0 (83.1-380.3)   Male 6 2.7 222.5 (81.2-484.3) 
Female 4 2.2 nc (nc-nc)   Female 7 7.5 93.8 (37.6-193.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.7 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 12 8.3 144.3 (74.5-252.1) 
Lung and Bronchus            All Sites / Types     
Male 20 18.1 110.6 (67.5-170.8)   Male 141 135.1 104.4 (87.8-123.1) 
Female 14 14.2 98.5 (53.8-165.3)   Female 124 113.1 109.6 (91.2-130.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
299 
Swampscott 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 16.9 171.4 (114.8-246.2)   Male 14 10.4 134.4 (73.4-225.5) 
Female 13 6.2 208.7 (111.0-356.9)   Female 16 8.4 190.0 (108.5-308.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.1 nc (nc-nc)   Male 1 3.4 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 4 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 14 9.4 149.5 (81.6-250.8) 
Female 76 68.8 110.5 (87.1-138.3)   Female 12 8.7 138.2 (71.3-241.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.8 64.0 (20.6-149.4) 
Female 3 2.2 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 18.2 93.6 (54.5-149.9)             
Female 19 18.2 104.2 (62.7-162.8)   Female 4 5.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 4.3 nc (nc-nc)   Male 6 6.0 100.4 (36.7-218.5) 
Female 2 1.2 nc (nc-nc)   Female 5 6.4 78.6 (25.3-183.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 56 51.7 108.3 (81.8-140.7) 
Female 4 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.1 109.8 (52.6-202.0)   Male 3 4.0 nc (nc-nc) 
Female 4 5.4 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Larynx            Testis     
Male 1 2.4 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.8 74.0 (23.9-172.8)   Male 5 3.9 129.0 (41.6-301.1) 
Female 11 4.9 222.5 (110.9-398.1)   Female 20 12.1 165.2 (100.9-255.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.8 nc (nc-nc)             
Female 2 2.0 nc (nc-nc)   Female 20 15.4 129.5 (79.1-200.0) 
Lung and Bronchus            All Sites / Types     
Male 27 29.4 91.9 (60.5-133.7)   Male 225 213.2 105.5 (92.2-120.3) 
Female 32 32.4 98.7 (67.5-139.4)   Female 273 230.5 118.4 (104.8-133.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
300 
Swansea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 18.8 111.9 (69.3-171.1)   Male 12 12.1 98.8 (51.0-172.5) 
Female 12 7.4 162.7 (83.9-284.1)   Female 6 10.0 60.3 (22.0-131.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 3.6 194.3 (77.8-400.3)   Male 4 3.9 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 14 10.9 129.0 (70.4-216.4) 
Female 65 84.2 77.2 (59.6-98.4)   Female 10 10.2 97.6 (46.7-179.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 9.3 64.5 (23.6-140.4) 
Female 3 2.6 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 20 20.2 98.8 (60.4-152.7)             
Female 18 21.2 84.9 (50.3-134.2)   Female 4 7.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 5.0 nc (nc-nc)   Male 8 6.8 116.8 (50.3-230.2) 
Female 0 1.5 nc (nc-nc)   Female 8 7.5 106.9 (46.0-210.6) 
Hodgkin Lymphoma            Prostate     
Male 4 1.3 nc (nc-nc)   Male 81 64.0 126.6 (100.6-157.4) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 10.9 183.0 (111.7-282.6)   Male 4 4.6 nc (nc-nc) 
Female 5 6.6 75.3 (24.3-175.8)   Female 5 2.9 174.3 (56.2-406.6) 
Larynx            Testis     
Male 3 3.0 nc (nc-nc)   Male 5 2.3 216.8 (69.9-506.0) 
Female 2 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 7.5 nc (nc-nc)   Male 5 4.8 103.1 (33.2-240.7) 
Female 5 5.7 87.2 (28.1-203.4)   Female 12 14.4 83.2 (43.0-145.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.8 88.0 (32.2-191.6)             
Female 2 2.4 nc (nc-nc)   Female 14 18.9 74.1 (40.5-124.3) 
Lung and Bronchus            All Sites / Types     
Male 33 34.5 95.7 (65.9-134.4)   Male 286 250.3 114.3 (101.4-128.3) 
Female 37 39.9 92.8 (65.3-127.9)   Female 240 277.2 86.6 (76.0-98.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
301 
Taunton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 55.1 94.4 (70.5-123.8)   Male 23 36.6 62.8 (39.8-94.2) 
Female 27 21.8 123.8 (81.6-180.2)   Female 25 30.8 81.1 (52.5-119.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 11.5 104.6 (54.0-182.7)   Male 9 11.8 76.5 (34.9-145.2) 
Female 9 9.9 91.3 (41.7-173.3)   Female 14 10.0 140.2 (76.6-235.2) 
Breast            Non-Hodgkin Lymphoma     
Male 5 2.0 252.5 (81.4-589.2)   Male 37 32.8 112.9 (79.5-155.6) 
Female 241 246.5 97.8 (85.8-110.9)   Female 41 30.8 133.0 (95.4-180.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 38 28.4 133.8 (94.7-183.7) 
Female 8 8.5 94.6 (40.7-186.4)   Female 11 13.0 84.5 (42.1-151.1) 
Colon / Rectum            Ovary     
Male 69 61.1 112.9 (87.8-142.9)             
Female 87 65.1 133.7 (107.1-165.0)   Female 15 21.1 71.0 (39.7-117.1) 
Esophagus            Pancreas     
Male 13 15.0 86.9 (46.2-148.5)   Male 17 20.2 84.0 (48.9-134.6) 
Female 1 4.2 nc (nc-nc)   Female 26 22.4 116.2 (75.9-170.3) 
Hodgkin Lymphoma            Prostate     
Male 8 4.6 172.2 (74.2-339.4)   Male 144 186.9 77.1 (65.0-90.7) 
Female 7 3.8 183.8 (73.6-378.8)             
Kidney & Renal Pelvis            Stomach     
Male 36 33.0 109.0 (76.3-150.9)   Male 13 13.6 95.5 (50.8-163.3) 
Female 19 19.4 97.8 (58.9-152.8)   Female 9 8.8 102.0 (46.6-193.7) 
Larynx            Testis     
Male 15 8.8 170.2 (95.2-280.8)   Male 10 8.4 119.0 (57.0-218.8) 
Female 6 2.7 224.9 (82.1-489.5)             
Leukemia            Thyroid     
Male 16 23.1 69.1 (39.5-112.3)   Male 20 15.3 130.6 (79.7-201.7) 
Female 14 18.1 77.3 (42.2-129.6)   Female 65 46.4 140.0 (108.0-178.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 20 20.6 97.0 (59.2-149.8)             
Female 7 7.2 97.5 (39.1-201.0)   Female 47 54.5 86.2 (63.3-114.7) 
Lung and Bronchus            All Sites / Types     
Male 134 101.0 132.6 (111.1-157.1)   Male 759 747.8 101.5 (94.4-109.0) 
Female 121 113.0 107.1 (88.8-127.9)   Female 853 825.1 103.4 (96.6-110.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
302 
Templeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 9.9 90.7 (41.4-172.2)   Male 6 6.3 95.1 (34.7-207.0) 
Female 3 3.0 nc (nc-nc)   Female 1 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.9 270.2 (87.1-630.7)   Male 2 2.1 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 5.7 nc (nc-nc) 
Female 25 37.0 67.6 (43.7-99.8)   Female 4 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 5.0 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 10.9 82.2 (37.5-156.1)             
Female 12 8.8 135.7 (70.1-237.1)   Female 5 3.1 160.0 (51.6-373.4) 
Esophagus            Pancreas     
Male 3 2.7 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 20 34.9 57.3 (35.0-88.5) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 5.8 154.6 (70.5-293.4)   Male 2 2.4 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.0 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 5 6.7 74.6 (24.1-174.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.6 137.1 (44.2-320.0)             
Female 0 1.0 nc (nc-nc)   Female 10 8.3 120.1 (57.5-220.8) 
Lung and Bronchus            All Sites / Types     
Male 19 17.7 107.6 (64.7-168.0)   Male 108 133.0 81.2 (66.6-98.1) 
Female 24 17.0 141.3 (90.5-210.3)   Female 112 119.6 93.6 (77.1-112.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
303 
Tewksbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 32.1 124.6 (89.0-169.7)   Male 16 21.1 75.8 (43.3-123.2) 
Female 13 12.6 103.3 (55.0-176.7)   Female 16 17.1 93.7 (53.5-152.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 6.4 141.1 (64.4-267.8)   Male 3 6.7 nc (nc-nc) 
Female 6 5.4 110.6 (40.4-240.7)   Female 5 5.7 87.9 (28.3-205.2) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.1 nc (nc-nc)   Male 18 18.7 96.2 (57.0-152.1) 
Female 143 139.8 102.3 (86.2-120.5)   Female 18 17.5 103.0 (61.0-162.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 16.3 92.3 (51.6-152.2) 
Female 8 4.5 176.8 (76.1-348.3)   Female 10 7.4 136.0 (65.1-250.1) 
Colon / Rectum            Ovary     
Male 34 35.6 95.5 (66.1-133.5)             
Female 34 36.7 92.6 (64.2-129.5)   Female 16 12.0 133.7 (76.4-217.2) 
Esophagus            Pancreas     
Male 13 8.6 151.9 (80.8-259.7)   Male 15 11.7 128.1 (71.7-211.3) 
Female 4 2.5 nc (nc-nc)   Female 11 12.8 86.2 (43.0-154.2) 
Hodgkin Lymphoma            Prostate     
Male 0 2.5 nc (nc-nc)   Male 101 106.2 95.1 (77.4-115.5) 
Female 4 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 18.8 154.4 (103.4-221.8)   Male 8 7.9 101.3 (43.6-199.7) 
Female 13 11.1 117.2 (62.3-200.4)   Female 4 5.0 nc (nc-nc) 
Larynx            Testis     
Male 5 5.0 99.2 (32.0-231.4)   Male 5 4.4 114.5 (36.9-267.3) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 23 13.1 175.5 (111.2-263.3)   Male 9 8.6 105.0 (47.9-199.3) 
Female 15 10.1 149.1 (83.4-246.0)   Female 26 25.0 104.1 (68.0-152.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 11.8 67.6 (29.1-133.3)             
Female 1 4.1 nc (nc-nc)   Female 26 30.8 84.4 (55.1-123.7) 
Lung and Bronchus            All Sites / Types     
Male 70 58.7 119.2 (92.9-150.6)   Male 456 428.6 106.4 (96.9-116.6) 
Female 81 66.5 121.8 (96.7-151.4)   Female 498 467.7 106.5 (97.3-116.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
304 
Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.4 146.4 (47.2-341.7)   Male 8 2.4 327.8 (141.1-645.9) 
Female 0 1.5 nc (nc-nc)   Female 7 2.2 313.3 (125.5-645.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 27 18.9 143.0 (94.2-208.0)   Female 2 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 1.9 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 4.1 nc (nc-nc)             
Female 4 4.3 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.0 nc (nc-nc)   Male 5 1.3 384.2 (123.8-896.7) 
Female 0 0.3 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 15 12.5 120.3 (67.3-198.5) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 2.2 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.5 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 2 3.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 1.4 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 6.4 nc (nc-nc)   Male 61 49.3 123.6 (94.5-158.8) 
Female 12 8.6 139.8 (72.2-244.3)   Female 74 61.1 121.1 (95.1-152.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
305 
Tolland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.8 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.4 nc (nc-nc)   Male 10 10.6 94.3 (45.1-173.4) 
Female 1 1.0 nc (nc-nc)   Female 3 7.8 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
306 
Topsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 8.6 nc (nc-nc)   Male 5 5.3 95.1 (30.6-221.8) 
Female 4 2.8 nc (nc-nc)   Female 5 3.7 136.5 (44.0-318.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.5 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.7 127.2 (46.4-276.9) 
Female 28 30.7 91.2 (60.6-131.8)   Female 4 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 9.0 nc (nc-nc)             
Female 4 8.4 nc (nc-nc)   Female 5 2.6 190.1 (61.3-443.7) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 32 26.7 120.0 (82.1-169.4) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.6 108.1 (34.8-252.3)   Male 2 2.0 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.3 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 3 5.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.9 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 7 6.7 103.8 (41.6-213.8) 
Lung and Bronchus            All Sites / Types     
Male 14 15.4 91.2 (49.8-153.0)   Male 93 108.2 86.0 (69.4-105.3) 
Female 16 14.6 109.4 (62.5-177.7)   Female 99 103.2 95.9 (78.0-116.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
307 
Townsend 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 7.2 194.5 (106.2-326.3)   Male 4 5.3 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 9 4.3 208.4 (95.1-395.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.8 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 4.8 167.3 (72.0-329.7) 
Female 35 35.7 98.2 (68.4-136.5)   Female 3 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.7 107.4 (34.6-250.6) 
Female 0 1.3 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 8.9 158.0 (86.3-265.1)             
Female 14 8.0 176.0 (96.1-295.3)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 8 2.3 353.8 (152.3-697.1)   Male 2 2.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 20 31.0 64.6 (39.4-99.8) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.3 133.0 (53.3-274.0)   Male 3 1.9 nc (nc-nc) 
Female 5 2.7 188.4 (60.7-439.7)   Female 2 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.3 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 5 2.3 217.4 (70.1-507.4)   Female 9 7.4 121.7 (55.6-231.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.3 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 2 8.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 15 13.9 107.8 (60.3-177.8)   Male 127 112.3 113.1 (94.2-134.5) 
Female 16 14.0 114.0 (65.1-185.1)   Female 123 111.5 110.3 (91.6-131.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
308 
Truro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.5 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 16 13.2 121.5 (69.4-197.2)   Female 2 1.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.6 140.8 (45.4-328.6)             
Female 4 3.1 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 0.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 12.3 65.0 (28.0-128.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 6.5 nc (nc-nc)   Male 39 45.4 85.8 (61.0-117.4) 
Female 3 6.4 nc (nc-nc)   Female 48 42.4 113.1 (83.4-150.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
309 
Tyngsborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 9.8 61.1 (22.3-133.1)   Male 4 7.2 nc (nc-nc) 
Female 6 3.6 169.0 (61.7-367.8)   Female 6 5.8 104.2 (38.0-226.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.3 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.5 nc (nc-nc) 
Female 42 46.9 89.5 (64.5-121.0)   Female 2 5.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.1 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 12.3 81.5 (39.0-149.8)             
Female 5 11.2 44.7 (14.4-104.2)   Female 3 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 2.9 171.9 (55.4-401.3)   Male 3 3.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 35 38.0 92.1 (64.2-128.1) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.8 102.5 (41.1-211.2)   Male 4 2.6 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.4 136.8 (50.0-297.8)   Male 1 3.4 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 7 9.5 74.0 (29.7-152.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.3 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 11 10.4 105.8 (52.8-189.4) 
Lung and Bronchus            All Sites / Types     
Male 22 18.4 119.5 (74.9-181.0)   Male 127 147.1 86.3 (72.0-102.7) 
Female 20 18.8 106.3 (64.9-164.2)   Female 127 149.5 85.0 (70.8-101.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
310 
Tyringham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 4 3.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.0 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 3.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.8 nc (nc-nc)   Male 3 12.1 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 7 11.4 61.4 (24.6-126.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Upton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 7.1 127.1 (58.0-241.3)   Male 7 5.0 140.8 (56.4-290.2) 
Female 1 2.4 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.6 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 5 4.4 112.6 (36.3-262.8) 
Female 35 30.9 113.2 (78.8-157.4)   Female 4 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 8.4 71.8 (26.2-156.4)             
Female 3 7.1 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.1 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 25 26.7 93.7 (60.6-138.3) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.7 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.1 161.3 (52.0-376.4)   Male 0 2.2 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 6 6.0 99.3 (36.3-216.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 3.0 233.0 (93.4-480.1)             
Female 2 0.8 nc (nc-nc)   Female 12 6.8 175.5 (90.6-306.7) 
Lung and Bronchus            All Sites / Types     
Male 10 13.1 76.1 (36.5-140.0)   Male 96 102.4 93.8 (76.0-114.5) 
Female 16 13.3 120.7 (68.9-196.0)   Female 106 98.4 107.7 (88.2-130.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Uxbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 11.1 135.5 (75.8-223.5)   Male 14 7.9 176.1 (96.2-295.5) 
Female 2 4.9 nc (nc-nc)   Female 5 7.1 70.0 (22.5-163.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.6 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 8 7.1 112.1 (48.3-220.9) 
Female 61 60.0 101.6 (77.7-130.6)   Female 6 7.1 84.3 (30.8-183.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 6.5 168.7 (84.1-301.8) 
Female 1 2.0 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 13.2 121.4 (69.4-197.2)             
Female 13 14.8 87.6 (46.6-149.7)   Female 6 5.1 118.6 (43.3-258.1) 
Esophagus            Pancreas     
Male 1 3.2 nc (nc-nc)   Male 3 4.3 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 5.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 52 41.6 125.1 (93.4-164.0) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 7.5 174.5 (92.8-298.4)   Male 4 2.9 nc (nc-nc) 
Female 3 4.6 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.9 142.3 (57.0-293.3)   Male 1 3.7 nc (nc-nc) 
Female 5 4.1 122.1 (39.3-284.9)   Female 10 11.1 90.2 (43.2-165.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.7 105.7 (34.1-246.6)             
Female 2 1.7 nc (nc-nc)   Female 12 13.2 90.7 (46.8-158.4) 
Lung and Bronchus            All Sites / Types     
Male 30 20.8 144.2 (97.3-205.9)   Male 212 162.5 130.5 (113.5-149.3) 
Female 25 26.5 94.3 (61.0-139.3)   Female 178 194.7 91.4 (78.5-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wakefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 30.4 108.7 (74.8-152.6)   Male 22 19.5 113.1 (70.8-171.2) 
Female 9 9.3 96.5 (44.0-183.2)   Female 22 13.9 158.7 (99.4-240.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 5.8 155.6 (71.0-295.3)   Male 3 6.3 nc (nc-nc) 
Female 7 4.4 159.7 (64.0-329.0)   Female 3 4.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 11 17.2 63.9 (31.8-114.3) 
Female 128 111.9 114.4 (95.4-136.0)   Female 14 13.5 103.6 (56.6-173.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 14.2 91.6 (48.7-156.7) 
Female 3 3.9 nc (nc-nc)   Female 6 5.8 103.3 (37.7-224.9) 
Colon / Rectum            Ovary     
Male 31 32.1 96.6 (65.6-137.1)             
Female 27 27.9 96.7 (63.7-140.7)   Female 6 9.6 62.8 (22.9-136.7) 
Esophagus            Pancreas     
Male 7 7.8 89.5 (35.9-184.4)   Male 7 10.8 64.8 (26.0-133.5) 
Female 0 1.9 nc (nc-nc)   Female 11 9.6 115.1 (57.4-206.0) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 61 93.0 65.6 (50.2-84.3) 
Female 0 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 16.8 53.7 (24.5-101.9)   Male 5 7.3 68.2 (22.0-159.2) 
Female 12 8.6 138.9 (71.7-242.7)   Female 2 3.8 nc (nc-nc) 
Larynx            Testis     
Male 4 4.6 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 12.2 90.2 (45.0-161.4)   Male 5 7.6 65.9 (21.2-153.8) 
Female 6 7.8 76.6 (28.0-166.7)   Female 23 21.5 107.1 (67.9-160.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 10.6 56.8 (20.7-123.5)             
Female 3 3.2 nc (nc-nc)   Female 25 25.1 99.7 (64.5-147.2) 
Lung and Bronchus            All Sites / Types     
Male 42 55.0 76.3 (55.0-103.2)   Male 309 389.7 79.3 (70.7-88.6) 
Female 61 49.3 123.7 (94.6-158.9)   Female 398 367.0 108.5 (98.1-119.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
314 
Wales 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.7 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 10 8.9 112.7 (54.0-207.4)   Female 0 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.8 nc (nc-nc)             
Female 7 2.1 325.9 (130.6-671.5)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 5 9.4 53.1 (17.1-123.8) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.0 nc (nc-nc)             
Female 1 0.3 nc (nc-nc)   Female 6 2.1 279.3 (102.0-608.0) 
Lung and Bronchus            All Sites / Types     
Male 4 4.9 nc (nc-nc)   Male 22 35.5 62.1 (38.9-94.0) 
Female 3 3.9 nc (nc-nc)   Female 33 28.8 114.7 (78.9-161.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
315 
Walpole 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 27.9 71.6 (43.7-110.5)   Male 21 18.0 116.9 (72.3-178.6) 
Female 11 10.3 106.3 (53.0-190.3)   Female 12 13.8 86.8 (44.8-151.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 5.3 nc (nc-nc)   Male 6 5.7 104.6 (38.2-227.7) 
Female 7 4.4 157.6 (63.1-324.7)   Female 6 4.7 127.2 (46.4-276.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 15 16.1 93.2 (52.1-153.7) 
Female 136 112.9 120.5 (101.1-142.5)   Female 9 14.5 62.3 (28.4-118.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 13.8 65.2 (29.8-123.8) 
Female 1 3.7 nc (nc-nc)   Female 6 6.0 99.3 (36.3-216.2) 
Colon / Rectum            Ovary     
Male 36 30.8 116.8 (81.8-161.7)             
Female 32 30.5 104.9 (71.7-148.1)   Female 13 9.7 133.9 (71.2-229.0) 
Esophagus            Pancreas     
Male 4 7.3 nc (nc-nc)   Male 11 10.1 108.6 (54.1-194.3) 
Female 3 2.0 nc (nc-nc)   Female 12 10.5 113.8 (58.7-198.8) 
Hodgkin Lymphoma            Prostate     
Male 3 2.0 nc (nc-nc)   Male 119 90.8 131.0 (108.6-156.8) 
Female 1 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 15.9 106.6 (62.1-170.7)   Male 7 6.8 102.8 (41.2-211.9) 
Female 7 9.0 78.2 (31.3-161.0)   Female 3 4.1 nc (nc-nc) 
Larynx            Testis     
Male 5 4.2 117.7 (37.9-274.7)   Male 5 3.5 143.3 (46.2-334.4) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 11.3 79.6 (36.3-151.1)   Male 4 7.2 nc (nc-nc) 
Female 10 8.3 121.2 (58.0-222.8)   Female 21 19.8 106.3 (65.8-162.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 10.1 89.4 (40.8-169.8)             
Female 3 3.4 nc (nc-nc)   Female 25 25.1 99.5 (64.3-146.8) 
Lung and Bronchus            All Sites / Types     
Male 41 49.7 82.5 (59.2-111.9)   Male 379 366.8 103.3 (93.2-114.3) 
Female 45 53.7 83.8 (61.1-112.2)   Female 394 380.4 103.6 (93.6-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
316 
Waltham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 62 54.1 114.6 (87.9-147.0)   Male 24 35.9 66.9 (42.9-99.6) 
Female 20 20.5 97.6 (59.6-150.7)   Female 13 29.8 43.6 (23.2-74.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 15 11.7 128.4 (71.8-211.7)   Male 11 11.1 99.1 (49.4-177.3) 
Female 12 9.6 125.5 (64.8-219.2)   Female 4 9.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.9 nc (nc-nc)   Male 23 32.2 71.4 (45.2-107.1) 
Female 229 223.3 102.6 (89.7-116.7)   Female 34 29.1 117.0 (81.0-163.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 26.0 65.3 (38.0-104.6) 
Female 9 8.1 111.0 (50.6-210.7)   Female 8 12.1 66.0 (28.4-130.1) 
Colon / Rectum            Ovary     
Male 63 58.9 106.9 (82.1-136.8)             
Female 59 60.2 98.1 (74.7-126.5)   Female 19 19.7 96.4 (58.0-150.6) 
Esophagus            Pancreas     
Male 7 13.9 50.3 (20.2-103.7)   Male 25 19.3 129.3 (83.7-190.9) 
Female 5 4.0 125.1 (40.3-292.1)   Female 26 21.0 124.0 (81.0-181.7) 
Hodgkin Lymphoma            Prostate     
Male 5 5.8 86.7 (27.9-202.3)   Male 140 167.9 83.4 (70.1-98.4) 
Female 5 4.8 104.7 (33.7-244.3)             
Kidney & Renal Pelvis            Stomach     
Male 37 30.9 119.7 (84.3-165.0)   Male 18 13.2 136.5 (80.9-215.8) 
Female 21 18.0 116.8 (72.3-178.6)   Female 10 8.2 122.2 (58.5-224.7) 
Larynx            Testis     
Male 6 8.1 74.1 (27.0-161.2)   Male 13 11.6 112.4 (59.8-192.1) 
Female 3 2.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 23.1 82.3 (49.5-128.5)   Male 17 15.6 109.2 (63.6-174.8) 
Female 15 17.4 86.2 (48.2-142.1)   Female 47 46.8 100.4 (73.8-133.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 27 18.8 143.2 (94.4-208.4)             
Female 4 6.7 nc (nc-nc)   Female 41 49.7 82.5 (59.2-111.9) 
Lung and Bronchus            All Sites / Types     
Male 103 96.5 106.8 (87.1-129.5)   Male 685 714.5 95.9 (88.8-103.3) 
Female 100 106.2 94.2 (76.6-114.5)   Female 747 769.9 97.0 (90.2-104.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
317 
Ware 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 10.8 65.1 (26.1-134.1)   Male 3 6.9 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.2 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 10 6.3 158.6 (75.9-291.8) 
Female 34 44.8 75.9 (52.5-106.1)   Female 6 5.2 114.8 (41.9-249.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.5 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 11.9 142.9 (83.2-228.8)             
Female 14 10.8 130.1 (71.1-218.4)   Female 5 3.8 132.1 (42.6-308.3) 
Esophagus            Pancreas     
Male 1 2.9 nc (nc-nc)   Male 8 3.9 203.0 (87.4-400.1) 
Female 1 0.7 nc (nc-nc)   Female 6 3.7 161.1 (58.8-350.6) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 26 37.5 69.4 (45.3-101.7) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.3 78.8 (25.4-183.8)   Male 2 2.6 nc (nc-nc) 
Female 8 3.5 231.4 (99.6-455.9)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.4 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 4 8.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.0 125.9 (40.6-293.8)             
Female 2 1.2 nc (nc-nc)   Female 9 10.1 89.2 (40.7-169.3) 
Lung and Bronchus            All Sites / Types     
Male 20 19.4 103.3 (63.1-159.5)   Male 133 145.3 91.6 (76.7-108.5) 
Female 20 20.0 99.8 (60.9-154.1)   Female 138 144.8 95.3 (80.1-112.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
318 
Wareham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 29.0 124.3 (87.0-172.1)   Male 14 17.9 78.3 (42.7-131.3) 
Female 16 10.1 158.3 (90.4-257.1)   Female 14 13.6 102.7 (56.1-172.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 5.1 196.3 (94.0-361.0)   Male 11 5.8 188.4 (93.9-337.2) 
Female 2 4.3 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 20 15.9 125.5 (76.6-193.8) 
Female 93 113.3 82.1 (66.2-100.5)   Female 9 14.1 64.0 (29.2-121.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 12.9 124.0 (70.8-201.4) 
Female 2 3.6 nc (nc-nc)   Female 6 6.0 100.6 (36.7-218.9) 
Colon / Rectum            Ovary     
Male 32 30.4 105.4 (72.1-148.7)             
Female 41 29.3 140.2 (100.6-190.1)   Female 7 9.7 72.1 (28.9-148.6) 
Esophagus            Pancreas     
Male 7 7.2 96.6 (38.7-199.0)   Male 12 10.2 118.1 (61.0-206.4) 
Female 2 2.0 nc (nc-nc)   Female 17 10.2 167.2 (97.3-267.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.9 nc (nc-nc)   Male 90 85.4 105.3 (84.7-129.5) 
Female 3 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 15.1 105.6 (60.3-171.6)   Male 5 6.9 72.5 (23.4-169.2) 
Female 16 9.0 177.1 (101.1-287.6)   Female 3 3.9 nc (nc-nc) 
Larynx            Testis     
Male 5 4.3 117.2 (37.8-273.5)   Male 4 3.2 nc (nc-nc) 
Female 4 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 11.1 107.6 (55.6-188.0)   Male 6 6.5 92.4 (33.7-201.1) 
Female 14 8.0 175.5 (95.8-294.4)   Female 17 19.6 86.6 (50.4-138.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 9.7 144.3 (78.8-242.2)             
Female 6 3.4 179.0 (65.4-389.6)   Female 21 25.7 81.8 (50.6-125.1) 
Lung and Bronchus            All Sites / Types     
Male 74 51.7 143.1 (112.4-179.7)   Male 420 360.7 116.4 (105.6-128.1) 
Female 81 54.1 149.7 (118.8-186.0)   Female 407 377.2 107.9 (97.7-118.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
319 
Warren 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.4 110.2 (40.3-239.9)   Male 2 3.5 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 13 20.7 62.8 (33.4-107.5)   Female 1 2.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.8 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 6.1 114.1 (45.7-235.0)             
Female 6 4.7 126.5 (46.2-275.3)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.4 nc (nc-nc)   Male 7 2.0 353.9 (141.8-729.2) 
Female 1 0.3 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 12 18.6 64.7 (33.4-113.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.2 157.0 (50.6-366.4)   Male 1 1.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 4 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.2 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.9 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 5 4.5 110.0 (35.5-256.7) 
Lung and Bronchus            All Sites / Types     
Male 10 9.7 103.2 (49.4-189.8)   Male 71 73.0 97.2 (75.9-122.7) 
Female 9 9.0 99.9 (45.6-189.7)   Female 47 65.9 71.3 (52.4-94.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
320 
Warwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 4.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.3 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 4.2 143.1 (52.3-311.5) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.4 nc (nc-nc)   Male 12 16.4 73.2 (37.8-127.8) 
Female 3 2.3 nc (nc-nc)   Female 14 15.6 89.6 (49.0-150.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 4 3.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.7 nc (nc-nc)   Male 5 13.0 38.5 (12.4-89.9) 
Female 1 1.6 nc (nc-nc)   Female 10 10.4 95.8 (45.9-176.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
322 
Watertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 29.9 100.4 (67.7-143.3)   Male 12 20.2 59.5 (30.7-103.9) 
Female 10 12.9 77.4 (37.1-142.3)   Female 22 18.5 118.7 (74.4-179.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 6.4 156.2 (74.8-287.2)   Male 4 6.4 nc (nc-nc) 
Female 8 5.7 141.2 (60.8-278.3)   Female 5 5.9 84.3 (27.2-196.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.1 nc (nc-nc)   Male 19 18.2 104.7 (63.0-163.5) 
Female 140 143.5 97.5 (82.1-115.1)   Female 17 18.3 92.9 (54.1-148.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 14.9 87.3 (46.4-149.3) 
Female 10 5.2 191.8 (91.8-352.7)   Female 9 7.6 117.9 (53.8-223.9) 
Colon / Rectum            Ovary     
Male 39 33.9 114.9 (81.7-157.1)             
Female 35 37.3 93.9 (65.4-130.6)   Female 15 12.4 120.6 (67.4-198.9) 
Esophagus            Pancreas     
Male 7 7.8 90.0 (36.1-185.4)   Male 11 10.8 101.5 (50.6-181.7) 
Female 1 2.6 nc (nc-nc)   Female 19 13.1 145.2 (87.4-226.7) 
Hodgkin Lymphoma            Prostate     
Male 5 2.8 177.0 (57.0-413.0)   Male 68 93.0 73.2 (56.8-92.7) 
Female 3 2.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 17.7 84.5 (47.3-139.4)   Male 9 7.5 120.7 (55.1-229.2) 
Female 2 11.4 nc (nc-nc)   Female 10 5.0 199.3 (95.4-366.5) 
Larynx            Testis     
Male 6 4.6 129.9 (47.4-282.7)   Male 6 5.8 102.8 (37.5-223.8) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 12.7 118.2 (66.1-195.0)   Male 8 8.9 89.9 (38.7-177.1) 
Female 12 10.4 115.6 (59.7-202.0)   Female 29 28.9 100.3 (67.2-144.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 10.7 74.7 (32.1-147.1)             
Female 4 4.2 nc (nc-nc)   Female 25 32.1 77.9 (50.4-115.0) 
Lung and Bronchus            All Sites / Types     
Male 51 53.4 95.5 (71.1-125.5)   Male 369 399.0 92.5 (83.3-102.4) 
Female 66 68.9 95.8 (74.1-121.9)   Female 480 486.7 98.6 (90.0-107.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
323 
Wayland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 17.6 73.7 (39.2-126.0)   Male 18 10.8 166.3 (98.5-262.9) 
Female 5 6.5 76.8 (24.8-179.3)   Female 13 8.3 157.4 (83.7-269.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.1 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 7 9.7 72.0 (28.9-148.4) 
Female 81 70.9 114.3 (90.8-142.0)   Female 13 9.0 145.0 (77.2-248.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 8.0 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 18.6 69.8 (37.1-119.4)             
Female 8 18.6 43.0 (18.5-84.8)   Female 5 6.0 82.8 (26.7-193.2) 
Esophagus            Pancreas     
Male 1 4.4 nc (nc-nc)   Male 4 6.2 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 8 6.5 122.8 (52.9-241.9) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 62 53.2 116.5 (89.3-149.3) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 9.3 64.3 (23.5-140.1)   Male 2 4.2 nc (nc-nc) 
Female 4 5.7 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Larynx            Testis     
Male 0 2.6 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 6.8 102.3 (41.0-210.9)   Male 5 3.9 126.7 (40.8-295.6) 
Female 2 5.0 nc (nc-nc)   Female 11 11.2 98.1 (48.9-175.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.9 nc (nc-nc)             
Female 0 2.1 nc (nc-nc)   Female 13 16.0 81.1 (43.2-138.7) 
Lung and Bronchus            All Sites / Types     
Male 18 31.1 57.9 (34.3-91.5)   Male 185 220.4 83.9 (72.3-96.9) 
Female 19 34.8 54.6 (32.8-85.2)   Female 204 236.5 86.3 (74.8-98.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
324 
Webster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 20.4 132.1 (87.0-192.2)   Male 11 12.5 88.2 (44.0-157.8) 
Female 6 7.6 78.9 (28.8-171.8)   Female 7 9.8 71.5 (28.6-147.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.6 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 0 3.2 nc (nc-nc)   Female 7 3.3 209.1 (83.8-430.8) 
Breast            Non-Hodgkin Lymphoma     
Male 4 0.7 nc (nc-nc)   Male 10 11.2 89.5 (42.8-164.6) 
Female 83 76.8 108.1 (86.1-134.1)   Female 9 10.3 87.8 (40.0-166.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 9.1 132.5 (68.4-231.4) 
Female 4 2.6 nc (nc-nc)   Female 5 4.2 118.2 (38.1-275.9) 
Colon / Rectum            Ovary     
Male 21 21.6 97.0 (60.0-148.3)             
Female 22 22.3 98.6 (61.7-149.2)   Female 12 6.7 179.7 (92.7-313.9) 
Esophagus            Pancreas     
Male 9 5.0 178.3 (81.3-338.4)   Male 7 7.1 98.7 (39.6-203.4) 
Female 2 1.4 nc (nc-nc)   Female 6 7.8 76.8 (28.0-167.1) 
Hodgkin Lymphoma            Prostate     
Male 3 1.4 nc (nc-nc)   Male 56 60.2 93.0 (70.2-120.7) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.7 93.7 (44.9-172.4)   Male 3 4.8 nc (nc-nc) 
Female 11 6.3 175.8 (87.7-314.6)   Female 2 3.1 nc (nc-nc) 
Larynx            Testis     
Male 6 2.9 207.0 (75.6-450.6)   Male 3 2.5 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 7.9 139.2 (69.4-249.1)   Male 6 4.7 128.6 (47.0-280.0) 
Female 5 6.1 82.1 (26.4-191.5)   Female 16 14.0 114.1 (65.2-185.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 6.7 134.6 (61.4-255.6)             
Female 5 2.4 211.3 (68.1-493.0)   Female 19 16.5 115.1 (69.2-179.7) 
Lung and Bronchus            All Sites / Types     
Male 43 35.7 120.3 (87.1-162.1)   Male 287 253.5 113.2 (100.5-127.1) 
Female 50 38.2 130.8 (97.1-172.5)   Female 302 267.7 112.8 (100.5-126.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
325 
Wellesley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 29.5 64.5 (38.8-100.7)   Male 28 18.2 154.0 (102.3-222.5) 
Female 6 9.9 60.6 (22.1-131.8)   Female 27 13.7 197.1 (129.9-286.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 5.5 nc (nc-nc)   Male 5 6.0 84.0 (27.1-195.9) 
Female 5 4.9 102.2 (32.9-238.4)   Female 6 4.5 134.0 (48.9-291.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 13 16.5 78.9 (42.0-134.9) 
Female 142 110.5 128.5 (108.3-151.5)   Female 10 14.0 71.4 (34.2-131.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 13.6 73.6 (35.2-135.4) 
Female 2 3.6 nc (nc-nc)   Female 5 5.9 84.9 (27.4-198.2) 
Colon / Rectum            Ovary     
Male 22 31.6 69.7 (43.7-105.5)             
Female 26 29.4 88.6 (57.8-129.8)   Female 11 9.6 115.0 (57.3-205.7) 
Esophagus            Pancreas     
Male 1 7.5 nc (nc-nc)   Male 11 10.4 105.9 (52.8-189.5) 
Female 1 1.9 nc (nc-nc)   Female 11 10.0 109.7 (54.7-196.4) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 115 90.2 127.6 (105.3-153.1) 
Female 2 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 16.0 87.7 (47.9-147.1)   Male 5 7.0 71.3 (23.0-166.4) 
Female 5 8.8 57.0 (18.4-133.0)   Female 1 4.0 nc (nc-nc) 
Larynx            Testis     
Male 3 4.3 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 11.9 109.6 (58.3-187.4)   Male 8 6.9 116.6 (50.2-229.7) 
Female 13 8.4 154.1 (82.0-263.5)   Female 20 21.1 94.6 (57.8-146.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.9 nc (nc-nc)             
Female 1 3.3 nc (nc-nc)   Female 21 24.0 87.6 (54.2-133.9) 
Lung and Bronchus            All Sites / Types     
Male 17 51.7 32.9 (19.1-52.6)   Male 313 372.8 83.9 (74.9-93.8) 
Female 34 51.8 65.6 (45.4-91.7)   Female 384 373.4 102.8 (92.8-113.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
326 
Wellfleet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.5 93.0 (37.3-191.7)   Male 4 4.2 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 6 3.7 161.8 (59.1-352.2) 
Female 23 25.1 91.8 (58.2-137.7)   Female 1 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.0 86.1 (31.4-187.3)             
Female 5 7.5 66.5 (21.4-155.2)   Female 2 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.8 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 5 2.9 171.5 (55.3-400.2) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 19 22.1 85.9 (51.7-134.1) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.5 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 4 1.1 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.6 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.3 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 4 5.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 13.8 nc (nc-nc)   Male 66 88.0 75.0 (58.0-95.4) 
Female 12 15.1 79.3 (40.9-138.6)   Female 71 90.2 78.7 (61.5-99.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wendell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.4 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 4.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.6 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 5.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.8 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.5 nc (nc-nc)   Male 11 19.4 56.8 (28.3-101.6) 
Female 2 1.9 nc (nc-nc)   Female 9 14.0 64.2 (29.3-122.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wenham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 5.3 133.0 (53.3-274.0)   Male 5 3.1 158.8 (51.2-370.6) 
Female 1 1.8 nc (nc-nc)   Female 7 2.4 296.1 (118.6-610.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 25 18.5 135.2 (87.5-199.6)   Female 2 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 5.4 nc (nc-nc)             
Female 9 5.3 170.5 (77.8-323.7)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.3 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 21 14.0 149.9 (92.7-229.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.6 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.1 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.6 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 8 4.1 195.7 (84.3-385.6) 
Lung and Bronchus            All Sites / Types     
Male 4 9.2 nc (nc-nc)   Male 61 63.0 96.8 (74.0-124.3) 
Female 11 9.2 119.5 (59.6-213.9)   Female 80 64.5 123.9 (98.3-154.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 8.5 223.3 (134.4-348.7)   Male 6 5.7 106.2 (38.8-231.1) 
Female 3 3.2 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.8 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 4 5.1 nc (nc-nc) 
Female 26 30.0 86.7 (56.6-127.0)   Female 3 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.2 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 9.2 54.1 (17.4-126.2)             
Female 5 9.2 54.3 (17.5-126.8)   Female 6 2.7 224.6 (82.0-489.0) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 6 3.3 180.6 (65.9-393.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 28 27.6 101.4 (67.4-146.6) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 4.9 163.0 (70.2-321.1)   Male 1 2.1 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.6 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 5 2.4 205.0 (66.1-478.3)   Female 11 4.8 231.5 (115.4-414.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.0 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 4 6.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 25 15.1 165.2 (106.9-243.9)   Male 133 114.0 116.6 (97.7-138.2) 
Female 16 15.8 101.0 (57.7-164.0)   Female 111 107.0 103.7 (85.3-124.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
330 
West Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 8.5 106.4 (48.6-202.0)   Male 10 5.3 189.4 (90.7-348.4) 
Female 3 2.7 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.6 319.9 (103.1-746.5)   Male 0 1.7 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 4.8 167.8 (72.2-330.6) 
Female 38 30.8 123.5 (87.4-169.5)   Female 9 3.8 234.5 (107.0-445.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 3.9 152.7 (55.7-332.3) 
Female 1 1.0 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.1 77.2 (30.9-159.1)             
Female 17 8.0 212.6 (123.8-340.4)   Female 1 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 2.2 229.9 (74.1-536.5)   Male 1 3.0 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 4 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 21 26.6 79.0 (48.9-120.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.6 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.3 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 11 5.5 201.1 (100.2-359.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 4 7.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 18 15.0 120.1 (71.1-189.8)   Male 111 108.3 102.5 (84.3-123.4) 
Female 19 14.2 134.1 (80.7-209.4)   Female 129 102.5 125.9 (105.1-149.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
331 
West Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 5.3 nc (nc-nc)   Male 5 3.2 154.7 (49.8-361.0) 
Female 0 1.6 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 15 16.7 89.6 (50.1-147.8)   Female 3 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.5 nc (nc-nc)             
Female 2 4.6 nc (nc-nc)   Female 4 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 13 16.0 81.1 (43.1-138.6) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.8 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 6 3.9 153.7 (56.1-334.4) 
Lung and Bronchus            All Sites / Types     
Male 7 9.2 75.9 (30.4-156.3)   Male 50 66.1 75.7 (56.2-99.8) 
Female 14 8.4 166.1 (90.7-278.6)   Female 58 58.2 99.7 (75.7-128.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
332 
West Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 4.4 159.8 (64.0-329.3)   Male 2 3.0 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.0 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 23 18.6 123.8 (78.4-185.7)   Female 0 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.1 nc (nc-nc)             
Female 1 4.4 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.2 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 21 16.0 131.5 (81.4-201.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 2.7 218.4 (79.7-475.3)   Male 2 1.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 3.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 3 4.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 7.9 nc (nc-nc)   Male 59 61.5 95.9 (73.0-123.7) 
Female 4 7.9 nc (nc-nc)   Female 47 59.3 79.3 (58.2-105.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
333 
West Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 30.2 119.1 (83.4-164.9)   Male 14 19.2 73.0 (39.9-122.5) 
Female 8 11.9 67.2 (28.9-132.4)   Female 11 15.9 69.2 (34.5-123.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.0 116.8 (46.8-240.7)   Male 2 6.2 nc (nc-nc) 
Female 6 5.1 118.3 (43.2-257.4)   Female 4 5.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 20 17.2 116.2 (70.9-179.4) 
Female 105 126.1 83.3 (68.1-100.8)   Female 13 16.3 79.6 (42.3-136.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 14.2 112.6 (64.3-182.9) 
Female 9 4.2 215.1 (98.2-408.4)   Female 6 6.8 88.5 (32.3-192.6) 
Colon / Rectum            Ovary     
Male 43 32.0 134.4 (97.3-181.1)             
Female 42 34.5 121.9 (87.8-164.8)   Female 7 10.9 64.1 (25.7-132.0) 
Esophagus            Pancreas     
Male 12 7.8 153.3 (79.1-267.8)   Male 12 10.8 111.6 (57.6-194.9) 
Female 1 2.3 nc (nc-nc)   Female 8 12.1 66.3 (28.6-130.7) 
Hodgkin Lymphoma            Prostate     
Male 1 2.4 nc (nc-nc)   Male 79 95.4 82.8 (65.6-103.2) 
Female 2 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 16.8 95.5 (54.6-155.1)   Male 5 7.3 69.0 (22.2-160.9) 
Female 10 10.2 97.9 (46.9-180.1)   Female 5 4.7 107.1 (34.5-250.0) 
Larynx            Testis     
Male 4 4.6 nc (nc-nc)   Male 6 4.3 139.1 (50.8-302.7) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 12.4 88.4 (44.1-158.2)   Male 12 7.5 160.1 (82.6-279.7) 
Female 11 9.6 115.1 (57.4-206.0)   Female 25 23.1 108.2 (70.0-159.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 10.6 113.2 (58.4-197.7)             
Female 4 3.8 nc (nc-nc)   Female 24 27.9 86.1 (55.1-128.1) 
Lung and Bronchus            All Sites / Types     
Male 49 54.2 90.4 (66.9-119.6)   Male 386 391.5 98.6 (89.0-108.9) 
Female 81 61.7 131.2 (104.2-163.1)   Female 423 431.5 98.0 (88.9-107.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
334 
West Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.8 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 5 7.4 67.2 (21.6-156.8)   Female 2 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.0 nc (nc-nc)             
Female 1 1.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 9 6.7 134.0 (61.1-254.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 3.5 201.6 (80.8-415.4)   Male 34 25.1 135.4 (93.8-189.3) 
Female 0 3.6 nc (nc-nc)   Female 17 24.3 70.0 (40.8-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
335 
West Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 2.0 349.8 (140.1-720.8)   Male 4 1.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 23 14.9 154.1 (97.6-231.2)   Female 4 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.3 nc (nc-nc)             
Female 4 3.8 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 14 8.5 164.3 (89.8-275.7) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 2 0.4 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.9 nc (nc-nc)   Male 47 29.6 158.7 (116.6-211.0) 
Female 6 6.1 98.2 (35.8-213.7)   Female 55 48.7 112.9 (85.0-146.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
336 
Westborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 17.8 73.1 (38.9-124.9)   Male 12 11.9 101.2 (52.2-176.8) 
Female 8 6.9 115.7 (49.8-228.0)   Female 6 9.8 61.4 (22.4-133.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.7 nc (nc-nc)   Male 6 3.8 158.8 (58.0-345.6) 
Female 6 3.2 190.4 (69.5-414.5)   Female 3 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 9 10.6 84.5 (38.6-160.4) 
Female 79 78.1 101.2 (80.1-126.1)   Female 6 9.8 61.4 (22.4-133.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 9.1 99.2 (45.3-188.4) 
Female 1 2.6 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 20.4 93.1 (56.0-145.4)             
Female 19 21.0 90.4 (54.4-141.2)   Female 5 6.7 74.3 (24.0-173.5) 
Esophagus            Pancreas     
Male 3 4.7 nc (nc-nc)   Male 6 6.5 92.8 (33.9-202.0) 
Female 3 1.3 nc (nc-nc)   Female 10 7.2 138.9 (66.5-255.4) 
Hodgkin Lymphoma            Prostate     
Male 3 1.5 nc (nc-nc)   Male 51 55.8 91.4 (68.1-120.2) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 10.5 nc (nc-nc)   Male 5 4.4 113.3 (36.5-264.3) 
Female 1 6.1 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Larynx            Testis     
Male 1 2.7 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 7.5 147.0 (73.3-263.0)   Male 7 5.1 137.0 (54.9-282.3) 
Female 9 5.8 155.6 (71.0-295.4)   Female 13 14.6 88.8 (47.2-151.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.5 77.4 (24.9-180.6)             
Female 2 2.3 nc (nc-nc)   Female 20 17.0 117.6 (71.8-181.7) 
Lung and Bronchus            All Sites / Types     
Male 20 31.4 63.7 (38.9-98.5)   Male 213 236.5 90.1 (78.4-103.0) 
Female 28 35.1 79.7 (53.0-115.2)   Female 245 261.4 93.7 (82.3-106.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
337 
Westfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 43.1 99.8 (72.2-134.4)   Male 20 27.1 73.7 (45.0-113.8) 
Female 14 14.5 96.4 (52.7-161.8)   Female 20 20.5 97.4 (59.5-150.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 8.5 nc (nc-nc)   Male 10 8.8 114.1 (54.6-209.8) 
Female 6 6.8 88.4 (32.3-192.5)   Female 3 6.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.5 nc (nc-nc)   Male 22 24.6 89.4 (56.0-135.3) 
Female 198 164.0 120.7 (104.5-138.8)   Female 21 20.6 101.7 (62.9-155.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 20.4 83.5 (48.6-133.8) 
Female 8 5.4 148.8 (64.1-293.3)   Female 9 8.7 103.2 (47.1-195.8) 
Colon / Rectum            Ovary     
Male 63 46.2 136.3 (104.7-174.4)             
Female 51 42.4 120.2 (89.5-158.1)   Female 19 14.3 133.3 (80.2-208.2) 
Esophagus            Pancreas     
Male 14 11.1 126.0 (68.8-211.3)   Male 13 15.3 84.8 (45.1-145.1) 
Female 3 2.9 nc (nc-nc)   Female 10 14.7 67.9 (32.5-124.9) 
Hodgkin Lymphoma            Prostate     
Male 6 3.5 170.5 (62.3-371.1)   Male 122 136.5 89.3 (74.2-106.7) 
Female 0 3.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 23.8 88.1 (54.5-134.7)   Male 11 10.3 106.6 (53.1-190.7) 
Female 8 13.0 61.5 (26.5-121.2)   Female 8 5.8 138.2 (59.5-272.3) 
Larynx            Testis     
Male 4 6.4 nc (nc-nc)   Male 7 6.1 114.5 (45.9-236.0) 
Female 4 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 17.7 107.3 (64.6-167.6)   Male 6 10.7 56.0 (20.5-122.0) 
Female 9 12.1 74.5 (34.0-141.5)   Female 22 30.9 71.2 (44.6-107.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 15.0 86.8 (46.2-148.5)             
Female 4 4.9 nc (nc-nc)   Female 37 37.0 99.9 (70.3-137.7) 
Lung and Bronchus            All Sites / Types     
Male 82 76.2 107.6 (85.5-133.5)   Male 549 557.9 98.4 (90.3-107.0) 
Female 80 76.8 104.1 (82.6-129.6)   Female 566 551.0 102.7 (94.4-111.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
338 
Westford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 20.1 74.5 (41.7-122.9)   Male 13 14.2 91.6 (48.7-156.7) 
Female 4 6.4 nc (nc-nc)   Female 12 10.7 112.2 (57.9-196.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.6 151.5 (60.7-312.3)   Male 8 4.6 173.9 (74.9-342.6) 
Female 5 3.6 140.3 (45.2-327.4)   Female 3 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 13 12.8 102.0 (54.2-174.4) 
Female 105 90.9 115.5 (94.4-139.8)   Female 8 10.0 80.3 (34.6-158.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 11.8 50.6 (18.5-110.2) 
Female 2 3.2 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 24.0 104.1 (67.3-153.6)             
Female 25 19.9 125.6 (81.2-185.4)   Female 6 7.5 79.5 (29.0-173.0) 
Esophagus            Pancreas     
Male 4 5.9 nc (nc-nc)   Male 9 7.8 116.0 (52.9-220.3) 
Female 2 1.3 nc (nc-nc)   Female 5 6.5 77.1 (24.8-179.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.7 nc (nc-nc)   Male 83 76.7 108.2 (86.2-134.1) 
Female 3 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 13.5 73.8 (35.3-135.7)   Male 7 5.2 134.9 (54.0-277.9) 
Female 3 6.7 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Larynx            Testis     
Male 4 3.5 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 8.8 113.0 (54.1-207.9)   Male 10 6.4 155.4 (74.4-285.7) 
Female 9 5.7 157.2 (71.7-298.5)   Female 17 18.0 94.4 (55.0-151.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.3 72.3 (26.4-157.4)             
Female 0 2.3 nc (nc-nc)   Female 34 20.4 166.8 (115.5-233.1) 
Lung and Bronchus            All Sites / Types     
Male 32 38.1 84.1 (57.5-118.7)   Male 289 293.4 98.5 (87.5-110.5) 
Female 25 36.0 69.4 (44.9-102.4)   Female 292 282.2 103.5 (91.9-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
339 
Westhampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.0 nc (nc-nc)   Male 6 1.3 458.1 (167.3-997.1) 
Female 0 0.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 10 7.8 128.8 (61.7-236.9)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.2 nc (nc-nc)             
Female 2 1.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 7.3 137.9 (66.0-253.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.2 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.7 nc (nc-nc)   Male 26 27.4 94.9 (62.0-139.1) 
Female 0 3.2 nc (nc-nc)   Female 14 24.4 57.4 (31.3-96.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
340 
Westminster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.9 76.0 (27.7-165.4)   Male 8 5.3 151.1 (65.0-297.6) 
Female 3 2.3 nc (nc-nc)   Female 6 3.7 160.9 (58.8-350.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.6 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.8 126.2 (46.1-274.8) 
Female 43 31.0 138.5 (100.2-186.6)   Female 2 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.3 116.8 (37.6-272.5) 
Female 0 1.1 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.2 76.3 (30.6-157.1)             
Female 7 7.0 99.3 (39.8-204.7)   Female 3 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.2 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 23 27.2 84.5 (53.6-126.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.8 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.3 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 7 6.0 116.6 (46.7-240.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.1 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 8 7.3 109.7 (47.2-216.2) 
Lung and Bronchus            All Sites / Types     
Male 10 13.9 71.8 (34.4-132.1)   Male 98 108.2 90.6 (73.5-110.4) 
Female 14 12.3 113.7 (62.1-190.8)   Female 107 97.8 109.4 (89.7-132.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
341 
Weston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 15.3 117.8 (69.8-186.2)   Male 11 9.2 119.9 (59.8-214.6) 
Female 1 5.0 nc (nc-nc)   Female 9 6.5 138.8 (63.3-263.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 10 8.2 122.0 (58.4-224.3) 
Female 52 53.8 96.7 (72.2-126.8)   Female 3 6.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.7 104.5 (41.9-215.3) 
Female 1 1.6 nc (nc-nc)   Female 0 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 15.6 76.8 (39.6-134.1)             
Female 10 14.6 68.6 (32.9-126.2)   Female 2 4.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.8 nc (nc-nc)   Male 6 5.3 112.6 (41.1-245.0) 
Female 0 1.0 nc (nc-nc)   Female 11 5.1 214.5 (106.9-383.8) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 47 46.4 101.3 (74.5-134.8) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.9 100.9 (43.4-198.8)   Male 2 3.6 nc (nc-nc) 
Female 1 4.3 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Larynx            Testis     
Male 1 2.2 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.9 101.0 (36.9-219.8)   Male 7 3.2 218.6 (87.6-450.4) 
Female 6 4.1 147.2 (53.7-320.3)   Female 7 9.0 77.9 (31.2-160.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.0 119.8 (43.7-260.7)             
Female 0 1.7 nc (nc-nc)   Female 9 12.1 74.2 (33.8-140.8) 
Lung and Bronchus            All Sites / Types     
Male 15 27.3 54.9 (30.7-90.5)   Male 188 189.2 99.3 (85.7-114.6) 
Female 17 26.3 64.8 (37.7-103.7)   Female 146 182.7 79.9 (67.5-94.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
342 
Westport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 23.8 104.9 (67.8-154.8)   Male 14 14.3 97.9 (53.5-164.2) 
Female 7 7.1 98.1 (39.3-202.0)   Female 6 9.5 62.9 (23.0-136.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.0 nc (nc-nc)   Male 5 4.8 104.4 (33.6-243.7) 
Female 2 3.0 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 16 12.8 124.8 (71.3-202.6) 
Female 69 80.8 85.4 (66.4-108.0)   Female 15 10.0 149.9 (83.8-247.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 10.3 77.6 (33.4-153.0) 
Female 3 2.5 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 24.0 91.6 (57.4-138.7)             
Female 19 20.4 93.0 (56.0-145.2)   Female 5 6.9 72.5 (23.4-169.2) 
Esophagus            Pancreas     
Male 8 6.0 132.4 (57.0-260.8)   Male 13 8.3 157.0 (83.5-268.5) 
Female 1 1.4 nc (nc-nc)   Female 9 7.3 122.5 (55.9-232.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 74 73.9 100.1 (78.6-125.7) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 12.4 64.7 (27.9-127.5)   Male 5 5.6 89.8 (28.9-209.5) 
Female 6 6.3 94.6 (34.6-206.0)   Female 3 2.7 nc (nc-nc) 
Larynx            Testis     
Male 3 3.5 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 9.0 77.8 (31.2-160.2)   Male 6 5.0 119.0 (43.5-259.0) 
Female 4 5.5 nc (nc-nc)   Female 18 13.7 131.2 (77.7-207.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.7 64.6 (20.8-150.7)             
Female 1 2.4 nc (nc-nc)   Female 11 18.8 58.4 (29.1-104.5) 
Lung and Bronchus            All Sites / Types     
Male 36 42.6 84.4 (59.1-116.9)   Male 272 295.9 91.9 (81.3-103.5) 
Female 41 38.4 106.7 (76.6-144.8)   Female 250 267.7 93.4 (82.2-105.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
343 
Westwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 21.3 98.8 (61.1-151.0)   Male 26 12.5 208.1 (135.9-305.0) 
Female 7 7.0 99.4 (39.8-204.8)   Female 20 8.7 230.3 (140.6-355.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.5 nc (nc-nc)   Male 7 4.1 171.9 (68.9-354.2) 
Female 5 2.8 177.3 (57.1-413.7)   Female 4 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 9 11.3 79.5 (36.3-150.9) 
Female 98 70.5 139.0 (112.8-169.4)   Female 6 9.5 63.5 (23.2-138.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.9 78.9 (31.6-162.6) 
Female 2 2.2 nc (nc-nc)   Female 5 3.9 127.6 (41.1-297.9) 
Colon / Rectum            Ovary     
Male 22 22.1 99.5 (62.3-150.7)             
Female 22 20.8 105.6 (66.1-159.8)   Female 10 6.1 163.2 (78.1-300.2) 
Esophagus            Pancreas     
Male 0 5.1 nc (nc-nc)   Male 9 7.3 122.9 (56.1-233.3) 
Female 1 1.3 nc (nc-nc)   Female 2 7.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 4 1.1 nc (nc-nc)   Male 61 59.0 103.5 (79.1-132.9) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 10.5 105.2 (52.4-188.3)   Male 1 4.9 nc (nc-nc) 
Female 6 5.7 105.7 (38.6-230.0)   Female 2 2.9 nc (nc-nc) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 5 1.7 299.8 (96.6-699.6) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 8.1 111.2 (50.7-211.1)   Male 4 4.3 nc (nc-nc) 
Female 10 5.5 181.1 (86.7-333.0)   Female 18 11.5 156.3 (92.6-247.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 6.6 120.9 (52.1-238.2)             
Female 4 2.2 nc (nc-nc)   Female 20 15.3 130.7 (79.8-201.9) 
Lung and Bronchus            All Sites / Types     
Male 24 35.8 67.0 (42.9-99.7)   Male 254 253.3 100.3 (88.3-113.4) 
Female 32 34.8 91.8 (62.8-129.7)   Female 296 244.4 121.1 (107.7-135.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
344 
Weymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 61 57.1 106.9 (81.8-137.3)   Male 41 37.0 110.7 (79.4-150.1) 
Female 42 24.0 175.1 (126.2-236.6)   Female 47 32.6 144.1 (105.9-191.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 11.3 97.1 (48.4-173.7)   Male 10 11.9 83.9 (40.2-154.3) 
Female 10 10.3 97.4 (46.6-179.2)   Female 8 11.0 72.6 (31.3-143.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 2.0 nc (nc-nc)   Male 42 33.2 126.5 (91.1-171.0) 
Female 287 265.7 108.0 (95.9-121.3)   Female 30 33.6 89.2 (60.1-127.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 27.9 104.0 (69.6-149.3) 
Female 4 8.7 nc (nc-nc)   Female 20 14.1 141.5 (86.4-218.5) 
Colon / Rectum            Ovary     
Male 69 62.6 110.3 (85.8-139.6)             
Female 74 69.8 106.1 (83.3-133.2)   Female 22 22.8 96.4 (60.4-146.0) 
Esophagus            Pancreas     
Male 19 14.9 127.3 (76.6-198.8)   Male 17 20.6 82.6 (48.1-132.3) 
Female 5 4.7 106.8 (34.4-249.2)   Female 20 24.4 82.0 (50.1-126.7) 
Hodgkin Lymphoma            Prostate     
Male 7 4.5 156.8 (62.8-323.1)   Male 172 181.6 94.7 (81.1-110.0) 
Female 2 3.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 38 32.7 116.2 (82.2-159.5)   Male 16 13.9 114.7 (65.5-186.3) 
Female 31 21.0 147.6 (100.2-209.5)   Female 7 9.4 74.1 (29.7-152.7) 
Larynx            Testis     
Male 14 8.8 159.7 (87.2-268.0)   Male 9 8.2 110.2 (50.3-209.2) 
Female 4 3.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 23.5 81.0 (48.8-126.5)   Male 14 15.0 93.1 (50.8-156.2) 
Female 14 19.1 73.5 (40.1-123.3)   Female 44 47.6 92.5 (67.2-124.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 22 20.4 107.6 (67.4-162.9)             
Female 9 7.9 114.0 (52.0-216.5)   Female 64 60.0 106.7 (82.2-136.3) 
Lung and Bronchus            All Sites / Types     
Male 117 102.6 114.1 (94.3-136.7)   Male 799 749.6 106.6 (99.3-114.2) 
Female 163 126.2 129.2 (110.1-150.6)   Female 971 891.5 108.9 (102.2-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
345 
Whately 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.6 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 4 7.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 1.8 nc (nc-nc)             
Female 0 1.9 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 6.5 106.9 (42.8-220.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.0 nc (nc-nc)   Male 24 23.3 103.0 (66.0-153.3) 
Female 2 3.1 nc (nc-nc)   Female 13 23.6 55.0 (29.3-94.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
346 
Whitman 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 12.5 192.0 (123.0-285.6)   Male 8 8.7 91.9 (39.5-181.0) 
Female 8 4.5 176.7 (76.1-348.2)   Female 14 7.1 195.9 (107.0-328.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.9 nc (nc-nc)   Male 0 2.8 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 2 7.8 nc (nc-nc) 
Female 58 57.7 100.5 (76.3-129.9)   Female 5 6.8 73.7 (23.8-172.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 7.0 100.3 (40.2-206.7) 
Female 5 2.1 240.3 (77.5-560.9)   Female 6 2.9 205.3 (75.0-446.8) 
Colon / Rectum            Ovary     
Male 16 14.5 110.2 (62.9-178.9)             
Female 14 13.6 102.6 (56.0-172.1)   Female 3 4.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 3.5 169.7 (62.0-369.5)   Male 2 4.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 7 4.6 152.7 (61.2-314.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 45 45.0 100.0 (72.9-133.8) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 8.1 210.2 (122.4-336.5)   Male 4 3.2 nc (nc-nc) 
Female 4 4.4 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 3 2.1 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 5.5 162.7 (74.3-308.9)   Male 2 4.0 nc (nc-nc) 
Female 3 4.0 nc (nc-nc)   Female 9 11.7 76.7 (35.0-145.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.9 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 7 13.0 53.9 (21.6-111.1) 
Lung and Bronchus            All Sites / Types     
Male 32 23.1 138.3 (94.6-195.3)   Male 193 177.8 108.6 (93.8-125.0) 
Female 43 24.6 174.6 (126.3-235.2)   Female 205 186.5 109.9 (95.4-126.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
347 
Wilbraham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 21.3 84.6 (50.1-133.7)   Male 16 12.7 125.9 (71.9-204.5) 
Female 10 7.0 142.2 (68.1-261.5)   Female 9 8.9 101.1 (46.2-192.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 7 2.8 247.5 (99.2-510.0)   Female 2 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 9 11.5 78.4 (35.8-148.8) 
Female 80 74.0 108.1 (85.7-134.6)   Female 11 9.5 115.4 (57.5-206.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.3 85.6 (36.9-168.7) 
Female 1 2.2 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 22.1 95.0 (58.8-145.3)             
Female 15 20.7 72.4 (40.5-119.5)   Female 8 6.4 125.1 (53.9-246.4) 
Esophagus            Pancreas     
Male 2 5.3 nc (nc-nc)   Male 3 7.5 nc (nc-nc) 
Female 4 1.4 nc (nc-nc)   Female 10 7.3 136.4 (65.3-250.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 45 65.1 69.2 (50.4-92.5) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 11.0 91.2 (43.6-167.7)   Male 5 5.0 100.2 (32.3-233.9) 
Female 4 5.9 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Larynx            Testis     
Male 2 3.0 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 8.1 nc (nc-nc)   Male 4 4.5 nc (nc-nc) 
Female 7 5.5 128.0 (51.3-263.8)   Female 10 11.8 84.8 (40.6-156.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 6.9 100.8 (40.4-207.7)             
Female 2 2.2 nc (nc-nc)   Female 12 16.5 72.8 (37.5-127.1) 
Lung and Bronchus            All Sites / Types     
Male 25 37.2 67.1 (43.4-99.1)   Male 207 263.2 78.7 (68.3-90.1) 
Female 24 35.7 67.2 (43.0-100.0)   Female 241 250.8 96.1 (84.3-109.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
348 
Williamsburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 3.3 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 18 13.6 132.7 (78.6-209.8)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.6 nc (nc-nc)             
Female 4 3.5 nc (nc-nc)   Female 4 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 6 11.6 51.6 (18.8-112.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 6.1 82.4 (26.5-192.3)   Male 30 44.2 67.8 (45.7-96.8) 
Female 4 6.2 nc (nc-nc)   Female 43 44.8 96.0 (69.5-129.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
349 
Williamstown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 10.6 94.7 (45.3-174.2)   Male 4 5.8 nc (nc-nc) 
Female 4 3.9 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.6 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 5.3 150.8 (64.9-297.1) 
Female 25 33.8 74.0 (47.9-109.3)   Female 4 5.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 10.2 68.7 (27.5-141.6)             
Female 8 11.1 71.9 (31.0-141.7)   Female 4 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.4 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 25 27.6 90.5 (58.5-133.5) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.6 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.9 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 5 5.3 93.9 (30.2-219.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.0 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 4 7.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 17.4 28.7 (9.2-66.9)   Male 84 119.5 70.3 (56.1-87.1) 
Female 15 19.1 78.6 (44.0-129.7)   Female 94 126.1 74.6 (60.2-91.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
350 
Wilmington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 22.7 92.3 (57.1-141.1)   Male 12 14.8 81.0 (41.8-141.5) 
Female 9 8.4 107.6 (49.1-204.2)   Female 11 11.9 92.1 (45.9-164.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.7 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 4 3.8 nc (nc-nc)   Female 6 3.8 155.8 (56.9-339.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 6 13.4 44.7 (16.3-97.3) 
Female 127 96.4 131.7 (109.8-156.7)   Female 16 11.9 134.2 (76.7-218.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 11.4 114.1 (60.7-195.2) 
Female 3 3.3 nc (nc-nc)   Female 3 5.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 25.5 86.2 (54.0-130.5)             
Female 28 25.1 111.3 (74.0-160.9)   Female 5 8.3 60.5 (19.5-141.2) 
Esophagus            Pancreas     
Male 4 5.9 nc (nc-nc)   Male 6 8.3 72.7 (26.5-158.2) 
Female 0 1.6 nc (nc-nc)   Female 6 8.5 70.2 (25.6-152.9) 
Hodgkin Lymphoma            Prostate     
Male 4 1.9 nc (nc-nc)   Male 49 72.3 67.8 (50.2-89.6) 
Female 1 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 13.2 159.0 (98.4-243.1)   Male 4 5.6 nc (nc-nc) 
Female 7 7.5 92.9 (37.2-191.3)   Female 5 3.4 146.3 (47.1-341.4) 
Larynx            Testis     
Male 3 3.4 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 9.6 145.1 (79.3-243.5)   Male 7 6.2 112.9 (45.2-232.6) 
Female 5 6.9 72.1 (23.2-168.1)   Female 13 18.1 72.0 (38.3-123.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.1 74.4 (27.2-162.0)             
Female 2 2.8 nc (nc-nc)   Female 21 21.2 99.0 (61.2-151.3) 
Lung and Bronchus            All Sites / Types     
Male 46 39.7 115.9 (84.9-154.6)   Male 270 299.9 90.0 (79.6-101.4) 
Female 43 43.7 98.4 (71.2-132.6)   Female 343 320.2 107.1 (96.1-119.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
351 
Winchendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.7 93.7 (46.7-167.6)   Male 1 7.7 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.3 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 6.8 nc (nc-nc) 
Female 35 47.4 73.8 (51.4-102.6)   Female 4 5.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 5.9 119.0 (47.7-245.2) 
Female 4 1.5 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 13.1 76.5 (36.6-140.8)             
Female 16 11.6 138.3 (79.0-224.6)   Female 5 4.0 124.4 (40.1-290.4) 
Esophagus            Pancreas     
Male 2 3.1 nc (nc-nc)   Male 9 4.3 211.8 (96.6-402.0) 
Female 1 0.8 nc (nc-nc)   Female 5 3.9 127.3 (41.0-297.0) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 26 37.2 69.8 (45.6-102.3) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.8 118.1 (50.9-232.8)   Male 2 2.9 nc (nc-nc) 
Female 5 3.7 136.5 (44.0-318.6)   Female 2 1.5 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.9 123.5 (45.1-268.7)   Male 2 3.1 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 7 8.5 82.4 (33.0-169.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.3 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 9 10.6 84.9 (38.7-161.1) 
Lung and Bronchus            All Sites / Types     
Male 14 21.1 66.5 (36.3-111.6)   Male 120 154.6 77.6 (64.3-92.8) 
Female 19 21.5 88.2 (53.1-137.8)   Female 136 153.6 88.6 (74.3-104.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
352 
Winchester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 23.6 93.4 (58.5-141.4)   Male 16 15.0 106.5 (60.8-172.9) 
Female 6 9.1 66.2 (24.2-144.1)   Female 13 12.1 107.8 (57.3-184.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.6 nc (nc-nc)   Male 5 4.9 102.0 (32.9-238.1) 
Female 7 4.0 175.3 (70.2-361.2)   Female 3 4.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 17 13.5 125.6 (73.1-201.1) 
Female 116 100.8 115.0 (95.1-138.0)   Female 15 12.6 119.3 (66.7-196.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 11.2 44.6 (14.4-104.1) 
Female 2 3.3 nc (nc-nc)   Female 5 5.3 94.1 (30.3-219.6) 
Colon / Rectum            Ovary     
Male 28 25.7 108.9 (72.4-157.5)             
Female 27 27.0 99.8 (65.8-145.3)   Female 8 8.5 93.8 (40.4-184.8) 
Esophagus            Pancreas     
Male 3 6.1 nc (nc-nc)   Male 5 8.4 59.2 (19.1-138.1) 
Female 0 1.8 nc (nc-nc)   Female 10 9.4 106.6 (51.0-196.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 70 72.7 96.3 (75.1-121.7) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 13.3 37.7 (12.1-87.9)   Male 4 5.7 nc (nc-nc) 
Female 12 7.9 151.8 (78.4-265.2)   Female 3 3.7 nc (nc-nc) 
Larynx            Testis     
Male 0 3.6 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 9.6 156.5 (87.5-258.1)   Male 5 5.9 84.4 (27.2-196.9) 
Female 7 7.4 95.2 (38.1-196.1)   Female 24 17.7 136.0 (87.1-202.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.1 73.8 (26.9-160.6)             
Female 2 2.9 nc (nc-nc)   Female 24 21.8 110.1 (70.5-163.9) 
Lung and Bronchus            All Sites / Types     
Male 22 42.3 52.0 (32.6-78.7)   Male 266 303.8 87.6 (77.4-98.8) 
Female 43 47.0 91.5 (66.2-123.2)   Female 353 336.4 104.9 (94.3-116.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
353 
Windsor 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 4 4.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 1.5 334.4 (107.8-780.4)             
Female 3 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 0 4.7 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.4 nc (nc-nc)   Male 11 18.0 61.2 (30.5-109.5) 
Female 4 1.8 nc (nc-nc)   Female 20 13.4 149.6 (91.3-231.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
354 
Winthrop 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 22.1 95.1 (58.8-145.3)   Male 28 14.2 197.6 (131.3-285.6) 
Female 9 6.9 129.6 (59.1-246.0)   Female 19 10.0 189.6 (114.1-296.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.2 nc (nc-nc)   Male 5 4.6 108.0 (34.8-252.1) 
Female 2 3.1 nc (nc-nc)   Female 6 3.2 186.2 (68.0-405.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 6 12.6 47.6 (17.4-103.7) 
Female 83 81.5 101.9 (81.1-126.3)   Female 8 10.0 80.2 (34.5-158.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 10.8 93.0 (44.5-171.0) 
Female 3 2.7 nc (nc-nc)   Female 2 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 23.5 106.3 (68.8-157.0)             
Female 28 20.2 138.9 (92.3-200.7)   Female 6 7.0 86.1 (31.4-187.4) 
Esophagus            Pancreas     
Male 7 5.9 118.4 (47.4-243.9)   Male 15 8.0 188.0 (105.1-310.0) 
Female 1 1.4 nc (nc-nc)   Female 5 7.0 71.8 (23.1-167.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.6 nc (nc-nc)   Male 69 74.5 92.6 (72.1-117.2) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 12.7 197.5 (127.7-291.5)   Male 5 5.4 93.2 (30.0-217.6) 
Female 12 6.4 187.2 (96.6-327.0)   Female 3 2.7 nc (nc-nc) 
Larynx            Testis     
Male 4 3.5 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 8.8 56.7 (18.3-132.2)   Male 7 5.5 127.1 (50.9-261.9) 
Female 6 5.6 106.6 (38.9-232.1)   Female 14 15.2 91.9 (50.2-154.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 8.0 112.3 (51.3-213.3)             
Female 1 2.3 nc (nc-nc)   Female 19 18.4 103.1 (62.1-161.1) 
Lung and Bronchus            All Sites / Types     
Male 53 40.9 129.7 (97.2-169.7)   Male 325 292.5 111.1 (99.4-123.9) 
Female 43 37.9 113.5 (82.2-152.9)   Female 292 268.7 108.7 (96.6-121.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
355 
Woburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 41.0 126.8 (94.7-166.3)   Male 29 26.4 109.9 (73.6-157.9) 
Female 21 16.3 129.0 (79.8-197.2)   Female 17 22.0 77.3 (45.0-123.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 8.1 61.6 (19.9-143.8)   Male 10 8.2 121.2 (58.0-223.0) 
Female 11 6.9 160.5 (80.0-287.2)   Female 8 7.3 109.3 (47.0-215.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.4 nc (nc-nc)   Male 34 23.6 144.1 (99.8-201.4) 
Female 214 171.8 124.6 (108.5-142.4)   Female 30 22.5 133.2 (89.9-190.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 19.3 88.2 (51.4-141.3) 
Female 8 5.8 138.6 (59.7-273.0)   Female 6 9.3 64.2 (23.5-139.8) 
Colon / Rectum            Ovary     
Male 60 44.5 134.9 (102.9-173.6)             
Female 53 48.0 110.4 (82.7-144.3)   Female 15 15.0 100.0 (55.9-165.0) 
Esophagus            Pancreas     
Male 12 10.4 115.9 (59.8-202.5)   Male 12 14.6 82.0 (42.3-143.3) 
Female 1 3.1 nc (nc-nc)   Female 19 16.7 114.1 (68.6-178.1) 
Hodgkin Lymphoma            Prostate     
Male 3 3.4 nc (nc-nc)   Male 120 124.7 96.2 (79.8-115.1) 
Female 1 2.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 24 22.7 105.7 (67.7-157.3)   Male 8 9.9 80.7 (34.7-158.9) 
Female 16 13.8 115.9 (66.2-188.2)   Female 6 6.6 91.4 (33.4-199.0) 
Larynx            Testis     
Male 4 6.0 nc (nc-nc)   Male 6 6.5 91.7 (33.5-199.6) 
Female 6 1.9 311.3 (113.7-677.6)             
Leukemia            Thyroid     
Male 21 16.9 124.5 (77.0-190.3)   Male 14 10.7 130.6 (71.3-219.1) 
Female 11 13.1 83.7 (41.7-149.8)   Female 37 31.7 116.8 (82.2-161.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 14.1 113.7 (65.0-184.7)             
Female 3 5.2 nc (nc-nc)   Female 35 37.8 92.5 (64.4-128.7) 
Lung and Bronchus            All Sites / Types     
Male 98 72.2 135.7 (110.2-165.4)   Male 607 527.9 115.0 (106.0-124.5) 
Female 82 83.0 98.7 (78.5-122.6)   Female 664 590.1 112.5 (104.1-121.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Worcester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 169 150.9 112.0 (95.8-130.2)   Male 72 99.2 72.6 (56.8-91.4) 
Female 60 62.0 96.8 (73.9-124.6)   Female 61 88.7 68.7 (52.6-88.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 32 33.0 97.0 (66.3-136.9)   Male 24 31.0 77.4 (49.6-115.2) 
Female 23 29.2 78.7 (49.9-118.2)   Female 27 28.1 96.1 (63.3-139.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 5.2 nc (nc-nc)   Male 105 89.8 116.9 (95.6-141.5) 
Female 617 676.9 91.1 (84.1-98.6)   Female 72 87.4 82.4 (64.5-103.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 72 74.0 97.3 (76.1-122.5) 
Female 30 24.2 124.2 (83.8-177.3)   Female 37 36.7 100.9 (71.0-139.1) 
Colon / Rectum            Ovary     
Male 156 167.6 93.1 (79.0-108.9)             
Female 177 185.0 95.7 (82.1-110.9)   Female 47 59.4 79.1 (58.1-105.2) 
Esophagus            Pancreas     
Male 53 38.9 136.3 (102.1-178.3)   Male 52 54.3 95.8 (71.5-125.6) 
Female 18 11.9 151.3 (89.6-239.1)   Female 63 63.5 99.2 (76.2-126.9) 
Hodgkin Lymphoma            Prostate     
Male 14 15.1 92.9 (50.8-155.9)   Male 476 470.6 101.2 (92.3-110.7) 
Female 18 13.4 134.5 (79.6-212.5)             
Kidney & Renal Pelvis            Stomach     
Male 93 86.4 107.6 (86.9-131.8)   Male 35 36.9 94.9 (66.1-132.0) 
Female 64 54.3 117.9 (90.8-150.5)   Female 22 25.1 87.6 (54.9-132.6) 
Larynx            Testis     
Male 19 22.6 84.2 (50.7-131.6)   Male 23 29.0 79.3 (50.2-119.0) 
Female 12 7.5 159.8 (82.5-279.2)             
Leukemia            Thyroid     
Male 74 65.5 113.0 (88.7-141.9)   Male 44 42.6 103.4 (75.1-138.8) 
Female 52 53.1 97.8 (73.1-128.3)   Female 131 137.9 95.0 (79.4-112.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 82 53.9 152.2 (121.1-188.9)             
Female 26 20.1 129.1 (84.3-189.2)   Female 167 148.2 112.7 (96.2-131.1) 
Lung and Bronchus            All Sites / Types     
Male 325 264.2 123.0 (110.0-137.2)   Male 2080 1994.9 104.3 (99.8-108.8) 
Female 350 318.6 109.8 (98.6-122.0)   Female 2274 2324.2 97.8 (93.9-101.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Worthington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 5 6.3 78.8 (25.4-183.8)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.0 nc (nc-nc)             
Female 3 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 6.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 5 1.6 318.7 (102.7-743.6) 
Lung and Bronchus            All Sites / Types     
Male 7 3.5 200.4 (80.3-413.0)   Male 26 25.0 103.8 (67.8-152.1) 
Female 0 2.8 nc (nc-nc)   Female 21 20.4 102.7 (63.6-157.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wrentham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 9.7 103.5 (49.6-190.4)   Male 9 6.8 132.7 (60.6-252.0) 
Female 4 4.4 nc (nc-nc)   Female 10 6.2 160.1 (76.6-294.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.2 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 14 6.1 229.1 (125.2-384.5) 
Female 64 51.4 124.5 (95.9-159.0)   Female 5 6.3 78.9 (25.4-184.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.5 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 11.8 160.6 (96.6-250.8)             
Female 12 13.6 88.2 (45.5-154.1)   Female 6 4.4 136.6 (49.9-297.4) 
Esophagus            Pancreas     
Male 5 2.7 186.8 (60.2-435.9)   Male 5 3.7 135.4 (43.6-316.0) 
Female 0 0.8 nc (nc-nc)   Female 5 4.5 111.8 (36.0-260.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 56 33.0 169.8 (128.3-220.5) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.2 96.3 (35.2-209.5)   Male 3 2.5 nc (nc-nc) 
Female 4 4.0 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.2 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 1 3.6 nc (nc-nc)   Female 8 9.2 87.1 (37.5-171.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.0 nc (nc-nc)             
Female 3 1.5 nc (nc-nc)   Female 6 11.2 53.4 (19.5-116.2) 
Lung and Bronchus            All Sites / Types     
Male 19 17.4 109.0 (65.6-170.2)   Male 179 136.0 131.6 (113.0-152.3) 
Female 15 22.8 65.7 (36.7-108.3)   Female 165 169.3 97.4 (83.1-113.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Yarmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 46.2 116.9 (87.8-152.6)   Male 42 25.3 166.0 (119.6-224.4) 
Female 21 17.2 122.1 (75.6-186.7)   Female 43 18.6 230.8 (167.0-310.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 6.4 125.8 (54.2-247.9)   Male 7 8.4 83.6 (33.5-172.3) 
Female 8 5.9 136.7 (58.9-269.4)   Female 8 7.4 108.4 (46.7-213.6) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.4 nc (nc-nc)   Male 25 22.8 109.9 (71.1-162.2) 
Female 179 154.9 115.5 (99.2-133.8)   Female 24 21.8 109.9 (70.4-163.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 16.1 118.1 (71.1-184.5) 
Female 1 4.2 nc (nc-nc)   Female 14 8.8 159.6 (87.2-267.7) 
Colon / Rectum            Ovary     
Male 40 44.2 90.5 (64.6-123.2)             
Female 37 47.1 78.5 (55.3-108.2)   Female 9 13.6 66.4 (30.3-126.0) 
Esophagus            Pancreas     
Male 17 10.2 167.0 (97.3-267.5)   Male 18 15.1 119.4 (70.7-188.8) 
Female 6 3.3 184.1 (67.2-400.8)   Female 19 17.3 109.5 (65.9-171.1) 
Hodgkin Lymphoma            Prostate     
Male 4 2.0 nc (nc-nc)   Male 140 110.7 126.4 (106.4-149.2) 
Female 3 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 19.6 76.5 (42.8-126.2)   Male 6 10.3 58.4 (21.3-127.0) 
Female 12 13.2 91.2 (47.1-159.3)   Female 7 6.4 108.5 (43.5-223.6) 
Larynx            Testis     
Male 4 5.7 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 35 16.3 214.5 (149.4-298.3)   Male 9 7.3 123.0 (56.1-233.4) 
Female 21 12.3 170.7 (105.6-260.9)   Female 11 21.7 50.7 (25.3-90.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 19 12.6 150.2 (90.4-234.6)             
Female 9 5.2 174.8 (79.7-331.8)   Female 29 34.2 84.7 (56.7-121.7) 
Lung and Bronchus            All Sites / Types     
Male 78 76.5 101.9 (80.5-127.2)   Male 581 505.6 114.9 (105.8-124.6) 
Female 99 88.6 111.8 (90.9-136.1)   Female 611 553.9 110.3 (101.7-119.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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